No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, d1b0eA_, 1.0000, 0.00, 1.000, 240, 240, CRYSTAL STRUCTURE OF PORCINE PANCREATIC ELASTASE WITH MDL 101146
2, d2fo9A_, 0.9964, 0.35, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 95% ACETONE
3, d2fodA_, 0.9962, 0.36, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 80% ETHANOL
4, d2fofA_, 0.9961, 0.36, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 80% ISOPROPANOL
5, d2fobA_, 0.9960, 0.36, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 40/50/10 CYCLOHEXANE
6, d2foaA_, 0.9960, 0.37, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 40/50/10 % BENZENE
7, d2fogA_, 0.9958, 0.37, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 40% TRIFLUOROETHANOL
8, d1okxB_, 0.9957, 0.38, 1.000, 240, 240, BINDING STRUCTURE OF ELASTASE INHIBITOR SCYPTOLIN A
9, d1okxA_, 0.9957, 0.38, 1.000, 240, 240, BINDING STRUCTURE OF ELASTASE INHIBITOR SCYPTOLIN A
10, d4ym9A_, 0.9954, 0.39, 0.996, 240, 240, CRYSTAL STRUCTURE OF PORCINE PANCREATIC ELASTASE (PPE) IN COMPLEX WITH THE NOVEL INHIBITOR JM102
11, d2foeA_, 0.9952, 0.40, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 80% HEXANE
12, d1fleE_, 0.9952, 0.40, 1.000, 240, 240, CRYSTAL STRUCTURE OF ELAFIN COMPLEXED WITH PORCINE PANCREATIC ELASTASE
13, d1eatA_, 0.9951, 0.41, 1.000, 240, 240, NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 5. DESIGN SYNTHESIS AND X-RAY CRYSTALLOGRAPHY OF A SERIES OF ORALLY ACTIVE 5- AMINO-PYRIMIDIN-6-ONE-CONTAINING TRIFLUOROMETHYLKETONES
14, d1qixB_, 0.9950, 0.41, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH HUMAN BETA-CASOMORPHIN-7
15, d1haxB_, 0.9950, 0.41, 0.996, 240, 240, SNAPSHOTS OF SERINE PROTEASE CATALYSIS: (A) ACYL-ENZYME INTERMEDIATE BETWEEN PORCINE PANCREATIC ELASTASE AND HUMAN BETA-CASOMORPHIN-7 AT PH 5
16, d1fzzA_, 0.9950, 0.42, 0.996, 240, 240, THE CRYSTAL STRUCTURE OF THE COMPLEX OF NON-PEPTIDIC INHIBITOR ONO-6818 AND PORCINE PANCREATIC ELASTASE.
17, d3estA_, 0.9949, 0.42, 1.000, 240, 240, STRUCTURE OF NATIVE PORCINE PANCREATIC ELASTASE AT 1.65 ANGSTROMS RESOLUTION
18, d2fohA_, 0.9949, 0.42, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 40% TRIFLUOROETHANOL
19, d1eauA_, 0.9949, 0.42, 1.000, 240, 240, NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 6. DESIGN OF A POTENT INTRATRACHEALLY ACTIVE PYRIDONE-BASED TRIFLUOROMETHYL KETONE
20, d2focA_, 0.9948, 0.42, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE IN 55% DIMETHYLFORMAMIDE
21, d1easA_, 0.9948, 0.42, 1.000, 240, 240, NONPEPTIDIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE. 3. DESIGN SYNTHESIS X-RAY CRYSTALLOGRAPHIC ANALYSIS AND STRUCTURE-ACTIVITY RELATIONSHIPS FOR A SERIES OF ORALLY ACTIVE 3-AMINO-6-PHENYLPYRIDIN- 2-ONE TRIFLUOROMETHYL KETONES
22, d1lvyA_, 0.9947, 0.43, 1.000, 240, 240, PORCINE ELASTASE
23, d9estA_, 0.9946, 0.43, 1.000, 240, 240, STRUCTURAL STUDY OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH 7- AMINO-3-(2-BROMOETHOXY)-4-CHLOROISOCOUMARIN AS A NONREACTIVATABLE DOUBLY COVALENT ENZYME-INHIBITOR COMPLEX
24, d1jimA_, 0.9945, 0.44, 1.000, 240, 240, STEREOSPECIFIC REACTION OF 3-METHOXY-4-CHLORO-7- AMINOISOCOUMARIN WITH CRYSTALLINE PORCINE PANCREATIC ELASTASE
25, d1esbA_, 0.9945, 0.43, 1.000, 240, 240, DIRECT STRUCTURE OBSERVATION OF AN ACYL-ENZYME INTERMEDIATE IN THE HYDROLYSIS OF AN ESTER SUBSTRATE BY ELASTASE
26, d1mmjN_, 0.9943, 0.44, 0.996, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH A POTENT PEPTIDYL INHIBITOR FR136706
27, d1incA_, 0.9943, 0.44, 1.000, 240, 240, CRYSTAL STRUCTURES OF THE COMPLEX OF PORCINE PANCREATIC ELASTASE WITH TWO VALINE-DERIVED BENZOXAZINONE INHIBITORS
28, d1hv7A_, 0.9943, 0.44, 0.996, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH GW311616A
29, d1esaA_, 0.9943, 0.44, 1.000, 240, 240, DIRECT STRUCTURE OBSERVATION OF AN ACYL-ENZYME INTERMEDIATE IN THE HYDROLYSIS OF AN ESTER SUBSTRATE BY ELASTASE
30, d1eleE_, 0.9943, 0.44, 1.000, 240, 240, STRUCTURAL ANALYSIS OF THE ACTIVE SITE OF PORCINE PANCREATIC ELASTASE BASED ON THE X-RAY CRYSTAL STRUCTURES OF COMPLEXES WITH TRIFLUOROACETYL-DIPEPTIDE-ANILIDE INHIBITORS
31, d4estE_, 0.9942, 0.44, 1.000, 240, 240, CRYSTAL STRUCTURE OF THE COVALENT COMPLEX FORMED BY A PEPTIDYL ALPHA ALPHA-DIFLUORO-BETA-KETO AMIDE WITH PORCINE PANCREATIC ELASTASE AT 1.78-ANGSTROMS RESOLUTION
32, d1elfA_, 0.9942, 0.44, 1.000, 240, 240, NATURE OF THE INACTIVATION OF ELASTASE BY N-PEPTIDYL-O- AROYL HYDROXYLAMINE AS A FUNCTION OF PH
33, d8estE_, 0.9941, 0.45, 1.000, 240, 240, REACTION OF PORCINE PANCREATIC ELASTASE WITH 7-SUBSTITUTED 3-ALKOXY-4-CHLOROISOCOUMARINS: DESIGN OF POTENT INHIBITORS USING THE CRYSTAL STRUCTURE OF THE COMPLEX FORMED WITH 4- CHLORO-3-ETHOXY-7-GUANIDINO-ISOCOUMARIN
34, d4gvuA_, 0.9941, 0.45, 1.000, 240, 240, LYNGBYASTATIN 7-PORCINE PANCREATIC ELASTASE CO-CRYSTAL STRUCTURE
35, d2bd9A_, 0.9941, 0.45, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND ARG- PHE AT PH 5.0 (50 MIN SOAK) AND IMMERSED IN PH 9 BUFFER FOR 28 SECONDS (2ND PH JUMP)
36, d1qr3E_, 0.9941, 0.45, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE IN COMPLEX WITH FR901277 A NOVEL MACROCYCLIC INHIBITOR OF ELASTASES AT 1.6 ANGSTROM RESOLUTION
37, d1nesE_, 0.9941, 0.45, 1.000, 240, 240, STRUCTURE OF THE PRODUCT COMPLEX OF ACETYL-ALA-PRO-ALA WITH PORCINE PANCREATIC ELASTASE AT 1.65 ANGSTROMS RESOLUTION
38, d1bmaA_, 0.9940, 0.45, 1.000, 240, 240, BENZYL METHYL AMINIMIDE INHIBITOR COMPLEXED TO PORCINE PANCREATIC ELASTASE
39, d3hgnA_, 0.9939, 0.46, 0.996, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH A POTENT PEPTIDYL INHIBITOR FR130180 DETERMINED BY NEUTRON CRYSTALLOGRAPHY
40, d2v0bA_, 0.9939, 0.45, 0.996, 240, 240, SAD STRUCTURE SOLUTION PORCINE PANCREATIC ELASTASE FROM A SELENATE DERIVATIVE
41, d2estE_, 0.9937, 0.47, 1.000, 240, 240, CRYSTALLOGRAPHIC STUDY OF THE BINDING OF A TRIFLUOROACETYL DIPEPTIDE ANILIDE INHIBITOR WITH ELASTASE
42, d1elgA_, 0.9937, 0.46, 1.000, 240, 240, NATURE OF THE INACTIVATION OF ELASTASE BY N-PEPTIDYL-O- AROYL HYDROXYLAMINE AS A FUNCTION OF PH
43, d1eldE_, 0.9937, 0.46, 1.000, 240, 240, STRUCTURAL ANALYSIS OF THE ACTIVE SITE OF PORCINE PANCREATIC ELASTASE BASED ON THE X-RAY CRYSTAL STRUCTURES OF COMPLEXES WITH TRIFLUOROACETYL-DIPEPTIDE-ANILIDE INHIBITORS
44, d1c1mA_, 0.9937, 0.46, 0.996, 240, 240, PORCINE ELASTASE UNDER XENON PRESSURE (8 BAR)
45, d2bd5A_, 0.9936, 0.47, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND LYS- SER AT PH 5 AND IMMERSED IN PH 9 BUFFER FOR 30 SECONDS
46, d1hazB_, 0.9936, 0.47, 1.000, 240, 240, SNAPSHOTS OF SERINE PROTEASE CATALYSIS: (C) ACYL-ENZYME INTERMEDIATE BETWEEN PORCINE PANCREATIC ELASTASE AND HUMAN BETA-CASOMORPHIN-7 JUMPED TO PH 9 FOR 1 MINUTE
47, d1hayB_, 0.9936, 0.47, 0.996, 240, 240, SNAPSHOTS OF SERINE PROTEASE CATALYSIS: (B) ACYL-ENZYME INTERMEDIATE BETWEEN PORCINE PANCREATIC ELASTASE AND HUMAN BETA-CASOMORPHIN-7 JUMPED TO PH 10 FOR 10 SECONDS
48, d1elaA_, 0.9936, 0.47, 1.000, 240, 240, ANALOGOUS INHIBITORS OF ELASTASE DO NOT ALWAYS BIND ANALOGOUSLY
49, d2bd8A_, 0.9935, 0.47, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND ARG- PHE AT PH 5.0 (50 MIN SOAK) AND IMMERSED IN PH 9 BUFFER FOR 30 SECONDS
50, d1elcA_, 0.9935, 0.47, 1.000, 240, 240, ANALOGOUS INHIBITORS OF ELASTASE DO NOT ALWAYS BIND ANALOGOUSLY
51, d1elbA_, 0.9935, 0.47, 1.000, 240, 240, ANALOGOUS INHIBITORS OF ELASTASE DO NOT ALWAYS BIND ANALOGOUSLY
52, d3mu1A_, 0.9934, 0.47, 1.000, 240, 240, COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION A OF THE CRYSTAL. FIFTH STEP OF RADIATION DAMAGE
53, d1gwaA_, 0.9934, 0.47, 0.996, 240, 240, TRIIODIDE DERIVATIVE OF PORCINE PANCREAS ELASTASE
54, d5estE_, 0.9933, 0.48, 1.000, 240, 240, CRYSTALLOGRAPHIC ANALYSIS OF THE INHIBITION OF PORCINE PANCREATIC ELASTASE BY A PEPTIDYL BORONIC ACID: STRUCTURE OF A REACTION INTERMEDIATE
55, d3e3tA_, 0.9933, 0.48, 1.000, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE WITH THE MAGIC TRIANGLE I3C
56, d2bdaA_, 0.9933, 0.48, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH N-ACETYL-NPI AND ALA-ALA AT PH 5.0
57, d6estA_, 0.9932, 0.48, 1.000, 240, 240, INTERACTION OF THE PEPTIDE CF3-LEU-ALA-NH-C6H4-CF3(TFLA) WITH PORCINE PANCREATIC ELASTASE. X-RAY STUDIES AT 1.8 ANGSTROMS
58, d2bd3A_, 0.9932, 0.48, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND LYS- ALA-NH2 AT PH 5.0
59, d1mcvA_, 0.9932, 0.48, 0.996, 240, 240, CRYSTAL STRUCTURE ANALYSIS OF A HYBRID SQUASH INHIBITOR IN COMPLEX WITH PORCINE PANCREATIC ELASTASE
60, d1hb0B_, 0.9932, 0.48, 0.996, 240, 240, SNAPSHOTS OF SERINE PROTEASE CATALYSIS: (D) ACYL-ENZYME INTERMEDIATE BETWEEN PORCINE PANCREATIC ELASTASE AND HUMAN BETA-CASOMORPHIN-7 JUMPED TO PH 10 FOR 2 MINUTES
61, d3mo3A_, 0.9931, 0.49, 1.000, 240, 240, INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. FIFTH STAGE OF RADIATION DAMAGE
62, d3mu8A_, 0.9930, 0.49, 1.000, 240, 240, COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION B OF THE CRYSTAL. FIFTH STEP OF RADIATION DAMAGE
63, d3mu0A_, 0.9930, 0.49, 1.000, 240, 240, COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION A OF THE CRYSTAL. THIRD STEP OF RADIATION DAMAGE
64, d3mocA_, 0.9930, 0.49, 1.000, 240, 240, INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. EIGHTH STAGE OF RADIATION DAMAGE
65, d3mo6A_, 0.9930, 0.49, 1.000, 240, 240, INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. SIXTH STAGE OF RADIATION DAMAGE
66, d2bdbA_, 0.9930, 0.49, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH ASN-PRO-ILE AND ALA-ALA AT PH 5.0
67, d2bd2A_, 0.9930, 0.49, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND ARG- PHE AT PH 5.0
68, d3mo9A_, 0.9929, 0.49, 1.000, 240, 240, INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. SEVENTH STAGE OF RADIATION DAMAGE
69, d2bd4A_, 0.9929, 0.49, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN- 7 AND LYS-SER AT PH 5.0
70, d1h9lB_, 0.9929, 0.49, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH ACETYL-VAL-GLU-PRO-ILE-COOH
71, d1estA_, 0.9929, 0.49, 1.000, 240, 240, THE ATOMIC STRUCTURE OF CRYSTALLINE PORCINE PANCREATIC ELASTASE AT 2.5 ANGSTROMS RESOLUTION. COMPARISONS WITH THE STRUCTURE OF ALPHA- CHYMOTRYPSIN
72, d1btuA_, 0.9929, 0.50, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S 4R)-1- TOLUENESULPHONYL-3-ETHYL-AZETIDIN-2-ONE-4-CARBOXYLIC ACID
73, d3mu5A_, 0.9928, 0.50, 1.000, 240, 240, COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION B OF THE CRYSTAL. THIRD STEP OF RADIATION DAMAGE
74, d3mnxA_, 0.9928, 0.50, 1.000, 240, 240, INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. FOURTH STAGE OF RADIATION DAMAGE
75, d2v35A_, 0.9928, 0.50, 0.996, 240, 240, PORCINE PANCREATIC ELASTASE IN COMPLEX WITH INHIBITOR JM54
76, d2a7cA_, 0.9928, 0.50, 0.996, 240, 240, ON THE ROUTINE USE OF SOFT X-RAYS IN MACROMOLECULAR CRYSTALLOGRAPHY PART III- THE OPTIMAL DATA COLLECTION WAVELENGTH
77, d1uo6A_, 0.9928, 0.50, 0.996, 240, 240, PORCINE PANCREATIC ELASTASE/XE-COMPLEX
78, d1e34B_, 0.9928, 0.50, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S 4S)N-PARA- TOLUENESULPHONYL-3-ETHYL-4-(CARBOXYLIC ACID) PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR ONE MINUTE
79, d7estE_, 0.9927, 0.50, 1.000, 240, 240, INTERACTION OF THE PEPTIDE CF3-LEU-ALA-NH-C6H4-CF3(TFLA) WITH PORCINE PANCREATIC ELASTASE. X-RAY STUDIES AT 1.8 ANGSTROMS
80, d2oquA_, 0.9927, 0.50, 0.996, 240, 240, HIGH PRESSURE CRYOCOOLING OF CAPILLARY SAMPLE CRYOPROTECTION AND DIFFRACTION PHASING AT LONG WAVELENGTHS
81, d2cv3A_, 0.9927, 0.50, 0.996, 240, 240, CRYSTAL STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH A MACROCLYCLIC PEPTIDE INHIBITOR
82, d1l1gA_, 0.9927, 0.50, 0.996, 240, 240, THE STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH XENON AND BROMIDE CRYOPROTECTED WITH GLYCEROL
83, d1gvkB_, 0.9927, 0.50, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE ACYL ENZYME AT 0.95 A RESOLUTION
84, d1e37B_, 0.9927, 0.50, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S 4S)N-PARA-NITROBENZENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR 1 MINUTE
85, d3mnsA_, 0.9926, 0.51, 1.000, 240, 240, INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. THIRD STAGE OF RADIATION DAMAGE
86, d1e38B_, 0.9926, 0.51, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S 4S)N-PARA-NITROBENZENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR 2 MINUTES
87, d1e35B_, 0.9925, 0.51, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S 4S)N-PARA- TOLUENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE SOAKED IN PH 9 BUFFER FOR TWO MINUTES
88, d3odfA_, 0.9923, 0.51, 1.000, 240, 240, COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION A OF THE CRYSTAL. SECOND STEP OF RADIATION DAMAGE
89, d2de9A_, 0.9923, 0.51, 0.996, 240, 240, CRYSTAL STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH TRIS AFTER SOAKING A TRIS-FREE SOLUTION
90, d1lkbA_, 0.9923, 0.51, 0.996, 240, 240, PORCINE PANCREATIC ELASTASE/NA-COMPLEX
91, d1lkaA_, 0.9923, 0.51, 0.996, 240, 240, PORCINE PANCREATIC ELASTASE/CA-COMPLEX
92, d3oddA_, 0.9922, 0.52, 1.000, 240, 240, COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION B OF THE CRYSTAL. SECOND STEP OF RADIATION DAMAGE
93, d2bd7A_, 0.9922, 0.52, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND ARG- PHE AT PH 5.0 (50 MIN SOAK)
94, d1qgfA_, 0.9922, 0.52, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3R 4S)N-PARA- TOLUENESULPHONYL-3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2- ONE
95, d2g4uA_, 0.9921, 0.52, 0.996, 240, 240, ANOMALOUS SUBSTRUCTURE OF PORCINE PANCREATIC ELASTAASE (CA)
96, d2bdcA_, 0.9921, 0.52, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH ASN-PRO-ILE AT PH 5.0
97, d1qnjA_, 0.9921, 0.52, 0.996, 240, 240, THE STRUCTURE OF NATIVE PORCINE PANCREATIC ELASTASE AT ATOMIC RESOLUTION (1.1 A)
98, d3mncA_, 0.9920, 0.52, 1.000, 240, 240, INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. SECOND STAGE OF RADIATION DAMAGE
99, d5avdA_, 0.9919, 0.53, 1.000, 240, 240, THE 0.86 ANGSTROM STRUCTURE OF ELASTASE CRYSTALLIZED IN HIGH-STRENGTH AGAROSE HYDROGEL
100, d3uouA_, 0.9919, 0.54, 0.996, 240, 240, CRYSTAL STRUCTURE OF THE KUNITZ-TYPE PROTEASE INHIBITOR SHPI-1 LYS13LEU MUTANT IN COMPLEX WITH PANCREATIC ELASTASE
101, d3mu4A_, 0.9919, 0.53, 1.000, 240, 240, COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION B OF THE CRYSTAL. FIRST STEP OF RADIATION DAMAGE
102, d3mtyA_, 0.9919, 0.53, 1.000, 240, 240, COMPARISON OF THE CHARACTER AND THE SPEED OF X-RAY-INDUCED STRUCTURAL CHANGES OF PORCINE PANCREATIC ELASTASE AT TWO TEMPERATURES 100 AND 15K. THE DATA SET WAS COLLECTED FROM REGION A OF THE CRYSTAL. FIRST STEP OF RADIATION DAMAGE
103, d2h1uA_, 0.9919, 0.53, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH METPHELEUGLU AT PH 5.0
104, d2bb4A_, 0.9919, 0.53, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH BETA-CASOMORPHIN-7 AND ASP- PHE AT PH 5.0
105, d1e36B_, 0.9918, 0.53, 1.000, 240, 240, PORCINE PANCREATIC ELASTASE COMPLEXED WITH (3S 4S)N-PARA- NITROBENZENESULPHONYL -3-ETHYL-4-(CARBOXYLIC ACID)PYRROLIDIN-2-ONE
106, d2blqA_, 0.9915, 0.54, 0.996, 240, 240, ELASTASE AFTER A HIGH DOSE X-RAY BURN
107, d3mnbA_, 0.9914, 0.54, 1.000, 240, 240, INVESTIGATION OF GLOBAL AND LOCAL EFFECTS OF RADIATION DAMAGE ON PORCINE PANCREATIC ELASTASE. FIRST STAGE OF RADIATION DAMAGE
108, d2g4tA_, 0.9914, 0.54, 0.996, 240, 240, ANOMALOUS SUBSTRUCTURE OF PORCINE PANCREATIC ELASTASE (NA)
109, d2bloA_, 0.9914, 0.54, 0.996, 240, 240, ELASTASE BEFORE A HIGH DOSE X-RAY BURN
110, d2iotA_, 0.9910, 0.56, 0.996, 240, 240, CLAVULANIC ACID BOUND TO ELASTASE
111, d3hgpA_, 0.9909, 0.57, 0.996, 240, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH A POTENT PEPTIDYL INHIBITOR FR130180 DETERMINED BY HIGH RESOLUTION CRYSTALLOGRAPHY
112, d1l0zA_, 0.9909, 0.56, 0.996, 240, 240, THE STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH XENON AND BROMIDE CRYOPROTECTED WITH DRY PARAFFIN OIL
113, d1uvoA_, 0.9906, 0.57, 0.996, 240, 240, STRUCTURE OF THE COMPLEX OF PORCINE PANCREATIC ELASTASE IN COMPLEX WITH CADMIUM REFINED AT 1.85 A RESOLUTION (CRYSTAL A)
114, d1uvpA_, 0.9905, 0.57, 0.996, 240, 240, STRUCTURE OF THE COMPLEX OF PORCINE PANCREATIC ELASTASE IN COMPLEX WITH CADMIUM REFINED AT 1.85 A RESOLUTION (CRYSTAL B)
115, d1eaiA_, 0.9893, 0.60, 0.996, 240, 240, COMPLEX OF ASCARIS CHYMOTRPSIN/ELASTASE INHIBITOR WITH PORCINE ELASTASE
116, d2a7jA_, 0.9889, 0.62, 0.996, 240, 240, ON THE ROUTINE USE OF SOFT X-RAYS IN MACROMOLECULAR CRYSTALLOGRAPHY PART III- THE OPTIMAL DATA COLLECTION WAVELENGTH
117, d2de8A_, 0.9877, 0.67, 0.996, 240, 240, CRYSTAL STRUCTURE OF PORCINE PANCREATIC ELASTASE WITH A UNIQUE CONFORMATION INDUCED BY TRIS
118, d1bruP_, 0.9872, 0.68, 0.583, 241, 240, STRUCTURE OF PORCINE PANCREATIC ELASTASE COMPLEXED WITH THE ELASTASE INHIBITOR GR143783
119, d1eaiB_, 0.9871, 0.67, 0.996, 240, 240, COMPLEX OF ASCARIS CHYMOTRPSIN/ELASTASE INHIBITOR WITH PORCINE ELASTASE
120, d1eltA_, 0.9773, 0.45, 0.678, 236, 236, STRUCTURE OF NATIVE PANCREATIC ELASTASE FROM NORTH ATLANTIC SALMON AT 1.61 ANGSTROMS RESOLUTION
121, p4h4fA_, 0.9650, 0.94, 0.515, 239, 237, CRYSTAL STRUCTURE OF HUMAN CHYMOTRYPSIN C (CTRC) BOUND TO INHIBITOR EGLIN C FROM HIRUDO MEDICINALIS
122, d1pytC_, 0.9481, 1.37, 0.534, 248, 236, TERNARY COMPLEX OF PROCARBOXYPEPTIDASE A PROPROTEINASE E AND CHYMOTRYPSINOGEN C
123, p3oy6U_, 0.9390, 1.44, 0.304, 247, 237, THE CRYSTAL STRUCTURE OF UPA COMPLEX WITH PEPTIDE INHIBITOR MH036 AT PH4.6
124, d1w10U_, 0.9390, 1.49, 0.304, 247, 237, UROKINASE TYPE PLASMINOGEN ACTIVATOR
125, d1w0zU_, 0.9386, 1.50, 0.304, 247, 237, UROKINASE TYPE PLASMINOGEN ACTIVATOR
126, d1w11U_, 0.9384, 1.50, 0.300, 247, 237, UROKINASE TYPE PLASMINOGEN ACTIVATOR
127, p4x1pU_, 0.9382, 1.48, 0.304, 247, 237, THE CRYSTAL STRUCTURE OF MUPAIN-1-17 IN COMPLEX WITH MURINISED HUMAN UPA AT PH4.6
128, d2vinA_, 0.9382, 1.50, 0.304, 247, 237, FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
129, d1f92A_, 0.9382, 1.50, 0.304, 247, 237, UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX
130, d1vjaU_, 0.9381, 1.51, 0.304, 247, 237, UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT463 COMPLEX
131, p4zkoU_, 0.9380, 1.47, 0.304, 247, 237, THE CRYSTAL STRUCTURE OF UPAIN-1-W3A IN COMPLEX WITH UPA AT PH7.4
132, p4x0wU_, 0.9380, 1.49, 0.304, 247, 237, THE CRYSTAL STRUCTURE OF MUPAIN-1-17 IN COMPLEX WITH MURINISED HUMAN UPA
133, d1w14U_, 0.9379, 1.51, 0.300, 247, 237, UROKINASE TYPE PLASMINOGEN ACTIVATOR
134, d1w13U_, 0.9379, 1.51, 0.304, 247, 237, UROKINASE TYPE PLASMINOGEN ACTIVATOR
135, d1sc8U_, 0.9379, 1.51, 0.300, 247, 237, UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-J435 COMPLEX
136, d1ejnA_, 0.9379, 1.51, 0.300, 247, 237, UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEX
137, d1f5kU_, 0.9378, 1.50, 0.300, 247, 237, UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-BENZAMIDINE COMPLEX
138, p2vntC_, 0.9377, 1.57, 0.294, 258, 238, UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE
139, p3m61U_, 0.9375, 1.49, 0.304, 247, 237, CRYSTAL STRUCTURE OF COMPLEX OF UROKINASE AND A UPAIN-1 VARIANT(W3A) IN PH4.6 CONDITION
140, d2viwA_, 0.9375, 1.51, 0.304, 247, 237, FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
141, d2r2wU_, 0.9373, 1.51, 0.300, 247, 237, UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-GPPE COMPLEX
142, d1vj9U_, 0.9373, 1.52, 0.304, 247, 237, UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-JT464 COMPLEX
143, d2vipA_, 0.9370, 1.51, 0.304, 247, 237, FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
144, d2vioA_, 0.9369, 1.52, 0.304, 247, 237, FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
145, p4x1nU_, 0.9368, 1.52, 0.304, 247, 237, THE CRYSTAL STRUCTURE OF MUPAIN-1-16 IN COMPLEX WITH MURINISED HUMAN UPA AT PH7.4
146, p3oy5U_, 0.9367, 1.40, 0.301, 246, 236, THE CRYSTAL STRUCTURE OF UPA COMPLEX WITH PEPTIDE INHIBITOR MH027 AT PH7.4
147, d3mhwU_, 0.9367, 1.41, 0.305, 246, 236, THE COMPLEX CRYSTAL STRUCTURE OF UROKIANSE AND 2- AMINOBENZOTHIAZOLE
148, d4fujA_, 0.9363, 1.46, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
149, d4fudA_, 0.9361, 1.46, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
150, d4fu9A_, 0.9360, 1.46, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
151, p2vntD_, 0.9360, 1.61, 0.294, 258, 238, UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE
152, p2vntE_, 0.9359, 1.61, 0.298, 258, 238, UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE
153, d2viqA_, 0.9359, 1.53, 0.304, 247, 237, FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
154, d4fubA_, 0.9357, 1.47, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
155, d4h42U_, 0.9356, 1.52, 0.304, 247, 237, SYNTHESIS OF A WEAK BASIC UPA INHIBITOR AND CRYSTAL STRUCTURE OF COMPLEX WITH UPA
156, d4fufA_, 0.9356, 1.47, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
157, d4fuhA_, 0.9354, 1.48, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
158, d4fueA_, 0.9354, 1.48, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
159, d4fucA_, 0.9354, 1.48, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
160, d4fu8A_, 0.9353, 1.48, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
161, p3ox7U_, 0.9353, 1.35, 0.302, 245, 235, THE CRYSTAL STRUCTURE OF UPA COMPLEX WITH PEPTIDE INHIBITOR MH027 AT PH4.6
162, d4fugA_, 0.9352, 1.48, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
163, p2vntA_, 0.9352, 1.60, 0.294, 257, 238, UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE
164, d2vivA_, 0.9352, 1.55, 0.304, 247, 237, FRAGMENT-BASED DISCOVERY OF MEXILETINE DERIVATIVES AS ORALLY BIOAVAILABLE INHIBITORS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
165, p1lmwD_, 0.9352, 1.58, 0.294, 248, 238, LMW U-PA STRUCTURE COMPLEXED WITH EGRCMK (GLU-GLY-ARG CHLOROMETHYL KETONE)
166, d1lmw.2, 0.9352, 1.58, 0.294, 256, 238, LMW U-PA STRUCTURE COMPLEXED WITH EGRCMK (GLU-GLY-ARG CHLOROMETHYL KETONE)
167, d4fu7A_, 0.9351, 1.48, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
168, p1lmwB_, 0.9348, 1.60, 0.298, 248, 238, LMW U-PA STRUCTURE COMPLEXED WITH EGRCMK (GLU-GLY-ARG CHLOROMETHYL KETONE)
169, d1lmw.1, 0.9348, 1.60, 0.298, 256, 238, LMW U-PA STRUCTURE COMPLEXED WITH EGRCMK (GLU-GLY-ARG CHLOROMETHYL KETONE)
170, d4fuiA_, 0.9344, 1.49, 0.305, 246, 236, CRYSTAL STRUCTURE OF THE UROKINASE
171, p2vntF_, 0.9344, 1.61, 0.294, 256, 238, UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE
172, p4x1sU_, 0.9341, 1.49, 0.305, 246, 236, THE CRYSTAL STRUCTURE OF MUPAIN-1-16-D9A IN COMPLEX WITH MURINISED HUMAN UPA AT PH7.4
173, d3mwiU_, 0.9339, 1.48, 0.305, 246, 236, THE COMPLEX CRYSTAL STRUCTURE OF UROKIANSE AND 5-NITRO-1H-INDOLE-2- AMIDINE
174, p5wxoU_, 0.9337, 1.50, 0.305, 246, 236, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH UPAIN-2-2-W3A 
175, d4xskU_, 0.9337, 1.50, 0.297, 246, 236, STRUCTURE OF PAITRAP AN UPA MUTANT
176, d4dvaU_, 0.9337, 1.49, 0.305, 246, 236, THE CRYSTAL STRUCTURE OF HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR CATALYTIC DOMAIN
177, d3pb1E_, 0.9337, 1.58, 0.300, 247, 237, CRYSTAL STRUCTURE OF A MICHAELIS COMPLEX BETWEEN PLASMINOGEN ACTIVATOR INHIBITOR-1 AND UROKINASE-TYPE PLASMINOGEN ACTIVATOR
178, p4x1qU_, 0.9336, 1.56, 0.304, 247, 237, THE CRYSTAL STRUCTURE OF MUPAIN-1 IN COMPLEX WITH MURINISED HUMAN UPA AT PH7.4
179, d5hggB_, 0.9335, 1.49, 0.301, 246, 236, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH A CAMELID-DERIVED ANTIBODY FRAGMENT
180, p4zknU_, 0.9334, 1.39, 0.306, 245, 235, THE CRYSTAL STRUCTURE OF UPAIN-1-W3A IN COMPLEX WITH UPA AT PH5.5
181, p4zksU_, 0.9332, 1.51, 0.301, 246, 236, THE CRYSTAL STRUCTURE OF UPAIN-1-W3A IN COMPLEX WITH INACTIVE UPA (UPA-S195A) AT PH7.4
182, p4zkrU_, 0.9329, 1.50, 0.305, 246, 236, THE CRYSTAL STRUCTURE OF UPAIN-1-W3A IN COMPLEX WITH UPA AT PH9.0
183, d1w12U_, 0.9329, 1.60, 0.304, 247, 237, UROKINASE TYPE PLASMINOGEN ACTIVATOR
184, p4zhmU_, 0.9326, 1.57, 0.304, 247, 237, THE CRYSTAL STRUCTURE OF MUPAIN-1--16-IG IN COMPLEX WITH MURINISED HUMAN UPA AT PH7.4
185, p4zhlU_, 0.9325, 1.57, 0.304, 247, 237, THE CRYSTAL STRUCTURE OF MUPAIN-1-IG IN COMPLEX WITH MURINISED HUMAN UPA AT PH7.4
186, d5xg4U_, 0.9319, 1.53, 0.305, 246, 236, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH QUERCETIN
187, p4glyA_, 0.9318, 1.44, 0.306, 245, 235, HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR UPA IN COMPLEX WITH THE TWO-DISULFIDE BRIDGE PEPTIDE UK504
188, p1gj9B_, 0.9318, 1.52, 0.297, 246, 236, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
189, d1gj9.1, 0.9318, 1.52, 0.297, 256, 236, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
190, p5wxpU_, 0.9317, 1.60, 0.304, 247, 237, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH UPAIN-2-3-W3A 
191, p4x1rU_, 0.9317, 1.59, 0.304, 247, 237, THE CRYSTAL STRUCTURE OF MUPAIN-1-12 IN COMPLEX WITH MURINISED HUMAN UPA AT PH7.4
192, p1c5xB_, 0.9317, 1.68, 0.295, 248, 237, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
193, d1c5x.1, 0.9317, 1.68, 0.295, 257, 237, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
194, p2vntB_, 0.9316, 1.69, 0.294, 258, 238, UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7-SULPHOAMIDOISOQUINOLINYL)GUANIDINE
195, p1o5cB_, 0.9316, 1.53, 0.297, 246, 236, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
196, d1o5c.1, 0.9316, 1.53, 0.297, 255, 236, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
197, p1c5wB_, 0.9316, 1.68, 0.295, 248, 237, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
198, d1c5w.1, 0.9316, 1.68, 0.295, 257, 237, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
199, d4jnlU_, 0.9315, 1.54, 0.305, 246, 236, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH ITS INHIBITOR 4- BROMOBENZYLAMINE AT PH 7.4
200, p5wxsU_, 0.9314, 1.55, 0.305, 246, 236, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH S2444 
201, p1c5yB_, 0.9314, 1.68, 0.295, 248, 237, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
202, d1c5y.1, 0.9314, 1.68, 0.295, 257, 237, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
203, p1o3pB_, 0.9313, 1.54, 0.297, 246, 236, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
204, d1o3p.1, 0.9313, 1.54, 0.297, 254, 236, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
205, p1gjcB_, 0.9313, 1.54, 0.297, 246, 236, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
206, d1gjc.1, 0.9313, 1.54, 0.297, 255, 236, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
207, p1gj7B_, 0.9312, 1.54, 0.297, 246, 236, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
208, d1gj7.1, 0.9312, 1.54, 0.297, 256, 236, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
209, d5lhrA_, 0.9310, 1.55, 0.309, 245, 236, THE CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH THE ACTIVE SITE BINDING INHIBITORY NANOBODY NB22
210, d5hggA_, 0.9308, 1.53, 0.305, 246, 236, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH A CAMELID-DERIVED ANTIBODY FRAGMENT
211, p1fizA_, 0.9307, 1.60, 0.336, 263, 235, THREE DIMENSIONAL STRUCTURE OF BETA-ACROSIN FROM BOAR SPERMATOZOA
212, d1fiz.1, 0.9307, 1.60, 0.336, 276, 235, THREE DIMENSIONAL STRUCTURE OF BETA-ACROSIN FROM BOAR SPERMATOZOA
213, p5wxqU_, 0.9305, 1.60, 0.336, 276, 235, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH UPAIN-2-4 
214, p4mnxA_, 0.9305, 1.49, 0.306, 245, 235, CRYSTAL STRUCTURE OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) COMPLEXED WITH BICYCLIC PEPTIDE UK811
215, d1f5lA_, 0.9305, 1.50, 0.302, 245, 235, UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX
216, p4mnvA_, 0.9304, 1.49, 0.302, 245, 235, CRYSTAL STRUCTURE OF BICYCLIC PEPTIDE UK729 BOUND AS AN ACYL-ENZYME INTERMEDIATE TO UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA)
217, p4mnwA_, 0.9303, 1.51, 0.306, 245, 235, CRYSTAL STRUCTURE OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) COMPLEXED WITH BICYCLIC PEPTIDE UK749
218, d1u6qA_, 0.9302, 1.50, 0.302, 245, 235, SUBSTITUTED 2-NAPHTHAMADINE INHIBITORS OF UROKINASE
219, p1o5aB_, 0.9302, 1.48, 0.302, 245, 235, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
220, d1o5a.1, 0.9302, 1.56, 0.297, 246, 236, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
221, d4os7A_, 0.9301, 1.56, 0.297, 255, 236, CRYSTAL STRUCTURE OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) COMPLEXED WITH BICYCLIC PEPTIDE UK607 (BICYCLIC)
222, d4os4A_, 0.9301, 1.50, 0.306, 245, 235, CRYSTAL STRUCTURE OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) COMPLEXED WITH BICYCLIC PEPTIDE UK603 (BICYCLIC 1)
223, p5wxrU_, 0.9300, 1.50, 0.306, 245, 235, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH UPAIN-2-4-W3A 
224, d1oweA_, 0.9300, 1.50, 0.306, 245, 235, SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
225, p1gjbB_, 0.9300, 1.49, 0.302, 245, 235, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
226, d1gjb.1, 0.9300, 1.56, 0.297, 246, 236, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
227, d4os5A_, 0.9299, 1.56, 0.297, 254, 236, CRYSTAL STRUCTURE OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) COMPLEXED WITH BICYCLIC PEPTIDE UK603 (BICYCLIC 2)
228, d1owiA_, 0.9298, 1.50, 0.306, 245, 235, SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
229, d1owdA_, 0.9298, 1.49, 0.302, 245, 235, SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
230, d2o8wA_, 0.9297, 1.49, 0.302, 245, 235, CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS
231, d1sqtA_, 0.9297, 1.49, 0.302, 245, 235, SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
232, d1sqoA_, 0.9296, 1.50, 0.302, 245, 235, SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
233, d1owhA_, 0.9296, 1.50, 0.302, 245, 235, SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
234, d1sqaA_, 0.9295, 1.50, 0.302, 245, 235, SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
235, p4mnyB_, 0.9293, 1.50, 0.298, 245, 235, CRYSTAL STRUCTURE OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) COMPLEXED WITH BICYCLIC PEPTIDE UK903
236, p3ig6B_, 0.9292, 1.52, 0.306, 245, 235, LOW MOLECULAR WEIGTH HUMAN UROKINASE TYPE PLASMINOGEN ACTIVATOR 2-[6- (3 -AMINOMETHYL-BIPHENYL-3-YLOXY)-4-(3-DIMETHYLAMINO-PYRROLIDIN-1- YL)-35-DIFLUORO-PYRIDIN-2-YLOXY]-4-DIMETHYLAMINO-BENZOIC ACID COMPLEX
237, p1fiwA_, 0.9291, 1.54, 0.302, 245, 235, THREE-DIMENSIONAL STRUCTURE OF BETA-ACROSIN FROM RAM SPERMATOZOA
238, d1fiw.1, 0.9291, 1.63, 0.323, 260, 235, THREE-DIMENSIONAL STRUCTURE OF BETA-ACROSIN FROM RAM SPERMATOZOA
239, d1owkA_, 0.9288, 1.63, 0.323, 274, 235, SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
240, p4mnyA_, 0.9286, 1.51, 0.302, 245, 235, CRYSTAL STRUCTURE OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) COMPLEXED WITH BICYCLIC PEPTIDE UK903
241, d4os1A_, 0.9284, 1.54, 0.306, 245, 235, CRYSTAL STRUCTURE OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) COMPLEXED WITH BICYCLIC PEPTIDE UK601 (BICYCLIC 1)
242, p1gjaB_, 0.9283, 1.52, 0.306, 245, 235, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
243, d1gja.1, 0.9283, 1.52, 0.298, 245, 235, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
244, p1gjdB_, 0.9282, 1.52, 0.298, 258, 235, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
245, d1gjd.1, 0.9282, 1.52, 0.298, 245, 235, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
246, d4os6A_, 0.9280, 1.52, 0.298, 258, 235, CRYSTAL STRUCTURE OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) COMPLEXED WITH BICYCLIC PEPTIDE UK604 (BICYCLIC 2)
247, d4os2A_, 0.9280, 1.53, 0.306, 245, 235, CRYSTAL STRUCTURE OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) COMPLEXED WITH BICYCLIC PEPTIDE UK602 (BICYCLIC 1)
248, d1owjA_, 0.9280, 1.53, 0.306, 245, 235, SUBSTITUTED 2-NAPHTHAMIDINE INHIBITORS OF UROKINASE
249, p1gj8B_, 0.9277, 1.51, 0.302, 245, 235, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
250, d1gj8.1, 0.9277, 1.54, 0.298, 245, 235, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
251, d1o5b.1, 0.9276, 1.54, 0.298, 258, 235, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
252, p1o5bB_, 0.9275, 1.54, 0.298, 258, 235, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
253, p5wxtU_, 0.9273, 1.54, 0.298, 253, 235, CRYSTAL STRUCTURE OF UPA-S195A IN COMPLEX WITH S2444 
254, p1gi9B_, 0.9272, 1.54, 0.298, 245, 235, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
255, d1gi9.1, 0.9272, 1.54, 0.302, 245, 235, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
256, p1gi7B_, 0.9270, 1.55, 0.298, 245, 235, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
257, d1gi7.1, 0.9270, 1.55, 0.298, 254, 235, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
258, p1c5zB_, 0.9270, 1.54, 0.298, 245, 235, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
259, d1c5z.1, 0.9270, 1.54, 0.298, 254, 235, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
260, p1gi8B_, 0.9266, 1.55, 0.298, 245, 235, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
261, d1gi8.1, 0.9266, 1.55, 0.298, 254, 235, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
262, p4jk6A_, 0.9260, 1.56, 0.298, 245, 235, HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) IN COMPLEX WITH A BICYCLIC PEPTIDE INHIBITOR (UK18-D-ABA)
263, d1fv9A_, 0.9255, 1.56, 0.298, 254, 235, CRYSTAL STRUCTURE OF HUMAN MICROUROKINASE IN COMPLEX WITH 2- AMINO-5-HYDROXY-BENZIMIDAZOLE
264, p3qn7A_, 0.9254, 1.56, 0.306, 245, 235, POTENT AND SELECTIVE BICYCLIC PEPTIDE INHIBITOR (UK18) OF HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR(UPA)
265, d2f91A1, 0.9252, 1.55, 0.302, 245, 235, 1.2A RESOLUTION STRUCTURE OF A CRAYFISH TRYPSIN COMPLEXED WITH A PEPTIDE INHIBITOR SGTI
266, p4jk5A_, 0.9247, 1.58, 0.306, 245, 235, HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR (UPA) IN COMPLEX WITH A BICYCLIC PEPTIDE INHIBITOR (UK18-D-SER)
267, d1pytD_, 0.9236, 1.17, 0.348, 237, 230, TERNARY COMPLEX OF PROCARBOXYPEPTIDASE A PROPROTEINASE E AND CHYMOTRYPSINOGEN C
268, d4bnrA_, 0.9229, 1.17, 0.348, 237, 230, EXTREMELY STABLE COMPLEX OF CRAYFISH TRYPSIN WITH BOVINE TRYPSIN INHIBITOR
269, p3ig6D_, 0.9228, 1.59, 0.306, 245, 235, LOW MOLECULAR WEIGTH HUMAN UROKINASE TYPE PLASMINOGEN ACTIVATOR 2-[6- (3 -AMINOMETHYL-BIPHENYL-3-YLOXY)-4-(3-DIMETHYLAMINO-PYRROLIDIN-1- YL)-35-DIFLUORO-PYRIDIN-2-YLOXY]-4-DIMETHYLAMINO-BENZOIC ACID COMPLEX
270, p2nwnA_, 0.9226, 1.95, 0.542, 251, 236, NEW PHARMACOPHORE FOR SERINE PROTEASE INHIBITION REVEALED BY CRYSTAL STRUCTURE OF HUMAN UROKINASE-TYPE PLASMINOGEN ACTIVATOR COMPLEXED WITH A CYCLIC PEPTIDYL INHIBITOR UPAIN-1
271, d1z8gA1, 0.9226, 1.95, 0.542, 251, 236, CRYSTAL STRUCTURE OF THE EXTRACELLULAR REGION OF THE TRANSMEMBRANE SERINE PROTEASE HEPSIN WITH COVALENTLY BOUND PREFERRED SUBSTRATE.
272, p5wxfU_, 0.9222, 1.31, 0.346, 237, 231, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH UPAIN-2-2 
273, d4isnA_, 0.9219, 1.55, 0.303, 243, 234, CRYSTAL STRUCTURE OF MATRIPTASE IN COMPLEX WITH ITS INHIBITOR HAI-1
274, d4jniU_, 0.9217, 1.30, 0.303, 240, 231, CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH ITS INHIBITOR 4- BROMOBENZYLAMINE AT PH 4.6
275, d4islA_, 0.9214, 1.36, 0.371, 255, 232, CRYSTAL STRUCTURE OF THE INACTIVE MATRIPTASE IN COMPLEX WITH ITS INHIBITOR HAI-1
276, d4bnrB_, 0.9214, 1.63, 0.305, 246, 236, EXTREMELY STABLE COMPLEX OF CRAYFISH TRYPSIN WITH BOVINE TRYPSIN INHIBITOR
277, d2gv7A_, 0.9210, 1.35, 0.339, 241, 230, STRUCTURE OF MATRIPTASE IN COMPLEX WITH INHIBITOR CJ-672
278, d4r0iA_, 0.9208, 1.65, 0.305, 246, 236, CRYSTAL STRUCTURE OF MATRIPTASE IN COMPLEX WITH INHIBITOR
279, d4isoA_, 0.9207, 1.37, 0.335, 241, 230, CRYSTAL STRUCTURE OF MATRIPTASE IN COMPLEX WITH ITS INHIBITOR HAI-1
280, d4jz1A_, 0.9206, 1.34, 0.346, 237, 231, CRYSTAL STRUCTURE OF MATRIPTASE IN COMPLEX WITH INHIBITOR
281, p3p8fA_, 0.9205, 1.36, 0.339, 241, 230, CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH SFTI-1
282, d2gv6A_, 0.9205, 1.37, 0.339, 241, 230, CRYSTAL STRUCTURE OF MATRIPTASE WITH INHIBITOR CJ-730
283, d4jziA_, 0.9204, 1.38, 0.339, 241, 230, CRYSTAL STRUCTURE OF MATRIPTASE IN COMPLEX WITH INHIBITOR.
284, d1eaxA_, 0.9204, 1.37, 0.339, 241, 230, CRYSTAL STRUCTURE OF MTSP1 (MATRIPTASE)
285, d4o9vA_, 0.9203, 1.37, 0.339, 241, 230, CRYSTAL STRUCTURE OF MATRIPTASE IN COMPLEX WITH INHIBITOR
286, d4o97A_, 0.9201, 1.37, 0.339, 241, 230, CRYSTAL STRUCTURE OF MATRIPTASE IN COMPLEX WITH INHIBITOR
287, d4jytA_, 0.9200, 1.37, 0.339, 241, 230, CRYSTAL STRUCTURE OF MATRIPTASE IN COMPLEX WITH INHIBITOR
288, d3so3A_, 0.9200, 1.38, 0.339, 241, 230, STRUCTURES OF FAB-PROTEASE COMPLEXES REVEAL A HIGHLY SPECIFIC NON- CANONICAL MECHANISM OF INHIBITION.
289, d3p8gA_, 0.9200, 1.37, 0.339, 241, 230, CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH BENZAMIDINE
290, d1eawA_, 0.9199, 1.38, 0.339, 241, 230, CRYSTAL STRUCTURE OF THE MTSP1 (MATRIPTASE)-BPTI (APROTININ) COMPLEX
291, d4is5A_, 0.9195, 1.38, 0.339, 241, 230, CRYSTAL STRUCTURE OF THE LIGAND-FREE INACTIVE MATRIPTASE
292, d3fvfB_, 0.9194, 1.38, 0.339, 240, 230, THE CRYSTAL STRUCTURE OF PROSTASIN COMPLEXED WITH CAMOSTAT AT 1.6 ANGSTROMS RESOLUTION
293, d3npsA_, 0.9188, 1.38, 0.339, 241, 230, CRYSTAL STRUCTURE OF MEMBRANE-TYPE SERINE PROTEASE 1 (MT-SP1) IN COMPLEX WITH THE FAB INHIBITOR S4
294, d1eawC_, 0.9188, 1.37, 0.339, 241, 230, CRYSTAL STRUCTURE OF THE MTSP1 (MATRIPTASE)-BPTI (APROTININ) COMPLEX
295, d3khvA_, 0.9184, 1.40, 0.335, 241, 230, CRYSTAL STRUCTURES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH 4-(AMINOMETHYL) BENZOIC ACID AND 4- (AMINOMETHYL-PHENYL)-METHANOL
296, d3bn9A_, 0.9181, 1.42, 0.351, 248, 231, CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH FAB INHIBITOR E2
297, d3kgpA_, 0.9179, 1.40, 0.335, 241, 230, CRYSTAL STRUCTURES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH 4-(AMINOMETHYL) BENZOIC ACID AND 4- (AMINOMETHYL-PHENYL)-METHANOL
298, d3bn9B_, 0.9178, 1.39, 0.339, 241, 230, CRYSTAL STRUCTURE OF MT-SP1 IN COMPLEX WITH FAB INHIBITOR E2
299, d3e16B_, 0.9176, 1.30, 0.300, 239, 230, X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH BENZOXAZOLE WARHEAD PEPTIDOMIMIC LYSINE IN P3
300, d3dflA_, 0.9176, 1.41, 0.335, 241, 230, CRYSTAL STRUCTURE OF HUMAN PROSTASIN COMPLEXED TO 4- GUANIDINOBENZOIC ACID
301, d4ylqH_, 0.9173, 1.32, 0.300, 239, 230, CRYSTAL STRUCTURE OF A FVIIA-TRYPSIN CHIMERA (FT) IN COMPLEX WITH SOLUBLE TISSUE FACTOR
302, d3e0nB_, 0.9172, 1.42, 0.335, 241, 230, THE X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH DFFR- CHLOROMETHYL KETONE INHIBITOR
303, p5brrE_, 0.9163, 1.46, 0.351, 247, 231, MICHAELIS COMPLEX OF TPA-S195A:PAI-1
304, p2wucA_, 0.9161, 1.46, 0.346, 245, 231, CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON- INHIBITORY ANTIBODY FAB40.DELTATRP AND AC-KQLR-CHLOROMETHYLKETONE
305, d1ym0A_, 0.9161, 1.34, 0.339, 249, 230, CRYSTAL STRUCTURE OF EARTHWORM FIBRINOLYTIC ENZYME COMPONENT B: A NOVEL GLYCOSYLATED TWO-CHAINED TRYPSIN
306, p1nu7B_, 0.9160, 1.52, 0.343, 251, 230, STAPHYLOCOAGULASE-THROMBIN COMPLEX
307, d1nu7.1, 0.9160, 1.52, 0.343, 251, 230, STAPHYLOCOAGULASE-THROMBIN COMPLEX
308, p5ce1A2, 0.9159, 1.66, 0.312, 251, 234, CRYSTAL STRUCTURE OF SERINE PROTEASE HEPSIN IN COMPLEX WITH INHIBITOR
309, p1a5hB_, 0.9157, 1.33, 0.330, 239, 230, CATALYTIC DOMAIN OF HUMAN TWO-CHAIN TISSUE PLASMINOGEN ACTIVATOR COMPLEX OF A BIS-BENZAMIDINE
310, d1a5h.2, 0.9157, 1.45, 0.307, 238, 231, CATALYTIC DOMAIN OF HUMAN TWO-CHAIN TISSUE PLASMINOGEN ACTIVATOR COMPLEX OF A BIS-BENZAMIDINE
311, d5lhqA_, 0.9156, 1.45, 0.307, 238, 231, THE EGR-CMK ACTIVE SITE INHIBITED CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH THE ALLOSTERIC INHIBITORY NANOBODY NB7
312, p1nu7F_, 0.9156, 1.60, 0.296, 258, 233, STAPHYLOCOAGULASE-THROMBIN COMPLEX
313, d1nu7.2, 0.9156, 1.60, 0.296, 286, 233, STAPHYLOCOAGULASE-THROMBIN COMPLEX
314, d3nclA_, 0.9155, 1.37, 0.374, 257, 230, CRYSTAL STRUCTURE OF MT-SP1 BOUND TO BENZAMIDINE PHOSPHONATE INHIBITOR
315, p1a5hA_, 0.9153, 1.37, 0.374, 257, 230, CATALYTIC DOMAIN OF HUMAN TWO-CHAIN TISSUE PLASMINOGEN ACTIVATOR COMPLEX OF A BIS-BENZAMIDINE
316, d1a5h.1, 0.9153, 1.74, 0.315, 252, 235, CATALYTIC DOMAIN OF HUMAN TWO-CHAIN TISSUE PLASMINOGEN ACTIVATOR COMPLEX OF A BIS-BENZAMIDINE
317, d3kidU_, 0.9152, 1.74, 0.315, 259, 235, THE CRYSTAL STRUCTURES OF 2-AMINOBENZOTHIAZOLE-BASED INHIBITORS IN COMPLEXES WITH UROKINASE-TYPE PLASMINOGEN ACTIVATOR
318, p4ch8H_, 0.9149, 1.69, 0.305, 247, 233, HIGH-SALT CRYSTAL STRUCTURE OF A THROMBIN-GPIBALPHA PEPTIDE COMPLEX
319, p2r0lA_, 0.9149, 1.61, 0.296, 258, 233, SHORT FORM HGFA WITH INHIBITORY FAB75
320, d3e0pB_, 0.9146, 1.61, 0.296, 285, 233, THE X-RAY STRUCTURE OF HUMAN PROSTASIN IN COMPLEX WITH A COVALENT BENZOXAZOLE INHIBITOR
321, d4z6aH_, 0.9144, 1.47, 0.335, 241, 230, CRYSTAL STRUCTURE OF A FVIIA-TRYPSIN CHIMERA (YT) IN COMPLEX WITH SOLUBLE TISSUE FACTOR
322, d2o8uA_, 0.9143, 1.75, 0.315, 252, 235, CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q/S195A) IN COMPLEX WITH INHIBITORS
323, p6cymC_, 0.9142, 1.75, 0.315, 259, 235, REVERSIBLE COVALENT DIRECT THROMBIN INHIBITORS 
324, p1xmnF_, 0.9142, 1.28, 0.301, 238, 229, CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
325, d1xmn.3, 0.9142, 1.67, 0.296, 259, 233, CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
326, p6b77B_, 0.9139, 1.35, 0.335, 239, 230, STRUCTURES OF THE TWO-CHAIN HUMAN PLASMA FACTOR XIIA CO-CRYSTALLIZED WITH POTENT INHIBITORS
327, p1xmnB_, 0.9139, 1.66, 0.351, 246, 231, CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
328, d1xmn.1, 0.9139, 1.40, 0.339, 249, 230, CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
329, p5f8zA_, 0.9138, 1.32, 0.297, 238, 229, THE CRYSTAL STRUCTURE OF HUMAN PLASMA KALLIKREIN IN COMPLEX WITH ITS PEPTIDE INHIBITOR PKALIN-1
330, d2anwA_, 0.9138, 1.63, 0.296, 257, 233, EXPRESSION CRYSTALLIZATION AND THREE-DIMENSIONAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PLASMA KALLIKREIN: IMPLICATIONS FOR STRUCTURE-BASED DESIGN OF PROTEASE INHIBITORS
331, p5f8xA_, 0.9137, 1.69, 0.296, 254, 233, THE CRYSTAL STRUCTURE OF HUMAN PLASMA KALLIKREIN IN COMPLEX WITH ITS PEPTIDE INHIBITOR PKALIN-3
332, p3bv9B_, 0.9136, 1.69, 0.296, 283, 233, STRUCTURE OF THROMBIN BOUND TO THE INHIBITOR FM19
333, d1o5eH_, 0.9135, 1.38, 0.343, 243, 230, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
334, p1sfqB_, 0.9133, 1.66, 0.296, 256, 233, FAST FORM OF THROMBIN MUTANT R(77A)A BOUND TO PPACK
335, d1sfq.1, 0.9133, 1.66, 0.296, 287, 233, FAST FORM OF THROMBIN MUTANT R(77A)A BOUND TO PPACK
336, p5f8tA_, 0.9132, 1.62, 0.346, 239, 231, THE CRYSTAL STRUCTURE OF HUMAN PLASMA KALLIKREIN IN COMPLEX WITH ITS PEPTIDE INHIBITOR PKALIN-2
337, p6b74B_, 0.9131, 1.72, 0.346, 238, 231, STRUCTURES OF THE TWO-CHAIN HUMAN PLASMA FACTOR XIIA CO-CRYSTALLIZED WITH POTENT INHIBITORS
338, d5lhpA_, 0.9131, 1.63, 0.346, 239, 231, THE P-AMINOBENZAMIDINE ACTIVE SITE INHIBITED CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH THE ALLOSTERIC INHIBITORY NANOBODY NB7
339, p2r0kA_, 0.9131, 1.65, 0.296, 259, 233, PROTEASE DOMAIN OF HGFA WITH INHIBITOR FAB58
340, p4ch8D_, 0.9130, 1.32, 0.376, 248, 229, HIGH-SALT CRYSTAL STRUCTURE OF A THROMBIN-GPIBALPHA PEPTIDE COMPLEX
341, d1yc0A_, 0.9129, 1.69, 0.296, 251, 233, SHORT FORM HGFA WITH FIRST KUNITZ DOMAIN FROM HAI-1
342, d1p57B_, 0.9129, 1.69, 0.296, 280, 233, EXTRACELLULAR DOMAIN OF HUMAN HEPSIN
343, p4e05H_, 0.9128, 1.63, 0.346, 239, 231, ANOPHELIN FROM THE MALARIA VECTOR INHIBITS THROMBIN THROUGH A NOVEL REVERSE-BINDING MECHANISM
344, p1xmnH_, 0.9127, 1.41, 0.348, 243, 230, CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
345, d1xmn.4, 0.9127, 1.82, 0.308, 247, 234, CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
346, p5nhuH_, 0.9126, 1.38, 0.330, 239, 230, HUMAN ALPHA THROMBIN COMPLEXED WITH ANOPHELES GAMBIAE CE5 ANTICOAGULANT
347, p1shhB_, 0.9126, 1.61, 0.297, 252, 232, SLOW FORM OF THROMBIN BOUND WITH PPACK
348, d1shh.1, 0.9126, 1.38, 0.335, 247, 230, SLOW FORM OF THROMBIN BOUND WITH PPACK
349, d1o5fH_, 0.9126, 1.38, 0.335, 247, 230, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
350, p4ch2B_, 0.9125, 1.33, 0.376, 247, 229, LOW-SALT CRYSTAL STRUCTURE OF A THROMBIN-GPIBALPHA PEPTIDE COMPLEX
351, d3e1xB_, 0.9125, 1.66, 0.296, 253, 233, THE CRYSTAL STRUCTURE OF APO PROSTASIN AT 1.7 ANGSTROMS RESOLUTION
352, p5lpdH_, 0.9124, 1.71, 0.296, 253, 233, THROMBIN IN COMPLEX WITH (S)-1-((R)-2-AMINO-3-CYCLOHEXYLPROPANOYL)-N- (2-(AMINOMETHYL)-5-CHLOROBENZYL) PYRROLIDINE-2-CARBOXAMIDE
353, p3lu9B_, 0.9124, 1.71, 0.296, 284, 233, CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT S195A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1
354, p3e6pH_, 0.9124, 1.66, 0.296, 252, 233, CRYSTAL STRUCTURE OF HUMAN MEIZOTHROMBIN DESF1
355, d1bdaB_, 0.9124, 1.69, 0.296, 252, 233, CATALYTIC DOMAIN OF HUMAN SINGLE CHAIN TISSUE PLASMINOGEN ACTIVATOR IN COMPLEX WITH DANSYL-EGR-CMK (DANSYL-GLU-GLY-ARG CHLOROMETHYL KETONE)
356, d3w94B_, 0.9123, 1.69, 0.296, 281, 233, STRUCTURE OF ORYZIAS LATIPES ENTEROPEPTIDASE LIGHT CHAIN
357, p1tq7B_, 0.9120, 1.33, 0.376, 248, 229, CRYSTAL STRUCTURE OF THE ANTICOAGULANT THROMBIN MUTANT W215A/E217A BOUND TO PPACK
358, d1tq7.1, 0.9120, 1.69, 0.296, 258, 233, CRYSTAL STRUCTURE OF THE ANTICOAGULANT THROMBIN MUTANT W215A/E217A BOUND TO PPACK
359, p1jouB_, 0.9118, 1.56, 0.351, 247, 231, CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH AN UNOCCUPIED ACTIVE SITE
360, d1jou.1, 0.9118, 1.65, 0.296, 251, 233, CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH AN UNOCCUPIED ACTIVE SITE
361, d3gylB_, 0.9117, 1.66, 0.292, 251, 233, STRUCTURE OF PROSTASIN AT 1.3 ANGSTROMS RESOLUTION IN COMPLEX WITH A CALCIUM ION.
362, p3gisD_, 0.9117, 1.67, 0.296, 251, 233, CRYSTAL STRUCTURE OF NA-FREE THROMBIN IN COMPLEX WITH THROMBOMODULIN
363, p2hppH_, 0.9117, 1.83, 0.315, 265, 235, STRUCTURES OF THE NONCOVALENT COMPLEXES OF HUMAN AND BOVINE PROTHROMBIN FRAGMENT 2 WITH HUMAN PPACK-THROMBIN
364, d2hpp.1, 0.9117, 1.29, 0.373, 235, 228, STRUCTURES OF THE NONCOVALENT COMPLEXES OF HUMAN AND BOVINE PROTHROMBIN FRAGMENT 2 WITH HUMAN PPACK-THROMBIN
365, p5l6nH_, 0.9116, 1.69, 0.296, 251, 233, DISULFATED MADANIN-THROMBIN COMPLEX
366, p1shhE_, 0.9116, 1.69, 0.296, 295, 233, SLOW FORM OF THROMBIN BOUND WITH PPACK
367, d1shh.2, 0.9116, 1.68, 0.292, 259, 233, SLOW FORM OF THROMBIN BOUND WITH PPACK
368, p3dd2H_, 0.9115, 1.68, 0.292, 304, 233, CRYSTAL STRUCTURE OF AN RNA APTAMER BOUND TO HUMAN THROMBIN
369, p2b5tD_, 0.9115, 1.55, 0.351, 247, 231, 2.1 ANGSTROM STRUCTURE OF A NONPRODUCTIVE COMPLEX BETWEEN ANTITHROMBIN SYNTHETIC HEPARIN MIMETIC SR123781 AND TWO S195A THROMBIN MOLECULES
370, p6eo6H_, 0.9113, 1.69, 0.292, 252, 233, X-RAY STRUCTURE OF THE COMPLEX BETWEEN HUMAN ALPHA-THROMBIN AND MODIFIED 15-MER DNA APTAMER CONTAINING 5-(3-(2-(1H-INDOL-3-YL) ACETAMIDE-N-YL)-1-PROPEN-1-YL)-2 -DEOXYURIDINE RESIDUE
371, p5luwH_, 0.9113, 1.68, 0.296, 251, 233, X-RAY STRUCTURE OF THE COMPLEX BETWEEN HUMAN ALPHA-THROMBIN AND MODIFIED 15-MER DNA APTAMER CONTAINING 5-(3-(2-(1H-INDOL-3-YL) ACETAMIDE-N-YL)-1-PROPEN-1-YL)-2 -DEOXYURIDINE RESIDUE
372, d1xm1A_, 0.9113, 1.68, 0.296, 281, 233, NONBASIC THROMBIN INHIBITOR COMPLEX
373, p1h8iH_, 0.9113, 1.71, 0.296, 254, 233, X-RAY CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.
374, d1h8i.1, 0.9113, 1.69, 0.296, 257, 233, X-RAY CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.
375, p5jfdH_, 0.9112, 1.69, 0.296, 286, 233, THROMBIN IN COMPLEX WITH (S)-N-(2-(AMINOMETHYL)-5-CHLOROBENZYL)-1- ((BENZYLSULFONYL)-D-ARGINYL)PYRROLIDINE-2-CARBOXAMIDE
376, p3p6zH_, 0.9112, 1.66, 0.296, 258, 233, STRUCTURAL BASIS OF THROMBIN MEDIATED FACTOR V ACTIVATION: ESSENTIAL ROLE OF THE HIRUDIN-LIKE SEQUENCE GLU666-GLU672 FOR PROCESSING AT THE HEAVY CHAIN-B DOMAIN JUNCTION
377, p3p6zB_, 0.9112, 1.61, 0.293, 252, 232, STRUCTURAL BASIS OF THROMBIN MEDIATED FACTOR V ACTIVATION: ESSENTIAL ROLE OF THE HIRUDIN-LIKE SEQUENCE GLU666-GLU672 FOR PROCESSING AT THE HEAVY CHAIN-B DOMAIN JUNCTION
378, p1xmnD_, 0.9112, 1.69, 0.296, 259, 233, CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
379, d1xmn.2, 0.9112, 1.69, 0.296, 259, 233, CRYSTAL STRUCTURE OF THROMBIN BOUND TO HEPARIN
380, p1rtfB_, 0.9111, 1.66, 0.296, 284, 233, COMPLEX OF BENZAMIDINE WITH THE CATALYTIC DOMAIN OF HUMAN TWO CHAIN TISSUE PLASMINOGEN ACTIVATOR [(TC)-T-PA]
381, d1rtf.1, 0.9111, 1.67, 0.296, 253, 233, COMPLEX OF BENZAMIDINE WITH THE CATALYTIC DOMAIN OF HUMAN TWO CHAIN TISSUE PLASMINOGEN ACTIVATOR [(TC)-T-PA]
382, d1bdaA_, 0.9111, 1.67, 0.296, 280, 233, CATALYTIC DOMAIN OF HUMAN SINGLE CHAIN TISSUE PLASMINOGEN ACTIVATOR IN COMPLEX WITH DANSYL-EGR-CMK (DANSYL-GLU-GLY-ARG CHLOROMETHYL KETONE)
383, p3befE_, 0.9110, 1.66, 0.296, 252, 233, CRYSTAL STRUCTURE OF THROMBIN BOUND TO THE EXTRACELLULAR FRAGMENT OF PAR1
384, p3b23B_, 0.9110, 1.69, 0.296, 255, 233, CRYSTAL STRUCTURE OF THROMBIN-VARIEGIN COMPLEX: INSIGHTS OF A NOVEL MECHANISM OF INHIBITION AND DESIGN OF TUNABLE THROMBIN INHIBITORS
385, p1w7gH_, 0.9110, 1.70, 0.296, 255, 233, ALPHA-THROMBIN COMPLEX WITH SULFATED HIRUDIN (RESIDUES 54-65) AND L- ARGININE TEMPLATE INHIBITOR CS107
386, p5do4H_, 0.9109, 1.77, 0.296, 254, 233, THROMBIN-RNA APTAMER COMPLEX
387, p3befB_, 0.9109, 1.77, 0.296, 286, 233, CRYSTAL STRUCTURE OF THROMBIN BOUND TO THE EXTRACELLULAR FRAGMENT OF PAR1
388, p3b9fH_, 0.9109, 1.69, 0.313, 242, 233, 1.6 A STRUCTURE OF THE PCI-THROMBIN-HEPARIN COMPLEX
389, p4hfpB_, 0.9108, 1.69, 0.313, 249, 233, STRUCTURE OF THROMBIN MUTANT S195A BOUND TO THE ACTIVE SITE INHIBITOR ARGATROBAN
390, d2anyA_, 0.9108, 1.83, 0.315, 265, 235, EXPRESSION CRYSTALLIZATION AND THE THREE-DIMENSIONAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN PLASMA KALLIKREIN: IMPLICATIONS FOR STRUCTURE-BASED DESIGN OF PROTEASE INHIBITORS
391, p1jmoH_, 0.9107, 1.69, 0.292, 251, 233, CRYSTAL STRUCTURE OF THE HEPARIN COFACTOR II-S195A THROMBIN COMPLEX
392, d1jmo.1, 0.9107, 1.70, 0.296, 259, 233, CRYSTAL STRUCTURE OF THE HEPARIN COFACTOR II-S195A THROMBIN COMPLEX
393, d1danH_, 0.9107, 1.67, 0.296, 252, 233, COMPLEX OF ACTIVE SITE INHIBITED HUMAN BLOOD COAGULATION FACTOR VIIA WITH HUMAN RECOMBINANT SOLUBLE TISSUE FACTOR
394, d1ekbB_, 0.9106, 1.70, 0.296, 256, 233, THE SERINE PROTEASE DOMAIN OF ENTEROPEPTIDASE BOUND TO INHIBITOR VAL- ASP-ASP-ASP-ASP-LYS-CHLOROMETHANE
395, p6eo7H_, 0.9105, 1.70, 0.292, 251, 233, X-RAY STRUCTURE OF THE COMPLEX BETWEEN HUMAN ALPHA-THROMBIN AND MODIFIED 15-MER DNA APTAMER CONTAINING 5-(3-(ACETAMIDE-N-YL)-1- PROPEN-1-YL)-2 -DEOXYURIDINE RESIDUE
396, p6cymA_, 0.9105, 1.69, 0.292, 253, 233, REVERSIBLE COVALENT DIRECT THROMBIN INHIBITORS 
397, p5nhuA_, 0.9105, 1.70, 0.292, 257, 233, HUMAN ALPHA THROMBIN COMPLEXED WITH ANOPHELES GAMBIAE CE5 ANTICOAGULANT
398, p5luyH_, 0.9105, 1.92, 0.348, 238, 233, X-RAY STRUCTURE OF THE COMPLEX BETWEEN HUMAN ALPHA-THROMBIN AND MODIFIED 15-MER DNA APTAMER CONTAINING 5-(3-(ACETAMIDE-N-YL)-1- PROPEN-1-YL)-2 -DEOXYURIDINE RESIDUE
399, p1tb6H_, 0.9105, 1.69, 0.292, 259, 233, 2.5A CRYSTAL STRUCTURE OF THE ANTITHROMBIN-THROMBIN-HEPARIN TERNARY COMPLEX
400, d1tb6.1, 0.9105, 1.69, 0.292, 306, 233, 2.5A CRYSTAL STRUCTURE OF THE ANTITHROMBIN-THROMBIN-HEPARIN TERNARY COMPLEX
401, p1aixH_, 0.9105, 1.71, 0.341, 254, 232, HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROVAL
402, d1aix.1, 0.9105, 1.32, 0.316, 235, 228, HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROVAL
403, d4dgjB_, 0.9104, 1.32, 0.316, 235, 228, STRUCTURE OF A HUMAN ENTEROPEPTIDASE LIGHT CHAIN VARIANT
404, p3p70H_, 0.9104, 1.70, 0.296, 259, 233, STRUCTURAL BASIS OF THROMBIN-MEDIATED FACTOR V ACTIVATION: ESSENTIAL ROLE OF THE HIRUDIN-LIKE SEQUENCE GLU666-GLU672 FOR PROCESSING AT THE HEAVY CHAIN-B DOMAIN JUNCTION
405, p1no9H_, 0.9104, 1.62, 0.297, 250, 232, DESIGN OF WEAKLY BASIC THROMBIN INHIBITORS INCORPORATING NOVEL P1 BINDING FUNCTIONS: MOLECULAR AND X-RAY CRYSTALLOGRAPHIC STUDIES.
406, d1no9.1, 0.9104, 1.63, 0.297, 251, 232, DESIGN OF WEAKLY BASIC THROMBIN INHIBITORS INCORPORATING NOVEL P1 BINDING FUNCTIONS: MOLECULAR AND X-RAY CRYSTALLOGRAPHIC STUDIES.
407, d2flbH_, 0.9103, 1.70, 0.296, 259, 233, DISCOVERY OF A NOVEL HYDROXY PYRAZOLE BASED FACTOR IXA INHIBITOR
408, d2b7dH_, 0.9102, 1.69, 0.292, 259, 233, FACTOR VIIA INHIBITORS: CHEMICAL OPTIMIZATION PRECLINICAL PHARMACOKINETICS PHARMACODYNAMICS AND EFFICACY IN A BABOON THROMBOSIS MODEL
409, p1ihsH_, 0.9102, 1.69, 0.292, 302, 233, CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON- HYDROLYZABLE BIFUNCTIONAL INHIBITORS HIRUTONIN-2 AND HIRUTONIN-6
410, d1ihs.1, 0.9102, 1.69, 0.296, 251, 233, CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON- HYDROLYZABLE BIFUNCTIONAL INHIBITORS HIRUTONIN-2 AND HIRUTONIN-6
411, d1gl0E_, 0.9102, 1.69, 0.296, 278, 233, STRUCTURE OF THE COMPLEX BETWEEN BOVINE ALPHA-CHYMOTRYPSIN AND PMP-D2V AN INHIBITOR FROM THE INSECT LOCUSTA MIGRATORIA
412, d4na9H_, 0.9101, 1.31, 0.320, 235, 228, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 3 -AMINO-5 -[(2S4R)-6- CARBAMIMIDOYL-4-PHENYL-1234-TETRAHYDROQUINOLIN-2-YL]BIPHENYL-2- CARBOXYLIC ACID
413, p2pv9B_, 0.9101, 1.69, 0.296, 254, 233, CRYSTAL STRUCTURE OF MURINE THROMBIN IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF MURINE PAR4
414, d2puqH_, 0.9101, 1.69, 0.296, 253, 233, CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA IN COMPLEX WITH SOLUBLE TISSUE FACTOR
415, p1tbqH_, 0.9101, 1.69, 0.296, 289, 233, CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
416, d1tbq.1, 0.9101, 1.73, 0.341, 254, 232, CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
417, p1nrsH_, 0.9101, 1.72, 0.341, 254, 232, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
418, d1nrs.1, 0.9101, 1.70, 0.296, 258, 233, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
419, p1haiH_, 0.9101, 1.70, 0.296, 287, 233, THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2 HIRUGEN-AND PPACK- THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
420, d1hai.1, 0.9101, 1.41, 0.389, 241, 229, THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2 HIRUGEN-AND PPACK- THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
421, p1dx5O_, 0.9101, 1.63, 0.333, 254, 231, CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
422, d1dx5.3, 0.9101, 1.69, 0.305, 258, 233, CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
423, p1a0hE_, 0.9101, 1.73, 0.341, 254, 232, THE X-RAY CRYSTAL STRUCTURE OF PPACK-MEIZOTHROMBIN DESF1: KRINGLE/THROMBIN AND CARBOHYDRATE/KRINGLE/THROMBIN INTERACTIONS AND LOCATION OF THE LINKER CHAIN
424, d1a0h.2, 0.9101, 1.70, 0.305, 259, 233, THE X-RAY CRYSTAL STRUCTURE OF PPACK-MEIZOTHROMBIN DESF1: KRINGLE/THROMBIN AND CARBOHYDRATE/KRINGLE/THROMBIN INTERACTIONS AND LOCATION OF THE LINKER CHAIN
425, d1j9cH_, 0.9100, 1.70, 0.305, 308, 233, CRYSTAL STRUCTURE OF TISSUE FACTOR-FACTOR VIIA COMPLEX
426, p1dlkB_, 0.9100, 1.70, 0.296, 252, 233, CRYSTAL STRUCTURE ANALYSIS OF DELTA-CHYMOTRYPSIN BOUND TO A PEPTIDYL CHLOROMETHYL KETONE INHIBITOR
427, d1dlk.1, 0.9100, 1.70, 0.296, 279, 233, CRYSTAL STRUCTURE ANALYSIS OF DELTA-CHYMOTRYPSIN BOUND TO A PEPTIDYL CHLOROMETHYL KETONE INHIBITOR
428, p5ew1H_, 0.9099, 1.70, 0.296, 253, 233, HUMAN THROMBIN SANDWICHED BETWEEN TWO DNA APTAMERS: HD22 AND HD1- DELTAT3
429, p4ch2D_, 0.9099, 1.70, 0.296, 289, 233, LOW-SALT CRYSTAL STRUCTURE OF A THROMBIN-GPIBALPHA PEPTIDE COMPLEX
430, p2hwlB_, 0.9099, 1.71, 0.300, 259, 233, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH FIBRINOGEN GAMMA  PEPTIDE
431, p1tmtH_, 0.9099, 1.71, 0.300, 295, 233, CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
432, d1tmt.1, 0.9099, 1.71, 0.305, 259, 233, CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
433, p1qj1B_, 0.9099, 1.71, 0.305, 309, 233, NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
434, d1qj1.1, 0.9099, 1.69, 0.341, 254, 232, NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
435, p1dx5M_, 0.9099, 1.41, 0.389, 230, 229, CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
436, d1dx5.1, 0.9099, 1.41, 0.389, 243, 229, CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
437, p1ai8H_, 0.9099, 1.66, 0.297, 251, 232, HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROMPG
438, d1ai8.1, 0.9099, 1.66, 0.297, 251, 232, HUMAN ALPHA-THROMBIN TERNARY COMPLEX WITH THE EXOSITE INHIBITOR HIRUGEN AND ACTIVE SITE INHIBITOR PHCH2OCO-D-DPA-PRO-BOROMPG
439, d5j4qA_, 0.9098, 1.73, 0.296, 251, 233, ALPHA-CHYMOTRYPSIN FROM BOVINE PANCREAS IN COMPLEX WITH BOWMAN-BIRK INHIBITOR FROM SOYBEAN
440, p4ud9H_, 0.9098, 1.73, 0.296, 257, 233, THROMBIN IN COMPLEX WITH 5-CHLOROTHIOPHENE-2-CARBOXAMIDE
441, d4cbnA_, 0.9098, 1.73, 0.296, 283, 233, CRYSTAL STRUCTURE OF COMPLEMENT FACTOR D MUTANT R202A AFTER CONVENTIONAL REFINEMENT
442, p1tmuH_, 0.9098, 1.69, 0.296, 259, 233, CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
443, d1tmu.1, 0.9098, 1.69, 0.296, 295, 233, CHANGES IN INTERACTIONS IN COMPLEXES OF HIRUDIN DERIVATIVES AND HUMAN ALPHA-THROMBIN DUE TO DIFFERENT CRYSTAL FORMS
444, d3w94A_, 0.9097, 1.71, 0.300, 259, 233, STRUCTURE OF ORYZIAS LATIPES ENTEROPEPTIDASE LIGHT CHAIN
445, d3th3H_, 0.9097, 1.71, 0.300, 295, 233, MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+
446, p2hpqH_, 0.9097, 1.71, 0.296, 251, 233, STRUCTURES OF THE NONCOVALENT COMPLEXES OF HUMAN AND BOVINE PROTHROMBIN FRAGMENT 2 WITH HUMAN PPACK-THROMBIN
447, d2hpq.1, 0.9097, 1.71, 0.296, 278, 233, STRUCTURES OF THE NONCOVALENT COMPLEXES OF HUMAN AND BOVINE PROTHROMBIN FRAGMENT 2 WITH HUMAN PPACK-THROMBIN
448, d1o5dH_, 0.9097, 1.40, 0.389, 241, 229, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
449, p1hgtH_, 0.9097, 1.69, 0.296, 254, 233, STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA- THROMBIN
450, d1hgt.1, 0.9097, 1.13, 0.336, 228, 226, STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA- THROMBIN
451, p1de7K_, 0.9097, 1.73, 0.296, 257, 233, INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX
452, d1de7.2, 0.9097, 1.73, 0.296, 285, 233, INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX
453, p1a3bH_, 0.9097, 1.34, 0.373, 235, 228, COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1
454, d1a3b.1, 0.9097, 1.74, 0.341, 254, 232, COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG1
455, p4e06H_, 0.9096, 1.71, 0.296, 251, 233, ANOPHELIN FROM THE MALARIA VECTOR INHIBITS THROMBIN THROUGH A NOVEL REVERSE-BINDING MECHANISM
456, p3vxeH_, 0.9096, 1.71, 0.296, 281, 233, HUMAN ALPHA-THROMBIN-BIVALIRUDIN COMPLEX AT PD5.0
457, p2bxuH_, 0.9096, 1.75, 0.341, 254, 232, DESIGN AND DISCOVERY OF NOVEL POTENT THROMBIN INHIBITORS WITH A SOLUBILIZING CATIONIC P1-P2-LINKER
458, p1sfqE_, 0.9096, 1.69, 0.296, 253, 233, FAST FORM OF THROMBIN MUTANT R(77A)A BOUND TO PPACK
459, d1sfq.2, 0.9096, 1.69, 0.296, 289, 233, FAST FORM OF THROMBIN MUTANT R(77A)A BOUND TO PPACK
460, d4ogyB_, 0.9095, 1.66, 0.297, 251, 232, CRYSTAL STRUCTURE OF FAB DX-2930 IN COMPLEX WITH HUMAN PLASMA KALLIKREIN AT 2.1 ANGSTROM RESOLUTION
461, p4mlfB_, 0.9095, 1.66, 0.297, 277, 232, CRYSTAL STRUCTURE FOR THE COMPLEX OF THROMBIN MUTANT D102N AND HIRUDIN
462, p3gisB_, 0.9095, 1.71, 0.296, 251, 233, CRYSTAL STRUCTURE OF NA-FREE THROMBIN IN COMPLEX WITH THROMBOMODULIN
463, p2bxtH_, 0.9095, 1.71, 0.296, 278, 233, DESIGN AND DISCOVERY OF NOVEL POTENT THROMBIN INHIBITORS WITH A SOLUBILIZING CATIONIC P1-P2-LINKER
464, p2b5tB_, 0.9095, 1.61, 0.297, 252, 232, 2.1 ANGSTROM STRUCTURE OF A NONPRODUCTIVE COMPLEX BETWEEN ANTITHROMBIN SYNTHETIC HEPARIN MIMETIC SR123781 AND TWO S195A THROMBIN MOLECULES
465, p1qj6B_, 0.9095, 1.73, 0.296, 257, 233, NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
466, d1qj6.1, 0.9095, 1.71, 0.296, 251, 233, NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
467, p1qhrB_, 0.9095, 1.76, 0.296, 251, 233, NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
468, d1qhr.1, 0.9095, 1.76, 0.296, 279, 233, NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
469, p1jouF_, 0.9095, 1.60, 0.348, 239, 230, CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH AN UNOCCUPIED ACTIVE SITE
470, d1jou.3, 0.9095, 1.71, 0.292, 259, 233, CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH AN UNOCCUPIED ACTIVE SITE
471, p1dx5P_, 0.9095, 1.64, 0.293, 252, 232, CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
472, p1dx5N_, 0.9095, 1.71, 0.296, 251, 233, CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
473, d1dx5.4, 0.9095, 1.64, 0.293, 252, 232, CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
474, d1dx5.2, 0.9095, 1.70, 0.296, 259, 233, CRYSTAL STRUCTURE OF THE THROMBIN-THROMBOMODULIN COMPLEX
475, d1dojA_, 0.9095, 1.70, 0.296, 295, 233, CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN*RWJ-51438 COMPLEX AT 1.7 A
476, p1awhB_, 0.9095, 1.70, 0.296, 259, 233, NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
477, d1awh.1, 0.9095, 1.70, 0.296, 295, 233, NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
478, d1avg.1, 0.9095, 1.71, 0.292, 259, 233, THROMBIN INHIBITOR FROM TRIATOMA PALLIDIPENNIS
479, d3th4H_, 0.9094, 1.71, 0.292, 305, 233, MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+
480, p3p70F_, 0.9094, 1.71, 0.300, 259, 233, STRUCTURAL BASIS OF THROMBIN-MEDIATED FACTOR V ACTIVATION: ESSENTIAL ROLE OF THE HIRUDIN-LIKE SEQUENCE GLU666-GLU672 FOR PROCESSING AT THE HEAVY CHAIN-B DOMAIN JUNCTION
481, d2c4fH1, 0.9094, 1.71, 0.300, 259, 233, CRYSTAL STRUCTURE OF FACTOR VII.STF COMPLEXED WITH PD0297121
482, d1wssH_, 0.9094, 1.71, 0.300, 295, 233, HUMAN FACTOR VIIA-TISSUE FACTOR IN COMPLEX WITH PEPTIDE-MIMETIC INHIBITOR THAT HAS TWO CHARGED GROUPS IN P2 AND P4
483, p1sg8E_, 0.9094, 1.71, 0.300, 295, 233, CRYSTAL STRUCTURE OF THE PROCOAGULANT FAST FORM OF THROMBIN
484, d1sg8.2, 0.9094, 1.72, 0.296, 293, 233, CRYSTAL STRUCTURE OF THE PROCOAGULANT FAST FORM OF THROMBIN
485, p1qj7B_, 0.9094, 1.72, 0.296, 259, 233, NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
486, d1qj7.1, 0.9094, 1.72, 0.296, 295, 233, NOVEL COVALENT ACTIVE SITE THROMBIN INHIBITORS
487, p1ihtH_, 0.9094, 1.73, 0.305, 300, 233, CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON- HYDROLYZABLE BIFUNCTIONAL INHIBITORS HIRUTONIN-2 AND HIRUTONIN-6
488, d1iht.1, 0.9094, 1.75, 0.341, 254, 232, CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN ALPHA-THROMBIN AND NON- HYDROLYZABLE BIFUNCTIONAL INHIBITORS HIRUTONIN-2 AND HIRUTONIN-6
489, d4jzeH_, 0.9093, 1.71, 0.296, 252, 233, STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 2-{2-[(1- AMINOISOQUINOLIN-6-YL)CARBAMOYL]-6-METHOXYPYRIDIN-3-YL}-5-{[(2S)-1- HYDROXY-33-DIMETHYLBUTAN-2-YL]CARBAMOYL}BENZOIC ACID
490, d4dgjD_, 0.9093, 1.74, 0.341, 254, 232, STRUCTURE OF A HUMAN ENTEROPEPTIDASE LIGHT CHAIN VARIANT
491, d2a2qH_, 0.9093, 1.73, 0.341, 254, 232, COMPLEX OF ACTIVE-SITE INHIBITED HUMAN COAGULATION FACTOR VIIA WITH HUMAN SOLUBLE TISSUE FACTOR IN THE PRESENCE OF CA2+ MG2+ NA+ AND ZN2+
492, p1z8iB_, 0.9093, 1.75, 0.296, 251, 233, CRYSTAL STRUCTURE OF THE THROMBIN MUTANT G193A BOUND TO PPACK
493, d1wqvH_, 0.9093, 1.75, 0.296, 278, 233, HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH PROPYLSULFONAMIDE-D- THR-MET-P-AMINOBENZAMIDINE
494, p1tbrH_, 0.9093, 1.70, 0.296, 259, 233, CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
495, d1tbr.1, 0.9093, 1.70, 0.296, 295, 233, CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
496, p1tbqK_, 0.9093, 1.71, 0.296, 258, 233, CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
497, d1tbq.2, 0.9093, 1.71, 0.296, 287, 233, CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
498, p3vxfH_, 0.9092, 1.67, 0.333, 254, 231, X/N JOINT REFINEMENT OF HUMAN ALPHA-THROMBIN-BIVALIRUDIN COMPLEX PD5
499, d3th2H_, 0.9092, 1.28, 0.322, 234, 227, MG2+ IS REQUIRED FOR OPTIMAL FOLDING OF THE GAMMA-CARBOXYGLUTAMIC ACID (GLA) DOMAINS OF VITAMIN K-DEPENDENT CLOTTING FACTORS AT PHYSIOLOGICAL CA2+
500, p3qx5H_, 0.9092, 1.74, 0.341, 254, 232, THROMBIN INHIBITION BY PYRIDIN DERIVATIVES
501, p2zf0H_, 0.9092, 1.66, 0.293, 250, 232, EXPLORING THROMBIN S1 POCKET
502, p2zc9H_, 0.9092, 1.72, 0.341, 254, 232, THROMBIN IN COMPLEX WITH INHIBITOR
503, d1w0yH_, 0.9092, 1.72, 0.305, 259, 233, TF7A_3771 COMPLEX
504, d1kliH_, 0.9092, 1.72, 0.305, 308, 233, COFACTOR-AND SUBSTRATE-ASSISTED ACTIVATION OF FACTOR VIIA
505, p1k22H_, 0.9092, 1.71, 0.305, 259, 233, HUMAN THROMBIN-INHIBITOR COMPLEX
506, d1k22.1, 0.9092, 1.71, 0.305, 308, 233, HUMAN THROMBIN-INHIBITOR COMPLEX
507, d1hah.1, 0.9092, 1.74, 0.296, 257, 233, THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2 HIRUGEN-AND PPACK- THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
508, p1awfH_, 0.9092, 1.74, 0.341, 254, 232, NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
509, d1awf.1, 0.9092, 1.64, 0.297, 251, 232, NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
510, d5pauC_, 0.9091, 1.64, 0.297, 251, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-(2-AMINO-1H- BENZIMIDAZOL-5-YL)-2-[3-[(2-AMINO-2-OXOETHYL)- METHYLSULFONYLAMINO]PHENYL]ACETAMIDE;222-TRIFLUOROACETIC ACID
511, p5j4sA_, 0.9091, 1.64, 0.297, 251, 232, ALPHA-CHYMOTRYPSIN FROM BOVINE PANCREAS IN COMPLEX WITH A MODIFIED BOWMAN-BIRK INHIBITOR FROM SOYBEAN
512, p5gimB_, 0.9091, 1.75, 0.341, 251, 232, CRYSTAL STRUCTURE OF THROMBIN-AVATHRIN COMPLEX
513, p4dy7B_, 0.9091, 1.68, 0.338, 254, 231, CRYSTAL STRUCTURES OF PROTEASE NEXIN-1 IN COMPLEX WITH S195A THROMBIN
514, p4bohH_, 0.9091, 1.64, 0.297, 251, 232, MADANINS (MEROPS I53) ARE CLEAVED BY THROMBIN AND FACTOR XA
515, p3uwjH_, 0.9091, 1.64, 0.297, 280, 232, HUMAN THROMBIN IN COMPLEX WITH MI353
516, p3u9aH_, 0.9091, 1.70, 0.296, 289, 233, HUMAN THROMBIN IN COMPLEX WITH MI330
517, p3t5fH_, 0.9091, 1.70, 0.296, 258, 233, HUMAN THROMBIN IN COMPLEX WITH MI340
518, p3rmmH_, 0.9091, 1.70, 0.296, 285, 233, HUMAN THROMBIN IN COMPLEX WITH MI332
519, p3qtvH_, 0.9091, 1.59, 0.330, 250, 230, THROMBIN INHIBITION BY PYRIDIN DERIVATIVES
520, p3qtoH_, 0.9091, 1.41, 0.389, 241, 229, THROMBIN INHIBITION BY PYRIDIN DERIVATIVES
521, p2jh6D_, 0.9091, 1.73, 0.296, 252, 233, HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
522, p2hgtH_, 0.9091, 1.70, 0.292, 253, 233, STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN
523, d2hgt.1, 0.9091, 1.75, 0.296, 258, 233, STRUCTURE OF THE HIRUGEN AND HIRULOG 1 COMPLEXES OF ALPHA-THROMBIN
524, p1ypgH_, 0.9091, 1.65, 0.297, 251, 232, THROMBIN INHIBITOR COMPLEX
525, p1ppbH_, 0.9091, 1.64, 0.297, 251, 232, THE REFINED 1.9 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: INTERACTION WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE AND SIGNIFICANCE OF THE TYR-PRO-PRO-TRP INSERTION SEGMENT
526, d1ppb.1, 0.9091, 1.64, 0.297, 251, 232, THE REFINED 1.9 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN: INTERACTION WITH D-PHE-PRO-ARG CHLOROMETHYLKETONE AND SIGNIFICANCE OF THE TYR-PRO-PRO-TRP INSERTION SEGMENT
527, p1hapH_, 0.9091, 1.64, 0.297, 251, 232, COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON X-RAY MODEL OF DNA)
528, d1hap.1, 0.9091, 1.64, 0.297, 251, 232, COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON X-RAY MODEL OF DNA)
529, p5afzH_, 0.9090, 1.64, 0.297, 251, 232, THROMBIN IN COMPLEX WITH (2R)-2-(BENZYLSULFONYLAMINO)-N-(2-( (4-CARBAMIMIDOYLPHENYL)METHYLAMINO)-2-OXO-PROPYL)-3-PHENYL- PROPANAMIDE
530, p3rmnH_, 0.9090, 1.64, 0.297, 251, 232, HUMAN THROMBIN IN COMPLEX WITH MI341
531, p3rlwH_, 0.9090, 1.72, 0.296, 253, 233, HUMAN THROMBIN IN COMPLEX WITH MI328
532, p3pmhB_, 0.9090, 1.72, 0.296, 286, 233, MECHANISM OF SULFOTYROSINE-MEDIATED GLYCOPROTEIN IB INTERACTION WITH TWO DISTINCT ALPHA-THROMBIN SITES
533, d2ec9H_, 0.9090, 1.71, 0.296, 251, 233, CRYSTAL STRUCTURE ANALYSIS OF HUMAN FACTOR VIIA  SOULUBLE TISSUE FACTOR COMPLEXED WITH BCX-3607
534, d1z6jH_, 0.9090, 1.73, 0.296, 259, 233, CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR/PYRAZINONE INHIBITOR
535, p1sg8B_, 0.9090, 1.73, 0.296, 295, 233, CRYSTAL STRUCTURE OF THE PROCOAGULANT FAST FORM OF THROMBIN
536, d1sg8.1, 0.9090, 1.70, 0.296, 253, 233, CRYSTAL STRUCTURE OF THE PROCOAGULANT FAST FORM OF THROMBIN
537, d1cvwH_, 0.9090, 1.70, 0.296, 280, 233, CRYSTAL STRUCTURE OF ACTIVE SITE-INHIBITED HUMAN COAGULATION FACTOR VIIA (DES-GLA)
538, p4ufgH_, 0.9089, 1.65, 0.297, 250, 232, THROMBIN IN COMPLEX WITH (2R)-2-(BENZYLSULFONYLAMINO)-N-(( 1S)-2-((4-CARBAMIMIDOYLPHENYL)METHYLAMINO)-1-METHYL-2-OXO- ETHYL)-N-METHYL-3-PHENYL-PROPANAMIDE ETHANE
539, d4isiH_, 0.9089, 1.64, 0.297, 251, 232, STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (6S)-N-(4- CARBAMIMIDOYLBENZYL)-1-CHLORO-3-(CYCLOBUTYLAMINO)-88-DIETHYL-4-OXO- 4678-TETRAHYDROPYRROLO[12-A]PYRAZINE-6-CARBOXAMIDE
540, d2aerH_, 0.9089, 1.65, 0.297, 251, 232, CRYSTAL STRUCTURE OF BENZAMIDINE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX.
541, p1ypjH_, 0.9089, 1.74, 0.296, 259, 233, THROMBIN INHIBITOR COMPLEX
542, p1umaH_, 0.9089, 1.74, 0.341, 254, 232, ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(NN-DIMETHYLCARBAMOYL)- ALPHA-AZALYSINE
543, d1uma.1, 0.9089, 1.76, 0.341, 254, 232, ALPHA-THROMBIN (HIRUGEN) COMPLEXED WITH NA-(NN-DIMETHYLCARBAMOYL)- ALPHA-AZALYSINE
544, p1ny22_, 0.9089, 1.71, 0.296, 251, 233, HUMAN ALPHA THROMBIN INHIBITED BY RPPGF AND HIRUGEN
545, d1ny2.1, 0.9089, 1.71, 0.296, 278, 233, HUMAN ALPHA THROMBIN INHIBITED BY RPPGF AND HIRUGEN
546, p1dm4B_, 0.9089, 1.67, 0.333, 254, 231, SER195ALA MUTANT OF HUMAN THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A (7- 16)
547, d1dm4.1, 0.9089, 1.67, 0.333, 254, 231, SER195ALA MUTANT OF HUMAN THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A (7- 16)
548, d1a0h.1, 0.9089, 1.65, 0.297, 251, 232, THE X-RAY CRYSTAL STRUCTURE OF PPACK-MEIZOTHROMBIN DESF1: KRINGLE/THROMBIN AND CARBOHYDRATE/KRINGLE/THROMBIN INTERACTIONS AND LOCATION OF THE LINKER CHAIN
549, p4yesB_, 0.9088, 1.67, 0.338, 254, 231, THROMBIN IN COMPLEX WITH (S)-(4-CHLORO-2-((1-(5-METHYL-1H-PYRROLE-2- CARBONYL)PYRROLIDINE-2-CARBOXAMIDO)METHYL)PHENYL)METHANAMINIUM
550, p4ayyB_, 0.9088, 1.75, 0.341, 254, 232, HUMAN THROMBIN - INHIBITOR COMPLEX
551, p3sv2H_, 0.9088, 1.70, 0.296, 251, 233, HUMAN THROMBIN IN COMPLEX WITH UBTHR105
552, d3elaH_, 0.9088, 1.70, 0.296, 253, 233, CRYSTAL STRUCTURE OF ACTIVE SITE INHIBITED COAGULATION FACTOR VIIA MUTANT IN COMPLEX WITH SOLUBLE TISSUE FACTOR
553, d2zwlH_, 0.9088, 1.70, 0.296, 289, 233, HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH HIGHLY SELECTIVE PEPTIDE INHIBITOR
554, d2zp0H_, 0.9088, 1.73, 0.296, 259, 233, HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH BENZYLSULFONAMIDE-D- ILE-GLN-P-AMINOBENZAMIDINE
555, d1ucy.1, 0.9088, 1.73, 0.296, 295, 233, THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7- 19). THREE COMPLEXES ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN
556, p1tbrK_, 0.9088, 1.65, 0.293, 252, 232, CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
557, d1tbr.2, 0.9088, 1.65, 0.293, 285, 232, CRYSTAL STRUCTURE OF INSECT DERIVED DOUBLE DOMAIN KAZAL INHIBITOR RHODNIIN IN COMPLEX WITH THROMBIN
558, p1sgiE_, 0.9088, 1.73, 0.305, 309, 233, CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
559, d1sgi.2, 0.9088, 1.65, 0.297, 252, 232, CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
560, p1eb1H_, 0.9088, 1.72, 0.296, 257, 233, COMPLEX STRUCTURE OF HUMAN THROMBIN WITH N-METHYL-ARGININE INHIBITOR
561, d1eb1.1, 0.9088, 1.65, 0.297, 251, 232, COMPLEX STRUCTURE OF HUMAN THROMBIN WITH N-METHYL-ARGININE INHIBITOR
562, d1bbr.1, 0.9088, 1.73, 0.345, 254, 232, THE STRUCTURE OF RESIDUES 7-16 OF THE A ALPHA CHAIN OF HUMAN FIBRINOGEN BOUND TO BOVINE THROMBIN AT 2.3 ANGSTROMS RESOLUTION
563, p5lceH_, 0.9087, 1.74, 0.341, 254, 232, THROMBIN IN COMPLEX WITH (S)-1-((R)-2-AMINO-3-CYCLOHEXYLPROPANOYL)-N- (5-CHLORO-2-(HYDROXYMETHYL)BENZY L)PYRROLIDINE-2-CARBOXAMIDE
564, p4ufeH_, 0.9087, 1.66, 0.333, 254, 231, THROMBIN IN COMPLEX WITH (2R)-2-(BENZYLSULFONYLAMINO)-N-(2-( (4-CARBAMIMIDOYLPHENYL)METHYLAMINO)-2-OXO-BUTYL)-3-PHENYL- PROPANAMIDE
565, p4iblH_, 0.9087, 1.75, 0.305, 295, 233, RUBIDIUM SITES IN BLOOD COAGULATION FACTOR VIIA
566, p4bahB_, 0.9087, 1.73, 0.305, 259, 233, THROMBIN IN COMPLEX WITH INHIBITOR
567, p3shcH_, 0.9087, 1.73, 0.305, 308, 233, HUMAN THROMBIN IN COMPLEX WITH UBTHR101
568, p3s7kB_, 0.9087, 1.67, 0.297, 250, 232, STRUCTURE OF THROMBIN MUTANT Y225P IN THE E FORM
569, p3rmoH_, 0.9087, 1.67, 0.297, 278, 232, HUMAN THROMBIN IN COMPLEX WITH MI004
570, p3rmlH_, 0.9087, 1.70, 0.296, 257, 233, HUMAN THROMBIN IN COMPLEX WITH MI331
571, p3rlyH_, 0.9087, 1.70, 0.296, 284, 233, HUMAN THROMBIN IN COMPLEX WITH MI329
572, d3dfjA1, 0.9087, 1.75, 0.305, 295, 233, CRYSTAL STRUCTURE OF HUMAN PROSTASIN
573, p2zdaH_, 0.9087, 1.65, 0.297, 250, 232, EXPLORING THROMBIN S1 POCKET
574, p2pgbB_, 0.9087, 1.65, 0.297, 251, 232, INHIBITOR-FREE HUMAN THROMBIN MUTANT C191A-C220A
575, d1wv7H_, 0.9087, 1.75, 0.341, 254, 232, HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5-PROPOXY-TRP-GLN-P-AMINOBENZAMIDINE
576, p1jouD_, 0.9087, 1.65, 0.297, 251, 232, CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH AN UNOCCUPIED ACTIVE SITE
577, d1jou.2, 0.9087, 1.65, 0.297, 251, 232, CRYSTAL STRUCTURE OF NATIVE S195A THROMBIN WITH AN UNOCCUPIED ACTIVE SITE
578, p1bmnH_, 0.9087, 1.75, 0.300, 252, 233, HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*R*)]-1-(AMINOIMINOMETHYL)- N-[[1-[N-[(2-NAPHTHALENYLSULFONYL)-L-SERYL]-PYRROLIDINYL]METHYL]-3- PIPERIDENECARBOXAMIDE (BMS-189090)
579, d1bmn.1, 0.9087, 1.65, 0.297, 251, 232, HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*R*)]-1-(AMINOIMINOMETHYL)- N-[[1-[N-[(2-NAPHTHALENYLSULFONYL)-L-SERYL]-PYRROLIDINYL]METHYL]-3- PIPERIDENECARBOXAMIDE (BMS-189090)
580, d1bbr.3, 0.9087, 1.65, 0.297, 251, 232, THE STRUCTURE OF RESIDUES 7-16 OF THE A ALPHA CHAIN OF HUMAN FIBRINOGEN BOUND TO BOVINE THROMBIN AT 2.3 ANGSTROMS RESOLUTION
581, d5patB_, 0.9086, 1.65, 0.297, 251, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-(2-AMINO-1H- BENZIMIDAZOL-5-YL)-2-(3-CHLOROPHENYL)ACETAMIDE
582, d5pamB_, 0.9086, 1.63, 0.346, 245, 231, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 2-[(1- AMINOISOQUINOLIN-6-YL)AMINO]-2-(5-ETHOXY-2-FLUOROPHENYL)-1-(2- PHENYLPYRROLIDIN-1-YL)ETHANONE
583, d4jzfH_, 0.9086, 1.65, 0.297, 251, 232, STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 2-{2-[(3- CARBAMOYLPHENYL)CARBAMOYL]-6-METHOXYPYRIDIN-3-YL}-5-{[(2S)-1-HYDROXY- 33-DIMETHYLBUTAN-2-YL]CARBAMOYL}BENZOIC ACID
584, p3rm0H_, 0.9086, 1.72, 0.288, 254, 233, HUMAN THROMBIN IN COMPLEX WITH MI354
585, p3p17H_, 0.9086, 1.76, 0.341, 254, 232, THROMBIN INHIBITION BY PYRIDIN DERIVATIVES
586, d2zzuH_, 0.9086, 1.73, 0.292, 257, 233, HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-5- (3-CARBOXYBENZYLOXY)-TRP-GLN-P-AMINOBENZAMIDINE
587, d2aeiH_, 0.9086, 1.73, 0.292, 304, 233, CRYSTAL STRUCTURE OF A TERNARY COMPLEX OF FACTOR VIIA/TISSUE FACTOR AND 2-[[6-[3-(AMINOIMINOMETHYL)PHENOXY]-35-DIFLURO-4-[(1-METHYL-3- PHENYLPROPYL)AMINO]-2-PYRIDINYL]OXY]-BENZOIC ACID
588, p1sgiB_, 0.9086, 1.74, 0.300, 257, 233, CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
589, d1sgi.1, 0.9086, 1.74, 0.300, 283, 233, CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
590, p1ookB_, 0.9086, 1.80, 0.305, 295, 233, CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND HUMAN ALPHA-THROMBIN
591, d1ook.1, 0.9086, 1.60, 0.330, 250, 230, CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND HUMAN ALPHA-THROMBIN
592, p1nrpH_, 0.9086, 1.59, 0.330, 250, 230, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
593, d1nrp.1, 0.9086, 1.70, 0.333, 254, 231, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
594, p1ae8H_, 0.9086, 1.65, 0.297, 251, 232, HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D-PHE-PRO-AZALYS-ONP
595, d1ae8.1, 0.9086, 1.65, 0.297, 251, 232, HUMAN ALPHA-THROMBIN INHIBITION BY EOC-D-PHE-PRO-AZALYS-ONP
596, p1a3eH_, 0.9086, 1.76, 0.341, 254, 232, COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2
597, d1a3e.1, 0.9086, 1.74, 0.341, 254, 232, COMPLEX OF HUMAN ALPHA-THROMBIN WITH THE BIFUNCTIONAL BORONATE INHIBITOR BOROLOG2
598, d5pawB_, 0.9085, 1.66, 0.297, 251, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH ISOQUINOLINE-16- DIAMINE
599, d5pafB_, 0.9085, 1.66, 0.297, 283, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-(2-AMINO-1H- BENZIMIDAZOL-5-YL)-2-[3-[(2-AMINO-2-OXOETHYL)-METHYLSULFONYLAMINO]-5- CHLOROPHENYL]ACETAMIDE;222-TRIFLUOROACETIC ACID
600, p5mm6H_, 0.9085, 1.74, 0.296, 259, 233, THROMBIN MUTANT A190S IN COMPLEX WITH (S)-1-(D-PHENYLALANYL)-N-(4- CARBAMIMIDOYLBENZYL)PYRROLIDINE-2-CARBOXAMIDE
601, p5jzyH_, 0.9085, 1.74, 0.296, 295, 233, THROMBIN IN COMPLEX WITH (S)-1-((R)-2-AMINO-3-CYCLOHEXYLPROPANOYL)-N- (4-CARBAMIMIDOYLBENZYL)PYRROLIDINE-2-CARBOXAMIDE
602, p4ufdH_, 0.9085, 1.71, 0.296, 257, 233, THROMBIN IN COMPLEX WITH 4-(((1-((2S)-1-((2R)-2-( BENZYLSULFONYLAMINO)-3-PHENYL-PROPANOYL)PYRROLIDIN-2-YL)-1- OXO-ETHYL)AMINO)METHYL)BENZAMIDINE
603, p4udwH_, 0.9085, 1.71, 0.296, 286, 233, THROMBIN IN COMPLEX WITH 1-(2R)-2-AMINO-3-PHENYL-PROPANOYL- N-(25DICHLOROPHENYL)METHYLPYRROLIDINE-2-CARBOXAMIDE
604, d4na7A_, 0.9085, 1.71, 0.296, 253, 233, FACTOR XIA IN COMPLEX WITH THE INHIBITOR 3 -[(2S4R)-6-CARBAMIMIDOYL- 4-METHYL-4-PHENYL-1234-TETRAHYDROQUINOLIN-2-YL]-4-CARBAMOYL-5 - [(3-METHYLBUTANOYL)AMINO]BIPHENYL-2-CARBOXYLIC ACID
605, d4jyvH_, 0.9085, 1.71, 0.296, 289, 233, STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[3- ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-2-(ISOQUINOLIN-6-YLAMINO)-N-[(3- SULFAMOYLPHENYL)SULFONYL]ETHANAMIDE
606, p3lu9E_, 0.9085, 1.73, 0.296, 251, 233, CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT S195A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1
607, p2znkH_, 0.9085, 1.73, 0.296, 278, 233, THROMBIN INHIBITION
608, p2hwlD_, 0.9085, 1.58, 0.330, 250, 230, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH FIBRINOGEN GAMMA  PEPTIDE
609, d2firH_, 0.9085, 1.68, 0.338, 250, 231, CRYSTAL STRUCTURE OF DFPR-VIIA/STF
610, d1wtgH_, 0.9085, 1.66, 0.297, 251, 232, HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-BIPHENYLALANINE-GLN-P-AMINOBENZAMIDINE
611, d1w2kH_, 0.9085, 1.65, 0.297, 250, 232, TF7A_4380 COMPLEX
612, p1dlkD_, 0.9085, 1.66, 0.297, 251, 232, CRYSTAL STRUCTURE ANALYSIS OF DELTA-CHYMOTRYPSIN BOUND TO A PEPTIDYL CHLOROMETHYL KETONE INHIBITOR
613, d1dlk.2, 0.9085, 1.65, 0.297, 251, 232, CRYSTAL STRUCTURE ANALYSIS OF DELTA-CHYMOTRYPSIN BOUND TO A PEPTIDYL CHLOROMETHYL KETONE INHIBITOR
614, p1bmmH_, 0.9085, 1.81, 0.355, 238, 231, HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*R*)]-4-[(AMINOIMINOMETHYL) AMINO]-N-[[1-[3-HYDROXY-2-[(2-NAPHTHALENYLSULFONYL)AMINO]-1- OXOPROPYL]-2-PYRROLIDINYL] METHYL]BUTANAMIDE (BMS-186282)
615, d1bmm.1, 0.9085, 1.68, 0.333, 254, 231, HUMAN ALPHA-THROMBIN COMPLEXED WITH [S-(R*R*)]-4-[(AMINOIMINOMETHYL) AMINO]-N-[[1-[3-HYDROXY-2-[(2-NAPHTHALENYLSULFONYL)AMINO]-1- OXOPROPYL]-2-PYRROLIDINYL] METHYL]BUTANAMIDE (BMS-186282)
616, d5pasC_, 0.9084, 1.66, 0.293, 251, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH (2S)-2-HYDROXY-N-[[3- [5-HYDROXY-4-(1H-PYRROLO[32-C]PYRIDIN-2-YL)PYRAZOL-1- YL]PHENYL]METHYL]-3-PHENYLPROPANAMIDE
617, p4uffH_, 0.9084, 1.66, 0.297, 251, 232, THROMBIN IN COMPLEX WITH (2R)-2-(BENZYLSULFONYLAMINO)-N-(2-( (4-CARBAMIMIDOYLPHENYL)METHYLAMINO)-2-OXO-ETHYL)-N-METHYL- 3-PHENYL-PROPANAMIDE
618, d4jzdH_, 0.9084, 1.76, 0.296, 251, 233, STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 2-{2-[(4- CARBAMIMIDOYLPHENYL)CARBAMOYL]-6-METHOXYPYRIDIN-3-YL}-5-{[(2S)-1- HYDROXY-33-DIMETHYLBUTAN-2-YL]CARBAMOYL}BENZOIC ACID
619, p4e7rG_, 0.9084, 1.77, 0.341, 254, 232, THROMBIN IN COMPLEX WITH 3-AMIDINOPHENYLALANINE INHIBITOR
620, p3u98H_, 0.9084, 1.76, 0.341, 254, 232, HUMAN THROMBIN IN COMPLEX WITH MI001
621, d3t62B_, 0.9084, 1.77, 0.341, 251, 232, CRYSTAL STRUCTURE OF RECOMBINANT KUNITZ TYPE SERINE PROTEASE INHIBITOR-1 FROM THE CARIBBEAN SEA ANEMONE STICHODACTYLA HELIANTHUS IN COMPLEX WITH BOVINE CHYMOTRYPSIN
622, p3si4H_, 0.9084, 1.44, 0.389, 230, 229, HUMAN THROMBIN IN COMPLEX WITH UBTHR104
623, p3rm2H_, 0.9084, 1.44, 0.389, 243, 229, HUMAN THROMBIN IN COMPLEX WITH MI003
624, p3da9B_, 0.9084, 1.75, 0.296, 258, 233, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH INHIBITOR
625, d1ygcH_, 0.9084, 1.75, 0.296, 286, 233, SHORT FACTOR VIIA WITH A SMALL MOLECULE INHIBITOR
626, d1wunH_, 0.9084, 1.59, 0.330, 250, 230, HUMAN FACTOR VIIA-TISSUE FACTOR COMPLEXED WITH ETHYLSULFONAMIDE-D-TRP-GLN-P-AMINOBENZAMIDINE
627, p1haoH_, 0.9084, 1.66, 0.297, 250, 232, COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON NMR MODEL OF DNA)
628, d1hao.1, 0.9084, 1.69, 0.333, 254, 231, COMPLEX OF HUMAN ALPHA-THROMBIN WITH A 15MER OLIGONUCLEOTIDE GGTTGGTGTGGTTGG (BASED ON NMR MODEL OF DNA)
629, p5gdsH_, 0.9083, 1.66, 0.297, 250, 232, HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPLEX
630, d5gds.1, 0.9083, 1.65, 0.297, 251, 232, HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPLEX
631, p3bivH_, 0.9083, 1.37, 0.390, 240, 228, HUMAN THROMBIN-IN COMPLEX WITH UB-THR11
632, d2xwaA_, 0.9083, 1.65, 0.297, 251, 232, CRYSTAL STRUCTURE OF COMPLEMENT FACTOR D MUTANT R202A
633, p2v3hH_, 0.9083, 1.65, 0.297, 251, 232, THROMBIN WITH 3-CYCLE NO F
634, p2uufB_, 0.9083, 1.66, 0.297, 251, 232, THROMBIN-HIRUGEN BINARY COMPLEX AT 1.26A RESOLUTION
635, p2bvsH_, 0.9083, 1.68, 0.333, 254, 231, HUMAN THROMBIN COMPLEXED WITH FRAGMENT-BASED SMALL MOLECULES OCCUPYING THE S1 POCKET
636, d5tqeH_, 0.9082, 1.75, 0.341, 254, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (5R)-5-[(1-AMINOISOQUINOLIN- 6-YL)AMINO]-19-(CYCLOPROPYLSULFONYL)-3-METHYL-13-OXA-315- DIAZATRICYCLO[14.3.1.1~610~]HENICOSA-1(20)6(21)791618-HEXAENE- 414-DIONE
637, d5pavC_, 0.9082, 1.72, 0.296, 253, 233, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-(6-AMINOPYRIDIN-3- YL)-5-HYDROXY-1-PHENYLPYRAZOLE-4-CARBOXAMIDE
638, p5mlsH_, 0.9082, 1.72, 0.296, 280, 233, THROMBIN MUTANT A190S IN COMPLEX WITH (S)-1-(D-PHENYLALANYL)-N-(3- CHLOROBENZYL)PYRROLIDINE-2-CARBOXAMIDE
639, p5ew2H_, 0.9082, 1.72, 0.296, 253, 233, HUMAN THROMBIN SANDWICHED BETWEEN TWO DNA APTAMERS: HD22 AND HD1- DELTAT12
640, p4rkjB_, 0.9082, 1.72, 0.296, 289, 233, CRYSTAL STRUCTURE OF THROMBIN MUTANT S195T (FREE FORM)
641, p4loyH_, 0.9082, 1.65, 0.297, 250, 232, CRYSTAL STRUCTURE ANALYSIS OF THROMBIN IN COMPLEX WITH COMPOUND D57 5-CHLOROTHIOPHENE-2-CARBOXYLIC ACID [(S)-2-[2-METHYL-3-(2- OXOPYRROLIDIN-1-YL)BENZENESULFONYLAMINO]-3-(4-METHYLPIPERAZIN-1- YL)- 3-OXOPROPYL]AMIDE (SAR107375)
642, p3shaH_, 0.9082, 1.23, 0.336, 228, 226, HUMAN THROMBIN IN COMPLEX WITH UBTHR97
643, p3qwcH_, 0.9082, 1.66, 0.297, 250, 232, THROMBIN INHIBITION BY PYRIDIN DERIVATIVES
644, p2zi2H_, 0.9082, 1.65, 0.297, 252, 232, THROMBIN INHIBITION
645, p2zffH_, 0.9082, 1.74, 0.296, 251, 233, EXPLORING THROMBIN S1-POCKET
646, p1ghyH_, 0.9082, 1.69, 0.333, 252, 231, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
647, d1ghy.1, 0.9082, 1.46, 0.332, 249, 229, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
648, p1afeH_, 0.9082, 1.66, 0.297, 250, 232, HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO-AZALYS-ONP
649, d1afe.1, 0.9082, 1.68, 0.297, 251, 232, HUMAN ALPHA-THROMBIN INHIBITION BY CBZ-PRO-AZALYS-ONP
650, p7kmeH_, 0.9081, 1.68, 0.293, 252, 232, CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711.
651, d7kme.1, 0.9081, 1.66, 0.297, 250, 232, CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2711.
652, p5to3B1, 0.9081, 1.66, 0.297, 251, 232, CRYSTAL STRUCTURE OF THROMBIN MUTANT W215A/E217A FUSED TO EGF456 OF THROMBOMODULIN VIA A 31-RESIDUE LINKER AND BOUND TO PPACK
653, p5mjtH_, 0.9081, 1.66, 0.297, 251, 232, THROMBIN MUTANT A190S IN COMPLEX WITH (S) -1 - ((R) -2-AMINO-33- DIPHENYLPROPANOYL) -N- (3-CHLOROBENZYL) PYRROLIDINE-2-CARBOXAMIDE
654, d5l2yH_, 0.9081, 1.66, 0.297, 250, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 1-[(2R15R)-2-[(1-AMINO-4- FLUOROISOQUINOLIN-6-YL)AMINO]-41520-TRIMETHYL-312-DIOXO-13-OXA-4 11-DIAZATRICYCLO[14.2.2.1~610~]HENICOSA-1(18)6810(21)1619- HEXAEN-7-YL] CYCLOBUTANE-1-CARBOXYLIC ACID
655, d4yt6H_, 0.9081, 1.66, 0.297, 251, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 4-{[(R)-[5-ETHOXY-2-FLUORO- 3-(PROPAN-2-YLOXY)PHENYL](4-PHENYL-1H-IMIDAZOL-2-YL) METHYL]AMINO}BENZENECARBOXIMIDAMIDE
656, p4lxbH_, 0.9081, 1.66, 0.297, 250, 232, CRYSTAL STRUCTURE ANALYSIS OF THROMBIN IN COMPLEX WITH COMPOUND D58
657, d4jyuH_, 0.9081, 1.66, 0.297, 286, 232, STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1- AMINOISOQUINOLIN-6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N- (PHENYLSULFONYL)ETHANAMIDE
658, d4ishH_, 0.9081, 1.71, 0.296, 253, 233, STRUCTURE OF FACTOR VIIA IN COMPLEX WITH THE INHIBITOR BMS-593214 ALSO KNOWN AS 2 -[(6R6AR11BR)-2-CARBAMIMIDOYL-66A711B-TETRAHYDRO-5H- INDENO[21-C]QUINOLIN-6-YL]-5 -HYDROXY-4 -METHOXYBIPHENYL-4- CARBOXYLIC ACID
659, p4az2B_, 0.9081, 1.71, 0.296, 289, 233, HUMAN THROMBIN - INHIBITOR COMPLEX
660, d5pb0B_, 0.9080, 1.66, 0.297, 252, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 2-(4-ETHOXY-3- METHOXYPHENYL)-2-(ISOQUINOLIN-6-YLAMINO)ACETIC ACID
661, d5parC_, 0.9080, 1.66, 0.297, 277, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1H-BENZIMIDAZOL-2- AMINE
662, d5l2zH_, 0.9080, 1.73, 0.296, 255, 233, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 1-[(2R15R)-2-[(1-AMINO-4- FLUOROISOQUINOLIN-6-YL)AMINO]-41517-TRIMETHYL-312-DIOXO-13-OXA-4 11-DIAZATRICYCLO[14.2.2.1~610~]HENICOSA-1(18)6(21)791619- HEXAEN-7-YL]CYCLOHEXANE-1-CARBOXYLIC ACID
663, d4x8uH_, 0.9080, 1.66, 0.297, 250, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-1H-INDOLE-2- CARBOXYLIC ACID
664, d4x8tH_, 0.9080, 1.69, 0.333, 254, 231, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 7-CHLORO-34- DIHYDROISOQUINOLIN-1(2H)-ONE
665, p4ayvB_, 0.9080, 1.69, 0.333, 254, 231, HUMAN THROMBIN - INHIBITOR COMPLEX
666, p3si3H_, 0.9080, 1.66, 0.297, 250, 232, HUMAN THROMBIN IN COMPLEX WITH UBTHR103
667, p3biuH_, 0.9080, 1.69, 0.333, 254, 231, HUMAN THROMBIN-IN COMPLEX WITH UB-THR10
668, p2zfqH_, 0.9080, 1.69, 0.333, 254, 231, EXPLORING THROMBIN S3 POCKET
669, d2bz6H_, 0.9080, 1.73, 0.296, 257, 233, ORALLY AVAILABLE FACTOR7A INHIBITOR
670, p1e0fF_, 0.9080, 1.58, 0.330, 250, 230, CRYSTAL STRUCTURE OF THE HUMAN ALPHA-THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II-BINDING INHIBITOR
671, d1e0f.3, 0.9080, 1.61, 0.330, 250, 230, CRYSTAL STRUCTURE OF THE HUMAN ALPHA-THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II-BINDING INHIBITOR
672, d5pa9C_, 0.9079, 1.69, 0.338, 254, 231, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH PHENYLMETHANAMINE;HYDROCHLORIDE
673, d4dgjC_, 0.9079, 1.78, 0.333, 251, 231, STRUCTURE OF A HUMAN ENTEROPEPTIDASE LIGHT CHAIN VARIANT
674, p2ziqH_, 0.9079, 1.60, 0.330, 250, 230, THROMBIN INHIBITION
675, p2zfpH_, 0.9079, 1.73, 0.296, 257, 233, THROMBIN INIBITION
676, p1ypkH_, 0.9079, 1.66, 0.297, 251, 232, THROMBIN INHIBITOR COMPLEX
677, d5u6jH_, 0.9078, 1.66, 0.297, 250, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 3-{[(2R)-17-ETHYL-4-METHYL- 312-DIOXO-7-[(PROPAN-2-YL)SULFONYL]-13-OXA-411- DIAZATRICYCLO[14.2.2.1~610~]HENICOSA-1(18)6(21)791619-HEXAEN-2- YL]AMINO}BENZAMIDE
678, p5a2mH_, 0.9078, 1.66, 0.297, 251, 232, THROMBIN INHIBITOR
679, p4uehH_, 0.9078, 1.68, 0.333, 254, 231, THROMBIN IN COMPLEX WITH BENZAMIDINE
680, p2cn0H_, 0.9078, 1.75, 0.296, 259, 233, COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED INHIBITOR
681, p1oytH_, 0.9078, 1.75, 0.296, 294, 233, COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR
682, d1oyt.1, 0.9078, 1.61, 0.330, 250, 230, COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH A DESIGNED FLUORINATED INHIBITOR
683, p1o5gH_, 0.9078, 1.30, 0.322, 234, 227, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
684, d1o5g.1, 0.9078, 1.66, 0.297, 251, 232, DISSECTING AND DESIGNING INHIBITOR SELECTIVITY DETERMINANTS AT THE S1 SITE USING AN ARTIFICIAL ALA190 PROTEASE (ALA190 UPA)
685, d1mh0A_, 0.9078, 1.66, 0.297, 251, 232, CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
686, d1ets.1, 0.9078, 1.66, 0.297, 250, 232, REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
687, p1e0fD_, 0.9078, 1.75, 0.333, 251, 231, CRYSTAL STRUCTURE OF THE HUMAN ALPHA-THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II-BINDING INHIBITOR
688, d1e0f.1, 0.9078, 1.66, 0.297, 250, 232, CRYSTAL STRUCTURE OF THE HUMAN ALPHA-THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II-BINDING INHIBITOR
689, d1abj.1, 0.9078, 1.66, 0.297, 251, 232, STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S  SUBSITES OF SUBSTRATES AND INHIBITORS
690, d5paxC_, 0.9077, 1.66, 0.297, 250, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1-(26- DIFLUOROPHENYL)-3-[[3-[5-HYDROXY-4-(1H-PYRROLO[32-C]PYRIDIN-2-YL) PYRAZOL-1-YL]PHENYL]METHYL]UREA
691, d4x8vH_, 0.9077, 1.66, 0.297, 250, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (METHYL {3-[(2R)-1-{(2R)-2- (34-DIMETHOXYPHENYL)-2-[(1-OXO-1234-TETRAHYDROISOQUINOLIN-7-YL) AMINO]ACETYL}PYRROLIDIN-2-YL]-4-(PROPAN-2-YLSULFONYL) PHENYL}CARBAMATE)
692, p4rkoB_, 0.9077, 1.66, 0.297, 277, 232, CRYSTAL STRUCTURE OF THROMBIN MUTANT S195T BOUND WITH PPACK
693, p4ch8B_, 0.9077, 1.67, 0.297, 250, 232, HIGH-SALT CRYSTAL STRUCTURE OF A THROMBIN-GPIBALPHA PEPTIDE COMPLEX
694, p1ypmH_, 0.9077, 1.67, 0.297, 283, 232, X-RAY CRYSTAL STRUCTURE OF THROMBIN INHIBITED BY SYNTHETIC CYANOPEPTIDE ANALOGUE RA-1014
695, p1hltK_, 0.9077, 1.68, 0.297, 277, 232, THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN
696, d1hlt.2, 0.9077, 1.76, 0.305, 295, 233, THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN
697, d4dgjA_, 0.9076, 1.73, 0.296, 257, 233, STRUCTURE OF A HUMAN ENTEROPEPTIDASE LIGHT CHAIN VARIANT
698, p2pw8H_, 0.9076, 1.73, 0.296, 293, 233, CRYSTAL STRUCTURE OF SULFO-HIRUDIN COMPLEXED TO THROMBIN
699, d2b8oH_, 0.9076, 1.75, 0.296, 285, 233, CRYSTAL STRUCTURE OF GLU-GLY-ARG-CHLOROMETHYL KETONE-FACTOR VIIA/SOLUBLE TISSUE FACTOR COMPLEX
700, p1yplH_, 0.9076, 1.61, 0.330, 250, 230, X-RAY CRYSTAL STRUCTURE OF THROMBIN INHIBITED BY SYNTHETIC CYANOPEPTIDE ANALOGUE RA-1008
701, p1ypeH_, 0.9076, 1.77, 0.341, 254, 232, THROMBIN INHIBITOR COMPLEX
702, p1h8dH_, 0.9076, 1.69, 0.293, 250, 232, X-RAY STRUCTURE OF THE HUMAN ALPHA-THROMBIN COMPLEX WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.
703, d1h8d.1, 0.9076, 1.63, 0.299, 249, 231, X-RAY STRUCTURE OF THE HUMAN ALPHA-THROMBIN COMPLEX WITH A TRIPEPTIDE PHOSPHONATE INHIBITOR.
704, p1c4y2_, 0.9076, 1.66, 0.297, 250, 232, SELECTIVE NON-ELECTROPHILIC THROMBIN INHIBITORS
705, d1c4y.1, 0.9076, 1.66, 0.297, 251, 232, SELECTIVE NON-ELECTROPHILIC THROMBIN INHIBITORS
706, d5paaC_, 0.9075, 1.66, 0.297, 278, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH CYCLOHEXYLMETHANAMINE
707, d5pa8C_, 0.9075, 1.39, 0.320, 235, 228, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH CYCLOHEXANAMINE
708, d4yt7H_, 0.9075, 1.68, 0.297, 251, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 2-(2-{(R)-[(4- CARBAMIMIDOYLPHENYL)AMINO][5-ETHOXY-2-FLUORO-3-(PROPAN-2-YLOXY) PHENYL]METHYL}-1H-IMIDAZOL-4-YL)BENZAMIDE
709, d4x8sH_, 0.9075, 1.77, 0.341, 254, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR 4-BROMO-2-METHOXYPHENOL
710, d4ng9H_, 0.9075, 1.67, 0.297, 250, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-AMINOISOQUINOLIN- 6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-(3- SULFAMOYLBENZYL)ETHANAMIDE
711, p3qlpH_, 0.9075, 1.66, 0.297, 250, 232, X-RAY STRUCTURE OF THE COMPLEX BETWEEN HUMAN ALPHA THROMBIN AND A MODIFIED THROMBIN BINDING APTAMER (MTBA)
712, p2jh0D_, 0.9075, 1.67, 0.297, 251, 232, HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
713, d1m9uA_, 0.9075, 1.67, 0.297, 279, 232, CRYSTAL STRUCTURE OF EARTHWORM FIBRINOLYTIC ENZYME COMPONENT A FROM EISENIA FETIDA
714, d1ij7A_, 0.9075, 1.74, 0.296, 254, 233,  
715, p1d4pB_, 0.9075, 1.74, 0.296, 281, 233, CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5- AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBITOR
716, d1d4p.1, 0.9075, 1.69, 0.338, 250, 231, CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH 5- AMIDINOINDOLE-4-BENZYLPIPERIDINE INHIBITOR
717, p6aodC_, 0.9074, 1.69, 0.338, 250, 231, FXIA ANTIBODY COMPLEX
718, d5tqgH_, 0.9074, 1.69, 0.333, 254, 231, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (5R11R)-11-[(1-AMINO-4- FLUOROISOQUINOLIN-6-YL)AMINO]-16-(CYCLOPROPYLSULFONYL)-7-(22- DIFLUOROETHOXY)-513-DIMETHYL-213-DIAZATRICYCLO[13.3.1.1~6 10~]ICOSA-1(19)6(20)791517-HEXAENE-312-DIONE
719, d5l30H_, 0.9074, 1.50, 0.332, 249, 229, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R15R)-2-[(1- AMINOISOQUINOLIN-6-YL)AMINO]-41517-TRIMETHYL-7-[1-(1H-TETRAZOL-5- YL)CYCLOPROPYL]-13-OXA-411-DIAZATRICYCLO[14.2.2.1~610~]HENICOSA- 1(18)6(21)791619-HEXAENE-312-DIONE
720, p5af9H_, 0.9074, 1.61, 0.330, 250, 230, THROMBIN IN COMPLEX WITH 4-METHOXY-N-(2-PYRIDINYL)BENZAMIDE
721, p4h6sB_, 0.9074, 1.76, 0.296, 259, 233, CRYSTAL STRUCTURE OF THROMBIN MUTANT E14EA/D14LA/E18A/S195A
722, p1tocF_, 0.9074, 1.67, 0.297, 251, 232, STRUCTURE OF SERINE PROTEINASE
723, d1toc.3, 0.9074, 1.83, 0.351, 241, 231, STRUCTURE OF SERINE PROTEINASE
724, p1c1uH_, 0.9074, 1.83, 0.351, 241, 231, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
725, d1c1u.1, 0.9074, 1.83, 0.351, 241, 231, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
726, d5tqfH_, 0.9073, 1.67, 0.297, 250, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (11R)-11-[(1- AMINOISOQUINOLIN-6-YL)AMINO]-16-(CYCLOPROPYLSULFONYL)-13-METHYL-213- DIAZATRICYCLO[13.3.1.1~610~]ICOSA-1(19)6(20)791517-HEXAENE-3 12-DIONE
727, d4zxyH_, 0.9073, 1.67, 0.297, 278, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-AMINOISOQUINOLIN- 6-YL)AMINO]-411-DIAZATRICYCLO[14.2.2.1~610~]HENICOSA-1(18)6(21)7 91619-HEXAENE-312-DIONE
728, d4a6lC_, 0.9073, 1.61, 0.349, 236, 229, BETA-TRYPTASE INHIBITOR
729, d2zecC_, 0.9073, 1.59, 0.330, 250, 230, POTENT NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
730, d2bm2C_, 0.9073, 1.74, 0.333, 251, 231, HUMAN BETA-II TRYPTASE IN COMPLEX WITH 4-(3-AMINOMETHYL- PHENYL)-PIPERIDIN-1-YL-(5-PHENETHYL- PYRIDIN-3-YL)- METHANONE
731, p1tocH_, 0.9073, 1.67, 0.297, 250, 232, STRUCTURE OF SERINE PROTEINASE
732, p1tocD_, 0.9073, 1.62, 0.294, 251, 231, STRUCTURE OF SERINE PROTEINASE
733, p1tocB_, 0.9073, 1.75, 0.305, 259, 233, STRUCTURE OF SERINE PROTEINASE
734, d1toc.4, 0.9073, 1.75, 0.305, 287, 233, STRUCTURE OF SERINE PROTEINASE
735, d1toc.2, 0.9073, 1.67, 0.297, 252, 232, STRUCTURE OF SERINE PROTEINASE
736, d1toc.1, 0.9073, 1.67, 0.297, 288, 232, STRUCTURE OF SERINE PROTEINASE
737, d1mh0B_, 0.9073, 1.63, 0.330, 250, 230, CRYSTAL STRUCTURE OF THE ANTICOAGULANT SLOW FORM OF THROMBIN
738, d5pajB_, 0.9072, 1.60, 0.330, 250, 230, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1-(1- AMINOISOQUINOLIN-6-YL)-3-BENZYLUREA
739, p5afyH_, 0.9072, 1.61, 0.402, 242, 229, THROMBIN IN COMPLEX WITH 3-CHLORO-BENZAMIDE
740, d4ngaH_, 0.9072, 1.61, 0.402, 242, 229, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-AMINOISOQUINOLIN- 6-YL)AMINO]-2-[3-ETHOXY-4-(PROPAN-2-YLOXY)PHENYL]-N-[2-(PROPAN-2- YLSULFONYL)BENZYL]ETHANAMIDE
741, d4mqaB_, 0.9072, 1.61, 0.402, 242, 229, HUMAN BETA-TRYPTASE CO-CRYSTAL STRUCTURE WITH {(1133- TETRAMETHYLDISILOXANE-13-DIYL)BIS[5-(METHYLSULFANYL)BENZENE-31- DIYL]}BIS({4-[3-(AMINOMETHYL)PHENYL]PIPERIDIN-1-YL}METHANONE)
742, p4i7yH_, 0.9072, 1.76, 0.305, 259, 233, CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH A 27-MER APTAMER BOUND TO EXOSITE II
743, p4dt7D_, 0.9072, 1.76, 0.305, 259, 233, CRYSTAL STRUCTURE OF THROMBIN BOUND TO THE ACTIVATION DOMAIN QEDQVDPRLIDGKMTRRGDS OF PROTEIN C
744, p1vzqH_, 0.9072, 1.76, 0.305, 259, 233, COMPLEX OF THROMBIN WITH DESIGNED INHIBITOR 7165
745, p1ucyN_, 0.9072, 1.76, 0.305, 287, 233, THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7- 19). THREE COMPLEXES ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN
746, d1ucy.3, 0.9072, 1.76, 0.305, 287, 233, THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7- 19). THREE COMPLEXES ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN
747, d5pakC_, 0.9071, 1.76, 0.305, 287, 233, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-[[4-(AMINOMETHYL)- 2-(2-AMINO-2-OXOETHOXY)PHENYL]METHYL]-2-(4-HYDROXYPHENYL)-2- METHOXYACETAMIDE;HYDROCHLORIDE
748, d5i46H_, 0.9071, 1.68, 0.297, 277, 232, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R15R)-2-[(1- AMINOISOQUINOLIN-6-YL)AMINO]-8-FLUORO-7-HYDROXY-41517-TRIMETHYL-13- OXA-411-DIAZATRICYCLO[14.2.2.1~610~]HENICOSA-1(18)6(21)791619- HEXAENE-312-DIONE
749, p4ue7H_, 0.9071, 1.69, 0.338, 250, 231, THROMBIN IN COMPLEX WITH 1-AMIDINOPIPERIDINE
750, p3s7kD_, 0.9071, 1.67, 0.297, 250, 232, STRUCTURE OF THROMBIN MUTANT Y225P IN THE E FORM
751, p2uukB_, 0.9071, 1.70, 0.333, 254, 231, THROMBIN-HIRUGEN-GW420128 TERNARY COMPLEX AT 1.39A RESOLUTION
752, p1twxB_, 0.9071, 1.60, 0.402, 243, 229, CRYSTAL STRUCTURE OF THE THROMBIN MUTANT D221A/D222K
753, p1o0dH_, 0.9071, 1.64, 0.299, 250, 231, HUMAN THROMBIN COMPLEXED WITH A D-PHE-PRO-ARG-TYPE INHIBITOR AND A C- TERMINAL HIRUDIN DERIVED EXO-SITE INHIBITOR
754, d1o0d.1, 0.9071, 1.78, 0.292, 253, 233, HUMAN THROMBIN COMPLEXED WITH A D-PHE-PRO-ARG-TYPE INHIBITOR AND A C- TERMINAL HIRUDIN DERIVED EXO-SITE INHIBITOR
755, p1ghvH_, 0.9071, 1.67, 0.297, 250, 232, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
756, d1ghv.1, 0.9071, 1.83, 0.305, 259, 233, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
757, d1d6wA_, 0.9071, 1.83, 0.305, 295, 233, STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTROPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1
758, p1c5oH_, 0.9071, 1.70, 0.338, 250, 231, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1-BINDING SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
759, d1c5o.1, 0.9071, 1.71, 0.333, 254, 231, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1-BINDING SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
760, p1c1wH_, 0.9071, 1.67, 0.297, 251, 232, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
761, d1c1w.1, 0.9071, 1.68, 0.302, 251, 232, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
762, d4cbnB_, 0.9070, 1.67, 0.297, 252, 232, CRYSTAL STRUCTURE OF COMPLEMENT FACTOR D MUTANT R202A AFTER CONVENTIONAL REFINEMENT
763, p2v3oH_, 0.9070, 1.67, 0.297, 252, 232, THROMBIN WITH 3-CYCLE WITH F
764, p1ucyK_, 0.9070, 1.69, 0.297, 250, 232, THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7- 19). THREE COMPLEXES ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN
765, d1ucy.2, 0.9070, 1.69, 0.297, 284, 232, THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7- 19). THREE COMPLEXES ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN
766, p1nzqH_, 0.9070, 1.68, 0.297, 250, 232, D-PHE-PRO-ARG-TYPE THROMBIN INHIBITOR
767, d1nzq.1, 0.9070, 1.68, 0.297, 286, 232, D-PHE-PRO-ARG-TYPE THROMBIN INHIBITOR
768, p1nroH_, 0.9070, 1.68, 0.297, 278, 232, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
769, d1nro.1, 0.9070, 1.68, 0.297, 252, 232, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
770, p1hdtH_, 0.9070, 1.68, 0.297, 288, 232, STRUCTURE OF A RETRO-BINDING PEPTIDE INHIBITOR COMPLEXED WITH HUMAN ALPHA-THROMBIN
771, d1hdt.1, 0.9070, 1.68, 0.297, 252, 232, STRUCTURE OF A RETRO-BINDING PEPTIDE INHIBITOR COMPLEXED WITH HUMAN ALPHA-THROMBIN
772, p1ghxH_, 0.9070, 1.68, 0.297, 288, 232, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
773, d1ghx.1, 0.9070, 1.25, 0.336, 228, 226, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
774, p1g30B_, 0.9070, 1.68, 0.297, 250, 232, THROMBIN INHIBITOR COMPLEX
775, d1g30.1, 0.9070, 1.81, 0.305, 259, 233, THROMBIN INHIBITOR COMPLEX
776, d1etr.1, 0.9070, 1.81, 0.305, 295, 233, REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
777, p1ba8B_, 0.9070, 1.69, 0.297, 250, 232, THROMBIN INHIBITOR WITH A RIGID TRIPEPTIDYL ALDEHYDES
778, d1ba8.1, 0.9070, 1.69, 0.297, 278, 232, THROMBIN INHIBITOR WITH A RIGID TRIPEPTIDYL ALDEHYDES
779, p6eo9H_, 0.9069, 1.73, 0.296, 257, 233, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL GLUCOSE- CONJUGATED POTENT INHIBITOR
780, p4hfpD_, 0.9069, 1.73, 0.296, 286, 233, STRUCTURE OF THROMBIN MUTANT S195A BOUND TO THE ACTIVE SITE INHIBITOR ARGATROBAN
781, d2zebC_, 0.9069, 1.75, 0.296, 259, 233, POTENT NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
782, d2xwaB_, 0.9069, 1.75, 0.296, 292, 233, CRYSTAL STRUCTURE OF COMPLEMENT FACTOR D MUTANT R202A
783, d2flrH_, 0.9069, 1.68, 0.297, 250, 232, NOVEL 5-AZAINDOLE FACTOR VIIA INHIBITORS
784, p2bvrH_, 0.9069, 1.68, 0.297, 286, 232, HUMAN THROMBIN COMPLEXED WITH FRAGMENT-BASED SMALL MOLECULES OCCUPYING THE S1 POCKET
785, p1kttB_, 0.9069, 1.67, 0.297, 252, 232, THROMBIN INHIBITOR COMPLEX
786, d1ktt.1, 0.9069, 1.67, 0.297, 279, 232, THROMBIN INHIBITOR COMPLEX
787, p1c4u2_, 0.9069, 1.80, 0.305, 295, 233, SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
788, d1c4u.1, 0.9069, 1.69, 0.297, 252, 232, SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
789, p5e8eH_, 0.9068, 1.69, 0.297, 282, 232, CRYSTAL STRUCTURE OF THROMBIN BOUND TO AN EXOSITE 1-SPECIFIC IGA FAB
790, p2ankH_, 0.9068, 1.68, 0.297, 250, 232, ORALLY ACTIVE THROMBIN INHIBITORS IN COMPLEX WITH THROMBIN AND AN EXOSITE DECAPEPTIDE
791, d1fakH_, 0.9068, 1.78, 0.292, 257, 233, HUMAN TISSUE FACTOR COMPLEXED WITH COAGULATION FACTOR VIIA INHIBITED WITH A BPTI-MUTANT
792, p1c4v2_, 0.9068, 1.61, 0.402, 242, 229, SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
793, d1c4v.1, 0.9068, 1.26, 0.336, 228, 226, SELECTIVE NON ELECTROPHILIC THROMBIN INHIBITORS WITH CYCLOHEXYL MOIETIES.
794, p4nzeH_, 0.9067, 1.78, 0.341, 254, 232, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL TETRA-O-ACETYL- GLUCOPYRANOSIDE-CONJUGATED POTENT INHIBITOR
795, p2uujB_, 0.9067, 1.68, 0.297, 250, 232, THROMBIN-HIRUGEN-GW473178 TERNARY COMPLEX AT 1.32A RESOLUTION
796, p2puxB_, 0.9067, 1.67, 0.297, 252, 232, CRYSTAL STRUCTURE OF MURINE THROMBIN IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF MURINE PAR3
797, p2cf8H_, 0.9067, 1.67, 0.297, 279, 232, COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH AN INHIBITOR
798, p1ktsB_, 0.9067, 1.69, 0.297, 252, 232, THROMBIN INHIBITOR COMPLEX
799, d1kts.1, 0.9067, 1.69, 0.297, 282, 232, THROMBIN INHIBITOR COMPLEX
800, p1gj5H_, 0.9067, 1.78, 0.296, 259, 233, SELECTIVITY AT S1 H2O DISPLACEMENT UPA TPA SER190/ALA190 PROTEASE STRUCTURE-BASED DRUG DESIGN
801, d1gj5.1, 0.9067, 1.69, 0.297, 250, 232, SELECTIVITY AT S1 H2O DISPLACEMENT UPA TPA SER190/ALA190 PROTEASE STRUCTURE-BASED DRUG DESIGN
802, p1abiH_, 0.9067, 1.79, 0.341, 251, 232, STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S  SUBSITES OF SUBSTRATES AND INHIBITORS
803, d1abi.1, 0.9067, 1.68, 0.297, 252, 232, STRUCTURE OF THE HIRULOG 3-THROMBIN COMPLEX AND NATURE OF THE S  SUBSITES OF SUBSTRATES AND INHIBITORS
804, p8kme2_, 0.9066, 1.68, 0.297, 288, 232, CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770.
805, d8kme.1, 0.9066, 1.68, 0.297, 250, 232, CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN INHIBITED WITH SEL2770.
806, p2xwbJ_, 0.9066, 1.67, 0.297, 252, 232, CRYSTAL STRUCTURE OF COMPLEMENT C3B IN COMPLEX WITH FACTORS B AND D
807, p2xwbI_, 0.9066, 1.77, 0.305, 258, 233, CRYSTAL STRUCTURE OF COMPLEMENT C3B IN COMPLEX WITH FACTORS B AND D
808, p2feqH_, 0.9066, 1.68, 0.297, 250, 232, ORALLY ACTIVE THROMBIN INHIBITORS
809, d1jwtA1, 0.9066, 1.67, 0.297, 252, 232, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL BICYCLIC LACTAM INHIBITOR
810, p1gj4H_, 0.9066, 1.67, 0.297, 279, 232, SELECTIVITY AT S1 H2O DISPLACEMENT UPA TPA SER190/ALA190 PROTEASE STRUCTURE-BASED DRUG DESIGN
811, d1gj4.1, 0.9066, 1.68, 0.297, 250, 232, SELECTIVITY AT S1 H2O DISPLACEMENT UPA TPA SER190/ALA190 PROTEASE STRUCTURE-BASED DRUG DESIGN
812, p1fphH_, 0.9066, 1.68, 0.297, 286, 232, THE INTERACTION OF THROMBIN WITH FIBRINOGEN: A STRUCTURAL BASIS FOR ITS SPECIFICITY
813, d1fph.1, 0.9066, 1.69, 0.297, 252, 232, THE INTERACTION OF THROMBIN WITH FIBRINOGEN: A STRUCTURAL BASIS FOR ITS SPECIFICITY
814, d1bhx.1, 0.9066, 1.69, 0.297, 285, 232, X-RAY STRUCTURE OF THE COMPLEX OF HUMAN ALPHA THROMBIN WITH THE INHIBITOR SDZ 229-357
815, d1bbr.2, 0.9066, 1.67, 0.297, 250, 232, THE STRUCTURE OF RESIDUES 7-16 OF THE A ALPHA CHAIN OF HUMAN FIBRINOGEN BOUND TO BOVINE THROMBIN AT 2.3 ANGSTROMS RESOLUTION
816, d5paqB_, 0.9065, 1.67, 0.297, 276, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 2-[(1- AMINOISOQUINOLIN-6-YL)AMINO]-2-(3-ETHOXY-4-PROPAN-2-YLOXYPHENYL)-1- (2-PHENYLPYRROLIDIN-1-YL)ETHANONE
817, p4dihH_, 0.9065, 1.22, 0.336, 228, 226, X-RAY STRUCTURE OF THE COMPLEX BETWEEN HUMAN ALPHA THROMBIN AND THROMBIN BINDING APTAMER IN THE PRESENCE OF SODIUM IONS
818, d3v7tC_, 0.9065, 1.22, 0.336, 228, 226, CRYSTAL STRUCTURE OF HUMAN BETA-TRYPTASE COMPLEXED WITH A SYNTHETIC INHIBITOR WITH A TROPANYLAMIDE SCAFFOLD
819, p3p70B_, 0.9065, 1.69, 0.297, 250, 232, STRUCTURAL BASIS OF THROMBIN-MEDIATED FACTOR V ACTIVATION: ESSENTIAL ROLE OF THE HIRUDIN-LIKE SEQUENCE GLU666-GLU672 FOR PROCESSING AT THE HEAVY CHAIN-B DOMAIN JUNCTION
820, d2za5C_, 0.9065, 1.74, 0.296, 289, 233, CRYSTAL STRUCTURE OF HUMAN TRYPTASE WITH POTENT NON-PEPTIDE INHIBITOR
821, p1ghwH_, 0.9065, 1.68, 0.297, 251, 232, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
822, d1ghw.1, 0.9065, 1.68, 0.297, 279, 232, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
823, p1g32B_, 0.9065, 1.81, 0.296, 259, 233, THROMBIN INHIBITOR COMPLEX
824, d1g32.1, 0.9065, 1.81, 0.296, 295, 233, THROMBIN INHIBITOR COMPLEX
825, p5wi6D_, 0.9064, 1.69, 0.297, 282, 232, HUMAN BETA-1 TRYPTASE MUTANT ILE99CYS 
826, d4mpwB_, 0.9064, 1.82, 0.305, 295, 233, HUMAN BETA-TRYPTASE CO-CRYSTAL STRUCTURE WITH [(1133- TETRAMETHYLDISILOXANE-13-DIYL)DI-1-BENZOFURAN-35-DIYL]BIS({4-[3- (AMINOMETHYL)PHENYL]PIPERIDIN-1-YL}METHANONE)
827, d4mpvB_, 0.9064, 1.61, 0.330, 250, 230, HUMAN BETA-TRYPTASE CO-CRYSTAL STRUCTURE WITH (2R4S)-NN -BIS[3-({4- [3-(AMINOMETHYL)PHENYL]PIPERIDIN-1-YL}CARBONYL)PHENYL]-4-HYDROXY-2- (2-HYDROXYPROPAN-2-YL)-55-DIMETHYL-13-DIOXOLANE-24-DICARBOXAMIDE
828, p1thrH_, 0.9064, 1.65, 0.299, 249, 231, STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
829, d1thr.1, 0.9064, 1.61, 0.402, 242, 229, STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
830, p1hltH_, 0.9064, 1.70, 0.297, 252, 232, THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN
831, d1hlt.1, 0.9064, 1.63, 0.402, 242, 229, THE STRUCTURE OF A NONADECAPEPTIDE OF THE FIFTH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN
832, p1awhD_, 0.9064, 1.69, 0.297, 250, 232, NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
833, d1awh.2, 0.9064, 1.69, 0.297, 286, 232, NOVEL COVALENT THROMBIN INHIBITOR FROM PLANT EXTRACT
834, p1ahtH_, 0.9064, 1.68, 0.297, 252, 232, CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6 ANGSTROMS RESOLUTION
835, d1aht.1, 0.9064, 1.68, 0.297, 279, 232, CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND P-AMIDINOPHENYLPYRUVATE AT 1.6 ANGSTROMS RESOLUTION
836, d4zxxH_, 0.9063, 1.62, 0.402, 243, 229, FACTOR VIIA IN COMPLEX WITH THE INHIBITOR N-{3-[(2R)-1-{(2R)-2-[(1- AMINOISOQUINOLIN-6-YL)AMINO]-2-PHENYLACETYL}PYRROLIDIN-2-YL]-4- (PROPAN-2-YLSULFONYL)PHENYL}ACETAMIDE
837, d2f9nA_, 0.9063, 1.62, 0.402, 243, 229, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT K192Q/D216G IN COMPLEX WITH LEUPEPTIN
838, d1w7xH_, 0.9063, 1.62, 0.402, 243, 229, FACTOR7- 413 COMPLEX
839, d1ca0.1, 0.9063, 1.69, 0.297, 252, 232, BOVINE CHYMOTRYPSIN COMPLEXED TO APPI
840, p1c5nH_, 0.9063, 1.69, 0.297, 278, 232, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1-BINDING SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
841, d1c5n.1, 0.9063, 1.69, 0.297, 251, 232, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1-BINDING SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
842, p1c1vH_, 0.9063, 1.69, 0.297, 278, 232, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
843, d1c1v.1, 0.9063, 1.79, 0.296, 259, 233, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
844, d1a0lA_, 0.9063, 1.79, 0.296, 295, 233, HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE
845, d2f9bH_, 0.9062, 1.69, 0.297, 251, 232, DISCOVERY OF NOVEL HETEROCYCLIC FACTOR VIIA INHIBITORS
846, p2cf9H_, 0.9062, 1.69, 0.297, 279, 232, COMPLEX OF RECOMBINANT HUMAN THROMBIN WITH AN INHIBITOR
847, d1dicA_, 0.9062, 1.80, 0.341, 254, 232, STRUCTURE OF 34-DICHLOROISOCOUMARIN-INHIBITED FACTOR D
848, p1de7H_, 0.9062, 1.62, 0.406, 243, 229, INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX
849, d1de7.1, 0.9062, 1.72, 0.338, 250, 231, INTERACTION OF FACTOR XIII ACTIVATION PEPTIDE WITH ALPHA-THROMBIN: CRYSTAL STRUCTURE OF THE ENZYME-SUBSTRATE COMPLEX
850, p1d3tB_, 0.9062, 1.41, 0.390, 239, 228, CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1
851, d1d3t.1, 0.9062, 1.69, 0.297, 252, 232, CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 1
852, d5pb2C_, 0.9061, 1.69, 0.297, 288, 232, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 2-PHENYL-4-(1H- PYRROLO[32-C]PYRIDIN-2-YL)PYRAZOL-3-OL
853, d2f9pA_, 0.9061, 1.69, 0.297, 252, 232, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G IN COMPLEX WITH LEUPEPTIN
854, d1zsjA_, 0.9061, 1.69, 0.297, 288, 232, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH N-(7-CARBAMIMIDOYL-NAPHTHALEN-1- YL)-3-HYDROXY-2-METHYL-BENZAMIDE
855, p1d3qB_, 0.9061, 1.61, 0.402, 244, 229, CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2
856, d1d3q.1, 0.9061, 1.61, 0.402, 244, 229, CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 2
857, p1d3pB_, 0.9061, 1.77, 0.341, 254, 232, CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3
858, d1d3p.1, 0.9061, 1.68, 0.297, 250, 232, CRYSTAL STRUCTURE OF HUMAN APLHA-THROMBIN IN COMPLEX WITH BENZO[B]THIOPHENE INHIBITOR 3
859, p1d3dB_, 0.9061, 1.28, 0.341, 228, 226, CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4
860, d1d3d.1, 0.9061, 1.66, 0.299, 249, 231, CRYSTAL STRUCTURE OF HUMAN ALPHA THROMBIN IN COMPLEX WITH BENZOTHIOPHENE INHIBITOR 4
861, d1a0lB_, 0.9061, 1.66, 0.299, 277, 231, HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE
862, p6ftzA_, 0.9060, 1.69, 0.297, 250, 232, COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 6 
863, p5wi6B_, 0.9060, 1.69, 0.297, 278, 232, HUMAN BETA-1 TRYPTASE MUTANT ILE99CYS 
864, d4mpuB_, 0.9060, 1.62, 0.330, 250, 230, HUMAN BETA-TRYPTASE CO-CRYSTAL STRUCTURE WITH (6S8R)-NN -BIS[3-({4- [3-(AMINOMETHYL)PHENYL]PIPERIDIN-1-YL}CARBONYL)PHENYL]-8-HYDROXY-6- (1-HYDROXYCYCLOBUTYL)-57-DIOXASPIRO[3.4]OCTANE-68-DICARBOXAMIDE
865, p4dt7B_, 0.9060, 1.62, 0.402, 243, 229, CRYSTAL STRUCTURE OF THROMBIN BOUND TO THE ACTIVATION DOMAIN QEDQVDPRLIDGKMTRRGDS OF PROTEIN C
866, d4crbA_, 0.9060, 1.79, 0.355, 238, 231, CREATING NOVEL F1 INHIBITORS THROUGH FRAGMENT BASED LEAD GENERATION AND STRUCTURE AIDED DRUG DESIGN
867, p4ax9H_, 0.9060, 1.69, 0.297, 250, 232, HUMAN THROMBIN COMPLEXED WITH NAPSAGATRAN RO0466240
868, d2zebB_, 0.9060, 1.69, 0.297, 278, 232, POTENT NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
869, d2f9pC_, 0.9060, 1.69, 0.297, 250, 232, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G IN COMPLEX WITH LEUPEPTIN
870, d2f9nB_, 0.9060, 1.69, 0.297, 278, 232, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT K192Q/D216G IN COMPLEX WITH LEUPEPTIN
871, p2anmH_, 0.9060, 1.69, 0.297, 250, 232, TERNARY COMPLEX OF AN ORALLY ACTIVE THROMBIN INHIBITOR WITH HUMAN THROMBIN AND A C-TERMINAL HIRUDIN DERIVED EXO-SIT INHIBITOR
872, p2a2xH_, 0.9060, 1.69, 0.297, 278, 232, ORALLY ACTIVE THROMBIN INHIBITORS IN COMPLEX WITH THROMBIN INH12
873, d1xxfB_, 0.9060, 1.62, 0.402, 244, 229, CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTIN MUTANT (ECOTINP)
874, p6fujC_, 0.9059, 1.24, 0.341, 228, 226, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR N-(3 -(AMINOMETHYL)- [1;1 -BIPHENYL]-3-YL)-3-METHYLBUTANAMIDE 
875, d5fbiA_, 0.9059, 1.63, 0.402, 244, 229, COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 3B
876, d2zecA_, 0.9059, 1.62, 0.402, 243, 229, POTENT NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
877, d2fpzA_, 0.9059, 1.81, 0.292, 252, 233, HUMAN TRYPTASE WITH 2-AMINO BENZIMIDAZOLE
878, d2f9pB_, 0.9059, 1.79, 0.355, 238, 231, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G IN COMPLEX WITH LEUPEPTIN
879, d1m9uB_, 0.9059, 1.70, 0.297, 250, 232, CRYSTAL STRUCTURE OF EARTHWORM FIBRINOLYTIC ENZYME COMPONENT A FROM EISENIA FETIDA
880, d1ij7B_, 0.9059, 1.63, 0.402, 242, 229,  
881, d1d9iA_, 0.9059, 1.63, 0.402, 243, 229, STRUCTURE OF THROMBIN COMPLEXED WITH SELECTIVE NON-ELECTOPHILIC INHIBITORS HAVING CYCLOHEXYL MOIETIES AT P1
882, d1a0lC_, 0.9059, 1.62, 0.406, 243, 229, HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE
883, p4lz1H_, 0.9058, 1.70, 0.297, 250, 232, X-RAY STRUCTURE OF THE COMPLEX BETWEEN HUMAN THROMBIN AND THE TBA DELETION MUTANT LACKING THYMINE 12 NUCLEOBASE
884, p3u8oH_, 0.9058, 1.70, 0.297, 250, 232, HUMAN THROMBIN COMPLEXED WITH D-PHE-PRO-D-ARG-D-THR
885, d2fpzC_, 0.9058, 1.61, 0.354, 237, 229, HUMAN TRYPTASE WITH 2-AMINO BENZIMIDAZOLE
886, d2f9pD_, 0.9058, 1.23, 0.341, 228, 226, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G IN COMPLEX WITH LEUPEPTIN
887, d2f9oB_, 0.9058, 1.27, 0.341, 228, 226, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G
888, d2f9nD_, 0.9058, 1.64, 0.402, 242, 229, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT K192Q/D216G IN COMPLEX WITH LEUPEPTIN
889, d1zrbA_, 0.9058, 1.63, 0.402, 243, 229, THROMBIN IN COMPLEX WITH AN AZAFLUORENYL INHIBITOR 23B
890, d4mpxB_, 0.9057, 1.62, 0.402, 243, 229, HUMAN BETA-TRYPTASE CO-CRYSTAL STRUCTURE WITH [(1133- TETRAMETHYLDISILOXANE-13-DIYL)DI-1-BENZOTHIENE-42-DIYL]BIS({4-[3- (AMINOMETHYL)PHENYL]PIPERIDIN-1-YL}METHANONE)
891, d4craA_, 0.9057, 1.69, 0.352, 241, 230, CREATING NOVEL F1 INHIBITORS THROUGH FRAGMENT BASED LEAD GENERATION AND STRUCTURE AIDED DRUG DESIGN
892, d2zebA_, 0.9057, 1.69, 0.352, 241, 230, POTENT NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
893, d2f9oA_, 0.9057, 1.68, 0.297, 279, 232, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G
894, d5payC_, 0.9056, 1.63, 0.402, 244, 229, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1-[[3-[5-HYDROXY-4- (1H-PYRROLO[32-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]-3- PHENYLUREA
895, d4zmaH_, 0.9056, 1.65, 0.299, 249, 231, CRYSTAL STRUCTURE OF A FVIIA-TRYPSIN CHIMERA (ST) IN COMPLEX WITH SOLUBLE TISSUE FACTOR
896, p3u69H_, 0.9056, 1.64, 0.299, 251, 231, UNLIGANDED WILD-TYPE HUMAN THROMBIN
897, p3pmaD_, 0.9056, 1.63, 0.402, 243, 229, 2.2 ANGSTROM CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN BOVINE THROMBIN AND SUCROSE OCTASULFATE
898, d1id5.1, 0.9056, 1.62, 0.402, 242, 229, CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEX WITH PROTEASE INHIBITOR ECOTIN
899, p1ad8H_, 0.9056, 1.63, 0.402, 242, 229, COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY
900, d1ad8.1, 0.9056, 1.62, 0.406, 243, 229, COMPLEX OF THROMBIN WITH AND INHIBITOR CONTAINING A NOVEL P1 MOIETY
901, p5wi6C_, 0.9055, 1.63, 0.299, 276, 231, HUMAN BETA-1 TRYPTASE MUTANT ILE99CYS 
902, d5mt4A_, 0.9055, 1.63, 0.402, 243, 229, COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE BENZOIC ACID BASED INHIBITOR
903, d5f03B_, 0.9055, 1.79, 0.355, 238, 231, TRYPTASE B2 IN COMPLEX WITH 5-(3-AMINOMETHYL-PHENOXYMETHYL)-3-[3-(2- CHLORO-PYRIDIN-3-YLETHYNYL)-PHENYL]-OXAZOLIDIN-2-ONE; COMPOUND WITH TRIFLUORO-ACETIC ACID
904, d2zecB_, 0.9055, 1.64, 0.402, 242, 229, POTENT NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
905, p2fesH_, 0.9055, 1.58, 0.402, 242, 229, ORALLY ACTIVE THROMBIN INHIBITORS
906, d2f9oD_, 0.9055, 1.63, 0.330, 250, 230, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G
907, d1xxdB_, 0.9055, 1.41, 0.342, 247, 228, CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH MUTATED ECOTIN
908, p6fujA_, 0.9054, 1.64, 0.299, 251, 231, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR N-(3 -(AMINOMETHYL)- [1;1 -BIPHENYL]-3-YL)-3-METHYLBUTANAMIDE 
909, d5pb3C_, 0.9054, 1.79, 0.305, 259, 233, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1-[[3-[4-(5-AMINO-1H- PYRROLO[32-B]PYRIDIN-2-YL)-5-HYDROXYPYRAZOL-1-YL]PHENYL]METHYL]-3- PHENYLUREA
910, d4x6pA_, 0.9054, 1.70, 0.306, 286, 232, FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR (2E)-N-{(1S)-1-[4-(3-AMINO-1H-INDAZOL-6-YL)-1H-IMIDAZOL-2- YL]-2-PHENYLETHYL}-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2- ENAMIDE
911, d4mpwA_, 0.9054, 1.72, 0.297, 250, 232, HUMAN BETA-TRYPTASE CO-CRYSTAL STRUCTURE WITH [(1133- TETRAMETHYLDISILOXANE-13-DIYL)DI-1-BENZOFURAN-35-DIYL]BIS({4-[3- (AMINOMETHYL)PHENYL]PIPERIDIN-1-YL}METHANONE)
912, p3p70D_, 0.9054, 1.72, 0.297, 278, 232, STRUCTURAL BASIS OF THROMBIN-MEDIATED FACTOR V ACTIVATION: ESSENTIAL ROLE OF THE HIRUDIN-LIKE SEQUENCE GLU666-GLU672 FOR PROCESSING AT THE HEAVY CHAIN-B DOMAIN JUNCTION
913, d3gymB_, 0.9054, 1.64, 0.402, 242, 229, STRUCTURE OF PROSTASIN IN COMPLEX WITH APROTININ
914, p2zdvH_, 0.9054, 1.28, 0.341, 228, 226, EXPLORING THROMBIN S1 POCKET
915, d2oq5A_, 0.9054, 1.64, 0.402, 243, 229, CRYSTAL STRUCTURE OF DESC1 A NEW MEMBER OF THE TYPE II TRANSMEMBRANE SERINE PROTEINASES FAMILY
916, d2gddB_, 0.9054, 1.63, 0.402, 242, 229, HUMAN BETA II TRYPTASE WITH INHIBITOR CRA-27592
917, p2bvxH_, 0.9054, 1.71, 0.297, 250, 232, DESIGN AND DISCOVERY OF NOVEL POTENT THROMBIN INHIBITORS WITH A SOLUBILIZING CATIONIC P1-P2-LINKER
918, d2bm2B_, 0.9054, 1.64, 0.402, 243, 229, HUMAN BETA-II TRYPTASE IN COMPLEX WITH 4-(3-AMINOMETHYL- PHENYL)-PIPERIDIN-1-YL-(5-PHENETHYL- PYRIDIN-3-YL)- METHANONE
919, d1zhrA_, 0.9054, 1.70, 0.357, 238, 230, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH BENZAMIDINE (S434A-T475A-C482S-K437A MUTANT)
920, d5fcrB_, 0.9053, 1.24, 0.341, 228, 226, MOUSE COMPLEMENT FACTOR D
921, d5fbeA_, 0.9053, 1.62, 0.330, 250, 230, COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND2
922, d3v7tA_, 0.9053, 1.71, 0.358, 236, 229, CRYSTAL STRUCTURE OF HUMAN BETA-TRYPTASE COMPLEXED WITH A SYNTHETIC INHIBITOR WITH A TROPANYLAMIDE SCAFFOLD
923, d3gymA_, 0.9053, 1.58, 0.402, 243, 229, STRUCTURE OF PROSTASIN IN COMPLEX WITH APROTININ
924, d2za5A_, 0.9053, 1.72, 0.297, 250, 232, CRYSTAL STRUCTURE OF HUMAN TRYPTASE WITH POTENT NON-PEPTIDE INHIBITOR
925, d1dsuB_, 0.9053, 1.70, 0.349, 241, 229, HUMAN FACTOR D COMPLEMENT ACTIVATING ENZYME
926, p1ay6H_, 0.9053, 1.65, 0.299, 250, 231, THROMBIN INHIBITOR FROM THEONALLA CYCLOTHEANAMIDE-BASED MACROCYCLIC TRIPEPTIDE MOTIF
927, d1ay6.1, 0.9053, 1.41, 0.313, 232, 227, THROMBIN INHIBITOR FROM THEONALLA CYCLOTHEANAMIDE-BASED MACROCYCLIC TRIPEPTIDE MOTIF
928, p6fujB_, 0.9052, 1.41, 0.313, 232, 227, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR N-(3 -(AMINOMETHYL)- [1;1 -BIPHENYL]-3-YL)-3-METHYLBUTANAMIDE 
929, d4cr9A_, 0.9052, 1.63, 0.402, 243, 229, CREATING NOVEL F1 INHIBITORS THROUGH FRAGMENT BASED LEAD GENERATION AND STRUCTURE AIDED DRUG DESIGN
930, d3bg8A_, 0.9052, 1.78, 0.296, 251, 233, CRYSTAL STRUCTURE OF FACTOR XIA IN COMPLEX WITH CLAVATADINE 2 A
931, d2fs8B_, 0.9052, 1.63, 0.402, 242, 229, HUMAN BETA-TRYPTASE II WITH INHIBITOR CRA-29382
932, d2f9oC_, 0.9052, 1.80, 0.355, 238, 231, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT D216G
933, d2f9nC_, 0.9052, 1.38, 0.339, 230, 227, CRYSTAL STRUCTURE OF THE RECOMBINANT HUMAN ALPHA I TRYPTASE MUTANT K192Q/D216G IN COMPLEX WITH LEUPEPTIN
934, p1tmbH_, 0.9052, 1.28, 0.341, 228, 226, MOLECULAR BASIS FOR THE INHIBITION OF HUMAN ALPHA-THROMBIN BY THE MACROCYCLIC PEPTIDE CYCLOTHEONAMIDE A
935, d1tmb.1, 0.9052, 1.64, 0.402, 242, 229, MOLECULAR BASIS FOR THE INHIBITION OF HUMAN ALPHA-THROMBIN BY THE MACROCYCLIC PEPTIDE CYCLOTHEONAMIDE A
936, d1g37A_, 0.9052, 1.70, 0.349, 241, 229, CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN COMPLEXED WITH BCH-10556 AND EXOSITE-DIRECTED PEPTIDE
937, p1a2cH_, 0.9052, 1.64, 0.402, 242, 229, STRUCTURE OF THROMBIN INHIBITED BY AERUGINOSIN298-A FROM A BLUE-GREEN ALGA
938, d1a2c.1, 0.9052, 1.29, 0.341, 228, 226, STRUCTURE OF THROMBIN INHIBITED BY AERUGINOSIN298-A FROM A BLUE-GREEN ALGA
939, p5wi6A_, 0.9051, 1.71, 0.297, 252, 232, HUMAN BETA-1 TRYPTASE MUTANT ILE99CYS 
940, p3dhkH_, 0.9051, 1.71, 0.297, 281, 232, BISPHENYLIC THROMBIN INHIBITORS
941, d2gddD_, 0.9051, 1.24, 0.341, 228, 226, HUMAN BETA II TRYPTASE WITH INHIBITOR CRA-27592
942, p1sb1H_, 0.9051, 1.80, 0.355, 238, 231, NOVEL NON-COVALENT THROMBIN INHIBITORS INCORPORATING P1 4567- TETRAHYDROBENZOTHIAZOLE ARGININE SIDE CHAIN MIMETICS
943, d1sb1.1, 0.9051, 1.80, 0.355, 238, 231, NOVEL NON-COVALENT THROMBIN INHIBITORS INCORPORATING P1 4567- TETRAHYDROBENZOTHIAZOLE ARGININE SIDE CHAIN MIMETICS
944, d4cr5A_, 0.9050, 1.64, 0.402, 243, 229, CREATING NOVEL F1 INHIBITORS THROUGH FRAGMENT BASED LEAD GENERATION AND STRUCTURE AIDED DRUG DESIGN
945, p2jh5D_, 0.9050, 1.59, 0.402, 243, 229, HUMAN THROMBIN HIRUGEN INHIBITOR COMPLEX
946, d2fpzB_, 0.9050, 1.64, 0.406, 243, 229, HUMAN TRYPTASE WITH 2-AMINO BENZIMIDAZOLE
947, d2bm2A_, 0.9050, 1.72, 0.297, 252, 232, HUMAN BETA-II TRYPTASE IN COMPLEX WITH 4-(3-AMINOMETHYL- PHENYL)-PIPERIDIN-1-YL-(5-PHENETHYL- PYRIDIN-3-YL)- METHANONE
948, p2a1dF_, 0.9050, 1.72, 0.297, 281, 232, STAPHYLOCOAGULASE BOUND TO BOVINE THROMBIN
949, p2a1dB_, 0.9050, 1.70, 0.297, 277, 232, STAPHYLOCOAGULASE BOUND TO BOVINE THROMBIN
950, d1zskA_, 0.9050, 1.71, 0.297, 252, 232, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 6-CARBAMIMIDOYL-4-(3-HYDROXY-2- METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC ACID METHYL ESTER
951, d1hfdA_, 0.9050, 1.71, 0.297, 288, 232, HUMAN COMPLEMENT FACTOR D IN A P21 CRYSTAL FORM
952, p6ftyA_, 0.9049, 1.64, 0.402, 243, 229, COMPLEMENT FACTOR D COMPLEXED WITH COMPOUND 5 
953, d5f03A_, 0.9049, 1.65, 0.299, 250, 231, TRYPTASE B2 IN COMPLEX WITH 5-(3-AMINOMETHYL-PHENOXYMETHYL)-3-[3-(2- CHLORO-PYRIDIN-3-YLETHYNYL)-PHENYL]-OXAZOLIDIN-2-ONE; COMPOUND WITH TRIFLUORO-ACETIC ACID
954, d3t62A_, 0.9049, 1.63, 0.402, 243, 229, CRYSTAL STRUCTURE OF RECOMBINANT KUNITZ TYPE SERINE PROTEASE INHIBITOR-1 FROM THE CARIBBEAN SEA ANEMONE STICHODACTYLA HELIANTHUS IN COMPLEX WITH BOVINE CHYMOTRYPSIN
955, p2zfrH_, 0.9049, 1.64, 0.299, 250, 231, EXPLORING THROMBIN S3 POCKET
956, d2za5B_, 0.9049, 1.64, 0.299, 279, 231, CRYSTAL STRUCTURE OF HUMAN TRYPTASE WITH POTENT NON-PEPTIDE INHIBITOR
957, d2fs9A_, 0.9049, 1.80, 0.355, 238, 231, HUMAN BETA TRYPTASE II WITH INHIBITOR CRA-28427
958, d2fpzD_, 0.9049, 1.65, 0.299, 250, 231, HUMAN TRYPTASE WITH 2-AMINO BENZIMIDAZOLE
959, d4a6lA_, 0.9048, 1.58, 0.402, 243, 229, BETA-TRYPTASE INHIBITOR
960, d3htc.1, 0.9048, 1.45, 0.408, 242, 228, THE STRUCTURE OF A COMPLEX OF RECOMBINANT HIRUDIN AND HUMAN ALPHA-THROMBIN
961, p3dt0H_, 0.9048, 1.79, 0.305, 259, 233, UNDERSTANDING THROMBIN INHIBITION
962, p2zhqH_, 0.9048, 1.79, 0.305, 259, 233, THROMBIN INHIBITION
963, d2fxrD_, 0.9048, 1.83, 0.355, 238, 231, HUMAN BETA TRYPTASE II COMPLEXED WITH ACTIVATED KETONE INHIBITOR CRA-29382
964, p1thsH_, 0.9048, 1.30, 0.341, 228, 226, STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
965, d1ths.1, 0.9048, 1.30, 0.341, 228, 226, STRUCTURES OF THROMBIN COMPLEXES WITH A DESIGNED AND A NATURAL EXOSITE INHIBITOR
966, d1sl3A_, 0.9048, 1.58, 0.402, 242, 229, CRYSTAL STRUCTUE OF THROMBIN IN COMPLEX WITH A POTENT P1 HETEROCYCLE- ARYL BASED INHIBITOR
967, d1nm6A_, 0.9048, 1.43, 0.390, 240, 228, THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR AT 1.8A
968, d1ca0.2, 0.9048, 1.65, 0.299, 250, 231, BOVINE CHYMOTRYPSIN COMPLEXED TO APPI
969, d4thn.1, 0.9047, 1.64, 0.402, 242, 229, THE CRYSTAL STRUCTURE OF ALPHA-THROMBIN-HIRUNORM IV COMPLEX REVEALS A NOVEL SPECIFICITY SITE RECOGNITION MODE.
970, d4mqaA_, 0.9047, 1.64, 0.402, 243, 229, HUMAN BETA-TRYPTASE CO-CRYSTAL STRUCTURE WITH {(1133- TETRAMETHYLDISILOXANE-13-DIYL)BIS[5-(METHYLSULFANYL)BENZENE-31- DIYL]}BIS({4-[3-(AMINOMETHYL)PHENYL]PIPERIDIN-1-YL}METHANONE)
971, d4mpvA_, 0.9047, 1.59, 0.402, 243, 229, HUMAN BETA-TRYPTASE CO-CRYSTAL STRUCTURE WITH (2R4S)-NN -BIS[3-({4- [3-(AMINOMETHYL)PHENYL]PIPERIDIN-1-YL}CARBONYL)PHENYL]-4-HYDROXY-2- (2-HYDROXYPROPAN-2-YL)-55-DIMETHYL-13-DIOXOLANE-24-DICARBOXAMIDE
972, d4creA_, 0.9047, 1.65, 0.402, 242, 229, CREATING NOVEL F1 INHIBITORS THROUGH FRAGMENT BASED LEAD GENERATION AND STRUCTURE AIDED DRUG DESIGN
973, p2zo3H_, 0.9047, 1.89, 0.296, 291, 233, BISPHENYLIC THROMBIN INHIBITORS
974, p2zhfH_, 0.9047, 1.65, 0.299, 250, 231, EXPLORING THROMBIN S3 POCKET
975, p2zg0H_, 0.9047, 1.65, 0.299, 250, 231, EXPLORING THROMBIN S3 POCKET
976, d1zpbA_, 0.9047, 1.65, 0.402, 243, 229, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 4-METHYL-PENTANOIC ACID {1-[4- GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYLCARBAMOYL]-2-METHYL- PROPYL}-AMIDE
977, d4mpuA_, 0.9046, 1.71, 0.297, 252, 232, HUMAN BETA-TRYPTASE CO-CRYSTAL STRUCTURE WITH (6S8R)-NN -BIS[3-({4- [3-(AMINOMETHYL)PHENYL]PIPERIDIN-1-YL}CARBONYL)PHENYL]-8-HYDROXY-6- (1-HYDROXYCYCLOBUTYL)-57-DIOXASPIRO[3.4]OCTANE-68-DICARBOXAMIDE
978, p3u8tH_, 0.9046, 1.71, 0.297, 285, 232, HUMAN THROMBIN COMPLEXED WITH D-PHE-PRO-D-ARG-CYS
979, p3u8rH_, 0.9046, 1.65, 0.299, 276, 231, HUMAN THROMBIN COMPLEXED WITH D-PHE-PRO-D-ARG-ILE
980, d2fs8D_, 0.9046, 1.65, 0.299, 276, 231, HUMAN BETA-TRYPTASE II WITH INHIBITOR CRA-29382
981, p1nrrH_, 0.9046, 1.43, 0.390, 239, 228, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
982, d1nrr.1, 0.9046, 1.77, 0.296, 289, 233, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
983, p1dwbH_, 0.9046, 1.58, 0.402, 243, 229, CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
984, d1dwb.1, 0.9046, 1.60, 0.402, 243, 229, CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
985, p4baqB_, 0.9045, 1.81, 0.355, 238, 231, THROMBIN IN COMPLEX WITH INHIBITOR
986, p4baoB_, 0.9045, 1.65, 0.299, 250, 231, THROMBIN IN COMPLEX WITH INHIBITOR
987, p4bakB_, 0.9045, 1.65, 0.299, 249, 231, THROMBIN IN COMPLEX WITH INHIBITOR
988, d4a6lB_, 0.9045, 1.65, 0.299, 249, 231, BETA-TRYPTASE INHIBITOR
989, d3v7tB_, 0.9045, 1.75, 0.357, 237, 230, CRYSTAL STRUCTURE OF HUMAN BETA-TRYPTASE COMPLEXED WITH A SYNTHETIC INHIBITOR WITH A TROPANYLAMIDE SCAFFOLD
990, p2zheH_, 0.9045, 1.59, 0.402, 243, 229, EXPLORING THROMBIN S3 POCKET
991, p2zgxH_, 0.9045, 1.66, 0.299, 249, 231, THROMBIN INHIBITION
992, p2c93B_, 0.9045, 1.66, 0.299, 251, 231, THROMBIN INHIBITORS
993, p2c8xB_, 0.9045, 1.65, 0.402, 243, 229, THROMBIN INHIBITORS
994, p1thpB_, 0.9045, 1.66, 0.299, 249, 231, STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D-PHE-PRO-ARG- CHLOROMETHYLKETONE
995, d1thp.1, 0.9045, 1.66, 0.299, 275, 231, STRUCTURE OF HUMAN ALPHA-THROMBIN Y225P MUTANT BOUND TO D-PHE-PRO-ARG- CHLOROMETHYLKETONE
996, p1dweH_, 0.9045, 1.90, 0.296, 257, 233, CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
997, d1dwe.1, 0.9045, 1.90, 0.296, 286, 233, CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
998, d1cbw.1, 0.9045, 1.66, 0.299, 249, 231, BOVINE CHYMOTRYPSIN COMPLEXED TO BPTI
999, d1bioA_, 0.9045, 1.65, 0.299, 249, 231, HUMAN COMPLEMENT FACTOR D IN COMPLEX WITH ISATOIC ANHYDRIDE INHIBITOR
1000, p6fuhA_, 0.9044, 1.65, 0.299, 249, 231, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (4-((3- (AMINOMETHYL)PHENYL)AMINO)QUINAZOLIN-2-YL)-L-VALINE 
1001, d5mt0A1, 0.9044, 1.65, 0.402, 242, 229, COMPLEMENT FACTOR D IN COMPLEX WITH A REVERSIBLE INDOLE CARBOXYLIC ACID BASED INHIBITOR
1002, d4mpxA_, 0.9044, 1.65, 0.402, 242, 229, HUMAN BETA-TRYPTASE CO-CRYSTAL STRUCTURE WITH [(1133- TETRAMETHYLDISILOXANE-13-DIYL)DI-1-BENZOTHIENE-42-DIYL]BIS({4-[3- (AMINOMETHYL)PHENYL]PIPERIDIN-1-YL}METHANONE)
1003, p4e7rH_, 0.9044, 1.65, 0.299, 250, 231, THROMBIN IN COMPLEX WITH 3-AMIDINOPHENYLALANINE INHIBITOR
1004, p4banB_, 0.9044, 1.66, 0.299, 250, 231, THROMBIN IN COMPLEX WITH INHIBITOR
1005, d2fs9D_, 0.9044, 1.66, 0.299, 251, 231, HUMAN BETA TRYPTASE II WITH INHIBITOR CRA-28427
1006, d2fs9C_, 0.9044, 1.66, 0.299, 251, 231, HUMAN BETA TRYPTASE II WITH INHIBITOR CRA-28427
1007, d2fs9B_, 0.9044, 1.72, 0.303, 249, 231, HUMAN BETA TRYPTASE II WITH INHIBITOR CRA-28427
1008, p1dwdH_, 0.9044, 1.72, 0.303, 276, 231, CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1009, d1dwd.1, 0.9044, 1.91, 0.296, 257, 233, CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1010, d5fcrA_, 0.9043, 1.91, 0.296, 285, 233, MOUSE COMPLEMENT FACTOR D
1011, d4y8xA_, 0.9043, 1.45, 0.390, 239, 228, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL (4-{4-CHLORO-2-[(1S)- 1-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)- 2-PHENYLETHYL]-1H-IMIDAZOL-5-YL}PHENYL)CARBAMATE
1012, p4htcH_, 0.9043, 1.30, 0.341, 228, 226, THE REFINED STRUCTURE OF THE HIRUDIN-THROMBIN COMPLEX
1013, d4htc.1, 0.9043, 1.27, 0.341, 228, 226, THE REFINED STRUCTURE OF THE HIRUDIN-THROMBIN COMPLEX
1014, p4bamB_, 0.9043, 1.31, 0.341, 228, 226, THROMBIN IN COMPLEX WITH INHIBITOR
1015, d3t62C_, 0.9043, 1.60, 0.402, 242, 229, CRYSTAL STRUCTURE OF RECOMBINANT KUNITZ TYPE SERINE PROTEASE INHIBITOR-1 FROM THE CARIBBEAN SEA ANEMONE STICHODACTYLA HELIANTHUS IN COMPLEX WITH BOVINE CHYMOTRYPSIN
1016, p3d49H_, 0.9043, 1.66, 0.299, 250, 231, THROMBIN INHIBITION
1017, p2zhwH_, 0.9043, 1.66, 0.299, 249, 231, EXPLORING THROMBIN S3 POCKET
1018, d2fxrB_, 0.9043, 1.59, 0.402, 243, 229, HUMAN BETA TRYPTASE II COMPLEXED WITH ACTIVATED KETONE INHIBITOR CRA-29382
1019, d2fdaA_, 0.9043, 1.65, 0.402, 243, 229, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COAGULATION FACTOR XIA IN COMPLEX WITH ALPHA-KETOTHIAZOLE ARGININE DERIVED LIGAND
1020, p1t4vH_, 0.9043, 1.59, 0.402, 243, 229, CRYSTAL STRUCTURE ANALYSIS OF A NOVEL OXYGUANIDINE BOUND TO THROMBIN
1021, p1ettH_, 0.9043, 1.90, 0.296, 257, 233, REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
1022, d1ett.1, 0.9043, 1.90, 0.296, 286, 233, REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
1023, d1acbE_, 0.9043, 1.40, 0.339, 230, 227, CRYSTAL AND MOLECULAR STRUCTURE OF THE BOVINE ALPHA-CHYMOTRYPSIN-EGLIN C COMPLEX AT 2.0 ANGSTROMS RESOLUTION
1024, p6c0sA_, 0.9042, 1.40, 0.339, 230, 227, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL (4-{6-[(1S)-2-[(3R)-1- ACETYLPIPERIDIN-3-YL]-1-({(2E)-3-[5-CHLORO-2- (1H-TETRAZOL-1-YL) PHENYL]PROP-2-ENOYL}AMINO)ETHYL]-3-CHLOROPYRIDAZIN-4-YL}PHENYL) CARBAMATE
1025, d5tksA_, 0.9042, 1.76, 0.357, 238, 230, FACTOR XIA IN COMPLEX WITH THE INHIBITOR ((15S)-18-CHLORO- 15-(((2E)- 3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2- PROPENOYL)AMINO)-1719- DIAZATRICYCLO[14.2.1.0~27~]NONADECA-1(18)24616(19)-PENTAEN-5- YL)CARBAMATE
1026, d5qckA_, 0.9042, 1.90, 0.296, 257, 233, FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(2~{S}3~{R})-1-[(~{E})- 3-[5-CHLORANYL-2-(1234-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL]-3- PHENYL-PYRROLIDIN-2-YL]CARBONYLAMINO]BENZOIC ACID
1027, p3ldxH_, 0.9042, 1.90, 0.296, 290, 233, DISCOVERY AND CLINICAL EVALUATION OF RWJ-671818 A THROMBIN INHIBITOR WITH AN OXYGUANIDINE P1 MOTIF
1028, p2thfB_, 0.9042, 1.66, 0.299, 249, 231, STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D-PHE-PRO-ARG- CHLOROMETHYLKETONE
1029, d2thf.1, 0.9042, 1.43, 0.390, 240, 228, STRUCTURE OF HUMAN ALPHA-THROMBIN Y225F MUTANT BOUND TO D-PHE-PRO-ARG- CHLOROMETHYLKETONE
1030, p2od3B_, 0.9042, 1.66, 0.299, 249, 231, HUMAN THROMBIN CHIMERA WITH HUMAN RESIDUES 184A 186 186A 186B 186C AND 222 REPLACED BY MURINE THROMBIN EQUIVALENTS.
1031, d2fwwD_, 0.9042, 1.66, 0.299, 249, 231, HUMAN BETA-TRYPTASE II COMPLEXED WITH 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME
1032, d1zmnA_, 0.9042, 1.66, 0.402, 243, 229, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH (R)-1-(4-(4-(HYDROXYMETHYL)-13 2-DIOXABOROLAN-2-YL)PHENYL)GUANIDINE
1033, p1dwcH_, 0.9042, 1.76, 0.357, 237, 230, CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1034, d1dwc.1, 0.9042, 1.66, 0.299, 249, 231, CRYSTALLOGRAPHIC ANALYSIS AT 3.0-ANGSTROMS RESOLUTION OF THE BINDING TO HUMAN THROMBIN OF FOUR ACTIVE SITE-DIRECTED INHIBITORS
1035, p6futA_, 0.9041, 1.84, 0.305, 259, 233, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (S)-3 - (AMINOMETHYL)-N-(1;2;3;4-TETRAHYDRONAPHTHALEN-1-YL)-[1;1 -BIPHENYL]- 3-CARBOXAMIDE 
1036, d2fwwA_, 0.9041, 1.84, 0.305, 295, 233, HUMAN BETA-TRYPTASE II COMPLEXED WITH 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME
1037, d2fs8C_, 0.9041, 1.43, 0.390, 241, 228, HUMAN BETA-TRYPTASE II WITH INHIBITOR CRA-29382
1038, d1m9uC_, 0.9041, 1.76, 0.357, 238, 230, CRYSTAL STRUCTURE OF EARTHWORM FIBRINOLYTIC ENZYME COMPONENT A FROM EISENIA FETIDA
1039, d1ij7C_, 0.9041, 1.77, 0.357, 238, 230,  
1040, d5q0dA_, 0.9040, 1.77, 0.357, 238, 230, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(7S)-7-({(2E)-3-[5- CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-2-OXO-1234 5679-OCTAHYDRO-118-(AZENO)-19-BENZODIAZACYCLOTRIDECIN-14- YL]CARBAMATE
1041, d5pb1D_, 0.9040, 1.66, 0.299, 249, 231, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH BENZENECARBOXIMIDAMIDE
1042, p3hatH_, 0.9040, 1.69, 0.299, 249, 231, ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
1043, d3hat.1, 0.9040, 1.69, 0.299, 275, 231, ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
1044, d2fwwC_, 0.9040, 1.68, 0.299, 249, 231, HUMAN BETA-TRYPTASE II COMPLEXED WITH 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME
1045, p1qbvH_, 0.9040, 1.60, 0.402, 243, 229, CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR
1046, d1qbv.1, 0.9040, 1.77, 0.357, 237, 230, CRYSTAL STRUCTURE OF THROMBIN COMPLEXED WITH AN GUANIDINE-MIMETIC INHIBITOR
1047, d1a0lD_, 0.9040, 1.90, 0.296, 257, 233, HUMAN BETA-TRYPTASE: A RING-LIKE TETRAMER WITH ACTIVE SITES FACING A CENTRAL PORE
1048, d5q0fA_, 0.9039, 1.90, 0.296, 286, 233, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(4R5E8S)-8-({(2E)- 3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-4-METHYL- 2-OXO-1347810-HEXAHYDRO-2H-129-(AZENO)-110- BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE
1049, d5exmA_, 0.9039, 1.24, 0.345, 228, 226, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ~{N}-[4-[2-[(1~{S})-1- [[4-(AMINOMETHYL)CYCLOHEXYL]CARBONYLAMINO]-2-PHENYL-ETHYL]PYRIDIN-4- YL]PHENYL]CARBAMATE
1050, d2o8tA_, 0.9039, 1.65, 0.402, 243, 229, CRYSTAL STRUCTURE AND BINDING EPITOPES OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (C122A/N145Q) IN COMPLEX WITH INHIBITORS
1051, d2gddC_, 0.9039, 1.60, 0.402, 243, 229, HUMAN BETA II TRYPTASE WITH INHIBITOR CRA-27592
1052, d2gddA_, 0.9039, 1.73, 0.352, 241, 230, HUMAN BETA II TRYPTASE WITH INHIBITOR CRA-27592
1053, d2fwwB_, 0.9039, 1.73, 0.352, 241, 230, HUMAN BETA-TRYPTASE II COMPLEXED WITH 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME
1054, p2a45B_, 0.9039, 1.77, 0.357, 238, 230, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THROMBIN AND THE CENTRAL E REGION OF FIBRIN
1055, d2a45.1, 0.9039, 1.69, 0.339, 249, 230, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THROMBIN AND THE CENTRAL E REGION OF FIBRIN
1056, d1zslA_, 0.9039, 1.67, 0.299, 251, 231, FACTOR XI COMPLEXED WITH A PYRIMIDINONE INHIBITOR
1057, d1zomA_, 0.9039, 1.67, 0.299, 287, 231, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH A PEPTIDOMIMETIC INHIBITOR
1058, p1wayB_, 0.9039, 1.65, 0.402, 243, 229, ACTIVE SITE THROMBIN INHIBITORS
1059, d1kljH_, 0.9039, 1.67, 0.299, 249, 231, CRYSTAL STRUCTURE OF UNINHIBITED FACTOR VIIA
1060, p1k21H_, 0.9039, 1.67, 0.299, 275, 231, HUMAN THROMBIN-INHIBITOR COMPLEX
1061, d1k21.1, 0.9039, 1.60, 0.402, 244, 229, HUMAN THROMBIN-INHIBITOR COMPLEX
1062, d5tktA_, 0.9038, 1.77, 0.357, 238, 230, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((12E15S)-15-(((2E)- 3-(5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-8 1719-TRIAZATRICYCLO[14.2.1.0~27~]NONADECA-1(18)2461216(19)- HEXAEN-5-YL)CARBAMATE
1063, d5qclA_, 0.9038, 1.78, 0.357, 238, 230, FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5- CHLORANYL-2-(1234-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL]-34-DIHYDRO- 1~{H}-ISOQUINOLIN-1-YL]CARBONYLAMINO]BENZOIC ACID
1064, d5e2pA_, 0.9038, 1.27, 0.296, 231, 226, FACTOR XIA IN COMPLEX WITH THE INHIBITOR N-[(1S)-1-BENZYL-2-[2-[5- CHLORO-2-(TETRAZOL-1-YL)PHENYL]ETHYLAMINO]-2-OXO-ETHYL]-4-HYDROXY-2- OXO-1H-QUINOLINE-6-CARBOXAMIDE
1065, d2zebD_, 0.9038, 1.60, 0.402, 243, 229, POTENT NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
1066, d2fxrA_, 0.9038, 1.60, 0.402, 243, 229, HUMAN BETA TRYPTASE II COMPLEXED WITH ACTIVATED KETONE INHIBITOR CRA-29382
1067, d1z71A_, 0.9038, 1.60, 0.402, 243, 229, THROMBIN AND P2 PYRIDINE N-OXIDE INHIBITOR COMPLEX STRUCTURE
1068, p1hrtH_, 0.9038, 1.78, 0.296, 258, 233, THE STRUCTURE OF A COMPLEX OF BOVINE ALPHA-THROMBIN AND RECOMBINANT HIRUDIN AT 2.8 ANGSTROMS RESOLUTION
1069, d1hrt.1, 0.9038, 1.78, 0.296, 290, 233, THE STRUCTURE OF A COMPLEX OF BOVINE ALPHA-THROMBIN AND RECOMBINANT HIRUDIN AT 2.8 ANGSTROMS RESOLUTION
1070, d5qcmA_, 0.9037, 1.76, 0.357, 237, 230, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ~{N}-[4-[[(1~{S})-2- [(~{E})-3-[3-CHLORANYL-2-FLUORANYL-6-(1234-TETRAZOL-1-YL) PHENYL]PROP-2-ENOYL]-34-DIHYDRO-1~{H}-ISOQUINOLIN-1- YL]CARBONYLAMINO]PHENYL]CARBAMATE
1071, p5natA_, 0.9037, 1.77, 0.357, 237, 230, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (S)-PYRROLIDINE-12- DICARBOXYLIC ACID 1-[(1-METHYL-1H-INDOL-3-YL)-AMIDE] 2-[(3- TRIFLUOROMETHOXY-PHENYL)-AMIDE]
1072, d5e2oA_, 0.9037, 1.66, 0.299, 251, 231, FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[(N-{(2E)-3-[5-CHLORO-2- (1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}-L-PHENYLALANYL)AMINO]BENZOIC ACID
1073, d4ty7A_, 0.9037, 1.46, 0.333, 248, 228, FACTOR XIA IN COMPLEX WITH THE INHIBITOR (2S)-6-AMINO-N-{(1S)-1-[4-(3- AMINO-2H-INDAZOL-6-YL)-5-CHLORO-1H-IMIDAZOL-2-YL]-2-PHENYLETHYL}-2- ETHYLHEXANAMIDE
1074, d2fxrC_, 0.9037, 1.67, 0.299, 249, 231, HUMAN BETA TRYPTASE II COMPLEXED WITH ACTIVATED KETONE INHIBITOR CRA-29382
1075, d2fs8A_, 0.9037, 1.67, 0.299, 276, 231, HUMAN BETA-TRYPTASE II WITH INHIBITOR CRA-29382
1076, p2c8zB_, 0.9037, 1.77, 0.357, 238, 230, THROMBIN INHIBITORS
1077, d1gg6.1, 0.9036, 1.77, 0.357, 238, 230, CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-PHENYLALANINE TRIFLUOROMETHYL KETONE BOUND AT THE ACTIVE SITE
1078, p1c5lH_, 0.9036, 1.86, 0.355, 238, 231, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1-BINDING SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1079, d1c5l.1, 0.9036, 1.60, 0.402, 242, 229, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1-BINDING SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1080, d5qcnA_, 0.9035, 1.60, 0.402, 243, 229, FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[[(1~{S})-2-[(~{E})-3-[5- CHLORANYL-2-(1234-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL]-5-[(3~{S})-3- ETHOXYCARBONYLPIPERIDIN-1-YL]CARBONYL-34-DIHYDRO-1~{H}-ISOQUINOLIN- 1-YL]CARBONYLAMINO]BENZOIC ACID
1081, d5q0hA_, 0.9035, 1.67, 0.299, 276, 231, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(4R5E8S)-11-CHLORO- 8-[(26-DIFLUORO-4-METHYLBENZENE-1-CARBONYL)AMINO]-4-METHYL-2-OXO-1 347810-HEXAHYDRO-2H-129-(AZENO)-110-BENZODIAZACYCLOTETRADECIN- 15-YL]CARBAMATE
1082, d5q0eA_, 0.9035, 1.83, 0.305, 259, 233, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(4S8S)-8-({(2E)-3- [5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-4-METHYL-2- OXO-134567810-OCTAHYDRO-2H-129-(AZENO)-110- BENZODIAZACYCLOTETRADECIN-15-YL]CARBAMATE
1083, d4x6oA_, 0.9035, 1.83, 0.305, 295, 233, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL (4-{4-CHLORO-2-[(1S)- 1-({3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROPANOYL}AMINO)-2- PHENYLETHYL]-1H-IMIDAZOL-5-YL}PHENYL)CARBAMATE
1084, d4x6mA_, 0.9035, 1.78, 0.357, 238, 230, FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-AMINO-1H- INDAZOL-6-YL)-5-CHLORO-1H-IMIDAZOL-2-YL]-2-PHENYLETHYL}-3-[2- (AMINOMETHYL)-5-CHLOROBENZYL]UREA
1085, p2r2mB_, 0.9035, 1.30, 0.341, 228, 226, 2-(2-CHLORO-6-FLUOROPHENYL)ACETAMIDES AS POTENT THROMBIN INHIBITORS
1086, d1zgiA_, 0.9035, 1.86, 0.355, 238, 231, THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 21
1087, d1vit.2, 0.9035, 1.78, 0.357, 238, 230, THROMBIN:HIRUDIN 51-65 COMPLEX
1088, d1hut.1, 0.9035, 1.60, 0.402, 243, 229, THE STRUCTURE OF ALPHA-THROMBIN INHIBITED BY A 15-MER SINGLE-STRANDED DNA APTAMER
1089, d5tkuA_, 0.9034, 1.60, 0.402, 243, 229, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL ((15S)-15-(((2E)-3-(5- CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL)-2-PROPENOYL)AMINO)-9-OXO-81719- TRIAZATRICYCLO[14.2.1.0~27~]NONADECA-1(18)24616(19)-PENTAEN-5- YL)CARBAMATE
1090, d4x6nA_, 0.9034, 1.66, 0.299, 251, 231, FACTOR XIA IN COMPLEX WITH THE INHIBITOR 1-{(1S)-1-[4-(3-AMINO-1H- INDAZOL-6-YL)-5-CHLORO-1H-IMIDAZOL-2-YL]-2-PHENYLETHYL}-3-[5-CHLORO- 2-(1H-TETRAZOL-1-YL)BENZYL]UREA
1091, d4q7zA_, 0.9034, 1.43, 0.390, 238, 228, NEUTROPHIL SERINE PROTEASE 4 (PRSS57) WITH PHE-PHE-ARG- CHLOROMETHYLKETONE (FFR-CMK)
1092, d4na8A_, 0.9034, 1.72, 0.297, 252, 232, FACTOR XIA IN COMPLEX WITH THE INHIBITOR 5-AMINOCARBONYL-2-[3-[(2S 4R)-6-CARBAMIMIDOYL-4-METHYL-4-PHENYL-23-DIHYDRO-1H-QUINOLIN-2- YL]PHENYL]BENZOIC ACID
1093, d4d9rB_, 0.9034, 1.72, 0.297, 288, 232, INHIBITING ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION BY TARGETING THE EXOSITE ON FACTOR D
1094, d4a6lD_, 0.9034, 1.78, 0.357, 238, 230, BETA-TRYPTASE INHIBITOR
1095, p3c27B_, 0.9034, 1.86, 0.355, 238, 231, CYANOFLUOROPHENYLACETAMIDES AS ORALLY EFFICACIOUS THROMBIN INHIBITORS
1096, d2za5D_, 0.9034, 1.87, 0.355, 238, 231, CRYSTAL STRUCTURE OF HUMAN TRYPTASE WITH POTENT NON-PEPTIDE INHIBITOR
1097, p2c8yB_, 0.9034, 1.86, 0.355, 238, 231, THROMBIN INHIBITORS
1098, d2bm2D_, 0.9034, 1.77, 0.357, 238, 230, HUMAN BETA-II TRYPTASE IN COMPLEX WITH 4-(3-AMINOMETHYL- PHENYL)-PIPERIDIN-1-YL-(5-PHENETHYL- PYRIDIN-3-YL)- METHANONE
1099, d2bdyA_, 0.9034, 1.68, 0.299, 249, 231, THROMBIN IN COMPLEX WITH INHIBITOR
1100, d1zmjA_, 0.9034, 1.67, 0.299, 276, 231, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FACTOR XI IN COMPLEX WITH 4-(GUANIDINOMETHYL)-PHENYLBORONIC ACID
1101, d1zlrA_, 0.9034, 1.83, 0.305, 295, 233, FACTOR XI CATALYTIC DOMAIN COMPLEXED WITH 2-GUANIDINO-1-(4-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)ETHYL NICOTINATE
1102, d1zhmA_, 0.9034, 1.81, 0.296, 289, 233, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF THE COAGULATION FACTOR XIA IN COMPLEX WITH BENZAMIDINE (S434A- T475A-K437 MUTANT)
1103, p1qurH_, 0.9034, 1.87, 0.355, 238, 231, HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT BENZAMIDINE-BASED SYNTHETIC INHIBITOR
1104, d1qur.1, 0.9034, 1.87, 0.355, 238, 231, HUMAN ALPHA-THROMBIN IN COMPLEX WITH BIVALENT BENZAMIDINE-BASED SYNTHETIC INHIBITOR
1105, p1o2gH_, 0.9034, 1.37, 0.339, 233, 227, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1106, d1o2g.1, 0.9034, 1.79, 0.352, 238, 230, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1107, p1lhdH_, 0.9034, 1.28, 0.341, 228, 226, HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROLYS-OH
1108, d1lhd.1, 0.9034, 1.61, 0.402, 242, 229, HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROLYS-OH
1109, p1hbtH_, 0.9034, 1.68, 0.299, 249, 231, HUMAN ALPHA-THROMBIN COMPLEXED WITH A PEPTIDYL PYRIDINIUM METHYL KETONE CONTAINING BIVALENT INHIBITOR
1110, d1hbt.1, 0.9034, 1.61, 0.402, 242, 229, HUMAN ALPHA-THROMBIN COMPLEXED WITH A PEPTIDYL PYRIDINIUM METHYL KETONE CONTAINING BIVALENT INHIBITOR
1111, d1b5g.1, 0.9034, 1.67, 0.299, 251, 231, HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
1112, d5wb6A_, 0.9033, 1.60, 0.402, 242, 229, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(11S)-11-({(2E)-3-[5- CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-6-FLUORO-2-OXO- 134101113-HEXAHYDRO-2H-59:1512-DI(AZENO)-113- BENZODIAZACYCLOHEPTADECIN-18-YL]CARBAMATE
1113, p5nhuC_, 0.9033, 1.68, 0.299, 276, 231, HUMAN ALPHA THROMBIN COMPLEXED WITH ANOPHELES GAMBIAE CE5 ANTICOAGULANT
1114, p5cmxH_, 0.9033, 1.77, 0.357, 237, 230, X-RAY STRUCTURE OF THE COMPLEX BETWEEN HUMAN ALPHA THROMBIN AND A DUPLEX/QUADRUPLEX 31-MER DNA APTAMER
1115, d4ty6A_, 0.9033, 1.77, 0.357, 237, 230, FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-{2-[(1S)-1-({[TRANS-4- (AMINOMETHYL)CYCLOHEXYL]CARBONYL}AMINO)-2-PHENYLETHYL]-1H-IMIDAZOL-4- YL}BENZAMIDE
1116, d2zecD_, 0.9033, 1.75, 0.357, 237, 230, POTENT NONPEPTIDE INHIBITORS OF HUMAN MAST CELL TRYPTASE
1117, d1zpcA_, 0.9033, 1.90, 0.296, 257, 233, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-[2-(3-CHLORO-PHENYL)-2-HYDROXY- ACETYLAMINO]-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)-BUTYL]- 3-METHYL-BUTYRAMIDE
1118, d1riw.1, 0.9033, 1.90, 0.296, 284, 233, THROMBIN IN COMPLEX WITH NATURAL PRODUCT INHIBITOR OSCILLARIN
1119, d5fcrC_, 0.9032, 1.68, 0.299, 251, 231, MOUSE COMPLEMENT FACTOR D
1120, p2c8wB_, 0.9032, 1.68, 0.299, 287, 231, THROMBIN INHIBITORS
1121, d1zrkA_, 0.9032, 1.68, 0.299, 249, 231, FACTOR XI COMPLEXED WITH 3-HYDROXYPROPYL 3-(7- AMIDINONAPHTHALENE-1-CARBOXAMIDO)BENZENESULFONATE
1122, d1zhpA_, 0.9032, 1.68, 0.299, 275, 231, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH BENZAMIDINE (S434A-T475A-K505 MUTANT)
1123, d1zgvA_, 0.9032, 1.68, 0.299, 249, 231, THROMBIN IN COMPLEX WITH AN OXAZOLOPYRIDINE INHIBITOR 2
1124, d1ta6A_, 0.9032, 1.68, 0.299, 276, 231, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 14B
1125, p1t4uH_, 0.9032, 1.68, 0.299, 279, 231, CRYSTAL STRUCTURE ANALYSIS OF A NOVEL OXYGUANIDINE BOUND TO THROMBIN
1126, p5tccB_, 0.9031, 1.86, 0.355, 238, 231, COMPLEMENT FACTOR D INHIBITED WITH JH4
1127, d3c1kA_, 0.9031, 1.70, 0.299, 249, 231, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH INHIBITOR 15
1128, d1ztkA_, 0.9031, 1.69, 0.299, 249, 231, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-(5-AMINO-6-OXO-2-M-TOLYL-6H- PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1-(THIAZOLE-2-CARBONYL)- BUTYL]-ACETAMIDE
1129, d5q0gA_, 0.9030, 1.79, 0.357, 238, 230, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL [(3R7S)-7-({(2E)-3- [5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)-3-ETHYL-2- OXO-12345679-OCTAHYDRO-118-(AZENO)-19- BENZODIAZACYCLOTRIDECIN-14-YL]CARBAMATE
1130, d4y8yA_, 0.9030, 1.60, 0.402, 242, 229, FACTOR XIA IN COMPLEX WITH THE INHIBITOR METHYL (4-{4-CHLORO-2-[(1S)- 1-({(2E)-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2-ENOYL}AMINO)- 3-(MORPHOLIN-4-YL)-3-OXOPROPYL]-1H-IMIDAZOL-5-YL}PHENYL)CARBAMATE
1131, d3v7tD_, 0.9030, 1.76, 0.357, 237, 230, CRYSTAL STRUCTURE OF HUMAN BETA-TRYPTASE COMPLEXED WITH A SYNTHETIC INHIBITOR WITH A TROPANYLAMIDE SCAFFOLD
1132, p2gdeH_, 0.9030, 1.68, 0.299, 276, 231, THROMBIN IN COMPLEX WITH INHIBITOR
1133, d1ztlA_, 0.9030, 1.31, 0.341, 229, 226, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH N-[4-GUANIDINO-1-(THIAZOLE-2- CARBONYL)-BUTYL]-2-{6-OXO-5-[(QUINOLIN-8-YLMETHYL)-AMINO]- 2-M-TOLYL-6H-PYRIMIDIN-1-YL}-ACETAMIDE
1134, d1xx9A_, 0.9030, 1.68, 0.299, 251, 231, CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTINM84R
1135, d1ta2A_, 0.9030, 1.77, 0.357, 237, 230, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH COMPOUND 1
1136, d1nt1A_, 0.9030, 1.70, 0.358, 237, 229, THROMBIN IN COMPLEX WITH SELECTIVE MACROCYCLIC INHIBITOR
1137, p1mueB_, 0.9030, 1.68, 0.299, 276, 231, THROMBIN-HIRUGEN-L405426
1138, d1mue.1, 0.9030, 1.68, 0.299, 276, 231, THROMBIN-HIRUGEN-L405426
1139, d1dfpA_, 0.9030, 1.68, 0.299, 249, 231, FACTOR D INHIBITED BY DIISOPROPYL FLUOROPHOSPHATE
1140, d5exlA_, 0.9029, 1.34, 0.341, 228, 226, FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-(AMINOMETHYL)-~{N}- [(1~{S})-1-[4-(3-OXIDANYL-1~{H}-INDAZOL-5-YL)PYRIDIN-2-YL]-2-PHENYL- ETHYL]CYCLOHEXANE-1-CARBOXAMIDE
1141, d4y8zA_, 0.9029, 1.68, 0.299, 276, 231, FACTOR XIA IN COMPLEX WITH THE INHIBITOR (2E)-N-[(1S)-1-[5-CHLORO-4- (4-HYDROXY-2-OXO-12-DIHYDROQUINOLIN-6-YL)-1H-IMIDAZOL-2-YL]-3-(4- METHYLPIPERAZIN-1-YL)-3-OXOPROPYL]-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL) PHENYL]PROP-2-ENAMIDE
1142, d1ztjA_, 0.9029, 1.78, 0.357, 237, 230, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH 2-(5-BENZYLAMINO-2- METHYLSULFANYL-6-OXO-6H-PYRIMIDIN-1-YL)-N-[4-GUANIDINO-1- (THIAZOLE-2-CARBONYL)-BUTYL]-ACETAMIDE
1143, d1p0sH_, 0.9029, 1.87, 0.355, 238, 231, CRYSTAL STRUCTURE OF BLOOD COAGULATION FACTOR XA IN COMPLEX WITH ECOTIN M84R
1144, p1mu8B_, 0.9029, 1.87, 0.355, 238, 231, THROMBIN-HIRUGEN_L-378650
1145, d1mu8.1, 0.9029, 1.61, 0.402, 242, 229, THROMBIN-HIRUGEN_L-378650
1146, d1eolA_, 0.9029, 1.69, 0.299, 249, 231, DESIGN OF P1  AND P3  RESIDUES OF TRIVALENT THROMBIN INHIBITORS AND THEIR CRYSTAL STRUCTURES
1147, p3tu7H_, 0.9028, 1.80, 0.357, 237, 230, HUMAN ALPHA-THROMBIN COMPLEXED WITH N-(METHYLSULFONYL)-D-PHENYLALANYL- N-((1-CARBAMIMIDOYL-4-PIPERIDINYL)METHYL)-L-PROLINAMIDE (BMS-189664)
1148, p1tbzH_, 0.9028, 1.67, 0.349, 237, 229, HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N-[5- (AMINOIMINOMETHYL)AMINO]-1-{{BENZOTHIAZOLYL)CARBONYL] BUTYL]-L- PROLINAMIDE TRIFLUROACETATE AND EXOSITE-HIRUGEN
1149, d1tbz.1, 0.9028, 1.69, 0.299, 276, 231, HUMAN THROMBIN WITH ACTIVE SITE N-METHYL-D PHENYLALANYL-N-[5- (AMINOIMINOMETHYL)AMINO]-1-{{BENZOTHIAZOLYL)CARBONYL] BUTYL]-L- PROLINAMIDE TRIFLUROACETATE AND EXOSITE-HIRUGEN
1150, d4crfA_, 0.9027, 1.69, 0.299, 276, 231, CREATING NOVEL F1 INHIBITORS THROUGH FRAGMENT BASED LEAD GENERATION AND STRUCTURE AIDED DRUG DESIGN
1151, d1zmlA_, 0.9027, 1.68, 0.299, 248, 231, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FACTOR XI IN COMPLEX WITH (R)-1-(4-(4-(HYDROXYMETHYL)-132- DIOXABOROLAN-2-YL)PHENETHYL)GUANIDINE
1152, d5pb6C_, 0.9026, 1.68, 0.299, 276, 231, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH N-[[3-[5-HYDROXY-4- (1H-PYRROLO[32-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]PENTANAMIDE
1153, d5nb7A1, 0.9026, 1.32, 0.341, 228, 226, COMPLEMENT FACTOR D
1154, d5nawA_, 0.9026, 1.88, 0.355, 238, 231, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (1R3S5R)-2-AZA- BICYCLO[3.1.0]HEXANE-23-DICARBOXYLIC ACID 2-[(1-CARBAMOYL-1H-INDOL- 3-YL)-AMIDE] 3-[(3-TRIFLUOROMETHOXY-PHENYL)-AMIDE]
1155, p5ahgH_, 0.9026, 1.88, 0.355, 238, 231, THROMBIN IN COMPLEX WITH ((4-CHLOROPHENYL)SULFAMOYL)) DIEMETHYLAMINE
1156, p2c90B_, 0.9026, 1.77, 0.357, 237, 230, THROMBIN INHIBITORS
1157, p1mu6B_, 0.9026, 1.66, 0.304, 235, 230, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH L-378622
1158, d1mu6.1, 0.9026, 1.68, 0.299, 250, 231, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH L-378622
1159, p1lhgH_, 0.9026, 1.68, 0.299, 276, 231, HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO- BOROORNITHINE-OH
1160, d1lhg.1, 0.9026, 1.69, 0.299, 278, 231, HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO- BOROORNITHINE-OH
1161, p1lhcH_, 0.9026, 1.71, 0.299, 250, 231, HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROARG-OH
1162, d1lhc.1, 0.9026, 1.70, 0.299, 251, 231, HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BOROARG-OH
1163, d1hja.1, 0.9026, 1.70, 0.299, 276, 231, LYS 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH ALPHA-CHYMOTRYPSIN
1164, d1xxfA_, 0.9025, 1.87, 0.355, 237, 231, CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTIN MUTANT (ECOTINP)
1165, p1ditH_, 0.9025, 1.80, 0.357, 237, 230, COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN
1166, d1dit.1, 0.9025, 1.62, 0.332, 249, 229, COMPLEX OF A DIVALENT INHIBITOR WITH THROMBIN
1167, d1cho.1, 0.9025, 1.34, 0.341, 228, 226, CRYSTAL AND MOLECULAR STRUCTURES OF THE COMPLEX OF ALPHA- *CHYMOTRYPSIN WITH ITS INHIBITOR TURKEY OVOMUCOID THIRD DOMAIN AT 1.8 ANGSTROMS RESOLUTION
1168, d2p3fH_, 0.9024, 1.34, 0.341, 228, 226, CRYSTAL STRUCTURE OF THE FACTOR XA/NAP5 COMPLEX
1169, p1tomH_, 0.9024, 1.68, 0.299, 250, 231, ALPHA-THROMBIN COMPLEXED WITH HIRUGEN
1170, d1tom.1, 0.9024, 1.68, 0.299, 251, 231, ALPHA-THROMBIN COMPLEXED WITH HIRUGEN
1171, p1p8vC_, 0.9024, 1.68, 0.299, 250, 231, CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND ALPHA-THROMBIN AT 2.6A
1172, d1p8v.1, 0.9024, 1.68, 0.299, 276, 231, CRYSTAL STRUCTURE OF THE COMPLEX OF PLATELET RECEPTOR GPIB-ALPHA AND ALPHA-THROMBIN AT 2.6A
1173, d1eojA_, 0.9024, 1.70, 0.299, 249, 231, DESIGN OF P1  AND P3  RESIDUES OF TRIVALENT THROMBIN INHIBITORS AND THEIR CRYSTAL STRUCTURES
1174, p1bcuH_, 0.9024, 1.70, 0.299, 275, 231, ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN
1175, d1bcu.1, 0.9024, 1.70, 0.299, 249, 231, ALPHA-THROMBIN COMPLEXED WITH HIRUGEN AND PROFLAVIN
1176, d5uggA_, 0.9023, 1.70, 0.299, 275, 231, PROTEASE INHIBITOR
1177, d5tcaB_, 0.9023, 1.47, 0.390, 238, 228, COMPLEMENT FACTOR D INHIBITED WITH JH3
1178, d4wxiA_, 0.9023, 1.69, 0.354, 237, 229, FACTOR XIA IN COMPLEX WITH THE INHIBITOR TRANS-N-{(1S)-1-[4-(3-AMINO- 2H-INDAZOL-6-YL)PYRIDIN-2-YL]-2-PHENYLETHYL}-4-(AMINOMETHYL) CYCLOHEXANECARBOXAMIDE
1179, p3gisF_, 0.9023, 1.69, 0.299, 251, 231, CRYSTAL STRUCTURE OF NA-FREE THROMBIN IN COMPLEX WITH THROMBOMODULIN
1180, d1xxdA_, 0.9023, 1.69, 0.299, 280, 231, CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH MUTATED ECOTIN
1181, p4bohA_, 0.9022, 1.49, 0.390, 238, 228, MADANINS (MEROPS I53) ARE CLEAVED BY THROMBIN AND FACTOR XA
1182, d1p2oA_, 0.9022, 1.67, 0.307, 235, 231, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1183, p1a61H_, 0.9022, 1.69, 0.299, 250, 231, THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR
1184, d1a61.1, 0.9022, 1.69, 0.299, 276, 231, THROMBIN COMPLEXED WITH A BETA-MIMETIC THIAZOLE-CONTAINING INHIBITOR
1185, p6fuiA_, 0.9021, 1.71, 0.299, 250, 231, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR 3-((3-((3- (AMINOMETHYL)PHENYL)AMINO)-1H-PYRAZOLO[3;4-D]PYRIMIDIN-4-YL)AMINO) PHENOL 
1186, d4crcA_, 0.9021, 1.71, 0.299, 279, 231, CREATING NOVEL F1 INHIBITORS THROUGH FRAGMENT BASED LEAD GENERATION AND STRUCTURE AIDED DRUG DESIGN
1187, p2zgbH_, 0.9021, 1.69, 0.299, 278, 231, THROMBIN INHIBITION
1188, d1p2oC_, 0.9021, 1.69, 0.299, 249, 231, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1189, p1lheH_, 0.9021, 1.69, 0.299, 275, 231, HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-N- BUTYL-AMIDINO-GLYCINE-OH
1190, d1lhe.1, 0.9021, 1.63, 0.385, 246, 226, HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO-N- BUTYL-AMIDINO-GLYCINE-OH
1191, d5ugdA_, 0.9020, 1.37, 0.341, 228, 226, PROTEASE INHIBITOR
1192, d4q80B_, 0.9020, 1.89, 0.355, 238, 231, NEUTROPHIL SERINE PROTEASE 4 (PRSS57) WITH VAL-LEU-LYS- CHLOROMETHYLKETONE (VLK-CMK)
1193, d4ogyA_, 0.9020, 1.63, 0.296, 248, 230, CRYSTAL STRUCTURE OF FAB DX-2930 IN COMPLEX WITH HUMAN PLASMA KALLIKREIN AT 2.1 ANGSTROM RESOLUTION
1194, d4d9qA_, 0.9020, 1.76, 0.357, 238, 230, INHIBITING ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION BY TARGETING THE EXOSITE ON FACTOR D
1195, d1t8nA_, 0.9020, 1.70, 0.299, 249, 231, CRYSTAL STRUCTURE OF THE P1 THR BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1196, d1nu9D_, 0.9020, 1.49, 0.390, 238, 228, STAPHYLOCOAGULASE-PRETHROMBIN-2 COMPLEX
1197, d1nu9A_, 0.9020, 1.70, 0.299, 250, 231, STAPHYLOCOAGULASE-PRETHROMBIN-2 COMPLEX
1198, p1e0fE_, 0.9020, 1.70, 0.299, 277, 231, CRYSTAL STRUCTURE OF THE HUMAN ALPHA-THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II-BINDING INHIBITOR
1199, d1e0f.2, 0.9020, 1.23, 0.338, 227, 225, CRYSTAL STRUCTURE OF THE HUMAN ALPHA-THROMBIN-HAEMADIN COMPLEX: AN EXOSITE II-BINDING INHIBITOR
1200, p1a5gH_, 0.9020, 1.79, 0.352, 237, 230, HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
1201, d1a5g.1, 0.9020, 1.64, 0.300, 249, 230, HUMAN THROMBIN COMPLEXED WITH NOVEL SYNTHETIC PEPTIDE MIMETIC INHIBITOR AND HIRUGEN
1202, p1lhfH_, 0.9019, 1.48, 0.390, 238, 228, HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO- HOMOLYS-OH
1203, d1lhf.1, 0.9019, 1.70, 0.299, 249, 231, HUMAN ALPHA-THROMBIN COMPLEXED WITH AC-(D)PHE-PRO-BORO- HOMOLYS-OH
1204, d1cbw.2, 0.9019, 1.70, 0.299, 275, 231, BOVINE CHYMOTRYPSIN COMPLEXED TO BPTI
1205, d4d9qB_, 0.9018, 1.63, 0.385, 246, 226, INHIBITING ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION BY TARGETING THE EXOSITE ON FACTOR D
1206, p2odyD_, 0.9018, 1.38, 0.335, 233, 227, THROMBIN-BOUND BOOPHILIN DISPLAYS A FUNCTIONAL AND ACCESSIBLE REACTIVE-SITE LOOP
1207, d4cboB_, 0.9017, 1.76, 0.348, 239, 230, CRYSTAL STRUCTURE OF COMPLEMENT FACTOR D MUTANT R202A AFTER ENSEMBLE REFINEMENT
1208, d1t8nC_, 0.9017, 1.76, 0.348, 239, 230, CRYSTAL STRUCTURE OF THE P1 THR BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1209, d5pagB_, 0.9016, 1.32, 0.336, 228, 226, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH (2R)-2-HYDROXY-N-[[3- [5-HYDROXY-4-(1H-PYRROLO[32-C]PYRIDIN-2-YL)PYRAZOL-1- YL]PHENYL]METHYL]-3-METHYLBUTANAMIDE;HYDROBROMIDE
1210, d1t7cA_, 0.9016, 1.50, 0.390, 239, 228, CRYSTAL STRUCTURE OF THE P1 GLU BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1211, p4ch8F_, 0.9015, 1.77, 0.294, 290, 231, HIGH-SALT CRYSTAL STRUCTURE OF A THROMBIN-GPIBALPHA PEPTIDE COMPLEX
1212, d2y6tA_, 0.9015, 1.81, 0.294, 290, 231, MOLECULAR RECOGNITION OF CHYMOTRYPSIN BY THE SERINE PROTEASE INHIBITOR ECOTIN FROM YERSINIA PESTIS
1213, d1t8lA_, 0.9015, 1.80, 0.302, 256, 232, CRYSTAL STRUCTURE OF THE P1 MET BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1214, d1cgiE_, 0.9015, 1.80, 0.302, 292, 232, THREE-DIMENSIONAL STRUCTURE OF THE COMPLEXES BETWEEN BOVINE CHYMOTRYPSINOGEN*A AND TWO RECOMBINANT VARIANTS OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL-TYPE)
1215, d1t8oA_, 0.9014, 1.70, 0.299, 250, 231, CRYSTAL STRUCTURE OF THE P1 TRP BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1216, d1t8mA_, 0.9014, 1.70, 0.299, 277, 231, CRYSTAL STRUCTURE OF THE P1 HIS BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1217, d1p2nA_, 0.9014, 1.71, 0.299, 249, 231, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1218, d1ltoB_, 0.9014, 1.71, 0.299, 275, 231, HUMAN ALPHA1-TRYPTASE
1219, p3duxH_, 0.9013, 1.48, 0.390, 239, 228, UNDERSTANDING THROMBIN INHIBITION
1220, d1t7cC_, 0.9013, 1.33, 0.336, 228, 226, CRYSTAL STRUCTURE OF THE P1 GLU BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1221, d1p2qA_, 0.9013, 1.71, 0.307, 255, 231, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1222, d1p2nC_, 0.9013, 1.39, 0.327, 228, 226, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1223, d1ltoD_, 0.9013, 1.50, 0.390, 239, 228, HUMAN ALPHA1-TRYPTASE
1224, d4d9rA_, 0.9012, 1.40, 0.335, 247, 227, INHIBITING ALTERNATIVE PATHWAY COMPLEMENT ACTIVATION BY TARGETING THE EXOSITE ON FACTOR D
1225, d1t8oC_, 0.9012, 1.50, 0.390, 239, 228, CRYSTAL STRUCTURE OF THE P1 TRP BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1226, d1t8mC_, 0.9012, 1.67, 0.300, 253, 230, CRYSTAL STRUCTURE OF THE P1 HIS BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1227, d1p2mA_, 0.9012, 1.49, 0.390, 239, 228, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1228, d1t8lC_, 0.9011, 1.50, 0.390, 239, 228, CRYSTAL STRUCTURE OF THE P1 MET BPTI MUTANT- BOVINE CHYMOTRYPSIN COMPLEX
1229, d1qfkH_, 0.9011, 1.65, 0.389, 245, 229, STRUCTURE OF HUMAN FACTOR VIIA AND ITS IMPLICATIONS FOR THE TRIGGERING OF BLOOD COAGULATION
1230, d1p2qC_, 0.9011, 1.65, 0.389, 245, 229, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1231, d5tcaG_, 0.9010, 1.50, 0.390, 239, 228, COMPLEMENT FACTOR D INHIBITED WITH JH3
1232, d2y6tB_, 0.9010, 1.51, 0.390, 239, 228, MOLECULAR RECOGNITION OF CHYMOTRYPSIN BY THE SERINE PROTEASE INHIBITOR ECOTIN FROM YERSINIA PESTIS
1233, d1p2mC_, 0.9010, 1.50, 0.390, 239, 228, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
1234, d1ltoA_, 0.9010, 1.71, 0.397, 243, 229, HUMAN ALPHA1-TRYPTASE
1235, p1wbgB_, 0.9009, 1.65, 0.300, 249, 230, ACTIVE SITE THROMBIN INHIBITORS
1236, d1afq.1, 0.9009, 1.51, 0.390, 239, 228, CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN COMPLEXED WITH A SYNTHETIC INHIBITOR
1237, d1a5iA_, 0.9009, 1.51, 0.390, 239, 228, CATALYTIC DOMAIN OF VAMPIRE BAT (DESMODUS ROTUNDUS) SALIVA PLASMINOGEN ACTIVATOR IN COMPLEX WITH EGR-CMK (GLU-GLY-ARG CHLOROMETHYL KETONE)
1238, p1a46H_, 0.9009, 1.50, 0.390, 239, 228, THROMBIN COMPLEXED WITH HIRUGEN AND A BETA-STRAND MIMETIC INHIBITOR
1239, d1a46.1, 0.9009, 1.71, 0.397, 243, 229, THROMBIN COMPLEXED WITH HIRUGEN AND A BETA-STRAND MIMETIC INHIBITOR
1240, d5exnA_, 0.9008, 1.33, 0.341, 228, 226, FACTOR XIA (C500S [C122S]) IN COMPLEX WITH THE INHIBITOR METHYL ~{N}- [4-[2-[(1~{S})-1-[[(~{E})-3-[5-CHLORANYL-2-(1234-TETRAZOL-1-YL) PHENYL]PROP-2-ENOYL]AMINO]-2-PHENYL-ETHYL]PYRIDIN-4- YL]PHENYL]CARBAMATE
1241, d2y6tC_, 0.9008, 1.51, 0.390, 239, 228, MOLECULAR RECOGNITION OF CHYMOTRYPSIN BY THE SERINE PROTEASE INHIBITOR ECOTIN FROM YERSINIA PESTIS
1242, p2odyB_, 0.9008, 1.50, 0.390, 239, 228, THROMBIN-BOUND BOOPHILIN DISPLAYS A FUNCTIONAL AND ACCESSIBLE REACTIVE-SITE LOOP
1243, p2a45E_, 0.9008, 1.51, 0.390, 238, 228, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THROMBIN AND THE CENTRAL E REGION OF FIBRIN
1244, d2a45.2, 0.9008, 1.51, 0.390, 239, 228, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THROMBIN AND THE CENTRAL E REGION OF FIBRIN
1245, d5paiB_, 0.9007, 1.87, 0.338, 252, 231, HUMAN FACTOR VIIA IN COMPLEX WITH N-(2-AMINO-1H-BENZIMIDAZOL-5-YL)-1- [3-[[(35-DIMETHYL-12-OXAZOL-4-YL)CARBAMOYLAMINO]METHYL]PHENYL]-5- HYDROXYPYRAZOLE-4-CARBOXAMIDE AT 1.73A
1246, p6fujF_, 0.9006, 1.51, 0.390, 239, 228, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR N-(3 -(AMINOMETHYL)- [1;1 -BIPHENYL]-3-YL)-3-METHYLBUTANAMIDE 
1247, p3utuH_, 0.9006, 1.39, 0.341, 228, 226, HIGH AFFINITY INHIBITOR OF HUMAN THROMBIN
1248, d2xbwA_, 0.9006, 1.53, 0.390, 239, 228, FACTOR XA IN COMPLEX WITH A PYRROLIDINE-34-DICARBOXYLIC ACID INHIBITOR
1249, p1ca8B_, 0.9006, 1.51, 0.390, 238, 228, THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1250, d1ca8.1, 0.9006, 1.72, 0.397, 243, 229, THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1251, p6fujD_, 0.9005, 1.71, 0.299, 251, 231, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR N-(3 -(AMINOMETHYL)- [1;1 -BIPHENYL]-3-YL)-3-METHYLBUTANAMIDE 
1252, p3egkH_, 0.9005, 1.42, 0.392, 237, 227, KNOBLE INHIBITOR
1253, d1n8o.1, 0.9005, 1.90, 0.316, 265, 234, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN BOVINE CHYMOTRYPSIN AND ECOTIN
1254, d1gmh.1, 0.9005, 1.90, 0.316, 265, 234, REFINED CRYSTAL STRUCTURE OF AGED AND NON-AGED ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN
1255, d5pb4C_, 0.9004, 1.71, 0.299, 250, 231, HUMAN FACTOR VIIA IN COMPLEX WITH 1-[[3-[5-HYDROXY-3-METHYL-4-(1H- PYRROLO[32-C]PYRIDIN-2-YL)PYRAZOL-1-YL]PHENYL]METHYL]-3-PHENYLUREA AT 2.43A
1256, p3f68H_, 0.9004, 1.71, 0.299, 276, 231, THROMBIN INHIBITION
1257, d1g2lA_, 0.9002, 1.81, 0.357, 237, 230, FACTOR XA INHIBITOR COMPLEX
1258, p1bb0B_, 0.9002, 1.48, 0.390, 239, 228, THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1259, d1bb0.1, 0.9002, 1.73, 0.307, 255, 231, THROMBIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1260, d5tcaD_, 0.9001, 1.83, 0.296, 258, 233, COMPLEMENT FACTOR D INHIBITED WITH JH3
1261, d4d7fA_, 0.9001, 1.83, 0.296, 290, 233, HUMAN FXIA IN COMPLEX WITH SMALL MOLECULE INHIBITORS.
1262, d2y6tD_, 0.9001, 1.41, 0.335, 247, 227, MOLECULAR RECOGNITION OF CHYMOTRYPSIN BY THE SERINE PROTEASE INHIBITOR ECOTIN FROM YERSINIA PESTIS
1263, d1ybwB_, 0.9001, 1.37, 0.341, 228, 226, PROTEASE DOMAIN OF HGFA WITH NO INHIBITOR
1264, d1ybwA_, 0.9001, 1.65, 0.300, 249, 230, PROTEASE DOMAIN OF HGFA WITH NO INHIBITOR
1265, d1mtn.1, 0.9001, 1.59, 0.306, 234, 229, BOVINE ALPHA-CHYMOTRYPSIN:BPTI CRYSTALLIZATION
1266, d4d76A_, 0.9000, 1.66, 0.296, 249, 230, HUMAN FXIA IN COMPLEX WITH SMALL MOLECULE INHIBITORS.
1267, d2xc5A_, 0.9000, 1.66, 0.296, 275, 230, FACTOR XA IN COMPLEX WITH A PYRROLIDINE-34-DICARBOXYLIC ACID INHIBITOR
1268, d1ltoC_, 0.9000, 1.36, 0.341, 228, 226, HUMAN ALPHA1-TRYPTASE
1269, d1iqeA_, 0.9000, 1.66, 0.300, 249, 230, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55590
1270, d1gcdA_, 0.9000, 1.63, 0.390, 239, 228, REFINED CRYSTAL STRUCTURE OF AGED AND NON-AGED ORGANOPHOSPHORYL CONJUGATES OF GAMMA-CHYMOTRYPSIN
1271, d5panB_, 0.8999, 1.42, 0.392, 237, 227, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 5-HYDROXY-N-(3-OXO-1 2-DIHYDROISOINDOL-5-YL)-1-[3-[(PHENYLCARBAMOYLAMINO) METHYL]PHENYL]PYRAZOLE-4-CARBOXAMIDE
1272, d5pacB_, 0.8999, 1.51, 0.342, 247, 228, HUMAN FACTOR VIIA IN COMPLEX WITH 5-HYDROXY-N-(4-OXO-3H-QUINAZOLIN-6- YL)-1-[3-[(PHENYLCARBAMOYLAMINO)METHYL]PHENYL]PYRAZOLE-4-CARBOXAMIDE AT 1.50A
1273, d1ab9.1, 0.8999, 1.66, 0.300, 249, 230, CRYSTAL STRUCTURE OF BOVINE GAMMA-CHYMOTRYPSIN
1274, d5tcaF_, 0.8998, 1.66, 0.304, 235, 230, COMPLEMENT FACTOR D INHIBITED WITH JH3
1275, d3k9xD_, 0.8998, 1.67, 0.296, 249, 230, X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-N-((2- METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL) ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE
1276, d1mtn.2, 0.8998, 1.67, 0.296, 275, 230, BOVINE ALPHA-CHYMOTRYPSIN:BPTI CRYSTALLIZATION
1277, p1mkxH_, 0.8998, 1.41, 0.341, 228, 226, THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA- THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1278, d1mkx.1, 0.8998, 1.76, 0.358, 236, 229, THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA- THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1279, d1cgjE_, 0.8998, 1.52, 0.390, 239, 228, THREE-DIMENSIONAL STRUCTURE OF THE COMPLEXES BETWEEN BOVINE CHYMOTRYPSINOGEN*A AND TWO RECOMBINANT VARIANTS OF HUMAN PANCREATIC SECRETORY TRYPSIN INHIBITOR (KAZAL-TYPE)
1280, p5tccG_, 0.8997, 1.56, 0.336, 246, 229, COMPLEMENT FACTOR D INHIBITED WITH JH4
1281, d5tcaE_, 0.8997, 1.56, 0.336, 246, 229, COMPLEMENT FACTOR D INHIBITED WITH JH3
1282, d4d7gA_, 0.8997, 1.55, 0.390, 239, 228, HUMAN FXIA IN COMPLEX WITH SMALL MOLECULE INHIBITORS.
1283, d2xc0A_, 0.8997, 1.77, 0.358, 236, 229, FACTOR XA IN COMPLEX WITH A PYRROLIDINE-34-DICARBOXYLIC ACID INHIBITOR
1284, d2xbvA_, 0.8997, 1.60, 0.306, 234, 229, FACTOR XA IN COMPLEX WITH A PYRROLIDINE-34-DICARBOXYLIC ACID INHIBITOR
1285, d4q7xB_, 0.8996, 1.67, 0.397, 243, 229, NEUTROPHIL SERINE PROTEASE 4 (PRSS57) APO FORM 1
1286, d1zjdA1, 0.8996, 1.67, 0.304, 235, 230, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF COAGULATION FACTOR XI IN COMPLEX WITH KUNITZ PROTEASE INHIBITOR DOMAIN OF PROTEASE NEXIN II
1287, p1vitH_, 0.8996, 1.43, 0.392, 237, 227, THROMBIN:HIRUDIN 51-65 COMPLEX
1288, d1vit.1, 0.8996, 1.52, 0.338, 247, 228, THROMBIN:HIRUDIN 51-65 COMPLEX
1289, d8gch.1, 0.8995, 1.42, 0.335, 247, 227, GAMMA-CHYMOTRYPSIN IS A COMPLEX OF ALPHA-CHYMOTRYPSIN WITH ITS OWN AUTOLYSIS PRODUCTS
1290, d4q7xA_, 0.8995, 1.43, 0.392, 237, 227, NEUTROPHIL SERINE PROTEASE 4 (PRSS57) APO FORM 1
1291, d2xbxA_, 0.8995, 1.41, 0.341, 228, 226, FACTOR XA IN COMPLEX WITH A PYRROLIDINE-34-DICARBOXYLIC ACID INHIBITOR
1292, d2vwlA_, 0.8995, 1.73, 0.307, 238, 231, AMINOPYRROLIDINE FACTOR XA INHIBITOR
1293, d5fcrD_, 0.8994, 1.54, 0.390, 239, 228, MOUSE COMPLEMENT FACTOR D
1294, d2wpiS_, 0.8994, 1.74, 0.307, 255, 231, FACTOR IXA SUPERACTIVE DOUBLE MUTANT
1295, d1ksnA_, 0.8994, 1.74, 0.307, 284, 231, CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH FXV673
1296, p5tccE_, 0.8993, 1.69, 0.389, 245, 229, COMPLEMENT FACTOR D INHIBITED WITH JH4
1297, d3m36A_, 0.8993, 1.41, 0.341, 226, 226, FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[3-(AMINOMETHYL) PHENYL]-N-[3-FLUORO-2 -(METHYLSULFONYL)BIPHENYL-4-YL]-3- (TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (DPC423)
1298, d2gd4B1, 0.8993, 1.43, 0.341, 228, 226, CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA-PENTASACCHARIDE COMPLEX
1299, d1ioeA_, 0.8993, 1.78, 0.358, 236, 229, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55532
1300, d4x6pB_, 0.8992, 1.61, 0.306, 234, 229, FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR (2E)-N-{(1S)-1-[4-(3-AMINO-1H-INDAZOL-6-YL)-1H-IMIDAZOL-2- YL]-2-PHENYLETHYL}-3-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]PROP-2- ENAMIDE
1301, d1f0rA_, 0.8992, 1.60, 0.306, 234, 229, CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208815
1302, d1dfpB_, 0.8992, 1.43, 0.344, 232, 227, FACTOR D INHIBITED BY DIISOPROPYL FLUOROPHOSPHATE
1303, d1bmlA_, 0.8992, 1.83, 0.358, 237, 229, COMPLEX OF THE CATALYTIC DOMAIN OF HUMAN PLASMIN AND STREPTOKINASE
1304, d5tcaC_, 0.8991, 1.85, 0.306, 259, 232, COMPLEMENT FACTOR D INHIBITED WITH JH3
1305, d3uirB_, 0.8991, 1.85, 0.306, 295, 232, CRYSTAL STRUCTURE OF THE PLASMIN-TEXTILININ-1 COMPLEX
1306, d2y82A_, 0.8991, 1.44, 0.392, 237, 227, STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
1307, d1lpkB_, 0.8991, 1.43, 0.344, 235, 227, CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 125.
1308, d1g2mA_, 0.8991, 1.43, 0.344, 235, 227, FACTOR XA INHIBITOR COMPLEX
1309, d5pb5B_, 0.8990, 1.61, 0.306, 234, 229, HUMAN FACTOR VIIA IN COMPLEX WITH 1-[[3-[5-HYDROXY-4-(7H-PYRROLO[23- D]PYRIMIDIN-6-YL)PYRAZOL-1-YL]PHENYL]METHYL]-3-PHENYLUREA AT 1.84A
1310, d4vgc.1, 0.8990, 1.61, 0.306, 234, 229, GAMMA-CHYMOTRYPSIN D-NAPHTHYL-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1311, d4q80A_, 0.8990, 1.46, 0.339, 230, 227, NEUTROPHIL SERINE PROTEASE 4 (PRSS57) WITH VAL-LEU-LYS- CHLOROMETHYLKETONE (VLK-CMK)
1312, d2bmgB_, 0.8990, 1.92, 0.368, 235, 231, CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 50
1313, d2vwoA_, 0.8989, 1.61, 0.306, 234, 229, AMINOPYRROLIDINE FACTOR XA INHIBITOR
1314, d2bqwB_, 0.8989, 1.42, 0.341, 228, 226, CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 45
1315, d1iqmA_, 0.8989, 1.60, 0.306, 234, 229, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M54471
1316, d5paoC_, 0.8988, 1.72, 0.299, 239, 231, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH (2S)-23-DIHYDROXY-N- [[3-[5-HYDROXY-4-(1H-PYRROLO[32-C]PYRIDIN-2-YL)PYRAZOL-1- YL]PHENYL]METHYL]PROPANAMIDE;HYDROBROMIDE
1317, d5paeB_, 0.8988, 1.75, 0.307, 235, 231, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH (2S)-2-HYDROXY-N-[[3- [5-HYDROXY-4-(1H-PYRROLO[32-C]PYRIDIN-2-YL)PYRAZOL-1- YL]PHENYL]METHYL]PROPANAMIDE
1318, d2pr3A_, 0.8988, 1.65, 0.355, 236, 228, FACTOR XA INHIBITOR
1319, d1iqgA_, 0.8988, 1.69, 0.309, 234, 230, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55159
1320, d1faxA_, 0.8988, 1.39, 0.341, 228, 226, COAGULATION FACTOR XA INHIBITOR COMPLEX
1321, d1ezqA_, 0.8988, 1.62, 0.381, 250, 226, CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR128515
1322, d2vwnA_, 0.8987, 1.62, 0.381, 250, 226, AMINOPYRROLIDINE FACTOR XA INHIBITOR
1323, d2bq7B_, 0.8987, 1.42, 0.341, 228, 226, CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 43
1324, d1iqnA_, 0.8987, 1.62, 0.385, 245, 226, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55192
1325, d1iqlA_, 0.8987, 1.69, 0.309, 234, 230, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M54476
1326, p1a4wH_, 0.8987, 1.70, 0.309, 234, 230, CRYSTAL STRUCTURES OF THROMBIN WITH THIAZOLE-CONTAINING INHIBITORS: PROBES OF THE S1  BINDING SITE
1327, d1a4w.1, 0.8987, 1.76, 0.307, 235, 231, CRYSTAL STRUCTURES OF THROMBIN WITH THIAZOLE-CONTAINING INHIBITORS: PROBES OF THE S1  BINDING SITE
1328, d4btiB_, 0.8986, 1.48, 0.330, 247, 227, FACTOR XA IN COMPLEX WITH THE DUAL THROMBIN-FXA INHIBITOR 58.
1329, d3ffgA_, 0.8986, 1.39, 0.394, 236, 226, FACTOR XA IN COMPLEX WITH THE INHIBITOR (R)-6-(2 -((3- HYDROXYPYRROLIDIN-1-YL)METHYL)BIPHENYL-4-YL)-1-(3-(5-OXO-4 5-DIHYDRO-1H-124-TRIAZOL-3-YL)PHENYL)-3- (TRIFLUOROMETHYL)-56-DIHYDRO-1H-PYRAZOLO[34-C]PYRIDIN- 7(4H)-ONE
1330, d1iqfA_, 0.8986, 1.43, 0.339, 233, 227, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55165
1331, p1hxeH_, 0.8986, 1.60, 0.306, 234, 229, SERINE PROTEASE
1332, d1hxe.1, 0.8986, 1.62, 0.306, 234, 229, SERINE PROTEASE
1333, d3m37A_, 0.8985, 1.62, 0.306, 234, 229, FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[2-(AMINOMETHYL) PHENYL]-N-(3-FLUORO-2 -SULFAMOYLBIPHENYL-4-YL)-3- (TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (DPC602)
1334, d3liwA_, 0.8985, 1.68, 0.304, 235, 230, FACTOR XA IN COMPLEX WITH (R)-2-(1-ADAMANTYLCARBAMOYLAMINO)- 3-(3-CARBAMIDOYL-PHENYL)-N-PHENETHYL-PROPIONIC ACID AMIDE
1335, d2xbyA_, 0.8985, 1.49, 0.335, 247, 227, FACTOR XA IN COMPLEX WITH A PYRROLIDINE-34-DICARBOXYLIC ACID INHIBITOR
1336, d1kyeA_, 0.8985, 1.49, 0.335, 247, 227,  
1337, d5k0hA_, 0.8984, 1.61, 0.306, 234, 229, HUMAN FACTOR XA IN COMPLEX WITH SYNTHETIC INHIBITOR BENZYLSULFONYL- DSER(BENZYL)-GLY-4-AMIDINOBENZYLAMIDE
1338, d4btiF_, 0.8984, 1.76, 0.307, 235, 231, FACTOR XA IN COMPLEX WITH THE DUAL THROMBIN-FXA INHIBITOR 58.
1339, d3vgc.1, 0.8984, 1.76, 0.303, 235, 231, GAMMA-CHYMOTRYPSIN L-NAPHTHYL-1-ACETAMIDO BORONIC ACID ACID INHIBITOR COMPLEX
1340, d2vgc.1, 0.8984, 1.69, 0.309, 234, 230, GAMMA-CHYMOTRYPSIN D-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1341, p5tccD_, 0.8983, 1.62, 0.306, 234, 229, COMPLEMENT FACTOR D INHIBITED WITH JH4
1342, d2y7xA_, 0.8983, 1.70, 0.309, 234, 230, THE DISCOVERY OF POTENT AND LONG-ACTING ORAL FACTOR XA INHIBITORS WITH TETRAHYDROISOQUINOLINE AND BENZAZEPINE P4 MOTIFS
1343, d2p16A_, 0.8983, 1.70, 0.304, 235, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR APIXABAN (BMS- 562247) AKA 1-(4-METHOXYPHENYL)-7-OXO-6-(4-(2-OXO-1- PIPERIDINYL)PHENYL)-4567-TETRAHYDRO-1H-PYRAZOLO[3 4- C]PYRIDINE-3-CARBOXAMIDE
1344, p1sr5C_, 0.8983, 1.66, 0.304, 235, 230, ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE
1345, d1sr5.1, 0.8983, 1.69, 0.300, 248, 230, ANTITHROMBIN-ANHYDROTHROMBIN-HEPARIN TERNARY COMPLEX STRUCTURE
1346, d1nfwA_, 0.8983, 1.69, 0.300, 274, 230, CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR209685
1347, d6cha.2, 0.8982, 1.62, 0.306, 234, 229, STRUCTURE OF A TETRAHEDRAL TRANSITION STATE COMPLEX OF ALPHA-*CHYMOTRYPSIN AT 1.8-*ANGSTROMS RESOLUTION
1348, d5tcaA_, 0.8982, 1.69, 0.309, 234, 230, COMPLEMENT FACTOR D INHIBITED WITH JH3
1349, d3uirA_, 0.8982, 1.70, 0.304, 235, 230, CRYSTAL STRUCTURE OF THE PLASMIN-TEXTILININ-1 COMPLEX
1350, d1lpgB_, 0.8982, 1.68, 0.300, 248, 230, CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 79.
1351, p5tccF_, 0.8981, 1.68, 0.300, 274, 230, COMPLEMENT FACTOR D INHIBITED WITH JH4
1352, p2zckP_, 0.8981, 1.62, 0.306, 234, 229, CRYSTAL STRUCTURE OF A TERNARY COMPLEX BETWEEN PSA A SUBSTRAT-ACYL INTERMEDIATE AND AN ACTIVATING ANTIBODY
1353, d2y80A_, 0.8981, 1.71, 0.309, 234, 230, STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
1354, d2y7zA_, 0.8981, 1.63, 0.306, 234, 229, STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
1355, d2g00A_, 0.8981, 1.71, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-(6-(2 - ((DIMETHYLAMINO)METHYL)-4-BIPHENYLYL)-7-OXO-3- (TRIFLUOROMETHYL)-4567-TETRAHYDRO-1H-PYRAZOLO[34- C]PYRIDIN-1-YL)BENZAMIDE
1356, d1nfxA_, 0.8981, 1.70, 0.309, 234, 230, CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208944
1357, d1k2i1_, 0.8981, 1.63, 0.306, 234, 229, CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN IN COMPLEX WITH 7- HYDROXYCOUMARIN
1358, p1hxfH_, 0.8981, 1.40, 0.394, 236, 226, HUMAN THROMBIN COMPLEX WITH HIRUDIN VARIANT
1359, d1hxf.1, 0.8981, 1.40, 0.394, 236, 226, HUMAN THROMBIN COMPLEX WITH HIRUDIN VARIANT
1360, p5tccC_, 0.8980, 1.45, 0.341, 228, 226, COMPLEMENT FACTOR D INHIBITED WITH JH4
1361, p3edxD_, 0.8980, 1.70, 0.309, 234, 230, CRYSTAL STRUCTURE OF THE W215A/E217A MUTANT OF MURINE THROMBIN
1362, d3cenA_, 0.8980, 1.70, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(2-(((5-CHLORO-2- PYRIDINYL) AMINO)SULFONYL)PHENYL)-4-(2-OXO-1(2H)- PYRIDINYL)BENZAMIDE
1363, d1vgc.1, 0.8980, 1.69, 0.300, 248, 230, GAMMA-CHYMOTRYPSIN L-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
1364, d1nfyA_, 0.8980, 1.69, 0.300, 280, 230, CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR200095
1365, d1lqdB_, 0.8980, 1.70, 0.309, 234, 230, CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 45.
1366, d1lpzB_, 0.8980, 1.55, 0.390, 236, 228, CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 41.
1367, d1iqiA_, 0.8980, 1.44, 0.341, 228, 226, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55125
1368, d1buiA_, 0.8980, 1.63, 0.385, 243, 226, STRUCTURE OF THE TERNARY MICROPLASMIN-STAPHYLOKINASE-MICROPLASMIN COMPLEX: A PROTEINASE-COFACTOR-SUBSTRATE COMPLEX IN ACTION
1369, d4a7iB_, 0.8979, 1.71, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH A POTENT 2-AMINO-ETHANE SULFONAMIDE INHIBITOR
1370, d2gd4H1, 0.8979, 1.44, 0.341, 228, 226, CRYSTAL STRUCTURE OF THE ANTITHROMBIN-S195A FACTOR XA-PENTASACCHARIDE COMPLEX
1371, d1f0sA_, 0.8979, 1.35, 0.338, 237, 225, CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR208707
1372, d5pabH_, 0.8978, 1.70, 0.309, 234, 230, CRYSTAL STRUCTURE OF FACTOR VIIA IN COMPLEX WITH 1-[[3-[2-HYDROXY-3- (1H-PYRROLO[32-C]PYRIDIN-2-YL)PHENYL]PHENYL]METHYL]-3-PHENYLUREA
1373, d3ensD_, 0.8978, 1.64, 0.306, 234, 229, CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH METHYL (2Z)-3-[(3- CHLORO-1H-INDOL-7-YL)AMINO]-2-CYANO-3-{[(3S)-2-OXO-1-(2-OXO-2- PYRROLIDIN-1-YLETHYL)AZEPAN-3-YL]AMINO}ACRYLATE
1374, p1mkwH_, 0.8978, 1.70, 0.309, 234, 230, THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA- THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1375, d1mkw.1, 0.8978, 1.70, 0.309, 234, 230, THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA- THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
1376, d1gl1C_, 0.8978, 1.41, 0.394, 236, 226, STRUCTURE OF THE COMPLEX BETWEEN BOVINE ALPHA-CHYMOTRYPSIN AND PMP-C AN INHIBITOR FROM THE INSECT LOCUSTA MIGRATORIA
1377, p1fpcH_, 0.8978, 1.70, 0.300, 248, 230, ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
1378, d1fpc.1, 0.8978, 1.70, 0.300, 274, 230, ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
1379, d6cha.1, 0.8977, 1.44, 0.341, 228, 226, STRUCTURE OF A TETRAHEDRAL TRANSITION STATE COMPLEX OF ALPHA-*CHYMOTRYPSIN AT 1.8-*ANGSTROMS RESOLUTION
1380, d4y71A_, 0.8977, 1.99, 0.300, 258, 233, FACTOR XA COMPLEX WITH GTC000398
1381, d4btuB_, 0.8977, 1.63, 0.306, 234, 229, FACTOR XA IN COMPLEX WITH THE DUAL THROMBIN-FXA INHIBITOR 57.
1382, d3ensB_, 0.8977, 1.40, 0.394, 236, 226, CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH METHYL (2Z)-3-[(3- CHLORO-1H-INDOL-7-YL)AMINO]-2-CYANO-3-{[(3S)-2-OXO-1-(2-OXO-2- PYRROLIDIN-1-YLETHYL)AZEPAN-3-YL]AMINO}ACRYLATE
1383, d3cs7A_, 0.8977, 1.71, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(4-METHOXYPHENYL)- 6-(4-(1-(PYRROLIDIN-1-YLMETHYL)CYCLOPROPYL)PHENYL)-3- (TRIFLUOROMETHYL)-56-DIHYDRO-1H-PYRAZOLO[34-C]PYRIDIN- 7(4H)-ONE
1384, d2vh0A_, 0.8977, 1.71, 0.309, 234, 230, STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: BIARYL PYRROLIDIN-2-ONES INCORPORATING BASIC HETEROCYCLIC MOTIFS
1385, d2fzzA_, 0.8977, 1.71, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-AMINO-12- BENZISOXAZOL-5-YL)-6-(2 -(((3R)-3-HYDROXY-1-PYRROLIDINYL) METHYL)-4-BIPHENYLYL)-3-(TRIFLUOROMETHYL)-1456- TETRAHYDRO-7H-PYRAZOLO[34-C]PYRIDIN-7-ONE
1386, d2bq6B_, 0.8977, 1.76, 0.307, 235, 231, CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH 21
1387, d2bohB_, 0.8977, 1.51, 0.387, 247, 225, CRYSTAL STRUCTURE OF FACTOR XA IN COMPLEX WITH COMPOUND 1
1388, d1iqkA_, 0.8977, 1.64, 0.306, 234, 229, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55113
1389, d1gl1A_, 0.8977, 1.61, 0.297, 234, 229, STRUCTURE OF THE COMPLEX BETWEEN BOVINE ALPHA-CHYMOTRYPSIN AND PMP-C AN INHIBITOR FROM THE INSECT LOCUSTA MIGRATORIA
1390, p3bf6H_, 0.8976, 1.70, 0.309, 234, 230, THROMBIN:SURAMIN COMPLEX
1391, d1nfuA_, 0.8976, 1.50, 0.335, 247, 227, CRYSTAL STRUCTURE OF HUMAN COAGULATION FACTOR XA COMPLEXED WITH RPR132747
1392, d1bmlB_, 0.8976, 1.75, 0.307, 238, 231, COMPLEX OF THE CATALYTIC DOMAIN OF HUMAN PLASMIN AND STREPTOKINASE
1393, p5ms4D_, 0.8975, 1.76, 0.307, 255, 231, KALLIKREIN-RELATED PEPTIDASE 8 LEUPEPTIN INHIBITOR COMPLEX
1394, d5cha.2, 0.8975, 1.76, 0.307, 284, 231, THE REFINEMENT AND THE STRUCTURE OF THE DIMER OF ALPHA- *CHYMOTRYPSIN AT 1.67-*ANGSTROMS RESOLUTION
1395, d4zhaA_, 0.8975, 1.47, 0.392, 239, 227, FACTOR XA COMPLEX WITH GTC000102
1396, d3kqbA_, 0.8975, 1.70, 0.300, 248, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR N-(3-FLUORO-2 - (METHYLSULFONYL)BIPHENYL-4-YL)-1-(3-(5-OXO-45-DIHYDRO-1H- 124- TRIAZOL-3-YL)PHENYL)-3-(TRIFLUOROMETHYL)-1H- PYRAZOLE-5-CARBOXAMIDE
1397, d2p94A_, 0.8975, 1.70, 0.300, 274, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-CHLORO-N-((1R2S)- 2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO)CYCLOHEXYL)-1H- INDOLE-6-CARBOXAMIDE
1398, d3hptB_, 0.8974, 1.48, 0.392, 236, 227, CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-2-CYANO-1-(2- METHYLBENZOFURAN-5-YL)-3-(2-OXO-1-(2-OXO-2-(PYRROLIDIN-1-YL)ETHYL) AZEPAN-3-YL)GUANIDINE
1399, d1xkaC_, 0.8974, 1.71, 0.309, 234, 230, FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A(2S)-(3 - AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1400, p1rd3D_, 0.8974, 1.71, 0.309, 234, 230, 2.5A STRUCTURE OF ANTICOAGULANT THROMBIN VARIANT E217K
1401, d1rd3.2, 0.8974, 1.76, 0.307, 238, 231, 2.5A STRUCTURE OF ANTICOAGULANT THROMBIN VARIANT E217K
1402, d1fjsA_, 0.8974, 1.71, 0.309, 234, 230, CRYSTAL STRUCTURE OF THE INHIBITOR ZK-807834 (CI-1031) COMPLEXED WITH FACTOR XA
1403, d3k9xB_, 0.8973, 1.71, 0.309, 234, 230, X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-N-((2- METHYLBENZOFURAN-5-YLAMINO)(2-OXO-1-(2-OXO-2- (PYRROLIDIN-1-YL) ETHYL)AZEPAN-3- YLAMINO)METHYLENE)NICOTINAMIDE
1404, d3gct.1, 0.8973, 1.71, 0.309, 234, 230, STRUCTURE OF GAMMA-*CHYMOTRYPSIN IN THE RANGE $P*H 2.0 TO $P*H 10.5 SUGGESTS THAT GAMMA-CHYMOTRYPSIN IS A COVALENT ACYL-ENZYME ADDUCT AT LOW $P*H
1405, d2phbA_, 0.8973, 1.63, 0.306, 234, 229, AN ORALLY EFFICACIOUS FACTOR XA INHIBITOR
1406, d3kqcA_, 0.8972, 1.71, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR 6-(2 - (METHYLSULFONYL) BIPHENYL-4-YL)-1-(3-(5-OXO-45-DIHYDRO-1H- 124-TRIAZOL-3-YL) PHENYL)-3-(TRIFLUOROMETHYL)-56- DIHYDRO-1H-PYRAZOLO[34-C]PYRIDIN- 7(4H)-ONE
1407, d1z6eA_, 0.8972, 1.78, 0.307, 235, 231, FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3 -AMINO-12-BENZISOXAZOL- 5 -YL)-N-(4-(2 -((DIMETHYLAMINO)METHYL)-1H-IMIDAZOL-1-YL)-2- FLUOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (RAZAXABAN; DPC906; BMS-561389)
1408, p1rd3B_, 0.8972, 1.47, 0.392, 239, 227, 2.5A STRUCTURE OF ANTICOAGULANT THROMBIN VARIANT E217K
1409, d1rd3.1, 0.8972, 1.71, 0.300, 250, 230, 2.5A STRUCTURE OF ANTICOAGULANT THROMBIN VARIANT E217K
1410, d1iqjA_, 0.8972, 1.71, 0.309, 234, 230, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55124
1411, d4q7yA_, 0.8971, 1.65, 0.381, 250, 226, NEUTROPHIL SERINE PROTEASE 4 (PRSS57) APO FORM 2
1412, d4cha.2, 0.8971, 1.34, 0.356, 228, 225, STRUCTURE OF ALPHA-*CHYMOTRYPSIN REFINED AT 1.68 ANGSTROMS RESOLUTION
1413, d4cha.1, 0.8971, 1.57, 0.390, 236, 228, STRUCTURE OF ALPHA-*CHYMOTRYPSIN REFINED AT 1.68 ANGSTROMS RESOLUTION
1414, d2uwpA_, 0.8971, 1.70, 0.309, 234, 230, FACTOR XA INHIBITOR COMPLEX
1415, d2p95A_, 0.8971, 1.64, 0.306, 234, 229, FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-((1R2S)- 2-(4-(2-OXOPYRIDIN-1(2H)-YL)BENZAMIDO) CYCLOPENTYL) THIOPHENE-2-CARBOXAMIDE
1416, p2h9tH_, 0.8971, 1.63, 0.306, 234, 229, CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN IN COMPLEX WITH SURAMIN
1417, d2cjiA_, 0.8971, 1.76, 0.307, 238, 231, CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
1418, d5fckA1, 0.8970, 1.77, 0.307, 235, 231, COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 5
1419, d3kqeA_, 0.8970, 1.99, 0.288, 258, 233, FACTOR XA IN COMPLEX WITH THE INHIBITOR 3-METHYL-1-(3-(5- OXO-45- DIHYDRO-1H-124-TRIAZOL-3-YL)PHENYL)-6-(2 - (PYRROLIDIN-1-YLMETHYL) BIPHENYL-4-YL)-56-DIHYDRO-1H- PYRAZOLO[34-C]PYRIDIN-7(4H)-ONE
1420, d2w3kA_, 0.8970, 1.99, 0.288, 289, 233, CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 44-DISUBSTITUTED PYRROLIDINE-12-DICARBOXAMIDE INHIBITOR 1
1421, d2q1jA_, 0.8970, 1.72, 0.304, 234, 230, THE DISCOVERY OF GLYCINE AND RELATED AMINO ACID-BASED FACTOR XA INHIBITORS
1422, p3hkiB_, 0.8969, 1.78, 0.307, 238, 231, CRYSTAL STRUCTURE OF MURINE THROMBIN MUTANT W215A/E217A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1
1423, p3edxF_, 0.8969, 1.41, 0.394, 236, 226, CRYSTAL STRUCTURE OF THE W215A/E217A MUTANT OF MURINE THROMBIN
1424, d1ggd.1, 0.8969, 1.63, 0.306, 234, 229, CRYSTAL STRUCTURE OF GAMMA CHYMOTRYPSIN WITH N-ACETYL-LEUCIL- PHENYLALANINE ALDEHYDE BOUND AT THE ACTIVE SITE
1425, d7gch.1, 0.8968, 1.65, 0.306, 234, 229, STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS
1426, p5tccA_, 0.8968, 1.71, 0.309, 234, 230, COMPLEMENT FACTOR D INHIBITED WITH JH4
1427, d5jbcS_, 0.8968, 1.98, 0.288, 259, 233, CRYSTAL STRUCTURE OF FACTOR IXA VARIANT V16I K98T Y177T I213V IN COMPLEX WITH PPACK
1428, d4y7bA_, 0.8968, 1.98, 0.288, 292, 233, FACTOR XA COMPLEX WITH GTC000441
1429, p3hk6D_, 0.8968, 1.77, 0.307, 235, 231, CRYSTAL STRUCTURE OF MURINE THROMBIN MUTANT W215A/E217A (TWO MOLECULES IN THE ASYMMETRIC UNIT)
1430, d2wphS_, 0.8968, 1.47, 0.344, 234, 227, FACTOR IXA SUPERACTIVE TRIPLE MUTANT
1431, d2uwlA_, 0.8968, 1.58, 0.390, 238, 228, SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
1432, d2j94A_, 0.8968, 1.59, 0.390, 239, 228, CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
1433, d5cha.1, 0.8967, 1.72, 0.309, 234, 230, THE REFINEMENT AND THE STRUCTURE OF THE DIMER OF ALPHA- *CHYMOTRYPSIN AT 1.67-*ANGSTROMS RESOLUTION
1434, d4crgA_, 0.8967, 1.64, 0.306, 234, 229, CREATING NOVEL F1 INHIBITORS THROUGH FRAGMENT BASED LEAD GENERATION AND STRUCTURE AIDED DRUG DESIGN
1435, d4crdA_, 0.8967, 1.71, 0.300, 250, 230, CREATING NOVEL F1 INHIBITORS THROUGH FRAGMENT BASED LEAD GENERATION AND STRUCTURE AIDED DRUG DESIGN
1436, d4btuF_, 0.8967, 1.72, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH THE DUAL THROMBIN-FXA INHIBITOR 57.
1437, d5gvtA_, 0.8966, 1.31, 0.344, 224, 224, CRYSTAL STRUCTURES OF THE SERINE PROTEASE DOMAIN OF MURINE PLASMA KALLIKREIN
1438, d4y7aA_, 0.8966, 1.65, 0.306, 234, 229, FACTOR XA COMPLEX WITH GTC000422
1439, d2wplS_, 0.8966, 1.65, 0.306, 234, 229, FACTOR IXA SUPERACTIVE TRIPLE MUTANT EDTA-SOAKED
1440, d2w3iA_, 0.8966, 1.65, 0.306, 234, 229, CRYSTAL STRUCTURE OF FXA IN COMPLEX WITH 44-DISUBSTITUTED PYRROLIDINE-12-DICARBOXAMIDE INHIBITOR 2
1441, d2p93A_, 0.8966, 2.03, 0.300, 255, 233, FACTOR XA IN COMPLEX WITH THE INHIBITOR 5-CHLORO-N-(2-(4-(2- OXOPYRIDIN-1(2H)-YL)BENZAMIDO)ETHYL)THIOPHENE-2-CARBOXAMIDE
1442, p1tq0D_, 0.8966, 2.04, 0.300, 258, 233, CRYSTAL STRUCTURE OF THE POTENT ANTICOAGULANT THROMBIN MUTANT W215A/E217A IN FREE FORM
1443, d1tq0.2, 0.8966, 1.42, 0.394, 236, 226, CRYSTAL STRUCTURE OF THE POTENT ANTICOAGULANT THROMBIN MUTANT W215A/E217A IN FREE FORM
1444, d1iqhA_, 0.8966, 1.42, 0.394, 236, 226, HUMAN COAGULATION FACTOR XA IN COMPLEX WITH M55143
1445, d1gl1B_, 0.8966, 1.49, 0.341, 228, 226, STRUCTURE OF THE COMPLEX BETWEEN BOVINE ALPHA-CHYMOTRYPSIN AND PMP-C AN INHIBITOR FROM THE INSECT LOCUSTA MIGRATORIA
1446, p6eo8H_, 0.8965, 2.05, 0.358, 235, 232, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL GLUCOSE- CONJUGATED POTENT INHIBITOR
1447, d5jbbS_, 0.8965, 1.72, 0.309, 234, 230, CRYSTAL STRUCTURE OF FACTOR IXA VARIANT V16I K98T Y177T I213V IN COMPLEX WITH EGR-CHLOROMETHYLKETONE
1448, d5jbaS_, 0.8965, 2.03, 0.300, 258, 233, CRYSTAL STRUCTURE OF FACTOR IXA VARIANT V16I K98T Y177T I212V IN COMPLEX WITH PPACK
1449, d4nffA_, 0.8965, 1.96, 0.368, 235, 231, HUMAN KALLIKREIN-RELATED PEPTIDASE 2 IN COMPLEX WITH PPACK
1450, d3kqdA_, 0.8965, 1.72, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-(3-(5-OXO-45- DIHYDRO-1H-1 24-TRIAZOL-3-YL)PHENYL)-6-(2 -(PYRROLIDIN-1- YLMETHYL)BIPHENYL-4- YL)-3-(TRIFLUOROMETHYL)-56-DIHYDRO- 1H-PYRAZOLO[34-C]PYRIDIN-7(4H)- ONE
1451, d2j95A_, 0.8965, 1.73, 0.309, 234, 230, CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
1452, p4n3lH_, 0.8964, 1.49, 0.392, 236, 227, CRYSTAL STRUCTURE OF THROMBIN IN COMPLEX WITH A NOVEL GLUCOSE- CONJUGATED POTENT INHIBITOR
1453, p2zclP_, 0.8964, 1.63, 0.361, 234, 227, CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
1454, d2psxA_, 0.8964, 1.76, 0.355, 235, 228, CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 5 IN COMPLEX WITH LEUPEPTIN
1455, p1uvtH_, 0.8964, 1.64, 0.306, 234, 229, BOVINE THROMBIN--BM14.1248 COMPLEX
1456, d1uvt.1, 0.8964, 1.72, 0.346, 236, 228, BOVINE THROMBIN--BM14.1248 COMPLEX
1457, d2xw9A_, 0.8963, 1.73, 0.309, 234, 230, CRYSTAL STRUCTURE OF COMPLEMENT FACTOR D MUTANT S183A
1458, d1xkbC_, 0.8961, 2.04, 0.362, 235, 232, FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A(2S)-(3 - AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1459, d4zh8A_, 0.8960, 1.73, 0.309, 234, 230, FACTOR XA COMPLEX WITH GTC000006
1460, d4y79A_, 0.8960, 1.73, 0.309, 234, 230, FACTOR XA COMPLEX WITH GTC000406
1461, d2d26C1, 0.8960, 1.77, 0.299, 246, 231, ACTIVE SITE DISTORTION IS SUFFICIENT FOR PROTEINASE INHIBIT SECOND CRYSTAL STRUCTURE OF COVALENT SERPIN-PROTEINASE COMPLEX
1462, d2gch.1, 0.8959, 1.77, 0.299, 274, 231, REFINED CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN AT 1.9 ANGSTROMS RESOLUTION
1463, d1gmd.1, 0.8959, 1.78, 0.307, 235, 231, X-RAY CRYSTAL STRUCTURE OF GAMMA-CHYMOTRYPSIN IN HEXANE
1464, p5ms3A_, 0.8958, 1.49, 0.392, 239, 227, KALLIKREIN-RELATED PEPTIDASE 8 CALCIUM COMPLEX
1465, d4bttF_, 0.8958, 1.66, 0.301, 247, 229, FACTOR XA IN COMPLEX WITH THE DUAL THROMBIN-FXA INHIBITOR 31.
1466, d2y81A_, 0.8958, 1.98, 0.364, 235, 231, STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH AMINOINDANE AND PHENYLPYRROLIDINE P4 MOTIFS
1467, p4djzD_, 0.8957, 1.97, 0.368, 235, 231, CATALYTIC FRAGMENT OF MASP-1 IN COMPLEX WITH ITS SPECIFIC INHIBITOR DEVELOPED BY DIRECTED EVOLUTION ON SGCI SCAFFOLD
1468, d2j34A_, 0.8957, 1.40, 0.347, 229, 225, CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
1469, d4ogxA_, 0.8956, 1.73, 0.309, 234, 230, CRYSTAL STRUCTURE OF FAB DX-2930 IN COMPLEX WITH HUMAN PLASMA KALLIKREIN AT 2.4 ANGSTROM RESOLUTION
1470, d4bttB_, 0.8956, 1.73, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH THE DUAL THROMBIN-FXA INHIBITOR 31.
1471, d3sw2B_, 0.8955, 1.66, 0.301, 247, 229, X-RAY CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH 6-CHLORO-N-((3S)- 2-OXO-1-(2-OXO-2-((5S)-8-OXO-56-DIHYDRO-1H-15-METHANOPYRIDO[12- A][15]DIAZOCIN-3(2H4H8H)-YL)ETHYL)PIPERIDIN-3-YL)NAPHTHALENE-2- SULFONAMIDE
1472, p3hkjB_, 0.8955, 1.39, 0.338, 237, 225, CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT W215A/E217A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1
1473, p3edxB_, 0.8955, 1.22, 0.263, 227, 224, CRYSTAL STRUCTURE OF THE W215A/E217A MUTANT OF MURINE THROMBIN
1474, d2zchP_, 0.8955, 1.22, 0.263, 227, 224, CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN COMPLEXED WITH AN ACTIVATING ANTIBODY
1475, p4djzB_, 0.8954, 1.69, 0.310, 247, 229, CATALYTIC FRAGMENT OF MASP-1 IN COMPLEX WITH ITS SPECIFIC INHIBITOR DEVELOPED BY DIRECTED EVOLUTION ON SGCI SCAFFOLD
1476, d2zghA_, 0.8954, 1.69, 0.310, 272, 229, CRYSTAL STRUCTURE OF ACTIVE GRANZYME M BOUND TO ITS PRODUCT
1477, d1xx9B_, 0.8954, 1.30, 0.339, 226, 224, CRYSTAL STRUCTURE OF THE FXIA CATALYTIC DOMAIN IN COMPLEX WITH ECOTINM84R
1478, d1gmc.1, 0.8954, 1.78, 0.307, 235, 231, THE X-RAY CRYSTAL STRUCTURE OF THE TETRAHEDRAL INTERMEDIATE OF GAMMA- CHYMOTRYPSIN IN HEXANE
1479, d2wpjS_, 0.8953, 1.74, 0.309, 234, 230, FACTOR IXA SUPERACTIVE TRIPLE MUTANT NACL-SOAKED
1480, d1wu1A_, 0.8953, 1.73, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR 4-[(5-CHLOROINDOL-2-YL) SULFONYL]-2-(2-METHYLPROPYL)-1-[[5-(PYRIDIN-4-YL) PYRIMIDIN-2- YL]CARBONYL]PIPERAZINE
1481, d3lc5A_, 0.8952, 1.20, 0.986, 223, 222, SELECTIVE BENZOTHIOPHINE INHIBITORS OF FACTOR IXA
1482, d2wpkS_, 0.8952, 1.44, 0.394, 236, 226, FACTOR IXA SUPERACTIVE TRIPLE MUTANT ETHYLENE GLYCOL-SOAKED
1483, d5jb9S_, 0.8951, 1.44, 0.394, 236, 226, CRYSTAL STRUCTURE OF FACTOR IXA K98T VARIANT IN COMPLEX WITH PPACK
1484, p3hkjE_, 0.8951, 1.38, 0.347, 228, 225, CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT W215A/E217A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1
1485, d2ra0A_, 0.8951, 1.38, 0.347, 228, 225, X-RAY STRUCTURE OF FXA IN COMPLEX WITH 7-FLUOROINDAZOLE
1486, d2j38A_, 0.8951, 1.67, 0.306, 234, 229, CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
1487, d2d1jA_, 0.8951, 1.60, 0.307, 233, 228, FACTOR XA IN COMPLEX WITH THE INHIBITOR 2-[[4-[(5- CHLOROINDOL-2-YL)SULFONYL]PIPERAZIN-1-YL] CARBONYL]THIENO[32-B]PYRIDINE N-OXIDE
1488, d1gha.1, 0.8951, 1.62, 0.291, 251, 227, A SECOND ACTIVE SITE IN CHYMOTRYPSIN? THE X-RAY CRYSTAL STRUCTURE OF N-ACETYL-D-TRYPTOPHAN BOUND TO GAMMA-CHYMOTRYPSIN
1489, p3hk6B_, 0.8950, 1.73, 0.309, 234, 230, CRYSTAL STRUCTURE OF MURINE THROMBIN MUTANT W215A/E217A (TWO MOLECULES IN THE ASYMMETRIC UNIT)
1490, d2cha.2, 0.8950, 1.74, 0.346, 236, 228, THE STRUCTURE OF CRYSTALLINE ALPHA-CHYMOTRYPSIN $V.THE ATOMIC STRUCTURE OF TOSYL-ALPHA-CHYMOTRYPSIN AT 2 ANGSTROMS RESOLUTION
1491, d2cha.1, 0.8950, 1.74, 0.309, 234, 230, THE STRUCTURE OF CRYSTALLINE ALPHA-CHYMOTRYPSIN $V.THE ATOMIC STRUCTURE OF TOSYL-ALPHA-CHYMOTRYPSIN AT 2 ANGSTROMS RESOLUTION
1492, p1ycpH_, 0.8950, 1.61, 0.307, 233, 228, THE CRYSTAL STRUCTURE OF FIBRINOGEN-AA PEPTIDE 1-23 (F8Y) BOUND TO BOVINE THROMBIN EXPLAINS WHY THE MUTATION OF PHE-8 TO TYROSINE STRONGLY INHIBITS NORMAL CLEAVAGE AT ARGININE-16
1493, d1ycp.1, 0.8950, 1.82, 0.299, 252, 231, THE CRYSTAL STRUCTURE OF FIBRINOGEN-AA PEPTIDE 1-23 (F8Y) BOUND TO BOVINE THROMBIN EXPLAINS WHY THE MUTATION OF PHE-8 TO TYROSINE STRONGLY INHIBITS NORMAL CLEAVAGE AT ARGININE-16
1494, d1ycp.2, 0.8948, 2.07, 0.300, 258, 233, THE CRYSTAL STRUCTURE OF FIBRINOGEN-AA PEPTIDE 1-23 (F8Y) BOUND TO BOVINE THROMBIN EXPLAINS WHY THE MUTATION OF PHE-8 TO TYROSINE STRONGLY INHIBITS NORMAL CLEAVAGE AT ARGININE-16
1495, d6gch.1, 0.8947, 1.40, 0.338, 237, 225, STRUCTURE OF CHYMOTRYPSIN-*TRIFLUOROMETHYL KETONE INHIBITOR COMPLEXES. COMPARISON OF SLOWLY AND RAPIDLY EQUILIBRATING INHIBITORS
1496, d2w26A_, 0.8947, 1.62, 0.291, 251, 227, FACTOR XA IN COMPLEX WITH BAY59-7939
1497, p1vr1H_, 0.8947, 1.59, 0.355, 231, 228, SPECIFITY FOR PLASMINOGEN ACTIVATOR INHIBITOR-1
1498, d1vr1.1, 0.8947, 1.58, 0.358, 233, 226, SPECIFITY FOR PLASMINOGEN ACTIVATOR INHIBITOR-1
1499, d3govB_, 0.8946, 1.44, 0.394, 236, 226, CRYSTAL STRUCTURE OF THE CATALYTIC REGION OF HUMAN MASP-1
1500, p1b7xB_, 0.8946, 2.06, 0.362, 235, 232, STRUCTURE OF HUMAN ALPHA-THROMBIN Y225I MUTANT BOUND TO D- PHE-PRO-ARG-CHLOROMETHYLKETONE
1501, d1b7x.1, 0.8946, 1.69, 0.310, 233, 229, STRUCTURE OF HUMAN ALPHA-THROMBIN Y225I MUTANT BOUND TO D- PHE-PRO-ARG-CHLOROMETHYLKETONE
1502, d1ghb.1, 0.8945, 1.97, 0.364, 235, 231, A SECOND ACTIVE SITE IN CHYMOTRYPSIN? THE X-RAY CRYSTAL STRUCTURE OF N-ACETYL-D-TRYPTOPHAN BOUND TO GAMMA-CHYMOTRYPSIN
1503, d3sosA_, 0.8944, 1.98, 0.368, 235, 231, BENZOTHIAZINONE INHIBITOR IN COMPLEX WITH FXIA
1504, p3hkiE_, 0.8943, 1.99, 0.368, 235, 231, CRYSTAL STRUCTURE OF MURINE THROMBIN MUTANT W215A/E217A IN COMPLEX WITH THE EXTRACELLULAR FRAGMENT OF HUMAN PAR1
1505, d2psyA_, 0.8943, 1.92, 0.297, 249, 232, CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 5 IN COMPLEX WITH LEUPEPTIN AND ZINC
1506, d2ei6A_, 0.8943, 1.78, 0.309, 234, 230, FACTOR XA IN COMPLEX WITH THE INHIBITOR (-)-CIS-N1-[(5- CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4567- TETRAHYDROTHIAZOLO[54-C]PYRIDIN-2-YL)CARBONYL]-12- CYCLOHEXANEDIAMINE
1507, d5jb8S_, 0.8942, 1.74, 0.309, 234, 230, CRYSTAL STRUCTURE OF FACTOR IXA VARIANT K98T IN COMPLEX WITH EGR- CHLOROMETHYLKETONE
1508, d3q3kA_, 0.8942, 1.70, 0.310, 233, 229, FACTOR XA IN COMPLEX WITH A PHENYLENEDIAMINE DERIVATIVE
1509, p3eq0H_, 0.8942, 1.45, 0.394, 236, 226, THROMBIN INHIBITOR
1510, d2wpmS_, 0.8942, 2.05, 0.300, 258, 233, FACTOR IXA SUPERACTIVE MUTANT EGR-CMK INHIBITED
1511, d2h9eH_, 0.8942, 1.52, 0.392, 236, 227, CRYSTAL STRUCTURE OF FXA/SELECTIDE/NAPC2 TERNARY COMPLEX
1512, d5gch.1, 0.8941, 1.52, 0.392, 236, 227, CHEMISTRY OF CAGED ENZYMES /II$. PHOTOACTIVATION OF INHIBITED CHYMOTRYPSIN
1513, d2ei7A_, 0.8941, 1.70, 0.310, 247, 229, FACTOR XA IN COMPLEX WITH THE INHIBITOR TRANS-N1-[(5- CHLOROINDOL-2-YL)CARBONYL]-N2-[(5-METHYL-4567- TETRAHYDROTHIAZOLO[54-C]PYRIDIN-2-YL)CARBONYL]-12- CYCLOHEXANEDIAMINE
1514, d1mq5A_, 0.8941, 1.70, 0.310, 276, 229, CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(4-CHLOROPHENYL) AMINO]CARBONYL]PHENYL]-4-[(4-METHYL-1-PIPERAZINYL)METHYL]-2- THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA
1515, d1v3xA_, 0.8940, 1.71, 0.310, 276, 229, FACTOR XA IN COMPLEX WITH THE INHIBITOR 1-[6-METHYL-4567- TETRAHYDROTHIAZOLO(54-C)PYRIDIN-2-YL] CARBONYL-2- CARBAMOYL-4-(6-CHLORONAPHTH-2-YLSULPHONYL)PIPERAZINE
1516, d1mq6A_, 0.8940, 1.46, 0.394, 236, 226, CRYSTAL STRUCTURE OF 3-CHLORO-N-[4-CHLORO-2-[[(5-CHLORO-2-PYRIDINYL) AMINO]CARBONYL]-6-METHOXYPHENYL]-4-[[(45-DIHYDRO-2-OXAZOLYL) METHYLAMINO]METHYL]-2-THIOPHENECARBOXAMIDE COMPLEXED WITH HUMAN FACTOR XA
1517, d5nbaA1, 0.8939, 1.70, 0.310, 233, 229, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (2S4R)-4-FLUORO- PYRROLIDINE-12-DICARBOXYLIC ACID 1-[(1-CARBAMOYL-1H-INDOL-3-YL)- AMIDE] 2-[(3-TRIFLUOROMETHOXY-PHENYL)-AMIDE]
1518, d3sorA_, 0.8939, 1.69, 0.293, 247, 229, FACTOR XIA IN COMPLEX WITH A CLOROPHENYL-TETRAZOLE INHIBITOR
1519, p5ms4B_, 0.8938, 1.69, 0.293, 274, 229, KALLIKREIN-RELATED PEPTIDASE 8 LEUPEPTIN INHIBITOR COMPLEX
1520, d4gch.1, 0.8936, 1.64, 0.291, 251, 227, STRUCTURE AND ACTIVITY OF TWO PHOTOREVERSIBLE CINNAMATES BOUND TO CHYMOTRYPSIN
1521, d2zgjA_, 0.8936, 1.72, 0.301, 246, 229, CRYSTAL STRUCTURE OF D86N-GZMM COMPLEXED WITH ITS OPTIMAL SYNTHESIZED SUBSTRATE
1522, d2vvvA_, 0.8934, 1.72, 0.301, 272, 229, AMINOPYRROLIDINE-RELATED TRIAZOLE FACTOR XA INHIBITOR
1523, d3iitA_, 0.8933, 1.46, 0.394, 226, 226, FACTOR XA IN COMPLEX WITH A CIS-12-DIAMINOCYCLOHEXANE DERIVATIVE
1524, d2zksA_, 0.8932, 1.76, 0.355, 236, 228, STRUCTURAL INSIGHTS INTO THE PROTEOLYTIC MACHINERY OF APOPTOSIS- INDUCING GRANZYME M
1525, d2p3uB_, 0.8932, 1.77, 0.304, 252, 230, CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3- CHLORO-N-(4-CHLORO-2-{[(5-CHLOROPYRIDIN-2-YL) AMINO]CARBONYL}-6-METHOXYPHENYL)-4-[(1-METHYL-1H-IMIDAZOL- 2-YL)METHYL]THIOPHENE-2-CARBOXAMIDE {PFIZER 320663}
1526, d1buiB_, 0.8932, 1.26, 0.263, 227, 224, STRUCTURE OF THE TERNARY MICROPLASMIN-STAPHYLOKINASE-MICROPLASMIN COMPLEX: A PROTEINASE-COFACTOR-SUBSTRATE COMPLEX IN ACTION
1527, d3kl6A_, 0.8931, 1.70, 0.310, 233, 229, DISCOVERY OF TETRAHYDROPYRIMIDIN-2(1H)-ONE DERIVATIVE TAK-442: A POTENT SELECTIVE AND ORALLY ACTIVE FACTOR XA INHIBITOR
1528, d3kcgH_, 0.8931, 2.01, 0.368, 235, 231, CRYSTAL STRUCTURE OF THE ANTITHROMBIN-FACTOR IXA- PENTASACCHARIDE COMPLEX
1529, d3hptD_, 0.8931, 1.71, 0.310, 233, 229, CRYSTAL STRUCTURE OF HUMAN FXA IN COMPLEX WITH (S)-2-CYANO-1-(2- METHYLBENZOFURAN-5-YL)-3-(2-OXO-1-(2-OXO-2-(PYRROLIDIN-1-YL)ETHYL) AZEPAN-3-YL)GUANIDINE
1530, d3tk6A_, 0.8930, 1.63, 0.303, 246, 228, FACTOR XA IN COMPLEX WITH D46-5241
1531, d2ei8A_, 0.8930, 2.00, 0.368, 235, 231, FACTOR XA IN COMPLEX WITH THE INHIBITOR (1S2R4S)-N1-[(5- CHLOROINDOL-2-YL)CARBONYL]-4-(NN-DIMETHYLCARBAMOYL)-N2- [(5-METHYL-4567-TETRAHYDROTHIAZOLO[54-C]PYRIDIN-2-YL) CARBONYL]-12-CYCLOHEXANEDIAMINE
1532, d5tjxA_, 0.8929, 1.63, 0.307, 233, 228, STRUCTURE OF HUMAN PLASMA KALLIKREIN
1533, d4y76A_, 0.8929, 1.47, 0.394, 236, 226, FACTOR XA COMPLEX WITH GTC000401
1534, p3k2uA_, 0.8928, 1.71, 0.310, 233, 229, CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC INHIBITORY ANTIBODY FAB40
1535, d2xc4A_, 0.8926, 1.71, 0.310, 233, 229, FACTOR XA IN COMPLEX WITH A PYRROLIDINE-34-DICARBOXYLIC ACID INHIBITOR
1536, d3tk5A_, 0.8925, 1.70, 0.310, 233, 229, FACTOR XA IN COMPLEX WITH D102-4380
1537, d1zpzA_, 0.8925, 1.71, 0.310, 233, 229, FACTOR XI CATALYTIC DOMAIN COMPLEXED WITH N-((R)-1-(4- BROMOPHENYL)ETHYL)UREA-ASN-VAL-ARG-ALPHA-KETOTHIAZOLE
1538, p3pmbD_, 0.8923, 1.28, 0.345, 223, 223, 2.9 ANGSTROM CRYSTAL STRUCTURE OF BOVINE THROMBIN IN TETRAGONAL SPACEGROUP
1539, p1nrnH_, 0.8923, 1.78, 0.355, 236, 228, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1540, d1nrn.1, 0.8923, 1.40, 0.351, 228, 225, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
1541, d2y5hA_, 0.8922, 1.47, 0.394, 236, 226, FACTOR XA - CATION INHIBITOR COMPLEX
1542, d1kigH_, 0.8921, 1.61, 0.351, 231, 228, BOVINE FACTOR XA
1543, d2uuyA_, 0.8920, 1.72, 0.310, 233, 229, STRUCTURE OF A TICK TRYPTASE INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1544, p1bthH_, 0.8919, 1.72, 0.310, 233, 229, STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1545, d1bth.1, 0.8919, 1.61, 0.355, 231, 228, STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1546, p4u2wA_, 0.8918, 1.72, 0.310, 233, 229, ATOMIC RESOLUTION CRYSTAL STRUCTURE OF HV-BBI PROTEASE INHIBITOR FROM AMPHIBIAN SKIN IN COMPLEX WITH BOVINE TRYPSIN
1547, d1xugA_, 0.8918, 1.39, 0.387, 248, 225, TRYPSIN-BABIM-ZN+2 PH 8.2
1548, d1o2yA_, 0.8918, 1.67, 0.311, 232, 228, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1549, d1o2vA_, 0.8918, 1.91, 0.365, 235, 230, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1550, d1ao5B_, 0.8918, 1.77, 0.309, 237, 230, MOUSE GLANDULAR KALLIKREIN-13 (PRORENIN CONVERTING ENZYME)
1551, d4nfeA_, 0.8917, 1.73, 0.310, 233, 229, HUMAN KALLIKREIN-RELATED PEPTIDASE 2 IN COMPLEX WITH BENZAMIDINE
1552, d1s84A_, 0.8917, 1.72, 0.310, 233, 229, PORCINE TRYPSIN COVALENT COMPLEX WITH 4-AMINO BUTANOL BORATE AND ETHYLENE GLYCOL
1553, d1o3lA_, 0.8917, 1.65, 0.347, 231, 225, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1554, d1o2xA_, 0.8917, 1.63, 0.311, 232, 228, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1555, d1o2wA_, 0.8917, 1.40, 0.338, 233, 225, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1556, d1gi4A_, 0.8917, 1.74, 0.310, 233, 229, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1557, d2jkhA_, 0.8916, 1.73, 0.310, 233, 229, FACTOR XA - CATION INHIBITOR COMPLEX
1558, d1s82A_, 0.8916, 1.68, 0.363, 233, 226, PORCINE TRYPSIN COMPLEXED WITH BORATE AND ETHYLENE GLYCOL
1559, d1rfnA_, 0.8916, 1.74, 0.310, 252, 229, HUMAN COAGULATION FACTOR IXA IN COMPLEX WITH P-AMINO BENZAMIDINE
1560, d3ljoA_, 0.8915, 1.76, 0.301, 247, 229, BOVINE TRYPSIN IN COMPLEX WITH UB-THR 11
1561, d1o3hA_, 0.8915, 1.76, 0.301, 276, 229, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1562, d1o30A_, 0.8915, 1.74, 0.310, 233, 229, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1563, d1o2uA_, 0.8915, 1.85, 0.325, 241, 231, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1564, d1gj6A_, 0.8915, 1.09, 0.385, 223, 221, ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRUG TARGETS
1565, d1dpoA_, 0.8915, 1.84, 0.309, 254, 230, STRUCTURE OF RAT TRYPSIN
1566, p5ms4C_, 0.8914, 1.84, 0.309, 285, 230, KALLIKREIN-RELATED PEPTIDASE 8 LEUPEPTIN INHIBITOR COMPLEX
1567, d2vvuA_, 0.8914, 1.09, 0.385, 223, 221, AMINOPYRROLIDINE FACTOR XA INHIBITOR
1568, d1s6fA_, 0.8914, 1.09, 0.385, 223, 221, PORCINE TRYPSIN COVALENT COMPLEX WITH BORATE AND GUANIDINE- 3 INHIBITOR
1569, d1o3kA_, 0.8914, 1.09, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1570, d1o3iA_, 0.8914, 1.09, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1571, d1o37A_, 0.8914, 1.47, 0.324, 236, 225, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1572, d1o36A_, 0.8914, 1.41, 0.348, 227, 224, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1573, d1g9iE_, 0.8914, 1.09, 0.389, 223, 221, CRYSTAL STRUCTURE OF BETA-TRYSIN COMPLEX IN CYCLOHEXANE
1574, p5xwjB_, 0.8913, 1.09, 0.385, 223, 221, CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR TRE AT PH 7
1575, d3lc3A_, 0.8913, 1.10, 0.385, 223, 221, BENZOTHIOPHENE INHIBITORS OF FACTOR IXA
1576, d2fx6A_, 0.8913, 1.10, 0.385, 223, 221, BOVINE TRYPSIN COMPLEXED WITH 2-AMINOBENZAMIDAZOLE
1577, d2fx4A_, 0.8913, 1.09, 0.385, 223, 221, BOVINE TRYPSIN BOUND BY 4-PIPERIDINEBUTYRATE TO MAKE ACYLENZYME COMPLEX
1578, d1pphE_, 0.8913, 1.76, 0.310, 233, 229, GEOMETRY OF BINDING OF THE NALPHA-TOSYLATED PIPERIDIDES OF M-AMIDINO- P-AMIDINO-AND P-GUANIDINO PHENYLALANINE TO THROMBIN AND TRYPSIN: X- RAY CRYSTAL STRUCTURES OF THEIR TRYPSIN COMPLEXES AND MODELING OF THEIR THROMBIN COMPLEXES
1579, d1o3jA_, 0.8913, 1.10, 0.389, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1580, d1o38A_, 0.8913, 1.98, 0.364, 235, 231, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1581, d1o33A_, 0.8913, 1.10, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1582, d1o2rA_, 0.8913, 1.09, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1583, d1g3dA_, 0.8913, 1.10, 0.385, 223, 221, BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE COPPER (II) CHELATE
1584, d2zq2A_, 0.8912, 1.10, 0.385, 223, 221, EXPLORING TRYPSIN S3 POCKET
1585, d2vvcA_, 0.8912, 1.10, 0.385, 223, 221, AMINOPYRROLIDINE FACTOR XA INHIBITOR
1586, d1yf4A_, 0.8912, 1.09, 0.380, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN-VASOPRESSIN COMPLEX
1587, d1v6dA_, 0.8912, 1.45, 0.347, 228, 225, THE CRYSTAL STRUCTURE OF THE TRYPSIN COMPLEX WITH SYNTHETIC HETEROCHIRAL PEPTIDE
1588, d1o3dA_, 0.8912, 1.75, 0.310, 233, 229, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1589, d1o2tA_, 0.8912, 1.10, 0.389, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1590, d1gi6A_, 0.8912, 1.10, 0.385, 223, 221, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1591, p4xojA_, 0.8911, 1.09, 0.385, 223, 221, STRUCTURE OF BOVINE TRYPSIN IN COMPLEX WITH ANALOGUES OF SUNFLOWER INHIBITOR 1 (SFTI-1)
1592, p4aoqC_, 0.8911, 1.09, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH MUTATED SPINACIA OLERACEA TRYPSIN INHIBITOR III (SOTI-III) (F14A)
1593, p2ocvB_, 0.8911, 1.10, 0.385, 223, 221, STRUCTURAL BASIS OF NA+ ACTIVATION MIMICRY IN MURINE THROMBIN
1594, d1s85A_, 0.8911, 1.10, 0.385, 223, 221, PORCINE TRYPSIN COMPLEXED WITH P-HYDROXYMETHYL BENZAMIDINE AND BORATE
1595, d1s6hA_, 0.8911, 1.11, 0.389, 222, 221, PORCINE TRYPSIN COMPLEXED WITH GUANIDINE-3-PROPANOL INHIBITOR
1596, d1op8A_, 0.8911, 2.05, 0.368, 235, 231, CRYSTAL STRUCTURE OF HUMAN GRANZYME A
1597, d1o3nA_, 0.8911, 1.10, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1598, d1o39A_, 0.8911, 1.10, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1599, d1o35A_, 0.8911, 1.10, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1600, d1o2qA_, 0.8911, 1.10, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1601, d1o2jA_, 0.8911, 1.10, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1602, d1k1mA_, 0.8911, 1.10, 0.385, 223, 221, BOVINE TRYPSIN-INHIBITOR COMPLEX
1603, d1k1jA_, 0.8911, 1.10, 0.385, 223, 221, BOVINE TRYPSIN-INHIBITOR COMPLEX
1604, d1g3eA_, 0.8911, 1.10, 0.385, 223, 221, BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF-BASE COPPER (II) CHELATE
1605, d1g36A_, 0.8911, 1.10, 0.385, 223, 221, TRYPSIN INHIBITOR COMPLEX
1606, d1c5qA_, 0.8911, 1.67, 0.307, 233, 228, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1607, d1btpA_, 0.8911, 1.10, 0.389, 223, 221, UNIQUE BINDING OF A NOVEL SYNTHETIC INHIBITOR N-[3-[4-[4- (AMIDINOPHENOXY)-CARBONYL]PHENYL]-2-METHYL-2-PROPENOYL]-N- ALLYLGLYCINE METHANESULFONATE TO BOVINE TRYPSIN REVEALED BY THE CRYSTAL STRUCTURE OF THE COMPLEX
1608, d3lc3C_, 0.8910, 1.11, 0.389, 223, 221, BENZOTHIOPHENE INHIBITORS OF FACTOR IXA
1609, d1o3mA_, 0.8910, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1610, d1o2kA_, 0.8910, 1.10, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1611, d1fn6A_, 0.8910, 1.11, 0.385, 223, 221, CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.1% POLYDOCANOL
1612, d1f0tA_, 0.8910, 1.10, 0.385, 223, 221, BOVINE TRYPSIN COMPLEXED WITH RPR131247
1613, d1braA_, 0.8910, 1.11, 0.385, 223, 221, RELOCATING A NEGATIVE CHARGE IN THE BINDING POCKET OF TRYPSIN
1614, d2tioA_, 0.8909, 1.62, 0.317, 245, 227, LOW PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE
1615, d1xkbD_, 0.8909, 1.11, 0.389, 223, 221, FACTOR XA COMPLEXED WITH A SYNTHETIC INHIBITOR FX-2212A(2S)-(3 - AMIDINO-3-BIPHENYLYL)-5-(4-PYRIDYLAMINO)PENTANOIC ACID
1616, d1tldA_, 0.8909, 1.11, 0.389, 223, 221, CRYSTAL STRUCTURE OF BOVINE BETA-TRYPSIN AT 1.5 ANGSTROMS RESOLUTION IN A CRYSTAL FORM WITH LOW MOLECULAR PACKING DENSITY. ACTIVE SITE GEOMETRY ION PAIRS AND SOLVENT STRUCTURE
1617, d1qquA_, 0.8909, 1.80, 0.314, 234, 229, CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH BOUND ACETATE ION
1618, d1ql9A_, 0.8909, 1.80, 0.314, 234, 229, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH RAT TRYPSIN MUTANT X99RT
1619, d1oyqA_, 0.8909, 1.11, 0.385, 223, 221, TRYPSIN INHIBITOR COMPLEX
1620, d1o3eA_, 0.8909, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1621, d1o31A_, 0.8909, 1.10, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1622, d1o2zA_, 0.8909, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1623, d1o2sA_, 0.8909, 1.10, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1624, d1o2pA_, 0.8909, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1625, d1o2oA_, 0.8909, 1.10, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1626, d1mtsA_, 0.8909, 1.11, 0.385, 223, 221, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1627, d1gi3A_, 0.8909, 1.10, 0.385, 223, 221, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1628, d1g3cA_, 0.8909, 1.11, 0.385, 223, 221, BOVINE BETA-TRYPSIN BOUND TO PARA-AMIDINO SCHIFF BASE IRON(III) CHELATE
1629, d1g34A_, 0.8909, 1.10, 0.385, 223, 221,  
1630, d1fniA_, 0.8909, 2.14, 0.362, 235, 232, CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.01% POLYDOCANOL
1631, d1eb2A_, 0.8909, 1.11, 0.385, 223, 221, TRYPSIN INHIBITOR COMPLEX (BPO)
1632, p6fujE_, 0.8908, 1.10, 0.385, 223, 221, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR N-(3 -(AMINOMETHYL)- [1;1 -BIPHENYL]-3-YL)-3-METHYLBUTANAMIDE 
1633, d5fxlA_, 0.8908, 1.12, 0.389, 223, 221, STRUCTURE OF TRYPSIN SOLVED BY MR FROM DATA COLLECTED BY DIRECT DATA COLLECTION (DDC) USING THE ESRF ROBODIFF GONIOMETER
1634, d3t29A_, 0.8908, 1.10, 0.385, 223, 221, TMAO-GROWN TRIGONAL TRYPSIN (BOVINE)
1635, d2bzaA_, 0.8908, 1.11, 0.385, 223, 221, BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZYLAMINE
1636, d1y3xA_, 0.8908, 1.11, 0.385, 223, 221, TRYPSIN INHIBITOR COMPLEX
1637, d1y3wA_, 0.8908, 1.86, 0.309, 234, 230, TRYPSIN INHIBITOR COMPLEX
1638, d1ppcE_, 0.8908, 1.11, 0.385, 223, 221, GEOMETRY OF BINDING OF THE BENZAMIDINE-AND ARGININE-BASED INHIBITORS N-ALPHA-(2-NAPHTHYL-SULPHONYL-GLYCYL)-DL-P-AMIDINOPHENYLALANYL- PIPERIDINE (NAPAP) AND (2R4R)-4-METHYL-1-[N-ALPHA-(3-METHYL-1234- TETRAHYDRO-8-QUINOLINESULPHONYL)-L-ARGINYL]-2-PIPERIDINE CARBOXYLIC ACID (MQPA) TO HUMAN ALPHA-THROMBIN: X-RAY CRYSTALLOGRAPHIC DETERMINATION OF THE NAPAP-TRYPSIN COMPLEX AND MODELING OF NAPAP- THROMBIN AND MQPA-THROMBIN
1639, d1o3gA_, 0.8908, 1.12, 0.389, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1640, d1o3fA_, 0.8908, 1.12, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1641, d1o34A_, 0.8908, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1642, d1o2mA_, 0.8908, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1643, d1o2hA_, 0.8908, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1644, d1mtuA_, 0.8908, 1.10, 0.385, 223, 221, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1645, d1k1lA_, 0.8908, 1.11, 0.385, 223, 221, BOVINE TRYPSIN-INHIBITOR COMPLEX
1646, d1h4wA_, 0.8908, 1.10, 0.385, 223, 221, STRUCTURE OF HUMAN TRYPSIN IV (BRAIN TRYPSIN)
1647, d1g3bA_, 0.8908, 1.11, 0.385, 223, 221, BOVINE BETA-TRYPSIN BOUND TO META-AMIDINO SCHIFF BASE MAGNESIUM(II) CHELATE
1648, d1f0uA_, 0.8908, 1.11, 0.385, 223, 221, BOVINE TRYPSIN COMPLEXED WITH RPR128515
1649, d1ce5A_, 0.8908, 1.11, 0.385, 223, 221, BOVINE PANCREAS BETA-TRYPSIN IN COMPLEX WITH BENZAMIDINE
1650, d1aneA_, 0.8908, 1.11, 0.385, 223, 221, ANIONIC TRYPSIN WILD TYPE
1651, p5xwlB_, 0.8907, 1.11, 0.385, 223, 221, CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR TRE AT PH 10
1652, d3t27A_, 0.8907, 1.12, 0.389, 223, 221, ORTHORHOMBIC TRYPSIN (BOVINE) IN THE PRESENCE OF BETAINE
1653, d2y5fA_, 0.8907, 1.11, 0.385, 223, 221, FACTOR XA - CATION INHIBITOR COMPLEX
1654, d2uwoA_, 0.8907, 1.33, 0.345, 223, 223, SELECTIVE AND DUAL ACTION ORALLY ACTIVE INHIBITORS OF THROMBIN AND FACTOR XA
1655, d1o32A_, 0.8907, 1.12, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1656, d1o2lA_, 0.8907, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1657, d1o2iA_, 0.8907, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1658, d1j14A_, 0.8907, 1.11, 0.385, 223, 221, BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99RT
1659, d1fmgA_, 0.8907, 1.11, 0.385, 223, 221, CRYSTAL STRUCTURE OF PORCINE BETA TRYPSIN WITH 0.04% POLYDOCANOL
1660, d1btwA_, 0.8907, 1.11, 0.385, 223, 221, EPISELECTION: NOVEL KI ~NANOMOLAR INHIBITORS OF SERINE PROTEASES SELECTED BY BINDING OR CHEMISTRY ON AN ENZYME SURFACE
1661, d1avwA_, 0.8907, 1.11, 0.385, 223, 221, COMPLEX PORCINE PANCREATIC TRYPSIN/SOYBEAN TRYPSIN INHIBITOR ORTHORHOMBIC CRYSTAL FORM
1662, d1andA_, 0.8907, 1.11, 0.385, 223, 221, ANIONIC TRYPSIN MUTANT WITH ARG 96 REPLACED BY HIS
1663, p5mnqA_, 0.8906, 1.11, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH A DERIVATIVE OF N-AMIDINOPIPERIDINE
1664, p5gxpB_, 0.8906, 1.11, 0.385, 223, 221, CATIONIC TRYPSIN WITH GOL/PGE AS DIMER AT PH 4.6
1665, p4aoqB_, 0.8906, 1.11, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH MUTATED SPINACIA OLERACEA TRYPSIN INHIBITOR III (SOTI-III) (F14A)
1666, d3m35A_, 0.8906, 1.11, 0.385, 223, 221, TRYPSIN IN COMPLEX WITH THE INHIBITOR 1-[3-(AMINOMETHYL) PHENYL]-N-[3-FLUORO-2 -(METHYLSULFONYL)BIPHENYL-4-YL]-3- (TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE (DPC423)
1667, d2aggX_, 0.8906, 1.11, 0.385, 223, 221, SUCCINYL-AAPK-TRYPSIN ACYL-ENZYME AT 1.28 A RESOLUTION
1668, d1y3vA_, 0.8906, 1.11, 0.376, 224, 221, TRYPSIN INHIBITOR COMPLEX
1669, p1tq0B_, 0.8906, 1.11, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE POTENT ANTICOAGULANT THROMBIN MUTANT W215A/E217A IN FREE FORM
1670, d1tq0.1, 0.8906, 1.11, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE POTENT ANTICOAGULANT THROMBIN MUTANT W215A/E217A IN FREE FORM
1671, d1jrsA_, 0.8906, 1.11, 0.385, 223, 221, HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN
1672, d1jirA_, 0.8906, 1.11, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEX WITH AMYLAMINE IN CYCLOHEXANE
1673, d1dsuA_, 0.8906, 1.12, 0.389, 222, 221, HUMAN FACTOR D COMPLEMENT ACTIVATING ENZYME
1674, p5xwjA_, 0.8905, 1.12, 0.385, 223, 221, CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR TRE AT PH 7
1675, d3p92A_, 0.8905, 1.77, 0.310, 233, 229, HUMAN MESOTRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR VARIANT (BPTI-K15R/R17G)
1676, d2zhdA_, 0.8905, 1.63, 0.304, 232, 227, EXPLORING TRYPSIN S3 POCKET
1677, d2cmyA_, 0.8905, 1.11, 0.385, 223, 221, CRYSTAL COMPLEX BETWEEN BOVINE TRYPSIN AND VERONICA HEDERIFOLIA TRYPSIN INHIBITOR
1678, d1tpsA_, 0.8905, 1.11, 0.385, 223, 221, ATOMIC STRUCTURE OF THE TRYPSIN-A90720A COMPLEX: A UNIFIED APPROACH TO STRUCTURE AND FUNCTION
1679, d1sgfZ_, 0.8905, 1.11, 0.385, 223, 221, CRYSTAL STRUCTURE OF 7S NGF: A COMPLEX OF NERVE GROWTH FACTOR WITH FOUR BINDING PROTEINS (SERINE PROTEINASES)
1680, d1qb1A_, 0.8905, 1.12, 0.385, 223, 221, BOVINE TRYPSIN WITH 1-[2-[5-[AMINO(IMINO)METHYL]-2- HYDROXYPHENOXY]-6-[3-(45-DIHYDRO-1-METHYL-1H-IMIDAZOL-2- YL)PHENOXY]PYRIDIN-4-YL]PIPERIDINE-3-CARBOXYLIC ACID (ZK- 806974)
1681, d1op8C_, 0.8905, 1.12, 0.389, 223, 221, CRYSTAL STRUCTURE OF HUMAN GRANZYME A
1682, d1o3cA_, 0.8905, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1683, d1o3bA_, 0.8905, 1.11, 0.389, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1684, d1o2nA_, 0.8905, 1.11, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1685, d1lqeA_, 0.8905, 1.12, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN IN COMPLEX WITH 79.
1686, d1gbtA_, 0.8905, 1.12, 0.385, 223, 221, STRUCTURE OF AN ACYL-ENZYME INTERMEDIATE DURING CATALYSIS: (GUANIDINOBENZOYL) TRYPSIN
1687, d1aks.1, 0.8905, 1.12, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE FIRST ACTIVE AUTOLYSATE FORM OF THE PORCINE ALPHA TRYPSIN
1688, d4z0kA_, 0.8904, 1.11, 0.385, 223, 221, RAPID DEVELOPMENT OF TWO FACTOR IXA INHIBITORS FROM HIT TO LEAD
1689, d1zzzA_, 0.8904, 1.11, 0.385, 223, 221, TRYPSIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1690, d1yyy1_, 0.8904, 1.12, 0.385, 223, 221, TRYPSIN INHIBITORS WITH RIGID TRIPEPTIDYL ALDEHYDES
1691, d1y5bT_, 0.8904, 1.77, 0.301, 247, 229, DIANHYDROSUGAR-BASED BENZAMIDINE FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1692, d1y3uA_, 0.8904, 1.77, 0.301, 278, 229, TRYPSIN INHIBITOR COMPLEX
1693, d1smfE_, 0.8904, 1.12, 0.385, 223, 221, STUDIES ON AN ARTIFICIAL TRYPSIN INHIBITOR PEPTIDE DERIVED FROM THE MUNG BEAN INHIBITOR
1694, d1s81A_, 0.8904, 1.11, 0.385, 223, 221, PORCINE TRYPSIN WITH NO INHIBITOR BOUND
1695, d1gi5A_, 0.8904, 1.58, 0.341, 228, 226, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1696, d1ancA_, 0.8904, 1.11, 0.389, 223, 221, ANIONIC TRYPSIN MUTANT WITH SER 214 REPLACED BY LYS
1697, d3ljjA_, 0.8903, 1.12, 0.371, 224, 221, BOVINE TRYPSIN IN COMPLEX WITH UB-THR 10
1698, p3jz1B_, 0.8903, 1.12, 0.385, 223, 221, CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT N143P IN E:NA+ FORM
1699, d2ageX_, 0.8903, 1.12, 0.385, 223, 221, SUCCINYL-AAPR-TRYPSIN ACYL-ENZYME AT 1.15 A RESOLUTION
1700, d2a32A_, 0.8903, 1.12, 0.385, 223, 221, TRYPSIN IN COMPLEX WITH BENZENE BORONIC ACID
1701, d1o3oA_, 0.8903, 1.49, 0.320, 232, 225, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1702, d1k1nA_, 0.8903, 1.11, 0.385, 223, 221, BOVINE TRYPSIN-INHIBITOR COMPLEX
1703, d1btzA_, 0.8903, 1.86, 0.314, 234, 229, EPISELECTION: NOVEL KI ~NANOMOLAR INHIBITORS OF SERINE PROTEASES SELECTED BY BINDING OR CHEMISTRY ON AN ENZYME SURFACE
1704, d5eg4A_, 0.8902, 1.12, 0.385, 223, 221, BOVINE TRYPSIN IN COMPLEX WITH CYCLIC INHIBITOR
1705, d3vpkA_, 0.8902, 1.12, 0.385, 223, 221, CRYSTAL STRUCTURE OF 6-GUANIDINOHEXANOYL TRYPSIN
1706, d2y5gA_, 0.8902, 1.12, 0.385, 223, 221, FACTOR XA - CATION INHIBITOR COMPLEX
1707, d2j9nA_, 0.8902, 1.11, 0.385, 223, 221, ROBOTICALLY HARVESTED TRYPSIN COMPLEXED WITH BENZAMIDINE CONTAINING POLYPEPTIDE MEDIATED CRYSTAL CONTACTS
1708, d2agiX_, 0.8902, 1.12, 0.385, 223, 221, THE LEUPEPTIN-TRYPSIN COVALENT COMPLEX AT 1.14 A RESOLUTION
1709, d1sfiA_, 0.8902, 1.14, 0.389, 223, 221, HIGH RESOLUTION STRUCTURE OF A POTENT CYCLIC PROTEASE INHIBITOR FROM SUNFLOWER SEEDS
1710, d1btxA_, 0.8902, 1.82, 0.371, 234, 229, EPISELECTION: NOVEL KI ~NANOMOLAR INHIBITORS OF SERINE PROTEASES SELECTED BY BINDING OR CHEMISTRY ON AN ENZYME SURFACE
1711, p5xwlA_, 0.8901, 1.12, 0.385, 223, 221, CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR TRE AT PH 10
1712, d4ncyA_, 0.8901, 1.12, 0.385, 223, 221, IN SITU TRYPSIN CRYSTALLIZED ON A MITEGEN MICROMESH WITH IMIDAZOLE LIGAND
1713, p4abjA_, 0.8901, 1.12, 0.385, 223, 221, CO-COMPLEX STRUCTURE OF BOVINE TRYPSIN WITH A MODIFIED BOWMAN-BIRK INHIBITOR (ICA)SFTI-1(114) THAT WAS 15- DISUBSTITUTED WITH 123-TRIZOL TO MIMIC A CIS AMIDE BOND
1714, d3p95A_, 0.8901, 1.12, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR VARIANT (BPTI-K15R/R17D)
1715, d2j4iA_, 0.8901, 1.12, 0.385, 223, 221, CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
1716, d1sbwA_, 0.8901, 1.13, 0.389, 223, 221, CRYSTAL STRUCTURE OF MUNG BEAN INHIBITOR LYSINE ACTIVE FRAGMENT COMPLEX WITH BOVINE BETA-TRYPSIN AT 1.8A RESOLUTION
1717, p1bthK_, 0.8901, 1.12, 0.385, 223, 221, STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1718, d1bth.2, 0.8901, 1.12, 0.380, 223, 221, STRUCTURE OF THROMBIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1719, p6fidA_, 0.8900, 1.12, 0.385, 223, 221, BOVINE TRYPSIN SOLVED BY S-SAD ON ID30B
1720, p4abiA_, 0.8900, 1.75, 0.301, 248, 229, CO-COMPLEX STRUCTURE OF BOVINE TRYPSIN WITH A MODIFIED BOWMAN-BIRK INHIBITOR (PTA)SFTI-1(114) THAT WAS 14-DISUBSTITUTED WITH A 123- TRIZOL TO MIMIC A TRANS AMIDE BOND
1721, d3qk1A1, 0.8900, 1.12, 0.385, 223, 221, CRYSTAL STRUCTURE OF ENTEROKINASE-LIKE TRYPSIN VARIANT
1722, d1uhb.1, 0.8900, 1.13, 0.389, 223, 221, CRYSTAL STRUCTURE OF PORCINE ALPHA TRYPSIN BOUND WITH AUTO CATALYTICALY PRODUCED NATIVE PEPTIDE AT 2.15 A RESOLUTION
1723, d5tp0A_, 0.8899, 1.12, 0.385, 223, 221, HUMAN MESOTRYPSIN IN COMPLEX WITH DIMINAZENE
1724, d1yp9A_, 0.8899, 1.13, 0.385, 223, 221, TRYPSIN INHIBITOR COMPLEX
1725, d1n6yA_, 0.8899, 1.12, 0.385, 223, 221, RIP-PHASING ON BOVINE TRYPSIN
1726, d1h9hE_, 0.8899, 1.12, 0.385, 223, 221, COMPLEX OF EETI-II WITH PORCINE TRYPSIN
1727, d1ao5A_, 0.8899, 1.13, 0.385, 223, 221, MOUSE GLANDULAR KALLIKREIN-13 (PRORENIN CONVERTING ENZYME)
1728, d5tz9E_, 0.8898, 1.78, 0.310, 233, 229, STRUCTURE OF PLASMA KALLIKREIN PROTEASE DOMAIN WITH INHIBITOR
1729, p5ms4A_, 0.8898, 1.13, 0.385, 223, 221, KALLIKREIN-RELATED PEPTIDASE 8 LEUPEPTIN INHIBITOR COMPLEX
1730, p5mosA_, 0.8898, 1.12, 0.385, 223, 221, JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH N- AMIDINOPIPERIDINE
1731, p5moqA_, 0.8898, 1.12, 0.385, 223, 221, JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH BENZAMIDINE
1732, d5mooA_, 0.8898, 1.12, 0.385, 223, 221, JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH ANILINE
1733, p5mnoA_, 0.8898, 1.12, 0.389, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH N-AMIDINOPIPERIDINE (DEUTERATED SAMPLE AT 295 K)
1734, d5mncA_, 0.8898, 1.12, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH ANILINE (DEUTERATED SAMPLE AT 100 K)
1735, d5mnaA_, 0.8898, 1.12, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH ANILINE (DEUTERATED SAMPLE AT 295 K)
1736, d5mn1A_, 0.8898, 1.13, 0.371, 224, 221, CATIONIC TRYPSIN IN COMPLEX WITH 2-AMINOPYRIDINE (DEUTERATED SAMPLE AT 100 K)
1737, d5f6mA_, 0.8898, 1.64, 0.304, 232, 227, ISOTROPIC TRYPSIN MODEL FOR COMPARISON OF DIFFUSE SCATTERING
1738, d4i8jA_, 0.8898, 1.12, 0.385, 223, 221, BOVINE TRYPSIN AT 0.87 A RESOLUTION
1739, p4aoqA_, 0.8898, 1.87, 0.309, 254, 230, CATIONIC TRYPSIN IN COMPLEX WITH MUTATED SPINACIA OLERACEA TRYPSIN INHIBITOR III (SOTI-III) (F14A)
1740, d2zgcA_, 0.8898, 1.87, 0.309, 285, 230, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME M
1741, d2oxsA_, 0.8898, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE TRYPSIN COMPLEX WITH BENZAMIDINE AT HIGH TEMPERATURE (35 C)
1742, d1tx8A_, 0.8898, 1.13, 0.385, 223, 221, BOVINE TRYPSIN COMPLEXED WITH AMSO
1743, d1s5sA_, 0.8898, 1.13, 0.385, 223, 221, PORCINE TRYPSIN COMPLEXED WITH GUANIDINE-3-PROPANOL INHIBITOR
1744, d1ql8A_, 0.8898, 1.14, 0.389, 223, 221, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1745, d1aq7A_, 0.8898, 1.13, 0.376, 224, 221, TRYPSIN WITH INHIBITOR AERUGINOSIN 98-B
1746, p5morA_, 0.8897, 1.13, 0.385, 223, 221, JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH BENZYLAMINE
1747, d5monA_, 0.8897, 1.14, 0.385, 223, 221, JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH 2- AMINOPYRIDINE
1748, p5mo0A_, 0.8897, 1.13, 0.389, 223, 221, NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH BENZAMIDINE
1749, d5mnyA_, 0.8897, 1.53, 0.324, 236, 225, NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH ANILINE
1750, p5mnhA_, 0.8897, 1.53, 0.324, 236, 225, CATIONIC TRYPSIN IN COMPLEX WITH BENZAMIDINE (DEUTERATED SAMPLE AT 295 K)
1751, p5mneA_, 0.8897, 1.77, 0.351, 232, 225, CATIONIC TRYPSIN IN ITS APO FORM (DEUTERATED SAMPLE AT 100 K)
1752, d4i8lA_, 0.8897, 1.46, 0.351, 228, 225, BOVINE TRYPSIN AT 0.87 RESOLUTION
1753, d4i8kA_, 0.8897, 1.13, 0.385, 223, 221, BOVINE TRYPSIN AT 0.85 RESOLUTION
1754, d3t26A_, 0.8897, 1.13, 0.385, 223, 221, ORTHORHOMBIC TRYPSIN (BOVINE) IN THE PRESENCE OF SARCOSINE
1755, d3nkkA_, 0.8897, 1.13, 0.385, 223, 221, TRYPSIN IN COMPLEX WITH FLUORINE CONTAINING FRAGMENT
1756, d3a8bA_, 0.8897, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-4-((4- BROMOPHENYLIMINO)METHYL)BENZIMIDAMIDE
1757, d1spjA_, 0.8897, 1.13, 0.385, 223, 221, STRUCTURE OF MATURE HUMAN TISSUE KALLIKREIN (HUMAN KALLIKREIN 1 OR KLK1) AT 1.70 ANGSTROM RESOLUTION WITH VACANT ACTIVE SITE
1758, d1ox1A_, 0.8897, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE BOVINE TRYPSIN COMPLEX WITH A SYNTHETIC 11 PEPTIDE INHIBITOR
1759, d1o3aA_, 0.8897, 1.13, 0.385, 223, 221, ELABORATE MANIFOLD OF SHORT HYDROGEN BOND ARRAYS MEDIATING BINDING OF ACTIVE SITE-DIRECTED SERINE PROTEASE INHIBITORS
1760, d1n6xA_, 0.8897, 1.13, 0.385, 223, 221, RIP-PHASING ON BOVINE TRYPSIN
1761, d1az8A_, 0.8897, 1.13, 0.385, 223, 221, BOVINE TRYPSIN COMPLEXED TO BIS-PHENYLAMIDINE INHIBITOR
1762, d6avlA_, 0.8896, 1.13, 0.385, 223, 221, ORTHORHOMBIC TRYPSIN (295 K) IN THE PRESENCE OF 50% XYLOSE
1763, p5mopA_, 0.8896, 1.68, 0.355, 231, 228, JOINT X-RAY/NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN ITS APO FORM
1764, p5mnpA_, 0.8896, 1.68, 0.355, 231, 228, CATIONIC TRYPSIN IN COMPLEX WITH N-AMIDINOPIPERIDINE (AT 295 K)
1765, p5mnmA_, 0.8896, 1.13, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH BENZYLAMINE (AT 295 K)
1766, p5mnfA_, 0.8896, 1.13, 0.385, 223, 221, CATIONIC TRYPSIN IN ITS APO FORM (DEUTERATED SAMPLE AT 295 K)
1767, d5mnbA_, 0.8896, 1.14, 0.389, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH 2-AMINOPYRIDINE (DEUTERATED SAMPLE AT 295 K)
1768, p4guxC_, 0.8896, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN:MCOTI-II COMPLEX
1769, d3rxeA_, 0.8896, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BENZAMIDE
1770, d3ptbA_, 0.8896, 1.13, 0.385, 223, 221, THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1771, d3mi4A_, 0.8896, 1.13, 0.385, 223, 221, BOVINE TRYPSIN AT 0.8 A RESOLUTION NON-RESTRAINED REFINEMENT
1772, d3mfjA_, 0.8896, 1.13, 0.385, 223, 221, BOVINE TRYPSIN AT 0.8 A RESOLUTION RESTRAINED REFINEMENT
1773, d2ptnA_, 0.8896, 1.13, 0.385, 223, 221, ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
1774, d2otvA_, 0.8896, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE TRYPSIN AND NICOTINAMIDE AT 1.56 A RESOLUTION
1775, d1tppA_, 0.8896, 1.13, 0.385, 223, 221, THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1776, d1tioA_, 0.8896, 1.13, 0.385, 223, 221, HIGH PACKING DENSITY FORM OF BOVINE BETA-TRYPSIN IN CYCLOHEXANE
1777, d1k1iA_, 0.8896, 1.13, 0.385, 223, 221, BOVINE TRYPSIN-INHIBITOR COMPLEX
1778, d1btyA_, 0.8896, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF BETA-TRYPSIN IN COMPLEX WITH BENZAMIDINE
1779, d6b6nA_, 0.8895, 1.13, 0.385, 223, 221, ORTHORHOMBIC TRYPSIN (295 K) IN THE PRESENCE OF 50% MPD
1780, p5mo2A_, 0.8895, 1.13, 0.385, 223, 221, NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH N- AMIDINOPIPERIDINE
1781, p4guxA_, 0.8895, 1.54, 0.351, 236, 225, CRYSTAL STRUCTURE OF TRYPSIN:MCOTI-II COMPLEX
1782, d3rxqA_, 0.8895, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BENZAMIDE (F01 AND F05 COCKTAIL EXPERIMENT)
1783, d2aywA_, 0.8895, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN TRYPSIN AND A DESIGNED SYNTHETIC HIGHLY POTENT INHIBITOR IN THE PRESENCE OF BENZAMIDINE AT 0.97 A RESOLUTION
1784, d2ah4X_, 0.8895, 1.14, 0.385, 223, 221, GUANIDINOBENZOYL-TRYPSIN ACYL-ENZYME AT 1.13 A RESOLUTION
1785, d1orfA_, 0.8895, 1.13, 0.385, 223, 221, THE OLIGOMERIC STRUCTURE OF HUMAN GRANZYME A REVEALS THE MOLECULAR DETERMINANTS OF SUBSTRATE SPECIFICITY
1786, d1ept.1, 0.8895, 1.14, 0.385, 223, 221, REFINED 1.8 ANGSTROMS RESOLUTION CRYSTAL STRUCTURE OF PORCINE EPSILON-TRYPSIN
1787, d6b6sA_, 0.8894, 1.13, 0.385, 223, 221, ORTHORHOMBIC TRYPSIN CRYOCOOLED TO 100 K WITH 50% ETHANOL AS CRYOPROTECTANT
1788, p5mnzA_, 0.8894, 1.13, 0.385, 223, 221, NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN ITS APO FORM
1789, p5mngA_, 0.8894, 1.13, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH BENZAMIDINE (DEUTERATED SAMPLE AT 100 K)
1790, d4i8hA_, 0.8894, 1.13, 0.385, 223, 221, BOVINE TRYPSIN AT 0.75 RESOLUTION
1791, d4i8gA_, 0.8894, 1.13, 0.385, 223, 221, BOVINE TRYPSIN AT 0.8 RESOLUTION
1792, d3rxuA_, 0.8894, 1.13, 0.389, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BENZAMIDE (F05 AND A06 COCKTAIL EXPERIMENT)
1793, d3rxrA_, 0.8894, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH CYCLOHEPTANAMINE (F01 AND F03 COCKTAIL EXPERIMENT)
1794, p3r3gB_, 0.8894, 1.13, 0.385, 223, 221, STRUCTURE OF HUMAN THROMBIN WITH RESIDUES 145-150 OF MURINE THROMBIN.
1795, d3a87A_, 0.8894, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-4-((2- NICOTINOYLHYDRAZONO)METHYL)BENZIMIDAMIDE (SOAKING 5 MINUTES)
1796, d3a85A_, 0.8894, 1.13, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-2-(4- CARBAMIMIDOYLBENZYLIDENEAMINOOXY)ACETIC ACID (SOAKING 15 SECONDS)
1797, p3a82A_, 0.8894, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH PRE-SYNTHESIZED (E)-2-(4- CARBAMIMIDOYLBENZYLIDENEAMINOOXY)ACETIC ACID
1798, d1xukA_, 0.8894, 1.14, 0.385, 223, 221, TRYPSIN-BABIM-SULFATE PH 5.9
1799, d1xufA_, 0.8894, 1.13, 0.385, 223, 221, TRYPSIN-BABIM-ZN+2 PH 8.2
1800, d1tnkA_, 0.8894, 1.13, 0.385, 223, 221, PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1801, d1tnjA_, 0.8894, 1.14, 0.385, 223, 221, PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1802, d1tnhA_, 0.8894, 1.13, 0.385, 223, 221, PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1803, d1bjuA_, 0.8894, 1.14, 0.385, 223, 221, BETA-TRYPSIN COMPLEXED WITH ACPU
1804, d1aujA_, 0.8894, 1.14, 0.385, 223, 221, BOVINE TRYPSIN COMPLEXED TO META-CYANO-BENZYLIC INHIBITOR
1805, d5t3hA_, 0.8893, 1.13, 0.385, 223, 221, BOVINE TRYPSIN SOAKED WITH SELENOUREA FOR 5 MIN
1806, p5mo1A_, 0.8893, 1.13, 0.385, 223, 221, NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH BENZYLAMINE
1807, d5mnxA_, 0.8893, 1.13, 0.385, 223, 221, NEUTRON STRUCTURE OF CATIONIC TRYPSIN IN COMPLEX WITH 2-AMINOPYRIDINE
1808, p5mnnA_, 0.8893, 1.14, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH N-AMIDINOPIPERIDINE (DEUTERATED SAMPLE AT 100 K)
1809, p5mnlA_, 0.8893, 1.70, 0.316, 232, 228, CATIONIC TRYPSIN IN COMPLEX WITH BENZYLAMINE (DEUTERATED SAMPLE AT 295 K)
1810, p5gxpA_, 0.8893, 1.15, 0.389, 223, 221, CATIONIC TRYPSIN WITH GOL/PGE AS DIMER AT PH 4.6
1811, d4wxvA_, 0.8893, 1.14, 0.385, 223, 221, HUMAN CATIONIC TRYPSIN K97D MUTANT IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
1812, d4abhA_, 0.8893, 1.14, 0.385, 223, 221, FRAGMENTS BOUND TO BOVINE TRYPSIN FOR THE SAMPL CHALLENGE
1813, d3a81A_, 0.8893, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-4-((2- NICOTINOYLHYDRAZONO)METHYL)BENZIMIDAMIDE (SOAKING 8 HOURS)
1814, d3a7vA_, 0.8893, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 3-FORMYLBENZIMIDAMIDE
1815, d1tx6A_, 0.8893, 1.14, 0.385, 223, 221, TRYPSIN:BBI COMPLEX
1816, d1tpoA_, 0.8893, 1.14, 0.385, 223, 221, THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1817, d1tnlA_, 0.8893, 1.14, 0.385, 223, 221, PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1818, d1tniA_, 0.8893, 1.71, 0.307, 253, 228, PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1819, d1tngA_, 0.8893, 1.14, 0.385, 223, 221, PREDICTION OF NOVEL SERINE PROTEASE INHIBITORS
1820, d1s0rA_, 0.8893, 1.15, 0.385, 223, 221, BOVINE PANCREATIC TRYPSIN INHIBITED WITH BENZAMIDINE AT ATOMIC RESOLUTION
1821, d1ntpA_, 0.8893, 1.14, 0.385, 223, 221, USE OF THE NEUTRON DIFFRACTION H/D EXCHANGE TECHNIQUE TO DETERMINE THE CONFORMATIONAL DYNAMICS OF TRYPSIN
1822, d1k1pA_, 0.8893, 1.14, 0.385, 223, 221, BOVINE TRYPSIN-INHIBITOR COMPLEX
1823, d1j8aA_, 0.8893, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF BENZAMIDINE INHIBITED BOVINE PANCREATIC TRYPSIN AT 105K TO 1.21A RESOLUTION FROM LABORATORY SOURCE WITH HIGH NUMBER OF WATERS MODELLED
1824, d6b6rA_, 0.8892, 1.14, 0.385, 223, 221, ORTHORHOMBIC TRYPSIN CRYOCOOLED TO 100 K WITH 50% MPD AS CRYOPROTECTANT
1825, p5mnkA_, 0.8892, 1.14, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH BENZYLAMINE (DEUTERATED SAMPLE AT 100 K)
1826, d4an7A_, 0.8892, 1.14, 0.385, 223, 221, KUNITZ TYPE TRYPSIN INHIBITOR COMPLEX WITH PORCINE TRYPSIN
1827, d3t25A_, 0.8892, 1.15, 0.385, 223, 221, TMAO-GROWN ORTHORHOMBIC TRYPSIN (BOVINE)
1828, d3rxvA_, 0.8892, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BENZAMIDE (F05 AND F03 COCKTAIL EXPERIMENT)
1829, d3rxkA_, 0.8892, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH METHYL 4-AMINO-1-METHYL- PYRROLIDINE-2-CARBOXYLATE
1830, d3rxgA_, 0.8892, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 4-AMINOCYCLOHEXANOL
1831, d3rxaA_, 0.8892, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH CYCLOHEPTANAMINE
1832, d3a89A_, 0.8892, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-4-((2- NICOTINOYLHYDRAZONO)METHYL)BENZIMIDAMIDE (SOAKING 4 HOURS)
1833, d3a88A_, 0.8892, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-4-((2- NICOTINOYLHYDRAZONO)METHYL)BENZIMIDAMIDE (SOAKING 30 MINUTES)
1834, d3a7tA_, 0.8892, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 4-FORMYLBENZIMIDAMIDE
1835, d2byaX_, 0.8892, 1.15, 0.371, 224, 221, IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
1836, d2by8X_, 0.8892, 1.14, 0.385, 223, 221, IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
1837, d2by6X_, 0.8892, 1.14, 0.385, 223, 221, IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
1838, d1tx7A_, 0.8892, 1.14, 0.385, 223, 221, BOVINE TRYPSIN COMPLEXED WITH P- AMIDINOPHENYLMETHYLPHOSPHINIC ACID (AMPA)
1839, d1s0qA_, 0.8892, 1.14, 0.389, 223, 221, NATIVE BOVINE PANCREATIC TRYPSIN
1840, d1mctA_, 0.8892, 1.14, 0.385, 223, 221, THE REFINED 1.6 ANGSTROMS RESOLUTION CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN PORCINE BETA-TRYPSIN AND MCTI-A A TRYPSIN INHIBITOR OF SQUASH FAMILY
1841, d1gi2A_, 0.8892, 1.14, 0.385, 223, 221, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1842, d1gi1A_, 0.8892, 1.14, 0.385, 223, 221, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1843, d1anbA_, 0.8892, 1.14, 0.385, 223, 221, ANIONIC TRYPSIN MUTANT WITH SER 214 REPLACED BY GLU
1844, d6b6pA_, 0.8891, 1.14, 0.385, 223, 221, ORTHORHOMBIC TRYPSIN CRYOCOOLED TO 100 K WITH 30% XYLOSE AS CRYOPROTECTANT
1845, d4abbA_, 0.8891, 1.14, 0.376, 223, 221, FRAGMENTS BOUND TO BOVINE TRYPSIN FOR THE SAMPL CHALLENGE
1846, d4ab9A_, 0.8891, 1.14, 0.385, 223, 221, FRAGMENTS BOUND TO BOVINE TRYPSIN FOR THE SAMPL CHALLENGE
1847, d3rxfA_, 0.8891, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 4-AMINOPYRIDINE
1848, d3a8aA_, 0.8891, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 4-FORMYLBENZIMIDAMIDE AND ANILINE
1849, d2by9X_, 0.8891, 1.14, 0.385, 223, 221, IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
1850, d2by7X_, 0.8891, 1.14, 0.389, 223, 221, IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
1851, d2blwA_, 0.8891, 1.14, 0.385, 223, 221, TRYPSIN AFTER A HIGH DOSE X-RAY BURN
1852, d1utnA_, 0.8891, 1.15, 0.385, 223, 221, TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1853, d1tx6B_, 0.8891, 1.14, 0.385, 223, 221, TRYPSIN:BBI COMPLEX
1854, d1tabE_, 0.8891, 1.14, 0.385, 223, 221, STRUCTURE OF THE TRYPSIN-BINDING DOMAIN OF BOWMAN-BIRK TYPE PROTEASE INHIBITOR AND ITS INTERACTION WITH TRYPSIN
1855, d1op8E_, 0.8891, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF HUMAN GRANZYME A
1856, d6b6qA_, 0.8890, 1.14, 0.385, 223, 221, ORTHORHOMBIC TRYPSIN CRYOCOOLED TO 100 K WITH 50% XYLOSE AS CRYOPROTECTANT
1857, d4tpyA_, 0.8890, 1.14, 0.385, 223, 221, HIGH THROUGHPUT SCREENING USING ACOUSTIC DROPLET EJECTION TO COMBINE PROTEIN CRYSTALS AND CHEMICAL LIBRARIES ON CRYSTALLIZATION PLATES AT HIGH DENSITY
1858, d4abfA_, 0.8890, 1.14, 0.385, 223, 221, FRAGMENTS BOUND TO BOVINE TRYPSIN FOR THE SAMPL CHALLENGE
1859, d4abeA_, 0.8890, 1.14, 0.385, 223, 221, FRAGMENTS BOUND TO BOVINE TRYPSIN FOR THE SAMPL CHALLENGE
1860, d4abdA_, 0.8890, 1.14, 0.385, 223, 221, FRAGMENTS BOUND TO BOVINE TRYPSIN FOR THE SAMPL CHALLENGE
1861, d4abaA_, 0.8890, 1.14, 0.385, 223, 221, FRAGMENTS BOUND TO BOVINE TRYPSIN FOR THE SAMPL CHALLENGE
1862, d3nk8A_, 0.8890, 1.14, 0.385, 223, 221, TRYPSIN IN COMPLEX WITH FLUORINE-CONTAINING FRAGMENT
1863, d3itiA_, 0.8890, 1.14, 0.385, 223, 221, STRUCTURE OF BOVINE TRYPSIN WITH THE MAD TRIANGLE B3C
1864, d3atmA_, 0.8890, 1.14, 0.389, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 2-(1H-INDOL-3-YL) ETHANAMINE
1865, d3atlA_, 0.8890, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BENZAMIDINE
1866, p3a83A_, 0.8890, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH PRE-SYNTHESIZED (E)-4-((2- NICOTINOYLHYDRAZONO)METHYL)BENZIMIDAMIDE
1867, d2trmA_, 0.8890, 1.15, 0.380, 223, 221, THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS
1868, d2by5X_, 0.8890, 1.14, 0.385, 223, 221, IS RADIATION DAMAGE DEPENDENT ON THE DOSE-RATE USED DURING MACROMOLECULAR CRYSTALLOGRAPHY DATA COLLECTION
1869, d2blvA_, 0.8890, 1.14, 0.385, 223, 221, TRYPSIN BEFORE A HIGH DOSE X-RAY BURN
1870, d1mtwA_, 0.8890, 1.15, 0.385, 223, 221, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1871, d1mayA_, 0.8890, 1.15, 0.385, 223, 221, BETA-TRYPSIN PHOSPHONATE INHIBITED
1872, d3rxjA_, 0.8889, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 4-GUANIDINOBENZOIC ACID
1873, d3atkA_, 0.8889, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH CYCLOHEPTANAMINE
1874, d3a7xA_, 0.8889, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-2-(4- CARBAMIMIDOYLBENZYLIDENEAMINOOXY)ACETIC ACID (SOAKING 45SECONDS)
1875, d3a7wA_, 0.8889, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-4-((TETRAHYDRO-2H- PYRAN-2-YLOXYIMINO)METHYL)BENZIMIDAMIDE (SOAKING 4HOURS)
1876, d1d6rA_, 0.8889, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF CANCER CHEMOPREVENTIVE BOWMAN-BIRK INHIBITOR IN TERNARY COMPLEX WITH BOVINE TRYPSIN AT 2.3 A RESOLUTION. STRUCTURAL BASIS OF JANUS-FACED SERINE PROTEASE INHIBITOR SPECIFICITY
1877, d1c2fA_, 0.8889, 1.15, 0.389, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1878, d1bjvA_, 0.8889, 1.14, 0.385, 223, 221, BETA-TRYPSIN COMPLEXED WITH APPU
1879, p6b6tA_, 0.8888, 1.85, 0.314, 234, 229, ORTHORHOMBIC TRYPSIN CRYOCOOLED TO 100 K WITH 50% METHANOL AS CRYOPROTECTANT
1880, p5lh4A_, 0.8888, 1.15, 0.385, 223, 221, TRYPSIN INHIBITORS FOR THE TREATMENT OF PANCREATITIS - CPD 1
1881, p4hgcA_, 0.8888, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF BOVINE TRYPSIN COMPLEXED WITH SFTI-1 ANALOG CONTAINING A PEPTOID RESIDUE AT POSITION P1
1882, d3rxsA_, 0.8888, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (3-METHOXYPHENYL) METHANAMINE (F04 AND A06 COCKTAIL EXPERIMENT)
1883, d3rxoA_, 0.8888, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (3-PYRROL-1-YLPHENYL) METHANAMINE
1884, d3rxiA_, 0.8888, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 2-(1H-INDOL-3-YL) ETHANAMINE
1885, d3rxcA_, 0.8888, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 2-AMINOPYRIDINE
1886, d3rxbA_, 0.8888, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 4-GUANIDINOBUTANOIC ACID
1887, d3gy4A_, 0.8888, 1.15, 0.385, 223, 221, A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS- BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
1888, d2a31A_, 0.8888, 1.15, 0.385, 223, 221, TRYPSIN IN COMPLEX WITH BORATE
1889, d1s83A_, 0.8888, 1.15, 0.385, 223, 221, PORCINE TRYPSIN COMPLEXED WITH 4-AMINO PROPANOL
1890, d1pfxC_, 0.8888, 1.15, 0.385, 223, 221, PORCINE FACTOR IXA
1891, d1c2hA_, 0.8888, 1.14, 0.380, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1892, d4mtbA_, 0.8887, 1.15, 0.385, 223, 221, BOVINE TRYPSIN IN COMPLEX WITH SMALL MOLECULE INHIBITOR
1893, d3rxhA_, 0.8887, 1.14, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH 2-(1H-IMIDAZOL-4-YL) ETHANAMINE
1894, d3fp8E_, 0.8887, 1.15, 0.385, 223, 221, ANIONIC TRYPSIN VARIANT S195A IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI) DETERMINED TO THE 1.46 A RESOLUTION LIMIT
1895, d3fp7E_, 0.8887, 1.15, 0.385, 223, 221, ANIONIC TRYPSIN VARIANT S195A IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI) CLEAVED AT THE SCISSILE BOND (LYS15-ALA16) DETERMINED TO THE 1.46 A RESOLUTION LIMIT
1896, d3aauA_, 0.8887, 1.15, 0.385, 223, 221, BOVINE BETA-TRYPSIN BOUND TO META-DIGUANIDINO SCHIFF BASE COPPER (II) CHELATE
1897, d3aasA_, 0.8887, 1.16, 0.385, 223, 221, BOVINE BETA-TRYPSIN BOUND TO META-GUANIDINO SCHIFF BASE COPPER (II) CHELATE
1898, d3a7zA_, 0.8887, 1.16, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-4-((1-METHYLPIPERIDIN- 4-YLOXYIMINO)METHYL)BENZIMIDAMIDE (SOAKING 3HOURS)
1899, d3a7yA_, 0.8887, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-4-((1-METHYLPIPERIDIN- 3-YLOXYIMINO)METHYL)BENZIMIDAMIDE (SOAKING 2HOURS)
1900, d1xujA_, 0.8887, 1.15, 0.385, 223, 221, TRYPSIN-KETO-BABIM-ZN+2 PH 8.2
1901, d1c2gA_, 0.8887, 1.15, 0.385, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1902, d1c1rA_, 0.8887, 1.15, 0.385, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1903, d4ktsA_, 0.8886, 1.15, 0.385, 223, 221, BOVINE TRYPSIN IN COMPLEX WITH MICROVIRIDIN J AT PH 8.5
1904, p4aorC_, 0.8886, 1.15, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH THE SPINACIA OLERACEA TRYPSIN INHIBITOR III (SOTI-III)
1905, d3t28A_, 0.8886, 1.15, 0.385, 223, 221, TMAO-GROWN TRYPSIN (BOVINE)-PREVIOUSLY UNREPORTED TETRAGONAL CRYSTAL FORM
1906, d3l33A_, 0.8886, 1.15, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH AMYLOID PRECURSOR PROTEIN INHIBITOR(APPI)
1907, d3a8dA_, 0.8886, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-2-(4- CARBAMIMIDOYLBENZYLIDENEAMINOOXY)ACETIC ACID (UNDER ANILINE-FREE CONDITION)
1908, d3a84A_, 0.8886, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH(E)-2-(4- CARBAMIMIDOYLBENZYLIDENEAMINOOXY)ACETIC ACID (SOAKING 5 SECONDS)
1909, d3a80A_, 0.8886, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-2-(4- CARBAMIMIDOYLBENZYLIDENEAMINOOXY)-2-METHYLPROPANOIC ACID (SOAKING 40SECONDS)
1910, d1ophB_, 0.8886, 1.15, 0.385, 223, 221, NON-COVALENT COMPLEX BETWEEN ALPHA-1-PI-PITTSBURGH AND S195A TRYPSIN
1911, d1h9iE_, 0.8886, 1.15, 0.385, 223, 221, COMPLEX OF EETI-II MUTANT WITH PORCINE TRYPSIN
1912, d1c2iA_, 0.8886, 1.16, 0.389, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1913, d1c2eA_, 0.8886, 1.16, 0.389, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1914, d5lh8A_, 0.8885, 2.10, 0.353, 235, 232, TRYPSIN INHIBITORS FOR THE TREATMENT OF PANCREATITIS - CPD 8
1915, d3rxpA_, 0.8885, 2.10, 0.353, 235, 232, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (15-DIMETHYLPYRAZOL-3- YL)METHANAMINE
1916, d3rxlA_, 0.8885, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (25-DIMETHYL-3-FURYL) METHANAMINE
1917, d3otjE_, 0.8885, 1.15, 0.385, 223, 221, A CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BPTI (BOVINE PANCREATIC TRYPSIN INHIBITOR) BY X-RAY/NEUTRON JOINT REFINEMENT
1918, d3atiA_, 0.8885, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (3-METHOXYPHENYL) METHANAMINE
1919, d3a8cA_, 0.8885, 1.16, 0.380, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-2-(4- CARBAMIMIDOYLBENZYLIDENEAMINOOXY)ACETIC ACID (SOAKING WITH MIXTURE OF [(E)-2-(4-CARBAMIMIDOYLBENZYLIDENEAMINOOXY)ACETIC ACID] AND [(E)-2- (4-CARBAMIMIDOYLBENZYLIDENEAMINOOXY)-2-METHYLPROPANOIC ACID])
1920, d3a86A_, 0.8885, 1.16, 0.380, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (E)-2-(4- CARBAMIMIDOYLBENZYLIDENEAMINOOXY)ACETIC ACID (SOAKING 30 SECONDS)
1921, d1xuhA_, 0.8885, 1.15, 0.385, 223, 221, TRYPSIN-KETO-BABIM-CO+2 PH 8.2
1922, d1tpaE_, 0.8885, 1.16, 0.385, 223, 221, THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1923, d1qa0A_, 0.8885, 1.15, 0.385, 223, 221, BOVINE TRYPSIN 2-AMINOBENZIMIDAZOLE COMPLEX
1924, d1c5rA_, 0.8885, 1.15, 0.385, 223, 221, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1925, p6b6oA_, 0.8884, 1.15, 0.385, 223, 221, ORTHORHOMBIC TRYPSIN CRYOCOOLED TO 100 K WITH 20% XYLOSE AS CRYOPROTECTANT
1926, d4ytaA_, 0.8884, 1.15, 0.385, 223, 221, BOND LENGTH ANALYSIS OF ASP GLU AND HIS RESIDUES IN TRYPSIN AT 1.2A RESOLUTION
1927, d4q2kC_, 0.8884, 1.15, 0.385, 223, 221, BOVINE ALPHA CHYMOTRYPSIN BOUND TO A CYCLIC PEPTIDE INHIBITOR 5B
1928, d3unrA_, 0.8884, 1.16, 0.385, 223, 221, BOND LENGTH ANALYSIS OF ASP GLU AND HIS RESIDUES IN TRYPSIN AT 1.2A RESOLUTION
1929, d3rxdA_, 0.8884, 1.16, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (3-METHOXYPHENYL) METHANAMINE
1930, d3fp6E_, 0.8884, 1.15, 0.385, 223, 221, ANIONIC TRYPSIN IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI) DETERMINED TO THE 1.49 A RESOLUTION LIMIT
1931, d2vh6A_, 0.8884, 1.16, 0.371, 224, 221, STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH BIARYL P4 MOTIFS
1932, d1yldA_, 0.8884, 1.16, 0.385, 223, 221, TRYPSIN/BPTI COMPLEX MUTANT
1933, d1ylcA_, 0.8884, 1.16, 0.385, 223, 221, TRYPSIN/BPTI COMPLEX MUTANT
1934, d1c5sA_, 0.8884, 1.16, 0.385, 223, 221, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1935, d1c2jA_, 0.8884, 1.15, 0.380, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1936, d2fi3E_, 0.8883, 1.15, 0.389, 223, 221, CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS14->SER CYS38->SER) IN COMPLEX WITH TRYPSIN
1937, d1tx6D_, 0.8883, 1.16, 0.385, 223, 221, TRYPSIN:BBI COMPLEX
1938, d1sgfG_, 0.8883, 1.15, 0.385, 223, 221, CRYSTAL STRUCTURE OF 7S NGF: A COMPLEX OF NERVE GROWTH FACTOR WITH FOUR BINDING PROTEINS (SERINE PROTEINASES)
1939, d1qb9A_, 0.8883, 1.15, 0.385, 223, 221, BOVINE TRYPSIN 7-[[2-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-9H- CARBOZOL-9-YL] METHYL]NAPHTHALENE-2-CARBOXIMIDAMIDE (ZK-806450) COMPLEX
1940, d1ldtT_, 0.8883, 1.16, 0.385, 223, 221, COMPLEX OF LEECH-DERIVED TRYPTASE INHIBITOR WITH PORCINE TRYPSIN
1941, d1f2sE_, 0.8883, 1.16, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA- TRYPSIN AND MCTI-A A TRYPSIN INHIBITOR OF SQUASH FAMILY AT 1.8 A RESOLUTION
1942, d1c1nA_, 0.8883, 1.16, 0.385, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1943, d4ktuA_, 0.8882, 1.16, 0.385, 223, 221, BOVINE TRYPSIN IN COMPLEX WITH MICROVIRIDIN J AT PH 6.5
1944, d3rxtA_, 0.8882, 1.16, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH (3-METHOXYPHENYL) METHANAMIN (F04 AND F03 COCKTAIL EXPERIMENT)
1945, d3rxmA_, 0.8882, 1.16, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH [2-(2-THIENYL)THIAZOL-4- YL]METHANAMINE
1946, d3ptnA_, 0.8882, 1.15, 0.385, 223, 221, ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
1947, d1nc6A_, 0.8882, 1.16, 0.385, 223, 221, POTENT SMALL MOLECULE INHIBITORS OF HUMAN MAST CELL TRYPTASE. ANTI-ASTHMATIC ACTION OF A DIPEPTIDE-BASED TRANSITION STATE ANALOGUE CONTAINING BENZOTHIAZOLE KETONE
1948, d1c2dA_, 0.8882, 1.16, 0.385, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1949, p4aorB_, 0.8881, 1.16, 0.385, 223, 221, CATIONIC TRYPSIN IN COMPLEX WITH THE SPINACIA OLERACEA TRYPSIN INHIBITOR III (SOTI-III)
1950, d3btfE_, 0.8881, 1.16, 0.385, 223, 221, THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA- TRYPSIN AND TEN P1 VARIANTS OF BPTI.
1951, d2ra3A_, 0.8881, 1.16, 0.385, 223, 221, HUMAN CATIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
1952, d2g5vA_, 0.8881, 1.44, 0.397, 234, 224, INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN
1953, d1y5uT_, 0.8881, 1.16, 0.385, 223, 221, DIANHYDROSUGAR-BASED BENZAMIDINE FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1954, d1xuiA_, 0.8881, 1.16, 0.385, 223, 221, TRYPSIN-KETO-BABIM ZN+2-FREE PH 8.2
1955, d1ql7A_, 0.8881, 1.16, 0.385, 223, 221, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
1956, d1c5uA_, 0.8881, 1.72, 0.307, 232, 228, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1-BINDING SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1957, d1c5pA_, 0.8881, 1.16, 0.380, 223, 221, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1958, d4wxvB_, 0.8880, 1.16, 0.380, 223, 221, HUMAN CATIONIC TRYPSIN K97D MUTANT IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
1959, d1y5aT_, 0.8880, 1.16, 0.385, 223, 221, DIANHYDROSUGAR-BASED BENZAMIDINE FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1960, d1y3yA_, 0.8880, 1.16, 0.385, 223, 221, TRYPSIN INHIBITOR COMPLEX
1961, d1k1oA_, 0.8880, 1.16, 0.385, 223, 221, BOVINE TRYPSIN-INHIBITOR COMPLEX
1962, d1ghzA_, 0.8880, 1.17, 0.389, 223, 221, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI- CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
1963, d1c5vA_, 0.8880, 1.54, 0.320, 232, 225, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1-BINDING SUB- MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1964, d1c5tA_, 0.8880, 1.16, 0.385, 223, 221, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
1965, d1c2mA_, 0.8880, 1.16, 0.389, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1966, d1brbE_, 0.8880, 1.16, 0.385, 223, 221, CRYSTAL STRUCTURES OF RAT ANIONIC TRYPSIN COMPLEXED WITH THE PROTEIN INHIBITORS APPI AND BPTI
1967, d3tgiE_, 0.8879, 1.16, 0.385, 223, 221, WILD-TYPE RAT ANIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
1968, d2r9pC_, 0.8879, 1.16, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR(BPTI)
1969, d1tx6C_, 0.8879, 1.17, 0.385, 223, 221, TRYPSIN:BBI COMPLEX
1970, d1rxpA_, 0.8879, 1.16, 0.385, 223, 221, STRUCTURE OF TRYPSIN (ORTHORHOMBIC) WITH 1-(4-TERT- BUTYLCARBAMOYL- PIPERAZINE-1-CARBONYL)-3-(3-GUANIDINO- PROPYL)-4-OXO-AZETIDINE-2-CARBOXYLIC ACID
1971, d1co7E_, 0.8879, 1.16, 0.385, 223, 221, R117H MUTANT RAT ANIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
1972, d1c1pA_, 0.8879, 1.16, 0.385, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1973, d1c1oA_, 0.8879, 1.17, 0.385, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1974, d1avxA_, 0.8879, 1.17, 0.385, 223, 221, COMPLEX PORCINE PANCREATIC TRYPSIN/SOYBEAN TRYPSIN INHIBITOR TETRAGONAL CRYSTAL FORM
1975, d1autC_, 0.8879, 1.17, 0.385, 223, 221, HUMAN ACTIVATED PROTEIN C
1976, d4wwyB_, 0.8878, 1.17, 0.367, 224, 221, HUMAN CATIONIC TRYPSIN G193R MUTANT IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
1977, d2r9pA_, 0.8878, 1.16, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR(BPTI)
1978, d2g8tA_, 0.8878, 1.16, 0.385, 223, 221, INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN
1979, d2g55A_, 0.8878, 1.17, 0.385, 223, 221, ANOMALOUS SUBSTRUCTURE OF TRYPSIN (P3121)
1980, d1yktA_, 0.8878, 1.18, 0.385, 223, 221, TRYPSIN/BPTI COMPLEX MUTANT
1981, d1tynA_, 0.8878, 1.17, 0.385, 223, 221, ATOMIC STRUCTURE OF THE TRYPSIN-CYCLOTHEONAMIDE A COMPLEX: LESSONS FOR THE DESIGN OF SERINE PROTEASE INHIBITORS
1982, d1y59T_, 0.8877, 1.16, 0.385, 223, 221, DIANHYDROSUGAR-BASED BENZAMIDINE FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN MUTANT
1983, d1j17T_, 0.8877, 1.17, 0.371, 224, 221, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT
1984, d1c1qA_, 0.8877, 1.17, 0.385, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
1985, d3l3tA_, 0.8876, 1.17, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH AMYLOID PRECURSOR PROTEIN INHIBITOR VARIANT (APPIR15K)
1986, d3aavB_, 0.8876, 1.17, 0.385, 223, 221, BOVINE BETA-TRYPSIN BOUND TO META-DIAMIDINO SCHIFF BASE COPPER (II) CHELATE
1987, d2zq1A_, 0.8876, 1.17, 0.385, 223, 221, EXPLORING TRYPSIN S3 POCKET
1988, d2zfsA_, 0.8876, 1.17, 0.385, 223, 221, EXPLORING TRYPSIN S3 POCKET
1989, d2zdkA_, 0.8876, 1.17, 0.385, 223, 221, EXPLORING TRYPSIN S3 POCKET
1990, d2ptcE_, 0.8876, 1.17, 0.385, 223, 221, THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
1991, d2ilnB_, 0.8876, 1.17, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE BOWMAN-BIRK INHIBITOR FROM SNAIL MEDIC SEEDS IN COMPLEX WITH BOVINE TRYPSIN
1992, d1utoA_, 0.8876, 1.17, 0.385, 223, 221, TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
1993, d1qboA_, 0.8876, 1.17, 0.371, 224, 221, BOVINE TRYPSIN 7-[[6-[[1-(1-IMINOETHYL)PIPERIDIN-4-YL]OXY]-2-METHYL- BENZIMIDAZOL-1-YL]METHYL]NAPHTHALENE-2-CARBOXIMIDAMID ZK-806711 INHIBITOR COMPLEX
1994, d1ejaA_, 0.8876, 1.16, 0.389, 223, 221, STRUCTURE OF PORCINE TRYPSIN COMPLEXED WITH BDELLASTASIN AN ANTISTASIN-TYPE INHIBITOR
1995, d4u30B_, 0.8875, 1.17, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH BIKUNIN KUNITZ DOMAIN 2
1996, d3l33C_, 0.8875, 1.17, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH AMYLOID PRECURSOR PROTEIN INHIBITOR(APPI)
1997, d3l33B_, 0.8875, 1.17, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH AMYLOID PRECURSOR PROTEIN INHIBITOR(APPI)
1998, d3aavA_, 0.8875, 1.17, 0.385, 223, 221, BOVINE BETA-TRYPSIN BOUND TO META-DIAMIDINO SCHIFF BASE COPPER (II) CHELATE
1999, d1qbnA_, 0.8875, 1.16, 0.389, 223, 221, BOVINE TRYPSIN 2-[AMINO(IMINO)METHYL]-2-HYDROXYPHENOXY]-6- [3-(45-DIHYDRO-1H-IMIDAZOL-2-YL)PHENOXY]PYRIDINE-4- CARBOXYLIC ACID (ZK-806688) COMPLEX
2000, d1qb6A_, 0.8875, 1.99, 0.314, 240, 229, BOVINE TRYPSIN 33 -[35-DIFLUORO-4-METHYL-2 6- PYRIDINEDIYLBIS(OXY)]BIS(BENZENECARBOXIMIDAMIDE) (ZK- 805623) COMPLEX
2001, d1oxgA_, 0.8875, 1.99, 0.314, 240, 229, CRYSTAL STRUCTURE OF A COMPLEX FORMED BETWEEN ORGANIC SOLVENT TREATED BOVINE ALPHA-CHYMOTRYPSIN AND ITS AUTOCATALYTICALLY PRODUCED HIGHLY POTENT 14-RESIDUE PEPTIDE AT 2.2 RESOLUTION
2002, d1c1sA_, 0.8875, 1.16, 0.367, 224, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
2003, d1brcE_, 0.8875, 1.16, 0.371, 224, 221, RELOCATING A NEGATIVE CHARGE IN THE BINDING POCKET OF TRYPSIN
2004, d3l33D_, 0.8874, 1.17, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH AMYLOID PRECURSOR PROTEIN INHIBITOR(APPI)
2005, d3e8lA_, 0.8874, 1.17, 0.385, 223, 221, THE CRYSTAL STRUCTURE OF THE DOUBLE-HEADED ARROWHEAD PROTEASE INHIBITOR A IN COMPLEX WITH TWO TRYPSINS
2006, d2plxA1, 0.8874, 1.17, 0.380, 223, 221, TRYPSIN COMPLEXED TO A SYNTHETIC PEPTIDE FROM VERONICA HEDERIFOLIA
2007, p4y11E_, 0.8873, 1.18, 0.385, 223, 221, TRYPSIN IN COMPLEX WITH WITH BPTI MUTANT (2S)-2-AMINO-444- TRIFLUOROBUTANOIC ACID
2008, d4u30A_, 0.8873, 1.17, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH BIKUNIN KUNITZ DOMAIN 2
2009, p4doqA_, 0.8873, 1.23, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE COMPLEX OF PORCINE PANCREATIC TRYPSIN WITH 1/2SLPI
2010, p3tvjB_, 0.8873, 1.17, 0.385, 223, 221, CATALYTIC FRAGMENT OF MASP-2 IN COMPLEX WITH ITS SPECIFIC INHIBITOR DEVELOPED BY DIRECTED EVOLUTION ON SGCI SCAFFOLD
2011, d2zdnA_, 0.8873, 1.18, 0.371, 224, 221, EXPLORING TRYPSIN S3 POCKET
2012, d2g5nA_, 0.8873, 1.17, 0.385, 223, 221, INDOLE-AMIDINE COMPLEXES WITH BOVINE TRYPSIN
2013, d1maxA_, 0.8873, 1.17, 0.385, 223, 221, BETA-TRYPSIN PHOSPHONATE INHIBITED
2014, d1jrtA_, 0.8873, 1.17, 0.385, 223, 221, HEMIACETAL COMPLEX BETWEEN LEUPEPTIN AND TRYPSIN
2015, d1gi0A_, 0.8873, 1.17, 0.385, 223, 221, A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK AT THE ACTIVE SITE
2016, d1c2kA_, 0.8873, 1.18, 0.385, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
2017, d1c1tA_, 0.8873, 1.18, 0.385, 223, 221, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
2018, d4yzuA_, 0.8872, 1.17, 0.385, 223, 221, RAPID DEVELOPMENT OF TWO FACTOR IXA INHIBITORS FROM HIT TO LEAD
2019, d3gy6A_, 0.8872, 1.17, 0.385, 223, 221, A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY THE BIS-BENZAMIDINES DIMINAZENE AND PENTAMIDINE
2020, d2zdlA_, 0.8872, 1.18, 0.389, 223, 221, EXPLORING TRYPSIN S3 POCKET
2021, d2ilnA_, 0.8872, 1.18, 0.371, 224, 221, CRYSTAL STRUCTURE OF THE BOWMAN-BIRK INHIBITOR FROM SNAIL MEDIC SEEDS IN COMPLEX WITH BOVINE TRYPSIN
2022, d1v2jT_, 0.8872, 1.17, 0.371, 224, 221, BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI) BT.C1
2023, d1utpA_, 0.8872, 1.17, 0.371, 224, 221, TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
2024, d1trmB_, 0.8872, 1.17, 0.385, 223, 221, THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS
2025, p4y10E_, 0.8871, 1.18, 0.385, 223, 221, TRYPSIN IN COMPLEX WITH WITH BPTI MUTANT (2S)-2-AMINO-44- DIFLUOROBUTANOIC ACID
2026, p4y0zE_, 0.8871, 1.18, 0.385, 223, 221, TRYPSIN IN COMPLEX WITH WITH BPTI MUTANT AMINOBUTYRIC ACID
2027, d4u30D_, 0.8871, 1.82, 0.392, 241, 227, HUMAN MESOTRYPSIN COMPLEXED WITH BIKUNIN KUNITZ DOMAIN 2
2028, d4u30C_, 0.8871, 1.18, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH BIKUNIN KUNITZ DOMAIN 2
2029, d4j2yB_, 0.8871, 1.18, 0.385, 223, 221, CRYSTAL STRUCTURE OF A PLANT TRYPSIN INHIBITOR ECTI IN COMPLEX WITH BOVINE TRYPSIN.
2030, d2vwmA_, 0.8871, 1.17, 0.371, 224, 221, AMINOPYRROLIDINE FACTOR XA INHIBITOR
2031, d1trmA_, 0.8871, 1.17, 0.385, 223, 221, THE THREE-DIMENSIONAL STRUCTURE OF ASN102 MUTANT OF TRYPSIN. ROLE OF ASP102 IN SERINE PROTEASE CATALYSIS
2032, d1qcpA_, 0.8871, 1.18, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE RWJ-51084 BOVINE PANCREATIC BETA- TRYPSIN AT 1.8 A
2033, d5tntA_, 0.8870, 1.18, 0.385, 223, 221, DISCOVERY OF NOVEL AMINOBENZISOXAZOLE DERIVATIVES AS ORALLY AVAILABLE FACTOR IXA INHIBITORS
2034, d5c67B_, 0.8870, 1.18, 0.371, 224, 221, HUMAN MESOTRYPSIN IN COMPLEX WITH AMYLOID PRECURSOR PROTEIN INHIBITOR VARIANT APPI-M17G/I18F/F34V
2035, d4wwyA_, 0.8870, 1.10, 0.391, 221, 220, HUMAN CATIONIC TRYPSIN G193R MUTANT IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
2036, p4guxB_, 0.8870, 1.92, 0.310, 242, 229, CRYSTAL STRUCTURE OF TRYPSIN:MCOTI-II COMPLEX
2037, p4dy7E_, 0.8870, 1.18, 0.385, 223, 221, CRYSTAL STRUCTURES OF PROTEASE NEXIN-1 IN COMPLEX WITH S195A THROMBIN
2038, d2zftA_, 0.8870, 1.18, 0.385, 223, 221, EXPLORING TRYPSIN S3 POCKET
2039, d2qyiA_, 0.8870, 1.20, 0.385, 223, 221, CRYSTAL STRUCTURE OF A BINARY COMPLEX BETWEEN AN ENGINEERED TRYPSIN INHIBITOR AND BOVINE TRYPSIN
2040, d2btcE_, 0.8870, 1.19, 0.385, 223, 221, BOVINE TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II)
2041, d1v2vT_, 0.8870, 1.18, 0.385, 223, 221, BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSAI) BT.C1
2042, d5lgoA_, 0.8869, 1.18, 0.385, 223, 221, TRYPSIN INHIBITORS FOR THE TREATMENT OF PANCREATITIS - CPD 15
2043, p4y0yE_, 0.8869, 1.18, 0.385, 223, 221, TRYPSIN IN COMPLEX WITH WITH BPTI
2044, p4aorA_, 0.8869, 2.03, 0.370, 235, 230, CATIONIC TRYPSIN IN COMPLEX WITH THE SPINACIA OLERACEA TRYPSIN INHIBITOR III (SOTI-III)
2045, d1mtvA_, 0.8869, 1.17, 0.385, 223, 221, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN
2046, d3mywA_, 0.8868, 1.18, 0.385, 223, 221, THE BOWMAN-BIRK TYPE INHIBITOR FROM MUNG BEAN IN TERNARY COMPLEX WITH PORCINE TRYPSIN
2047, d3l3tB_, 0.8868, 1.19, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH AMYLOID PRECURSOR PROTEIN INHIBITOR VARIANT (APPIR15K)
2048, d2pka.2, 0.8868, 1.19, 0.385, 223, 221, REFINED 2 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF PORCINE PANCREATIC KALLIKREIN A A SPECIFIC TRYPSIN-LIKE SERINE PROTEINASE. CRYSTALLIZATION STRUCTURE DETERMINATION CRYSTALLOGRAPHIC REFINEMENT STRUCTURE AND ITS COMPARISON WITH BOVINE TRYPSIN
2049, d1utqA_, 0.8868, 1.18, 0.385, 223, 221, TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
2050, d1ezsC_, 0.8868, 1.18, 0.380, 223, 221, CRYSTAL STRUCTURE OF ECOTIN MUTANT M84R W67A G68A Y69A D70A BOUND TO RAT ANIONIC TRYPSIN II
2051, d3mywB_, 0.8867, 1.18, 0.385, 223, 221, THE BOWMAN-BIRK TYPE INHIBITOR FROM MUNG BEAN IN TERNARY COMPLEX WITH PORCINE TRYPSIN
2052, d2zdmA_, 0.8867, 1.19, 0.385, 223, 221, EXPLORING TRYPSIN S3 POCKET
2053, p2xttB_, 0.8867, 1.19, 0.371, 224, 221, BOVINE TRYPSIN IN COMPLEX WITH EVOLUTIONARY ENHANCED SCHISTOCERCA GREGARIA PROTEASE INHIBITOR 1 (SGPI-1-P02)
2054, d1tfxB_, 0.8867, 1.19, 0.371, 224, 221, COMPLEX OF THE SECOND KUNITZ DOMAIN OF TISSUE FACTOR PATHWAY INHIBITOR WITH PORCINE TRYPSIN
2055, d1ppeE_, 0.8867, 1.17, 0.385, 223, 221, THE REFINED 2.0 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BETWEEN BOVINE BETA-TRYPSIN AND CMTI-I A TRYPSIN INHIBITOR FROM SQUASH SEEDS (CUCURBITA MAXIMA): TOPOLOGICAL SIMILARITY OF THE SQUASH SEED INHIBITORS WITH THE CARBOXYPEPTIDASE A INHIBITOR FROM POTATOES
2056, d1c2lA_, 0.8867, 1.67, 0.308, 232, 227, RECRUITING ZINC TO MEDIATE POTENT SPECIFIC INHIBITION OF SERINE PROTEASES
2057, d3gy2A_, 0.8866, 1.18, 0.380, 223, 221, A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS- BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
2058, d3d65E_, 0.8866, 1.18, 0.385, 223, 221, CRYSTAL STRUCTURE OF TEXTILININ-1 A KUNITZ-TYPE SERINE PROTEASE INHIBITOR FROM THE AUSTRALIAN COMMON BROWN SNAKE VENOM IN COMPLEX WITH TRYPSIN
2059, d2qyiC_, 0.8866, 2.02, 0.370, 235, 230, CRYSTAL STRUCTURE OF A BINARY COMPLEX BETWEEN AN ENGINEERED TRYPSIN INHIBITOR AND BOVINE TRYPSIN
2060, d2a7hA_, 0.8866, 1.18, 0.371, 224, 221, ON THE ROUTINE USE OF SOFT X-RAYS IN MACROMOLECULAR CRYSTALLOGRAPHY PART III- THE OPTIMAL DATA COLLECTION WAVELENGTH
2061, d1p2kA_, 0.8866, 1.18, 0.367, 224, 221, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
2062, d1ezsD_, 0.8866, 1.18, 0.385, 223, 221, CRYSTAL STRUCTURE OF ECOTIN MUTANT M84R W67A G68A Y69A D70A BOUND TO RAT ANIONIC TRYPSIN II
2063, d5jbtA_, 0.8865, 1.82, 0.297, 251, 229, MESOTRYPSIN IN COMPLEX WITH CLEAVED AMYLOID PRECURSOR LIKE PROTEIN 2 INHIBITOR (APLP2)
2064, d4zaeA_, 0.8865, 1.18, 0.385, 223, 221, DEVELOPMENT OF A NOVEL CLASS OF POTENT AND SELECTIVE FIXA INHIBITORS
2065, d3l3tC_, 0.8865, 1.19, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH AMYLOID PRECURSOR PROTEIN INHIBITOR VARIANT (APPIR15K)
2066, d3gy5A_, 0.8865, 1.18, 0.385, 223, 221, A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS- BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
2067, d3f6uH_, 0.8865, 1.24, 0.385, 223, 221, CRYSTAL STRUCTURE OF HUMAN ACTIVATED PROTEIN C (APC) COMPLEXED WITH PPACK
2068, d1tgcA_, 0.8864, 1.18, 0.385, 223, 221, ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2069, d1p2iA_, 0.8864, 1.19, 0.385, 223, 221, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
2070, d1c9tF_, 0.8864, 1.20, 0.385, 223, 221, COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN
2071, d1c9tC_, 0.8864, 1.19, 0.385, 223, 221, COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN
2072, d1c9tB_, 0.8864, 1.18, 0.389, 223, 221, COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN
2073, d1c9tE_, 0.8863, 1.19, 0.371, 224, 221, COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN
2074, d1c9tD_, 0.8863, 1.71, 0.333, 232, 225, COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN
2075, d5egmA_, 0.8862, 1.19, 0.385, 223, 221, DEVELOPMENT OF A NOVEL TRICYCLIC CLASS OF POTENT AND SELECTIVE FIXA INHIBITORS
2076, d3gy8A_, 0.8862, 1.19, 0.380, 223, 221, A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS- BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
2077, d1v2wT_, 0.8862, 1.18, 0.389, 223, 221, TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSAI)BT.B4
2078, d1c9tA_, 0.8862, 1.19, 0.385, 223, 221, COMPLEX OF BDELLASTASIN WITH BOVINE TRYPSIN
2079, d3veqB_, 0.8861, 1.19, 0.385, 223, 221, A BINARY COMPLEX BETWWEN BOVINE PANCREATIC TRYPSIN AND A ENGINEERED MUTANT TRYPSIN INHIBITOR
2080, d2tgaA_, 0.8861, 1.19, 0.389, 223, 221, ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2081, d1v2tT_, 0.8861, 1.19, 0.385, 223, 221, TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSFI.GLU)BT.B4
2082, d1v2oT_, 0.8861, 1.19, 0.385, 223, 221, TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSYI)BT.B4
2083, d3uopA_, 0.8860, 1.19, 0.385, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEPHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2084, d1v2mT_, 0.8860, 1.19, 0.385, 223, 221, BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.A1
2085, d3ru4T_, 0.8859, 1.20, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE BOWMAN-BIRK SERINE PROTEASE INHIBITOR BTCI IN COMPLEX WITH TRYPSIN AND CHYMOTRYPSIN
2086, d3e8lB_, 0.8859, 1.19, 0.385, 223, 221, THE CRYSTAL STRUCTURE OF THE DOUBLE-HEADED ARROWHEAD PROTEASE INHIBITOR A IN COMPLEX WITH TWO TRYPSINS
2087, d1v2rT_, 0.8859, 1.19, 0.385, 223, 221, TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSRI)BT.B4
2088, d1v2pT_, 0.8859, 1.19, 0.380, 223, 221, TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSYI)BT.A4
2089, d1tfxA_, 0.8859, 1.19, 0.371, 224, 221, COMPLEX OF THE SECOND KUNITZ DOMAIN OF TISSUE FACTOR PATHWAY INHIBITOR WITH PORCINE TRYPSIN
2090, d1dvaH_, 0.8859, 1.89, 0.371, 234, 229, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE PEPTIDE EXOSITE INHIBITOR E-76 AND COAGULATION FACTOR VIIA
2091, d3i29A_, 0.8858, 1.20, 0.371, 224, 221, CRYSTAL STRUCTURE OF A BINARY COMPLEX BETWEEN AN MUTANT TRYPSIN INHIBITOR WITH BOVINE TRYPSIN
2092, d2pka.1, 0.8858, 1.20, 0.385, 223, 221, REFINED 2 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF PORCINE PANCREATIC KALLIKREIN A A SPECIFIC TRYPSIN-LIKE SERINE PROTEINASE. CRYSTALLIZATION STRUCTURE DETERMINATION CRYSTALLOGRAPHIC REFINEMENT STRUCTURE AND ITS COMPARISON WITH BOVINE TRYPSIN
2093, d1tgbA_, 0.8858, 1.87, 0.316, 240, 228, CRYSTAL STRUCTURE OF BOVINE TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. II. CRYSTALLOGRAPHIC REFINEMENT REFINED CRYSTAL STRUCTURE AND COMPARISON WITH BOVINE TRYPSIN
2094, d4b2aC_, 0.8857, 1.21, 0.385, 223, 221, STRUCTURE OF THE FACTOR XA-LIKE TRYPSIN VARIANT TRIPLE-ALA (TGA) IN COMPLEX WITH EGLIN C
2095, d1op8F_, 0.8857, 1.20, 0.385, 223, 221, CRYSTAL STRUCTURE OF HUMAN GRANZYME A
2096, d1hia.1, 0.8857, 1.19, 0.385, 223, 221, KALLIKREIN COMPLEXED WITH HIRUSTASIN
2097, d1ezuC_, 0.8857, 1.19, 0.385, 223, 221, ECOTIN Y69F D70P BOUND TO D102N TRYPSIN
2098, d5ptpA_, 0.8856, 1.19, 0.385, 223, 221, STRUCTURE OF HYDROLASE (SERINE PROTEINASE)
2099, d4dg4D_, 0.8856, 1.19, 0.385, 223, 221, HUMAN MESOTRYPSIN-S39Y COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
2100, d3upeA_, 0.8856, 1.19, 0.385, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEPHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2101, d3pmjA_, 0.8856, 2.06, 0.370, 235, 230, BOVINE TRYPSIN VARIANT X(TRIPLEILE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2102, d3m7qA_, 0.8856, 1.20, 0.385, 223, 221, CRYSTAL STRUCTURE OF RECOMBINANT KUNITZ TYPE SERINE PROTEASE INHIBITOR-1 FROM THE CARIBBEAN SEA ANEMONE STICHODACTYLA HELIANTHUS IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN
2103, d1v2kT_, 0.8856, 1.23, 0.385, 223, 221, FACTOR XA SPECIFIC INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.D2
2104, d1tawA_, 0.8856, 1.19, 0.385, 223, 221, BOVINE TRYPSIN COMPLEXED TO APPI
2105, d1k9oE_, 0.8855, 1.20, 0.385, 223, 221, CRYSTAL STRUCTURE OF MICHAELIS SERPIN-TRYPSIN COMPLEX
2106, d5k7rA_, 0.8854, 1.21, 0.385, 223, 221, MICROED STRUCTURE OF TRYPSIN AT 1.7 A RESOLUTION
2107, d1q3xB1, 0.8854, 1.21, 0.380, 223, 221, CRYSTAL STRUCTURE OF THE CATALYTIC REGION OF HUMAN MASP-2
2108, d1q3xA1, 0.8854, 1.22, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE CATALYTIC REGION OF HUMAN MASP-2
2109, d1i99E_, 0.8854, 1.25, 0.380, 223, 221,  
2110, d5c67A_, 0.8853, 1.21, 0.380, 223, 221, HUMAN MESOTRYPSIN IN COMPLEX WITH AMYLOID PRECURSOR PROTEIN INHIBITOR VARIANT APPI-M17G/I18F/F34V
2111, d4b2aA_, 0.8853, 1.20, 0.385, 223, 221, STRUCTURE OF THE FACTOR XA-LIKE TRYPSIN VARIANT TRIPLE-ALA (TGA) IN COMPLEX WITH EGLIN C
2112, d4ab8A_, 0.8853, 1.20, 0.385, 223, 221, FRAGMENTS BOUND TO BOVINE TRYPSIN FOR THE SAMPL CHALLENGE
2113, d1z7kA_, 0.8853, 1.27, 0.385, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN- OVOMUCOID TURKEY EGG WHITE INHIBITOR COMPLEX
2114, d1r0tA_, 0.8853, 1.22, 0.385, 223, 221,  
2115, d1op8B_, 0.8853, 1.21, 0.389, 223, 221, CRYSTAL STRUCTURE OF HUMAN GRANZYME A
2116, p3s7hB_, 0.8851, 1.99, 0.336, 254, 229, STRUCTURE OF THROMBIN MUTANT Y225P IN THE E* FORM
2117, d2p3tB_, 0.8851, 1.20, 0.385, 223, 221, CRYSTAL STRUCTURE OF HUMAN FACTOR XA COMPLEXED WITH 3- CHLORO-4-(2-METHYLAMINO-IMIDAZOL-1-YLMETHYL)-THIOPHENE-2- CARBOXYLIC ACID [4-CHLORO-2-(5-CHLORO-PYRIDIN-2- YLCARBAMOYL)-6-METHOXY-PHENYL]-AMIDE
2118, d3v13A_, 0.8850, 1.71, 0.333, 232, 225, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2119, d3pwbA_, 0.8850, 1.21, 0.385, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217ILE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2120, d3plbA_, 0.8850, 1.22, 0.376, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEILE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2121, d3gy3A_, 0.8850, 1.89, 0.314, 234, 229, A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS- BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
2122, d1v2nT_, 0.8850, 1.57, 0.333, 230, 225, POTENT FACTOR XA INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(99/175/190)BT
2123, d3unqA_, 0.8849, 1.20, 0.380, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEPHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2124, d3pyhA_, 0.8849, 1.13, 0.382, 222, 220, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217ILE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2125, d4b1tC_, 0.8848, 1.31, 0.371, 224, 221, STRUCTURE OF THE FACTOR XA-LIKE TRYPSIN VARIANT TRIPLE-ALA ( TA) IN COMPLEX WITH EGLIN C
2126, d3pm3A_, 0.8848, 1.26, 0.376, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEILE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2127, d3plkA_, 0.8847, 1.22, 0.380, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEILE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2128, d1dvaI_, 0.8847, 1.22, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE PEPTIDE EXOSITE INHIBITOR E-76 AND COAGULATION FACTOR VIIA
2129, d4b1tA_, 0.8846, 1.27, 0.380, 223, 221, STRUCTURE OF THE FACTOR XA-LIKE TRYPSIN VARIANT TRIPLE-ALA ( TA) IN COMPLEX WITH EGLIN C
2130, d3unsA_, 0.8846, 1.22, 0.385, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEPHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2131, d1v2qT_, 0.8846, 1.20, 0.380, 223, 221, TRYPSIN INHIBITOR IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSWI)BT.B4
2132, d1hj9A_, 0.8846, 1.22, 0.385, 223, 221, ATOMIC RESOLUTION STRUCTURES OF TRYPSIN PROVIDE INSIGHT INTO STRUCTURAL RADIATION DAMAGE
2133, d1hia.2, 0.8846, 1.75, 0.313, 242, 227, KALLIKREIN COMPLEXED WITH HIRUSTASIN
2134, d4dg4G_, 0.8845, 1.75, 0.313, 242, 227, HUMAN MESOTRYPSIN-S39Y COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
2135, d4dg4A_, 0.8845, 1.75, 0.313, 242, 227, HUMAN MESOTRYPSIN-S39Y COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
2136, d3uuzA_, 0.8845, 1.20, 0.380, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEPHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2137, d2o9qA_, 0.8845, 1.21, 0.371, 224, 221, THE CRYSTAL STRUCTURE OF BOVINE TRYPSIN COMPLEXED WITH A SMALL INHIBITION PEPTIDE ORB2K
2138, d1mcuE_, 0.8845, 1.23, 0.376, 223, 221,  
2139, d1ezuD_, 0.8845, 1.14, 0.386, 222, 220, ECOTIN Y69F D70P BOUND TO D102N TRYPSIN
2140, d4dg4B_, 0.8844, 1.21, 0.389, 223, 221, HUMAN MESOTRYPSIN-S39Y COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
2141, d3gy7A_, 0.8844, 1.21, 0.389, 223, 221, A COMPARATIVE STUDY ON THE INHIBITION OF BOVINE BETA-TRYPSIN BY BIS- BENZAMIDINES DIMINAZENE AND PENTAMIDINE BY X-RAY CRYSTALLOGRAPHY AND ITC
2142, d3bttE_, 0.8844, 1.88, 0.314, 234, 229, THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA- TRYPSIN AND TEN P1 VARIANTS OF BPTI
2143, d1j15A_, 0.8844, 1.98, 0.296, 248, 230, BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT
2144, d3uuzB_, 0.8843, 1.66, 0.305, 231, 226, BOVINE TRYPSIN VARIANT X(TRIPLEPHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2145, d1dstA_, 0.8843, 1.28, 0.376, 223, 221, MUTANT OF FACTOR D WITH ENHANCED CATALYTIC ACTIVITY
2146, d4u32A_, 0.8842, 1.24, 0.376, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH HAI-2 KUNITZ DOMAIN 1
2147, d4b2cC_, 0.8842, 1.23, 0.380, 223, 221, STRUCTURE OF THE FACTOR XA-LIKE TRYPSIN VARIANT TRIPLE-ALA (TPA) IN COMPLEX WITH EGLIN C
2148, d3plpA_, 0.8842, 1.21, 0.385, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEILE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2149, d3btkE_, 0.8842, 1.24, 0.385, 223, 221, THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA- TRYPSIN AND TEN P1 VARIANTS OF BPTI
2150, d2qn5T_, 0.8842, 1.26, 0.376, 223, 221, CRYSTAL STRUCTURE AND FUNCTIONAL STUDY OF THE BOWMAN-BIRK INHIBITOR FROM RICE BRAN IN COMPLEX WITH BOVINE TRYPSIN
2151, d1trnA_, 0.8842, 1.28, 0.376, 223, 221, CRYSTAL STRUCTURE OF HUMAN TRYPSIN 1: UNEXPECTED PHOSPHORYLATION OF TYROSINE 151
2152, d3btgE_, 0.8841, 1.24, 0.380, 223, 221, THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA- TRYPSIN AND TEN P1 VARIANTS OF BPTI
2153, d3btdE_, 0.8841, 1.23, 0.380, 223, 221, THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN THE BOVINE BETA- TRYPSIN AND TEN P1 VARIANTS OF BPTI.
2154, d1trnB_, 0.8841, 1.24, 0.376, 223, 221, CRYSTAL STRUCTURE OF HUMAN TRYPSIN 1: UNEXPECTED PHOSPHORYLATION OF TYROSINE 151
2155, p4doqE_, 0.8840, 2.03, 0.332, 254, 229, CRYSTAL STRUCTURE OF THE COMPLEX OF PORCINE PANCREATIC TRYPSIN WITH 1/2SLPI
2156, d1op8D_, 0.8840, 1.24, 0.380, 223, 221, CRYSTAL STRUCTURE OF HUMAN GRANZYME A
2157, d1a0jB_, 0.8840, 1.27, 0.380, 223, 221, CRYSTAL STRUCTURE OF A NON-PSYCHROPHILIC TRYPSIN FROM A COLD-ADAPTED FISH SPECIES.
2158, d3l3tD_, 0.8839, 1.24, 0.385, 223, 221, HUMAN MESOTRYPSIN COMPLEXED WITH AMYLOID PRECURSOR PROTEIN INHIBITOR VARIANT (APPIR15K)
2159, d3btqE_, 0.8838, 1.25, 0.385, 223, 221, THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA- TRYPSIN AND TEN P1 VARIANTS OF BPTI
2160, d3btmE_, 0.8838, 1.62, 0.329, 230, 225, THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA- TRYPSIN AND TEN P1 VARIANTS OF BPTI
2161, d2r9pD_, 0.8838, 1.32, 0.371, 224, 221, HUMAN MESOTRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR(BPTI)
2162, d2r9pB_, 0.8838, 1.32, 0.371, 224, 221, HUMAN MESOTRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR(BPTI)
2163, d4b2bC_, 0.8837, 1.28, 0.376, 223, 221, STRUCTURE OF THE FACTOR XA-LIKE TRYPSIN VARIANT TRIPLE-ALA (TGPA) IN COMPLEX WITH EGLIN C
2164, d4abgA_, 0.8837, 1.23, 0.385, 223, 221, FRAGMENTS BOUND TO BOVINE TRYPSIN FOR THE SAMPL CHALLENGE
2165, d3pwcA_, 0.8836, 1.16, 0.386, 222, 220, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217ILE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2166, d2fi4E_, 0.8836, 1.22, 0.380, 223, 221, CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS14->SER) IN COMPLEX WITH TRYPSIN
2167, d1zr0A_, 0.8836, 1.32, 0.371, 224, 221, CRYSTAL STRUCTURE OF KUNITZ DOMAIN 1 OF TISSUE FACTOR PATHWAY INHIBITOR-2 WITH BOVINE TRYPSIN
2168, p5voeH_, 0.8835, 1.16, 0.382, 222, 220, DESGLA-XAS195A BOUND TO APTAMER 11F7T 
2169, d3uqvA_, 0.8835, 1.16, 0.382, 222, 220, BOVINE TRYPSIN VARIANT X(TRIPLEPHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2170, d2fi5E_, 0.8835, 1.28, 0.389, 223, 221, CRYSTAL STRUCTURE OF A BPTI VARIANT (CYS38->SER) IN COMPLEX WITH TRYPSIN
2171, p1uvuH_, 0.8835, 1.29, 0.376, 223, 221, BOVINE THROMBIN--BM12.1700 COMPLEX
2172, d1uvu.1, 0.8835, 1.64, 0.347, 228, 225, BOVINE THROMBIN--BM12.1700 COMPLEX
2173, p3uy9C_, 0.8834, 1.24, 0.371, 224, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2174, p3uy9G_, 0.8833, 1.25, 0.376, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2175, p3uy9F_, 0.8833, 1.25, 0.380, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2176, p3uy9D_, 0.8833, 1.16, 0.382, 222, 220, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2177, p3uy9B_, 0.8833, 1.23, 0.385, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2178, p3uy9A_, 0.8833, 1.25, 0.376, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2179, p3uy9K_, 0.8832, 1.16, 0.382, 222, 220, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2180, p3uy9J_, 0.8832, 1.16, 0.382, 222, 220, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2181, p3uy9I_, 0.8832, 1.26, 0.376, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2182, p3uy9E_, 0.8832, 1.09, 0.393, 220, 219, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2183, d2ra3B_, 0.8832, 1.89, 0.314, 234, 229, HUMAN CATIONIC TRYPSIN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
2184, d2ftlE_, 0.8832, 1.24, 0.394, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH BPTI AT 100K
2185, p4fxgH_, 0.8831, 1.24, 0.371, 224, 221, COMPLEMENT C4 IN COMPLEX WITH MASP-2
2186, d3v12A_, 0.8831, 1.17, 0.382, 222, 220, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2187, d1j16A_, 0.8831, 1.17, 0.382, 222, 220, BENZAMIDINE IN COMPLEX WITH RAT TRYPSIN MUTANT X99/175/190RT
2188, p3uy9L_, 0.8830, 1.34, 0.371, 224, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2189, p3uy9H_, 0.8830, 1.33, 0.371, 224, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2190, d3q00A_, 0.8830, 1.30, 0.371, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217ILE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2191, d4b2bA_, 0.8829, 1.17, 0.386, 222, 220, STRUCTURE OF THE FACTOR XA-LIKE TRYPSIN VARIANT TRIPLE-ALA (TGPA) IN COMPLEX WITH EGLIN C
2192, p3uy9P_, 0.8829, 1.26, 0.376, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2193, p3uy9M_, 0.8829, 1.17, 0.382, 222, 220, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2194, d3uqoA_, 0.8829, 1.27, 0.385, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEPHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2195, p3uy9O_, 0.8828, 1.68, 0.301, 231, 226, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2196, d2ftmA_, 0.8828, 1.32, 0.380, 223, 221, CRYSTAL STRUCTURE OF TRYPSIN COMPLEXED WITH THE BPTI VARIANT (TYR35- >GLY)
2197, d4b2cA_, 0.8827, 1.18, 0.382, 222, 220, STRUCTURE OF THE FACTOR XA-LIKE TRYPSIN VARIANT TRIPLE-ALA (TPA) IN COMPLEX WITH EGLIN C
2198, p2wubA_, 0.8827, 1.70, 0.310, 244, 226, CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP
2199, p3uy9N_, 0.8826, 1.70, 0.310, 268, 226, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2200, d2wyjA_, 0.8825, 1.32, 0.371, 223, 221, STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH MONOARYL P4 MOTIFS
2201, d3uwiA_, 0.8823, 1.32, 0.371, 223, 221, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2202, d2g81E_, 0.8822, 1.32, 0.371, 223, 221, CRYSTAL STRUCTURE OF THE BOWMAN-BIRK INHIBITOR FROM VIGNA UNGUICULATA SEEDS IN COMPLEX WITH BETA-TRYPSIN AT 1.55 ANGSTRONS RESOLUTION
2203, d4y6dA_, 0.8818, 1.32, 0.371, 223, 221, FACTOR XA COMPLEX WITH GTC000101
2204, d1an1E_, 0.8818, 1.32, 0.371, 223, 221, LEECH-DERIVED TRYPTASE INHIBITOR/TRYPSIN COMPLEX
2205, d2tgpZ_, 0.8816, 1.32, 0.371, 223, 221, THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
2206, d2kai.1, 0.8816, 1.33, 0.371, 223, 221, REFINED 2.5 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF THE COMPLEX FORMED BY PORCINE KALLIKREIN A AND THE BOVINE PANCREATIC TRYPSIN INHIBITOR. CRYSTALLIZATION PATTERSON SEARCH STRUCTURE DETERMINATION REFINEMENT STRUCTURE AND COMPARISON WITH ITS COMPONENTS AND WITH THE BOVINE TRYPSIN- PANCREATIC TRYPSIN INHIBITOR COMPLEX
2207, d1c9pA_, 0.8815, 1.32, 0.371, 223, 221, COMPLEX OF BDELLASTASIN WITH PORCINE TRYPSIN
2208, p3qgnB_, 0.8814, 1.32, 0.371, 223, 221, THE ALLOSTERIC E*-E EQUILIBRIUM IS A KEY PROPERTY OF THE TRYPSIN FOLD
2209, d1v2lT_, 0.8814, 1.32, 0.371, 223, 221, BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(TRIPLE.GLU)BT.D1
2210, d1ejmC_, 0.8812, 1.33, 0.367, 224, 221, CRYSTAL STRUCTURE OF THE BPTI ALA16LEU MUTANT IN COMPLEX WITH BOVINE TRYPSIN
2211, d3v0xA_, 0.8811, 1.18, 0.382, 222, 220, BOVINE TRYPSIN VARIANT X(TRIPLEGLU217PHE227) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2212, d3tpiZ_, 0.8811, 1.83, 0.308, 242, 227, THE GEOMETRY OF THE REACTIVE SITE AND OF THE PEPTIDE GROUPS IN TRYPSIN TRYPSINOGEN AND ITS COMPLEXES WITH INHIBITORS
2213, p5vofH_, 0.8810, 1.32, 0.371, 223, 221, DESGLA-XAS195A BOUND TO APTAMER 11F7T AND RIVAROXABAN 
2214, d4tpiZ_, 0.8810, 1.30, 0.389, 223, 221, THE REFINED 2.2-ANGSTROMS (0.22-NM) X-RAY CRYSTAL STRUCTURE OF THE TERNARY COMPLEX FORMED BY BOVINE TRYPSINOGEN VALINE-VALINE AND THE ARG15 ANALOGUE OF BOVINE PANCREATIC TRYPSIN INHIBITOR
2215, d1ejmE_, 0.8809, 1.33, 0.371, 223, 221, CRYSTAL STRUCTURE OF THE BPTI ALA16LEU MUTANT IN COMPLEX WITH BOVINE TRYPSIN
2216, p3ee0B_, 0.8808, 1.32, 0.371, 223, 221, CRYSTAL STRUCTURE OF THE W215A/E217A MUTANT OF HUMAN THROMBIN (SPACE GROUP P2(1)2(1)2(1))
2217, d5lhnA_, 0.8807, 1.31, 0.376, 223, 221, THE CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR IN COMPLEX WITH THE ALLOSTERIC INHIBITORY NANOBODY NB7
2218, d4q2kD_, 0.8806, 1.31, 0.371, 223, 221, BOVINE ALPHA CHYMOTRYPSIN BOUND TO A CYCLIC PEPTIDE INHIBITOR 5B
2219, d1ejmA_, 0.8805, 1.33, 0.371, 223, 221, CRYSTAL STRUCTURE OF THE BPTI ALA16LEU MUTANT IN COMPLEX WITH BOVINE TRYPSIN
2220, d2d8wA_, 0.8804, 1.33, 0.371, 223, 221, STRUCTURE OF HYPER-VIL-TRYPSIN
2221, d1v2sT_, 0.8803, 1.32, 0.380, 223, 221, BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARIANT X(SSFI.GLU)BT.D1
2222, p3jz2B_, 0.8800, 1.33, 0.371, 223, 221, CRYSTAL STRUCTURE OF HUMAN THROMBIN MUTANT N143P IN E* FORM
2223, d3bthE_, 0.8798, 1.19, 0.382, 222, 220, THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA- TRYPSIN AND TEN P1 VARIANTS OF BPTI
2224, d1npmB_, 0.8798, 1.30, 0.376, 223, 221, NEUROPSIN A SERINE PROTEASE EXPRESSED IN THE LIMBIC SYSTEM OF MOUSE BRAIN
2225, d1npmA_, 0.8798, 1.43, 0.332, 231, 223, NEUROPSIN A SERINE PROTEASE EXPRESSED IN THE LIMBIC SYSTEM OF MOUSE BRAIN
2226, d3bteE_, 0.8795, 1.33, 0.371, 223, 221, THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA-TRYPSIN AND TEN P1 VARIANTS OF BPTI.
2227, d1zr0C_, 0.8795, 1.62, 0.307, 230, 225, CRYSTAL STRUCTURE OF KUNITZ DOMAIN 1 OF TISSUE FACTOR PATHWAY INHIBITOR-2 WITH BOVINE TRYPSIN
2228, d1v2uT_, 0.8795, 1.33, 0.371, 223, 221, BENZAMIDINE IN COMPLEX WITH BOVINE TRYPSIN VARINAT X(SSAI) BT.D1
2229, p4bxwB_, 0.8794, 1.28, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE PROTHROMBINASE COMPLEX FROM THE VENOM OF PSEUDONAJA TEXTILIS
2230, d5y9lA_, 0.8791, 1.63, 0.302, 230, 225, HUMAN KALLIKREIN 7 IN COMPLEX WITH 136-TRISUBSTITUTED 14-DIAZEPANE- 7-ONE
2231, p1uvsH_, 0.8791, 1.20, 0.386, 222, 220, BOVINE THROMBIN--BM51.1011 COMPLEX
2232, d1uvs.1, 0.8791, 1.23, 0.386, 223, 220, BOVINE THROMBIN--BM51.1011 COMPLEX
2233, d4q2kA_, 0.8789, 1.89, 0.338, 232, 225, BOVINE ALPHA CHYMOTRYPSIN BOUND TO A CYCLIC PEPTIDE INHIBITOR 5B
2234, p5jpmH_, 0.8788, 1.21, 0.386, 222, 220, STRUCTURE OF THE COMPLEX OF HUMAN COMPLEMENT C4 WITH MASP-2 REBUILT USING IMDFF
2235, d1x7aC_, 0.8788, 1.76, 0.300, 247, 227, PORCINE FACTOR IXA COMPLEXED TO 1-{3-[AMINO(IMINO) METHYL]PHENYL}-N-[4-(1H-BENZIMIDAZOL-1-YL)-2-FLUOROPHENYL]- 3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE
2236, p4doqC_, 0.8787, 1.38, 0.380, 223, 221, CRYSTAL STRUCTURE OF THE COMPLEX OF PORCINE PANCREATIC TRYPSIN WITH 1/2SLPI
2237, d3btwE_, 0.8787, 1.35, 0.385, 223, 221, THE CRYSTAL STRUCTURES OF THE COMPLEXES BETWEEN BOVINE BETA- TRYPSIN AND TEN P1 VARIANTS OF BPTI
2238, d1c5mD_, 0.8784, 1.27, 0.368, 222, 220, STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE S1- BINDING SUB-MICROMOLAR INHIBITOR OF UROKINASE TYPE PLASMINOGEN ACTIVATOR
2239, d5yjkA_, 0.8783, 1.27, 0.386, 223, 220, HUMAN KALLIKREIN 7 IN COMPLEX WITH 14-DIAZEPANE-7-ONE 1-ACETAMIDE DERIVATIVE
2240, d3vfeA_, 0.8781, 1.72, 0.301, 231, 226, VIRTUAL SCREENING AND X-RAY CRYSTALLOGRAPHY FOR HUMAN KALLIKREIN 6 INHIBITORS WITH AN AMIDINOTHIOPHENE P1 GROUP
2241, p6fugC_, 0.8780, 1.28, 0.386, 223, 220, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR 3-((3-((3- (AMINOMETHYL)PHENYL)AMINO)-1H-PYRAZOLO[3;4-D]PYRIMIDIN-4-YL)AMINO) PHENOL 
2242, d4rn6B_, 0.8780, 1.34, 0.385, 223, 221, STRUCTURE OF PRETHROMBIN-2 MUTANT S195A BOUND TO THE ACTIVE SITE INHIBITOR ARGATROBAN
2243, d4hfyB_, 0.8780, 1.80, 0.295, 245, 227,  
2244, p2gp9B_, 0.8778, 1.85, 0.319, 238, 226, CRYSTAL STRUCTURE OF THE SLOW FORM OF THROMBIN IN A SELF- INHIBITED CONFORMATION
2245, d1a0jA_, 0.8778, 1.44, 0.396, 232, 222, CRYSTAL STRUCTURE OF A NON-PSYCHROPHILIC TRYPSIN FROM A COLD-ADAPTED FISH SPECIES.
2246, p4bxwA_, 0.8776, 1.37, 0.385, 223, 221, CRYSTAL STRUCTURE OF THE PROTHROMBINASE COMPLEX FROM THE VENOM OF PSEUDONAJA TEXTILIS
2247, d2qxiA_, 0.8776, 1.26, 0.391, 220, 220, HIGH RESOLUTION STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC-ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
2248, d1hcgA_, 0.8775, 1.40, 0.380, 223, 221, STRUCTURE OF HUMAN DES(1-45) FACTOR XA AT 2.2 ANGSTROMS RESOLUTION
2249, d2qxhA_, 0.8773, 2.00, 0.293, 247, 229, CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC- ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
2250, d2j2uA_, 0.8773, 1.17, 0.379, 221, 219, CRYSTAL STRUCTURE OF A HUMAN FACTOR XA INHIBITOR COMPLEX
2251, d1au8A_, 0.8773, 1.36, 0.326, 223, 221, HUMAN CATHEPSIN G
2252, d5gibA_, 0.8772, 1.36, 0.326, 223, 221, SUCCINIC ACID BOUND TRYPSIN CRYSTALLIZED AS DIMER
2253, d4rn6A_, 0.8772, 1.17, 0.379, 221, 219, STRUCTURE OF PRETHROMBIN-2 MUTANT S195A BOUND TO THE ACTIVE SITE INHIBITOR ARGATROBAN
2254, d4hfyA_, 0.8772, 1.34, 0.385, 223, 221,  
2255, d1amhA_, 0.8772, 1.41, 0.385, 223, 221, UNCOMPLEXED RAT TRYPSIN MUTANT WITH ASP 189 REPLACED WITH SER (D189S)
2256, p5nx1A_, 0.8771, 2.02, 0.301, 287, 229, COMBINATORIAL ENGINEERING OF PROTEOLYTICALLY RESISTANT APPI VARIANTS THAT SELECTIVELY INHIBIT HUMAN KALLIKREIN 6 FOR CANCER THERAPY 
2257, d4d8nA_, 0.8770, 2.02, 0.301, 287, 229, HUMAN KALLIKREIN 6 INHIBITORS WITH A PARA-AMIDOBENZYLANMINE P1 GROUP CARRY A HIGH BINDING EFFICIENCY
2258, d1azzB_, 0.8770, 1.33, 0.294, 224, 221, FIDDLER CRAB COLLAGENASE COMPLEXED TO ECOTIN
2259, d1a0jC_, 0.8770, 1.73, 0.307, 241, 225, CRYSTAL STRUCTURE OF A NON-PSYCHROPHILIC TRYPSIN FROM A COLD-ADAPTED FISH SPECIES.
2260, d5jyiA_, 0.8768, 1.73, 0.307, 268, 225, TRYPSIN BOUND WITH SUCCINIC ACID AT 1.9A
2261, d5tnoA_, 0.8767, 1.40, 0.398, 231, 221, DISCOVERY OF NOVEL AMINOBENZISOXAZOLE DERIVATIVES AS ORALLY AVAILABLE FACTOR IXA INHIBITORS
2262, d1azzA_, 0.8766, 1.91, 0.308, 242, 227, FIDDLER CRAB COLLAGENASE COMPLEXED TO ECOTIN
2263, d1amhB_, 0.8766, 2.20, 0.359, 235, 231, UNCOMPLEXED RAT TRYPSIN MUTANT WITH ASP 189 REPLACED WITH SER (D189S)
2264, d2qxgB_, 0.8765, 1.10, 0.394, 219, 218, CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH ALA- ALA-PHE-CHLOROMETHYLKETONE
2265, d2qxgA_, 0.8765, 1.19, 0.379, 221, 219, CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH ALA- ALA-PHE-CHLOROMETHYLKETONE
2266, d1cghA_, 0.8764, 1.98, 0.307, 241, 228, HUMAN CATHEPSIN G
2267, p5nx3A_, 0.8763, 1.35, 0.294, 224, 221, COMBINATORIAL ENGINEERING OF PROTEOLYTICALLY RESISTANT APPI VARIANTS THAT SELECTIVELY INHIBIT HUMAN KALLIKREIN 6 FOR CANCER THERAPY 
2268, d2tpiZ_, 0.8760, 1.49, 0.357, 222, 221, ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2269, d1tgtA_, 0.8759, 1.13, 0.349, 218, 218, ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2270, d3tk9A_, 0.8757, 2.24, 0.299, 284, 231, CRYSTAL STRUCTURE OF HUMAN GRANZYME H
2271, d1iauA_, 0.8757, 2.24, 0.299, 284, 231, HUMAN GRANZYME B IN COMPLEX WITH AC-IEPD-CHO
2272, d1bqyA_, 0.8757, 2.02, 0.288, 247, 229, PLASMINOGEN ACTIVATOR (TSV-PA) FROM SNAKE VENOM
2273, p2a0qB_, 0.8755, 1.39, 0.394, 223, 221, STRUCTURE OF THROMBIN IN 400 MM POTASSIUM CHLORIDE
2274, d1a0jD_, 0.8755, 1.98, 0.303, 286, 228, CRYSTAL STRUCTURE OF A NON-PSYCHROPHILIC TRYPSIN FROM A COLD-ADAPTED FISH SPECIES.
2275, p4k1eA_, 0.8753, 1.35, 0.294, 224, 221, ATOMIC RESOLUTION CRYSTAL STRUCTURES OF KALLIKREIN-RELATED PEPTIDASE 4 COMPLEXED WITH A MODIFIED SFTI INHIBITOR FCQR
2276, d2qxjA_, 0.8753, 1.77, 0.310, 236, 226, CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 IN COMPLEX WITH SUC- ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE AND COPPER
2277, p4kelA_, 0.8751, 1.36, 0.294, 224, 221, ATOMIC RESOLUTION CRYSTAL STRUCTURE OF KALLIKREIN-RELATED PEPTIDASE 4 COMPLEXED WITH A MODIFIED SFTI INHIBITOR FCQR(N)
2278, d3rdzB_, 0.8750, 1.65, 0.304, 229, 224, CRYSTAL STRUCTURE OF RBTI-TRYPSIN COMPLEX AT 2.26 ANGSTROM RESOLUTION
2279, d3rdzA_, 0.8750, 1.52, 0.329, 224, 222, CRYSTAL STRUCTURE OF RBTI-TRYPSIN COMPLEX AT 2.26 ANGSTROM RESOLUTION
2280, d1tryA_, 0.8749, 1.06, 0.392, 218, 217, STRUCTURE OF INHIBITED TRYPSIN FROM FUSARIUM OXYSPORUM AT 1.55 ANGSTROMS
2281, d1l2eA_, 0.8749, 2.25, 0.299, 284, 231, HUMAN KALLIKREIN 6 (HK6) ACTIVE FORM WITH BENZAMIDINE INHIBITOR
2282, d1lo6A_, 0.8745, 2.25, 0.299, 284, 231, HUMAN KALLIKREIN 6 (HK6) ACTIVE FORM WITH BENZAMIDINE INHIBITOR AT 1.56 A RESOLUTION
2283, d1hagE_, 0.8745, 1.50, 0.376, 223, 221, THE ISOMORPHOUS STRUCTURES OF PRETHROMBIN2 HIRUGEN-AND PPACK- THROMBIN: CHANGES ACCOMPANYING ACTIVATION AND EXOSITE BINDING TO THROMBIN
2284, p3gicB_, 0.8744, 1.49, 0.353, 222, 221, STRUCTURE OF THROMBIN MUTANT DELTA(146-149E) IN THE FREE FORM
2285, d4q2kB_, 0.8743, 1.50, 0.357, 222, 221, BOVINE ALPHA CHYMOTRYPSIN BOUND TO A CYCLIC PEPTIDE INHIBITOR 5B
2286, d2tgtA_, 0.8742, 1.68, 0.345, 226, 223, ON THE DISORDERED ACTIVATION DOMAIN IN TRYPSINOGEN. CHEMICAL LABELLING AND LOW-TEMPERATURE CRYSTALLOGRAPHY
2287, d2bdhB_, 0.8741, 1.40, 0.389, 223, 221, HUMAN KALLIKREIN 4 COMPLEX WITH ZINC AND P-AMINOBENZAMIDINE
2288, d2bdgB_, 0.8741, 1.33, 0.384, 219, 219, HUMAN KALLIKREIN 4 COMPLEX WITH NICKEL AND P-AMINOBENZAMIDINE
2289, d1fy5A_, 0.8741, 2.01, 0.374, 232, 227, FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
2290, d1utjA_, 0.8740, 1.68, 0.345, 226, 223, TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
2291, d1fxyA_, 0.8738, 1.68, 0.345, 226, 223, COAGULATION FACTOR XA-TRYPSIN CHIMERA INHIBITED WITH D-PHE-PRO-ARG- CHLOROMETHYLKETONE
2292, d1bqyB_, 0.8738, 1.50, 0.376, 223, 221, PLASMINOGEN ACTIVATOR (TSV-PA) FROM SNAKE VENOM
2293, d5dk1A1, 0.8737, 1.37, 0.294, 224, 221, S. ERYTHRAEA TRYPSIN MIXED CATALYTIC INTERMEDIATE
2294, d1p2jA_, 0.8737, 1.37, 0.294, 224, 221, STRUCTURAL CONSEQUENCES OF ACCOMMODATION OF FOUR NON- COGNATE AMINO-ACID RESIDUES IN THE S1 POCKET OF BOVINE TRYPSIN AND CHYMOTRYPSIN
2295, d1fn8A_, 0.8737, 1.37, 0.294, 224, 221, FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
2296, d2f3cE_, 0.8735, 1.54, 0.329, 224, 222, CRYSTAL STRUCTURE OF INFESTIN 1 A KAZAL-TYPE SERINEPROTEASE INHIBITOR IN COMPLEX WITH TRYPSIN
2297, d1utlM_, 0.8735, 1.46, 0.357, 222, 221, TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
2298, d1gdnA_, 0.8734, 1.17, 0.381, 220, 218, FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
2299, d4kgaB_, 0.8733, 1.46, 0.386, 223, 220, CRYSTAL STRUCTURE OF KALLIKREIN-RELATED PEPTIDASE 4
2300, d1gduA_, 0.8733, 1.96, 0.290, 226, 224, FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
2301, d1fy4A_, 0.8733, 1.61, 0.303, 226, 221, FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
2302, d1eq9A_, 0.8733, 1.64, 0.339, 234, 224, CRYSTAL STRUCTURE OF FIRE ANT CHYMOTRYPSIN COMPLEXED TO PMSF
2303, p6fugA_, 0.8732, 1.68, 0.304, 242, 224, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR 3-((3-((3- (AMINOMETHYL)PHENYL)AMINO)-1H-PYRAZOLO[3;4-D]PYRIMIDIN-4-YL)AMINO) PHENOL 
2304, d1eq9B_, 0.8731, 1.40, 0.394, 223, 221, CRYSTAL STRUCTURE OF FIRE ANT CHYMOTRYPSIN COMPLEXED TO PMSF
2305, p2wubC_, 0.8730, 1.62, 0.285, 223, 221, CRYSTAL STRUCTURE OF HGFA IN COMPLEX WITH THE ALLOSTERIC NON-INHIBITORY ANTIBODY FAB40.DELTATRP
2306, d1xvmA_, 0.8730, 1.40, 0.294, 224, 221, TRYPSIN FROM FUSARIUM OXYSPORUM- ROOM TEMPERATURE TO ATOMIC RESOLUTION
2307, d1bitA_, 0.8730, 1.62, 0.285, 223, 221, THE CRYSTAL STRUCTURE OF ANIONIC SALMON TRYPSIN IN A SECOND CRYSTAL FORM
2308, d2bdhA_, 0.8729, 1.18, 0.381, 220, 218, HUMAN KALLIKREIN 4 COMPLEX WITH ZINC AND P-AMINOBENZAMIDINE
2309, p5zfhA_, 0.8727, 1.18, 0.381, 220, 218, MOUSE KALLIKREIN 7 
2310, d2staE_, 0.8727, 1.26, 0.301, 224, 219, ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA MAXIMA TRYPSIN INHIBITOR I)
2311, d2cgaB_, 0.8727, 1.46, 0.359, 221, 220, BOVINE CHYMOTRYPSINOGEN A. X-RAY CRYSTAL STRUCTURE ANALYSIS AND REFINEMENT OF A NEW CRYSTAL FORM AT 1.8 ANGSTROMS RESOLUTION
2312, d2cgaA_, 0.8727, 1.47, 0.359, 221, 220, BOVINE CHYMOTRYPSINOGEN A. X-RAY CRYSTAL STRUCTURE ANALYSIS AND REFINEMENT OF A NEW CRYSTAL FORM AT 1.8 ANGSTROMS RESOLUTION
2313, d2bdiP_, 0.8727, 2.32, 0.293, 295, 232, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2314, d2bdiO_, 0.8727, 2.22, 0.291, 248, 230, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2315, d2bdiM_, 0.8727, 1.41, 0.400, 231, 220, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2316, d2bdiJ_, 0.8727, 1.49, 0.386, 223, 220, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2317, d2bdiF_, 0.8727, 1.63, 0.285, 223, 221, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2318, d2bdiE_, 0.8727, 1.64, 0.285, 223, 221, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2319, p3beiB_, 0.8726, 1.28, 0.301, 224, 219, CRYSTAL STRUCTURE OF THE SLOW FORM OF THROMBIN IN A SELF_INHIBITED CONFORMATION
2320, d2bdiL_, 0.8726, 1.68, 0.359, 222, 220, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2321, d2bdiB_, 0.8726, 1.62, 0.344, 228, 221, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2322, d1w8bH_, 0.8726, 1.67, 0.339, 234, 224, FACTOR7 - 413 COMPLEX
2323, d2bdiK_, 0.8725, 1.40, 0.350, 227, 220, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2324, d2bdiI_, 0.8725, 1.21, 0.381, 220, 218, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2325, d2bdiH_, 0.8725, 1.28, 0.301, 224, 219, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2326, d2bdiG_, 0.8725, 1.28, 0.301, 224, 219, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2327, d2bdiD_, 0.8725, 1.29, 0.384, 221, 219, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2328, d2bdiC_, 0.8725, 1.68, 0.359, 222, 220, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2329, d2bdiA_, 0.8725, 1.29, 0.301, 224, 219, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2330, d2bdiN_, 0.8724, 1.58, 0.286, 221, 220, HUMAN KALLIKREIN 4 COMPLEX WITH COBALT AND P- AMINOBENZAMIDINE
2331, d4gawF_, 0.8723, 1.29, 0.301, 224, 219, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2332, d2wygA_, 0.8723, 1.29, 0.301, 224, 219, STRUCTURE AND PROPERTY BASED DESIGN OF FACTOR XA INHIBITORS: PYRROLIDIN-2-ONES WITH MONOARYL P4 MOTIFS
2333, d2tbsA_, 0.8723, 1.39, 0.347, 222, 219, COLD-ADAPTION OF ENZYMES: STRUCTURAL COMPARISON BETWEEN SALMON AND BOVINE TRYPSINS
2334, d1bzxE_, 0.8723, 1.39, 0.347, 222, 219, THE CRYSTAL STRUCTURE OF ANIONIC SALMON TRYPSIN IN COMPLEX WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
2335, d5dj7A_, 0.8722, 1.06, 0.352, 216, 216, S. ERYTHRAEA TRYPSIN ACYL-ENZYME
2336, d1ex3A_, 0.8722, 1.39, 0.347, 222, 219, CRYSTAL STRUCTURE OF BOVINE CHYMOTRYPSINOGEN A (TETRAGONAL)
2337, d4gawJ_, 0.8720, 1.37, 0.336, 228, 220, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2338, d5gibB_, 0.8719, 1.29, 0.301, 224, 219, SUCCINIC ACID BOUND TRYPSIN CRYSTALLIZED AS DIMER
2339, d4gawL_, 0.8719, 1.68, 0.355, 222, 220, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2340, p1nrqH_, 0.8719, 1.65, 0.285, 223, 221, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
2341, d1nrq.1, 0.8719, 1.56, 0.281, 224, 221, CRYSTALLOGRAPHIC STRUCTURES OF THROMBIN COMPLEXED WITH THROMBIN RECEPTOR PEPTIDES: EXISTENCE OF EXPECTED AND NOVEL BINDING MODES
2342, d4kgaA_, 0.8716, 1.70, 0.359, 222, 220, CRYSTAL STRUCTURE OF KALLIKREIN-RELATED PEPTIDASE 4
2343, d2stbE_, 0.8713, 2.19, 0.393, 245, 229, ANIONIC SALMON TRYPSIN IN COMPLEX WITH SQUASH SEED INHIBITOR (CUCURBITA PEPO TRYPSIN INHIBITOR II)
2344, p2vu8E_, 0.8712, 2.17, 0.393, 245, 229, CRYSTAL STRUCTURE OF AN INSECT INHIBITOR WITH A FUNGAL TRYPSIN
2345, d2tldE_, 0.8712, 1.65, 0.285, 223, 221, CRYSTAL STRUCTURE OF AN ENGINEERED SUBTILISIN INHIBITOR COMPLEXED WITH BOVINE TRYPSIN
2346, d2g52A_, 0.8712, 1.65, 0.285, 223, 221, ANOMALOUS SUBSTRUCTURE OF TRYPSIN (P21)
2347, d3tjuA_, 0.8711, 1.65, 0.285, 223, 221, CRYSTAL STRUCTURE OF HUMAN GRANZYME H WITH AN INHIBITOR
2348, d1tgsZ_, 0.8711, 1.65, 0.285, 223, 221, THREE-DIMENSIONAL STRUCTURE OF THE COMPLEX BETWEEN PANCREATIC SECRETORY INHIBITOR (KAZAL TYPE) AND TRYPSINOGEN AT 1.8 ANGSTROMS RESOLUTION. STRUCTURE SOLUTION CRYSTALLOGRAPHIC REFINEMENT AND PRELIMINARY STRUCTURAL INTERPRETATION
2349, d3tjvA_, 0.8710, 1.65, 0.285, 223, 221, CRYSTAL STRUCTURE OF HUMAN GRANZYME H WITH A PEPTIDYL SUBSTRATE
2350, d2g51A_, 0.8709, 1.65, 0.285, 223, 221, ANOMALOUS SUBSTRUCTURE OF TRYPSIN (P1)
2351, d1utkA_, 0.8709, 2.05, 0.289, 246, 228, TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
2352, p5o32J_, 0.8708, 1.65, 0.285, 223, 221, THE STRUCTURE OF COMPLEMENT COMPLEX
2353, p4k8yA_, 0.8707, 1.65, 0.285, 223, 221, ATOMIC RESOLUTION CRYSTAL STRUCTURES OF KALLIKREIN-RELATED PEPTIDASE 4 COMPLEXED WITH SUNFLOWER TRYPSIN INHIBITOR (SFTI-1)
2354, d4cboA_, 0.8707, 1.83, 0.348, 247, 224, CRYSTAL STRUCTURE OF COMPLEMENT FACTOR D MUTANT R202A AFTER ENSEMBLE REFINEMENT
2355, d1xvoA_, 0.8707, 1.65, 0.285, 223, 221, TRYPSIN FROM FUSARIUM OXYSPORUM AT PH 6
2356, d4gawG_, 0.8706, 1.65, 0.285, 223, 221, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2357, d1pq8A_, 0.8705, 1.65, 0.285, 223, 221, TRYPSIN AT PH 4 AT ATOMIC RESOLUTION
2358, d1pq7A_, 0.8705, 1.65, 0.285, 223, 221, TRYPSIN AT 0.8 A PH5 / BORAX
2359, d1pq5A_, 0.8705, 1.65, 0.285, 223, 221, TRYPSIN AT PH 5 0.85 A
2360, d2bdhD_, 0.8703, 1.65, 0.285, 223, 221, HUMAN KALLIKREIN 4 COMPLEX WITH ZINC AND P-AMINOBENZAMIDINE
2361, d1t32A_, 0.8703, 1.65, 0.285, 223, 221, A DUAL INHIBITOR OF THE LEUKOCYTE PROTEASES CATHEPSIN G AND CHYMASE WITH THERAPEUTIC EFFICACY IN ANIMALS MODELS OF INFLAMMATION
2362, d1gdqA_, 0.8703, 1.65, 0.285, 223, 221, FUSARIUM OXYSPORUM TRYPSIN AT ATOMIC RESOLUTION
2363, p4ag2B_, 0.8700, 2.02, 0.295, 226, 224, HUMAN CHYMASE - FYNOMER COMPLEX
2364, p5zfiA_, 0.8699, 1.66, 0.300, 228, 223, MOUSE KALLIKREIN 7 IN COMPLEX WITH 6-BENZYL-1;4-DIAZEPAN-7-ONE DERIVATIVE 
2365, p4afqA_, 0.8698, 1.54, 0.356, 222, 219, HUMAN CHYMASE - FYNOMER COMPLEX
2366, d2bdhC_, 0.8698, 1.70, 0.359, 222, 220, HUMAN KALLIKREIN 4 COMPLEX WITH ZINC AND P-AMINOBENZAMIDINE
2367, d3sqeE_, 0.8696, 1.43, 0.350, 230, 220, CRYSTAL STRUCTURE OF PRETHROMBIN-2 MUTANT S195A IN THE ALTERNATIVE FORM
2368, d3bsqA1, 0.8695, 1.43, 0.350, 230, 220, CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 PRODUCED AS A SECRETION PROTEIN IN E.COLI
2369, d2bdgA_, 0.8692, 2.19, 0.393, 245, 229, HUMAN KALLIKREIN 4 COMPLEX WITH NICKEL AND P-AMINOBENZAMIDINE
2370, d5gvtB_, 0.8691, 1.99, 0.295, 226, 224, CRYSTAL STRUCTURES OF THE SERINE PROTEASE DOMAIN OF MURINE PLASMA KALLIKREIN
2371, d1mzaA_, 0.8691, 1.16, 0.392, 218, 217, CRYSTAL STRUCTURE OF HUMAN PRO-GRANZYME K
2372, d1fi8B_, 0.8689, 2.03, 0.295, 226, 224, RAT GRANZYME B [N66Q] COMPLEXED TO ECOTIN [81-84 IEPD]
2373, p5o32I_, 0.8688, 1.73, 0.299, 242, 224, THE STRUCTURE OF COMPLEMENT COMPLEX
2374, d3rp2B_, 0.8688, 1.73, 0.299, 265, 224, THE STRUCTURE OF RAT MAST CELL PROTEASE II AT 1.9-ANGSTROMS RESOLUTION
2375, p4afzA_, 0.8687, 1.62, 0.286, 221, 220, HUMAN CHYMASE - FYNOMER COMPLEX
2376, d3fzzB_, 0.8687, 1.73, 0.359, 222, 220, STRUCTURE OF GRC
2377, d3fzzA_, 0.8686, 1.33, 0.301, 224, 219, STRUCTURE OF GRC
2378, d3s69A_, 0.8685, 1.31, 0.388, 220, 219, CRYSTAL STRUCTURE OF SAXTHROMBIN
2379, d3bsqC1, 0.8685, 1.32, 0.301, 224, 219, CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 PRODUCED AS A SECRETION PROTEIN IN E.COLI
2380, d1fi8A_, 0.8683, 1.69, 0.294, 225, 221, RAT GRANZYME B [N66Q] COMPLEXED TO ECOTIN [81-84 IEPD]
2381, d1kltA_, 0.8682, 1.53, 0.385, 225, 221, CRYSTAL STRUCTURE OF PMSF-TREATED HUMAN CHYMASE AT 1.9 ANGSTROMS RESOLUTION
2382, d1hj8A_, 0.8679, 1.53, 0.385, 225, 221, 1.00 AA TRYPSIN FROM ATLANTIC SALMON
2383, d5dkmA_, 0.8677, 1.93, 0.291, 225, 223, S. ERYTHRAEA TRYPSIN MICHAELIS-MENTEN COMPLEX
2384, d3rp2A_, 0.8676, 1.33, 0.301, 224, 219, THE STRUCTURE OF RAT MAST CELL PROTEASE II AT 1.9-ANGSTROMS RESOLUTION
2385, p4kkdB3, 0.8675, 1.57, 0.361, 222, 219, THE X-RAY CRYSTAL STRUCTURE OF MANNOSE-BINDING LECTIN-ASSOCIATED SERINE PROTEINASE-3 REVEALS THE STRUCTURAL BASIS FOR ENZYME INACTIVITY ASSOCIATED WITH THE 3MC SYNDROME
2386, d2zpsA_, 0.8673, 1.80, 0.284, 241, 225, CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 3 FROM CHUM SALMON
2387, d1pqaA_, 0.8673, 1.70, 0.285, 223, 221, TRYPSIN WITH PMSF AT ATOMIC RESOLUTION
2388, d1utmA_, 0.8670, 1.96, 0.326, 228, 224, TRYPSIN SPECIFICITY AS ELUCIDATED BY LIE CALCULATIONS X-RAY STRUCTURES AND ASSOCIATION CONSTANT MEASUREMENTS
2389, d2zprA_, 0.8669, 1.33, 0.301, 224, 219, CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 2 FROM CHUM SALMON
2390, d1tonA_, 0.8669, 2.00, 0.295, 226, 224, RAT SUBMAXILLARY GLAND SERINE PROTEASE TONIN. STRUCTURE SOLUTION AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION
2391, d1op2A_, 0.8669, 1.33, 0.301, 224, 219, CRYSTAL STRUCTURE OF AAV-SP-II A GLYCOSYLATED SNAKE VENOM SERINE PROTEINASE FROM AGKISTRODON ACUTUS
2392, d1fq3B_, 0.8669, 1.33, 0.301, 224, 219, CRYSTAL STRUCTURE OF HUMAN GRANZYME B
2393, p5edmA3, 0.8665, 1.33, 0.301, 224, 219, CRYSTAL STRUCTURE OF PROTHROMBIN DELETION MUTANT RESIDUES 154-167 ( FORM I )
2394, d4e7nA_, 0.8665, 1.69, 0.285, 223, 221, CRYSTAL STRUCTURE OF AHV_TL-I A GLYCOSYLATED SNAKE-VENOM THROMBIN- LIKE ENZYME FROM AGKISTRODON HALYS
2395, d4gawC_, 0.8662, 1.66, 0.324, 224, 222, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2396, d2zprB_, 0.8662, 1.34, 0.301, 224, 219, CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 2 FROM CHUM SALMON
2397, d1eufA_, 0.8660, 2.04, 0.335, 226, 224, BOVINE DUODENASE(NEW SERINE PROTEASE) CRYSTAL STRUCTURE
2398, d1ppzA_, 0.8657, 1.62, 0.285, 224, 221, TRYPSIN COMPLEXES AT ATOMIC AND ULTRA-HIGH RESOLUTION
2399, d1fq3A_, 0.8655, 2.01, 0.330, 226, 224, CRYSTAL STRUCTURE OF HUMAN GRANZYME B
2400, p4o03A3, 0.8654, 1.68, 0.285, 223, 221, CRYSTAL STRUCTURE OF CA2+ BOUND PROTHROMBIN DELETION MUTANT RESIDUES 146-167
2401, d1op0A_, 0.8653, 2.33, 0.293, 289, 232, CRYSTAL STRUCTURE OF AAV-SP-I A GLYCOSYLATED SNAKE VENOM SERINE PROTEINASE FROM AGKISTRODON ACUTUS
2402, d1ddjA_, 0.8653, 1.38, 0.301, 221, 219, CRYSTAL STRUCTURE OF HUMAN PLASMINOGEN CATALYTIC DOMAIN
2403, d4gawB_, 0.8652, 1.71, 0.285, 223, 221, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2404, d3bsqB1, 0.8649, 1.52, 0.352, 225, 219, CRYSTAL STRUCTURE OF HUMAN KALLIKREIN 7 PRODUCED AS A SECRETION PROTEIN IN E.COLI
2405, d5narA1, 0.8645, 1.93, 0.332, 240, 226, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (S)-PYRROLIDINE-12- DICARBOXYLIC ACID 1-[(1-CARBAMOYL-1H-INDOL-3-YL)-AMIDE] 2-[(3- TRIFLUOROMETHOXY-PHENYL)-AMIDE]
2406, d1mbqA_, 0.8643, 1.93, 0.332, 240, 226, ANIONIC TRYPSIN FROM PACIFIC CHUM SALMON
2407, d1ddjC_, 0.8643, 1.99, 0.341, 227, 223, CRYSTAL STRUCTURE OF HUMAN PLASMINOGEN CATALYTIC DOMAIN
2408, p6fugE_, 0.8640, 1.99, 0.341, 227, 223, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR 3-((3-((3- (AMINOMETHYL)PHENYL)AMINO)-1H-PYRAZOLO[3;4-D]PYRIMIDIN-4-YL)AMINO) PHENOL 
2409, d4gawE_, 0.8638, 1.82, 0.293, 241, 225, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2410, d4gawD_, 0.8638, 1.82, 0.293, 241, 225, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2411, p4hzhA2, 0.8636, 1.93, 0.324, 224, 222, STRUCTURE OF RECOMBINANT GLA-DOMAINLESS PROTHROMBIN MUTANT S525A
2412, p2afqB_, 0.8636, 1.78, 0.338, 224, 222, 1.9 ANGSTROM CRYSTAL STRUCTURE OF WILD-TYPE HUMAN THROMBIN IN THE SODIUM FREE STATE
2413, p6fugF_, 0.8633, 2.00, 0.317, 227, 224, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR 3-((3-((3- (AMINOMETHYL)PHENYL)AMINO)-1H-PYRAZOLO[3;4-D]PYRIMIDIN-4-YL)AMINO) PHENOL 
2414, d1t31A_, 0.8631, 2.01, 0.317, 227, 224, A DUAL INHIBITOR OF THE LEUKOCYTE PROTEASES CATHEPSIN G AND CHYMASE WITH THERAPEUTIC EFFICACY IN ANIMALS MODELS OF INFLAMMATION
2415, d3i77A_, 0.8630, 1.76, 0.326, 234, 224, 35/99/170-LOOPS OF FXA IN SGT
2416, d5kwmA_, 0.8627, 1.39, 0.301, 221, 219, S. ERYTHRAEA TRYPSIN LONG CONSTRUCT APOENZYME
2417, p5jduB_, 0.8627, 1.83, 0.342, 226, 222, CRYSTAL STRUCTURE FOR HUMAN THROMBIN MUTANT D189A
2418, p6fugD_, 0.8626, 1.75, 0.335, 226, 221, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR 3-((3-((3- (AMINOMETHYL)PHENYL)AMINO)-1H-PYRAZOLO[3;4-D]PYRIMIDIN-4-YL)AMINO) PHENOL 
2419, p3pmaB_, 0.8626, 1.78, 0.359, 222, 220, 2.2 ANGSTROM CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN BOVINE THROMBIN AND SUCROSE OCTASULFATE
2420, d2hvxA_, 0.8626, 1.44, 0.352, 229, 219, DISCOVERY OF POTENT ORALLY ACTIVE NONPEPTIDE INHIBITORS OF HUMAN MAST CELL CHYMASE BY USING STRUCTURE-BASED DRUG DESIGN
2421, d1kynB_, 0.8626, 1.81, 0.330, 224, 221, CATHEPSIN-G
2422, d3sqhE_, 0.8625, 2.45, 0.278, 269, 230, CRYSTAL STRUCTURE OF PRETHROMBIN-2 MUTANT S195A IN THE THE OPEN FORM
2423, d2zpqA_, 0.8620, 2.45, 0.278, 269, 230, CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 1 FROM CHUM SALMON
2424, p4nzqA3, 0.8618, 1.75, 0.356, 221, 219, CRYSTAL STRUCTURE OF CA2+-FREE PROTHROMBIN DELETION MUTANT RESIDUES 146-167
2425, d1f5rA_, 0.8618, 1.32, 0.298, 223, 218, RAT TRYPSINOGEN MUTANT COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
2426, d4m7gA_, 0.8613, 1.63, 0.361, 222, 219, STREPTOMYCES ERYTHRAEUS TRYPSIN
2427, d1ddjB_, 0.8612, 1.73, 0.356, 221, 219, CRYSTAL STRUCTURE OF HUMAN PLASMINOGEN CATALYTIC DOMAIN
2428, d4gawK_, 0.8611, 1.72, 0.303, 227, 221, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2429, d1mkwK_, 0.8610, 1.79, 0.304, 234, 224, THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA- THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
2430, p5lyoB_, 0.8609, 1.79, 0.297, 227, 222, CRYSTAL STRUCTURE OF THE ZYMOGEN MATRIPTASE CATALYTIC DOMAIN
2431, d2zpqB_, 0.8607, 2.34, 0.290, 316, 231, CRYSTAL STRUCTURE OF ANIONIC TRYPSIN ISOFORM 1 FROM CHUM SALMON
2432, d1kynA_, 0.8607, 2.07, 0.317, 238, 227, CATHEPSIN-G
2433, d4gawI_, 0.8605, 2.07, 0.317, 238, 227, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2434, d1slxB_, 0.8605, 2.14, 0.290, 226, 224, RAT ANIONIC N143H E151H TRYPSIN COMPLEXED TO A86H ECOTIN; ZINC-BOUND
2435, d5nb6A1, 0.8604, 1.57, 0.358, 221, 218, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR (2S4S)-4-AMINO- PYRROLIDINE-12-DICARBOXYLIC ACID 1-[(1-CARBAMOYL-1H-INDOL-3-YL)- AMIDE] 2-[(3-TRIFLUOROMETHOXY-PHENYL)-AMIDE]
2436, d1fujD_, 0.8601, 2.08, 0.300, 224, 223, PR3 (MYELOBLASTIN)
2437, p3pmbB_, 0.8599, 1.35, 0.298, 223, 218, 2.9 ANGSTROM CRYSTAL STRUCTURE OF BOVINE THROMBIN IN TETRAGONAL SPACEGROUP
2438, d1qrzA_, 0.8599, 2.12, 0.290, 227, 224, CATALYTIC DOMAIN OF PLASMINOGEN
2439, d1pjpA_, 0.8598, 2.26, 0.287, 313, 230, THE 2.2 A CRYSTAL STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH SUCCINYL- ALA-ALA-PRO-PHE-CHLOROMETHYLKETONE
2440, d1qrzB_, 0.8596, 1.82, 0.304, 234, 224, CATALYTIC DOMAIN OF PLASMINOGEN
2441, d1mkxK_, 0.8595, 2.35, 0.376, 247, 226, THE CO-CRYSTAL STRUCTURE OF UNLIGANDED BOVINE ALPHA- THROMBIN AND PRETHROMBIN-2: MOVEMENT OF THE YPPW SEGMENT AND ACTIVE SITE RESIDUES UPON LIGAND BINDING
2442, p4iw4E_, 0.8594, 1.96, 0.296, 226, 223, CRYSTAL STRUCTURE OF THE SERINE PROTEASE DOMAIN OF MASP-3 IN COMPLEX WITH ECOTIN
2443, d1fy8E_, 0.8594, 1.37, 0.303, 220, 218, CRYSTAL STRUCTURE OF THE DELTAILE16VAL17 RAT ANIONIC TRYPSINOGEN-BPTI COMPLEX
2444, p4a5tS2, 0.8593, 1.24, 0.358, 215, 215, STRUCTURAL BASIS FOR THE CONFORMATIONAL MODULATION
2445, d2rdlA_, 0.8593, 1.53, 0.364, 220, 217, HAMSTER CHYMASE 2
2446, d2rdlB_, 0.8592, 2.35, 0.376, 247, 226, HAMSTER CHYMASE 2
2447, d1ddjD_, 0.8592, 0.99, 0.357, 213, 213, CRYSTAL STRUCTURE OF HUMAN PLASMINOGEN CATALYTIC DOMAIN
2448, d1qrzC_, 0.8590, 1.91, 0.293, 226, 222, CATALYTIC DOMAIN OF PLASMINOGEN
2449, p2afqD_, 0.8589, 2.14, 0.290, 226, 224, 1.9 ANGSTROM CRYSTAL STRUCTURE OF WILD-TYPE HUMAN THROMBIN IN THE SODIUM FREE STATE
2450, p5lyoA_, 0.8588, 2.25, 0.287, 312, 230, CRYSTAL STRUCTURE OF THE ZYMOGEN MATRIPTASE CATALYTIC DOMAIN
2451, d2eekA_, 0.8588, 1.96, 0.293, 245, 225, CRYSTAL STRUCTURE OF ATLANTIC COD TRYPSIN COMPLEXED WITH BENZAMIDINE
2452, d1tgnA_, 0.8588, 1.00, 0.357, 213, 213, STRUCTURE OF BOVINE TRYPSINOGEN AT 1.9 ANGSTROMS RESOLUTION
2453, d1ae5A_, 0.8588, 2.04, 0.341, 226, 223, HUMAN HEPARIN BINDING PROTEIN
2454, d1kdq.1, 0.8587, 2.04, 0.321, 230, 224, CRYSTAL STRUCTURE ANALYSIS OF THE MUTANT S189D RAT CHYMOTRYPSIN
2455, d1qrzD_, 0.8586, 2.04, 0.321, 230, 224, CATALYTIC DOMAIN OF PLASMINOGEN
2456, d1l4dA_, 0.8586, 1.38, 0.355, 222, 217, CRYSTAL STRUCTURE OF MICROPLASMINOGEN-STREPTOKINASE ALPHA DOMAIN COMPLEX
2457, d1fy1A_, 0.8586, 1.97, 0.293, 245, 225, [R23SF25E]HBP A MUTANT OF HUMAN HEPARIN BINDING PROTEIN (CAP37)
2458, d1sluB_, 0.8584, 1.12, 0.355, 214, 214, RAT ANIONIC N143H E151H TRYPSIN COMPLEXED TO A86H ECOTIN
2459, p4k3jA_, 0.8583, 1.73, 0.317, 238, 221, CRYSTAL STRUCTURE OF ONARTUZUMAB FAB IN COMPLEX WITH MET AND HGF-BETA
2460, d4gawA_, 0.8583, 1.99, 0.338, 226, 222, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2461, d4nzlA_, 0.8579, 1.92, 0.330, 225, 221, EXTRACELLULAR PROTEINS OF STAPHYLOCOCCUS AUREUS INHIBIT THE NEUTROPHIL SERINE PROTEASES
2462, d1l4zA_, 0.8579, 2.49, 0.286, 284, 231, X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF MICROPLASMINOGEN WITH ALPHA DOMAIN OF STREPTOKINASE IN THE PRESENCE CADMIUM IONS
2463, d2vwmB_, 0.8578, 1.75, 0.358, 220, 218, AMINOPYRROLIDINE FACTOR XA INHIBITOR
2464, d4h6tA_, 0.8575, 2.28, 0.287, 315, 230, CRYSTAL STRUCTURE OF PRETHROMBIN-2 MUTANT E14EA/D14LA/E18A/S195A
2465, d1shyA_, 0.8575, 1.26, 0.381, 216, 215, THE CRYSTAL STRUCTURE OF HGF BETA-CHAIN IN COMPLEX WITH THE SEMA DOMAIN OF THE MET RECEPTOR.
2466, p2a0qD_, 0.8572, 1.41, 0.350, 222, 217, STRUCTURE OF THROMBIN IN 400 MM POTASSIUM CHLORIDE
2467, d1b0fA_, 0.8571, 2.42, 0.378, 247, 225, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE WITH MDL 101 146
2468, p5lyoC_, 0.8570, 2.19, 0.295, 226, 224, CRYSTAL STRUCTURE OF THE ZYMOGEN MATRIPTASE CATALYTIC DOMAIN
2469, d3h7tA_, 0.8570, 2.31, 0.297, 287, 229, CRYSTAL STRUCTURE OF SCABIES MITE INACTIVATED PROTEASE PARALOGUE S-D1 (SMIPP-S-D1)
2470, p4hzhB3, 0.8569, 2.31, 0.330, 252, 227, STRUCTURE OF RECOMBINANT GLA-DOMAINLESS PROTHROMBIN MUTANT S525A
2471, d1slvB_, 0.8569, 1.59, 0.359, 220, 217, RAT ANIONIC N143H E151H TRYPSIN COMPLEXED TO A86H ECOTIN; COPPER- BOUND
2472, d4niyA_, 0.8568, 1.84, 0.327, 223, 220, CRYSTAL STRUCTURE OF TRYPSILIGASE (K60E/N143H/Y151H/D189K TRYPSIN) COMPLEXED TO YRH-ECOTIN (M84Y/M85R/A86H ECOTIN)
2473, d2vvcB_, 0.8567, 2.22, 0.290, 226, 224, AMINOPYRROLIDINE FACTOR XA INHIBITOR
2474, d1rjxB_, 0.8565, 1.61, 0.382, 219, 217, HUMAN PLASMINOGEN CATALYTIC DOMAIN K698M MUTANT
2475, d2tgdA_, 0.8562, 1.25, 0.360, 214, 214, LACK OF THE TRANSITION STATE STABILIZATION SITE IS A FACTOR IN THE INACTIVITY OF TRYPSINOGEN A SERINE PROTEASE ZYMOGEN. STRUCTURE OF DFP INHIBITED BOVINE TRYPSINOGEN AT 2.1 ANGSTROMS RESOLUTION
2476, d1fujB_, 0.8559, 1.42, 0.341, 221, 217, PR3 (MYELOBLASTIN)
2477, p6fugB_, 0.8558, 1.70, 0.318, 237, 220, COMPLEMENT FACTOR D IN COMPLEX WITH THE INHIBITOR 3-((3-((3- (AMINOMETHYL)PHENYL)AMINO)-1H-PYRAZOLO[3;4-D]PYRIMIDIN-4-YL)AMINO) PHENOL 
2478, p4durA2, 0.8558, 2.44, 0.381, 246, 226, THE X-RAY CRYSTAL STRUCTURE OF FULL-LENGTH TYPE II HUMAN PLASMINOGEN
2479, d1zjkA1, 0.8558, 2.07, 0.345, 226, 223, CRYSTAL STRUCTURE OF THE ZYMOGEN CATALYTIC REGION OF HUMAN MASP-2
2480, d3i78A_, 0.8557, 2.45, 0.381, 246, 226, 35/99/170/186/220-LOOPS OF FXA IN SGT
2481, d1slwB_, 0.8557, 2.34, 0.297, 287, 229, RAT ANIONIC N143H E151H TRYPSIN COMPLEXED TO A86H ECOTIN; NICKEL- BOUND
2482, d1mzdA_, 0.8557, 1.75, 0.291, 244, 220, CRYSTAL STRUCTURE OF HUMAN PRO-GRANZYME K
2483, d3tgkE_, 0.8556, 1.23, 0.388, 215, 214, TRYPSINOGEN MUTANT D194N AND DELETION OF ILE 16-VAL 17 COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
2484, d3s9bA_, 0.8556, 2.44, 0.381, 249, 226, RUSSELL S VIPER VENOM SERINE PROTEINASE RVV-V (OPEN-FORM)
2485, d1fujC_, 0.8556, 1.84, 0.330, 226, 221, PR3 (MYELOBLASTIN)
2486, d1ppfE_, 0.8555, 1.83, 0.330, 226, 221, X-RAY CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN LEUKOCYTE ELASTASE (PMN ELASTASE) AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR
2487, d3tgjE_, 0.8551, 2.41, 0.378, 247, 225, S195A TRYPSINOGEN COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR (BPTI)
2488, d3sbkA_, 0.8551, 2.44, 0.381, 246, 226, RUSSELL S VIPER VENOM SERINE PROTEINASE RVV-V (PPACK-BOUND FORM)
2489, p4afsA_, 0.8547, 1.99, 0.295, 238, 224, HUMAN CHYMASE - FYNOMER COMPLEX
2490, d1fujA_, 0.8547, 2.24, 0.327, 253, 226, PR3 (MYELOBLASTIN)
2491, d1hylA_, 0.8545, 1.63, 0.369, 220, 217, THE 1.8 A STRUCTURE OF COLLAGENASE FROM HYPODERMA LINEATUM
2492, d1f7zA_, 0.8545, 1.72, 0.394, 222, 218, RAT TRYPSINOGEN K15A COMPLEXED WITH BOVINE PANCREATIC TRYPSIN INHIBITOR
2493, d4gawH_, 0.8542, 1.37, 0.296, 223, 216, CRYSTAL STRUCTURE OF ACTIVE HUMAN GRANZYME H
2494, d2qy0B_, 0.8542, 2.05, 0.386, 225, 223, ACTIVE DIMERIC STRUCTURE OF THE CATALYTIC DOMAIN OF C1R REVEALS ENZYME-PRODUCT LIKE CONTACTS
2495, d3q76A_, 0.8540, 2.45, 0.381, 246, 226, STRUCTURE OF HUMAN NEUTROPHIL ELASTASE (UNCOMPLEXED)
2496, d3n7oA_, 0.8539, 2.02, 0.380, 249, 221, X-RAY STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH SMALL MOLECULE INHIBITOR.
2497, p5edkA3, 0.8538, 1.34, 0.296, 225, 216, CRYSTAL STRUCTURE OF PROTHROMBIN DELETION MUTANT RESIDUES 146-167 ( FORM II ).
2498, d3q77A_, 0.8537, 1.34, 0.296, 225, 216, STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR
2499, d2hlcA_, 0.8537, 1.27, 0.386, 216, 215, HL COLLAGENASE STRUCTURE AT 1.7A RESOLUTION
2500, d1a7sA_, 0.8536, 1.94, 0.320, 227, 222, ATOMIC RESOLUTION STRUCTURE OF HBP
2501, d2hlcB_, 0.8534, 1.90, 0.293, 224, 222, HL COLLAGENASE STRUCTURE AT 1.7A RESOLUTION
2502, d2qy0D_, 0.8533, 1.29, 0.386, 218, 215, ACTIVE DIMERIC STRUCTURE OF THE CATALYTIC DOMAIN OF C1R REVEALS ENZYME-PRODUCT LIKE CONTACTS
2503, d1ppgE_, 0.8531, 2.41, 0.378, 248, 225, THE REFINED 2.3 ANGSTROMS CRYSTAL STRUCTURE OF HUMAN LEUKOCYTE ELASTASE IN A COMPLEX WITH A VALINE CHLOROMETHYL KETONE INHIBITOR
2504, d1hneE_, 0.8531, 1.70, 0.309, 225, 220, STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A PEPTIDE CHLOROMETHYL KETONE INHIBITOR AT 1.84-ANGSTROMS RESOLUTION
2505, p5jduD_, 0.8530, 2.11, 0.298, 293, 225, CRYSTAL STRUCTURE FOR HUMAN THROMBIN MUTANT D189A
2506, d5a09A_, 0.8530, 2.02, 0.318, 228, 223, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR
2507, d5a0cA_, 0.8527, 2.02, 0.318, 228, 223, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR
2508, p3nxpA2, 0.8527, 2.03, 0.300, 245, 223, CRYSTAL STRUCTURE OF HUMAN PRETHROMBIN-1
2509, p4kkdA3, 0.8526, 1.30, 0.386, 218, 215, THE X-RAY CRYSTAL STRUCTURE OF MANNOSE-BINDING LECTIN-ASSOCIATED SERINE PROTEINASE-3 REVEALS THE STRUCTURAL BASIS FOR ENZYME INACTIVITY ASSOCIATED WITH THE 3MC SYNDROME
2510, d1hylB_, 0.8525, 2.27, 0.327, 255, 226, THE 1.8 A STRUCTURE OF COLLAGENASE FROM HYPODERMA LINEATUM
2511, d5a0cB_, 0.8523, 2.27, 0.327, 255, 226, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR
2512, p4wvpE_, 0.8522, 1.99, 0.229, 235, 223, CRYSTAL STRUCTURE OF AN ACTIVITY-BASED PROBE HNE COMPLEX
2513, p4ag1A_, 0.8522, 1.99, 0.229, 235, 223, HUMAN CHYMASE - FYNOMER COMPLEX
2514, d3q76B_, 0.8521, 2.34, 0.278, 312, 230, STRUCTURE OF HUMAN NEUTROPHIL ELASTASE (UNCOMPLEXED)
2515, d2z7fE_, 0.8519, 1.22, 0.388, 215, 214, CRYSTAL STRUCTURE OF THE COMPLEX OF HUMAN NEUTROPHIL ELASTASE WITH 1/2SLPI
2516, d2rg3A_, 0.8518, 1.35, 0.381, 216, 215, COVALENT COMPLEX STRUCTURE OF ELASTASE
2517, d3s0nA_, 0.8517, 1.72, 0.309, 225, 220, CRYSTAL STRUCTURE OF HUMAN CHYMASE WITH BENZIMIDAZOLONE INHIBITOR
2518, d4gsoA_, 0.8516, 1.84, 0.377, 243, 220, STRUCTURE OF JARARACUSSIN-I
2519, p4afqB_, 0.8516, 1.75, 0.394, 222, 218, HUMAN CHYMASE - FYNOMER COMPLEX
2520, p4iw4F_, 0.8515, 1.50, 0.341, 221, 217, CRYSTAL STRUCTURE OF THE SERINE PROTEASE DOMAIN OF MASP-3 IN COMPLEX WITH ECOTIN
2521, p4duuA2, 0.8512, 0.99, 0.355, 211, 211, THE X-RAY CRYSTAL STRUCTURE OF FULL-LENGTH TYPE I HUMAN PLASMINOGEN
2522, d1h1bA_, 0.8512, 2.27, 0.386, 246, 223, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE COMPLEXED WITH AN INHIBITOR (GW475151)
2523, p4ag2A_, 0.8508, 2.11, 0.299, 241, 224, HUMAN CHYMASE - FYNOMER COMPLEX
2524, d2aipA_, 0.8507, 1.99, 0.311, 229, 222, CRYSTAL STRUCTURE OF NATIVE PROTEIN C ACTIVATOR FROM THE VENOM OF COPPERHEAD SNAKE AGKISTRODON CONTORTRIX CONTORTRIX
2525, d2aiqA_, 0.8504, 1.25, 0.388, 215, 214, CRYSTAL STRUCTURE OF BENZAMIDINE-INHIBITED PROTEIN C ACTIVATOR FROM THE VENOM OF COPPERHEAD SNAKE AGKISTRODON CONTORTRIX CONTORTRIX
2526, d1h1bB_, 0.8504, 2.19, 0.332, 240, 226, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE COMPLEXED WITH AN INHIBITOR (GW475151)
2527, p5xrfA_, 0.8503, 1.43, 0.383, 217, 214, CRYSTAL STRUCTURE OF DA-36; A THROMBIN-LIKE ENZYME FROM DEINAGKISTRODON ACUTUS 
2528, d2asuB_, 0.8502, 2.05, 0.330, 234, 224, CRYSTAL STRUCTURE OF THE BETA-CHAIN OF HGFL/MSP
2529, d3beuA_, 0.8501, 1.61, 0.339, 221, 218, NA+-DEPENDENT ALLOSTERY MEDIATES COAGULATION FACTOR PROTEASE ACTIVE SITE SELECTIVITY
2530, p2olgA_, 0.8501, 1.37, 0.386, 218, 215, CRYSTAL STRUCTURE OF THE SERINE PROTEASE DOMAIN OF PROPHENOLOXIDASE ACTIVATING FACTOR-I IN A ZYMOGEN FORM
2531, d3h7tB_, 0.8499, 1.23, 0.390, 215, 213, CRYSTAL STRUCTURE OF SCABIES MITE INACTIVATED PROTEASE PARALOGUE S-D1 (SMIPP-S-D1)
2532, d5a8yA_, 0.8497, 2.10, 0.326, 234, 224, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR
2533, p4afzB_, 0.8496, 2.25, 0.333, 226, 225, HUMAN CHYMASE - FYNOMER COMPLEX
2534, d1gvzA_, 0.8493, 1.52, 0.341, 221, 217, PROSTATE SPECIFIC ANTIGEN (PSA) FROM STALLION SEMINAL PLASMA
2535, d1fonB_, 0.8492, 1.52, 0.341, 221, 217, CRYSTAL STRUCTURE OF BOVINE PROCARBOXYPEPTIDASE A-S6 SUBUNIT III A HIGHLY STRUCTURED TRUNCATED ZYMOGEN E
2536, p4afuA_, 0.8491, 2.08, 0.308, 230, 221, HUMAN CHYMASE - FYNOMER COMPLEX
2537, d3s9aA_, 0.8491, 2.08, 0.308, 230, 221, RUSSELL S VIPER VENOM SERINE PROTEINASE RVV-V (CLOSED-FORM)
2538, d3beuB_, 0.8490, 1.12, 0.396, 213, 212, NA+-DEPENDENT ALLOSTERY MEDIATES COAGULATION FACTOR PROTEASE ACTIVE SITE SELECTIVITY
2539, d1md8A1, 0.8488, 1.91, 0.301, 221, 219, MONOMERIC STRUCTURE OF THE ACTIVE CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R
2540, d5a0aE_, 0.8482, 2.38, 0.270, 236, 226, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR
2541, d1sgtA_, 0.8480, 1.37, 0.391, 218, 215, REFINED CRYSTAL STRUCTURE OF STREPTOMYCES GRISEUS TRYPSIN AT 1.7 ANGSTROMS RESOLUTION
2542, d5fahA_, 0.8479, 1.83, 0.344, 223, 218, KALLIKREIN-7 IN COMPLEX WITH COMPOUND1
2543, d2hnt.1, 0.8478, 2.54, 0.281, 307, 231, CRYSTALLOGRAPHIC STRUCTURE OF HUMAN GAMMA-THROMBIN
2544, d5a0bA_, 0.8474, 1.41, 0.391, 218, 215, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR
2545, d4niyB_, 0.8474, 2.14, 0.306, 230, 222, CRYSTAL STRUCTURE OF TRYPSILIGASE (K60E/N143H/Y151H/D189K TRYPSIN) COMPLEXED TO YRH-ECOTIN (M84Y/M85R/A86H ECOTIN)
2546, p4igdA3, 0.8474, 1.30, 0.299, 221, 214, CRYSTAL STRUCTURE OF THE ZYMOGEN CATALYTIC REGION OF HUMAN MASP-1
2547, d4niyC_, 0.8470, 2.07, 0.308, 230, 221, CRYSTAL STRUCTURE OF TRYPSILIGASE (K60E/N143H/Y151H/D189K TRYPSIN) COMPLEXED TO YRH-ECOTIN (M84Y/M85R/A86H ECOTIN)
2548, d1fy3A_, 0.8470, 2.33, 0.270, 237, 226, [G175Q]HBP A MUTANT OF HUMAN HEPARIN BINDING PROTEIN (CAP37)
2549, d1fonA_, 0.8470, 1.40, 0.386, 218, 215, CRYSTAL STRUCTURE OF BOVINE PROCARBOXYPEPTIDASE A-S6 SUBUNIT III A HIGHLY STRUCTURED TRUNCATED ZYMOGEN E
2550, p4afuB_, 0.8463, 1.43, 0.386, 218, 215, HUMAN CHYMASE - FYNOMER COMPLEX
2551, d2bokA_, 0.8460, 2.28, 0.296, 247, 226, FACTOR XA - CATION
2552, p5a8xA_, 0.8454, 1.41, 0.386, 218, 215, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR
2553, p4durB2, 0.8454, 1.45, 0.391, 218, 215, THE X-RAY CRYSTAL STRUCTURE OF FULL-LENGTH TYPE II HUMAN PLASMINOGEN
2554, d5abwA_, 0.8453, 2.59, 0.286, 308, 231, NEUTROPHIL ELASTASE INHIBITORS FOR THE TREATMENT OF (CARDIO)PULMONARY DISEASES
2555, d4k60A_, 0.8449, 2.30, 0.263, 252, 224, CRYSTAL STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH FRAGMENT 6-BROMO-1 3-DIHYDRO-2H-INDOL-2-ONE
2556, d4k5zA_, 0.8448, 2.14, 0.306, 230, 222, CRYSTAL STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH FRAGMENT INHIBITOR 6-CHLORO-23-DIHYDRO-1H-ISOINDOL-1-ONE
2557, d1os8A_, 0.8447, 1.46, 0.386, 218, 215, RECOMBINANT STREPTOMYCES GRISEUS TRYPSIN
2558, p5yjpA_, 0.8444, 1.47, 0.386, 218, 215, HUMAN CHYMASE IN COMPLEX WITH 3-(ETHOXYIMINO)-7-OXO-14-DIAZEPANE DERIVATIVE
2559, d1ossA_, 0.8444, 1.79, 0.346, 221, 217, T190P STREPTOMYCES GRISEUS TRYPSIN IN COMPLEX WITH BENZAMIDINE
2560, p5a8zA_, 0.8442, 1.44, 0.386, 218, 215, CRYSTAL STRUCTURE OF HUMAN NEUTROPHIL ELASTASE IN COMPLEX WITH A DIHYDROPYRIMIDONE INHIBITOR
2561, d2fmjA_, 0.8437, 1.46, 0.391, 218, 215, 220-LOOP MUTANT OF STREPTOMYCES GRISEUS TRYPSIN
2562, d1si5H_, 0.8427, 1.34, 0.383, 217, 214, PROTEASE-LIKE DOMAIN FROM 2-CHAIN HEPATOCYTE GROWTH FACTOR
2563, d4niwA_, 0.8424, 2.09, 0.342, 226, 222, CRYSTAL STRUCTURE OF TRYPSILIGASE (K60E/N143H/Y151H/D189K TRYPSIN) ORTHORHOMBIC FORM
2564, d4nixA_, 0.8422, 1.90, 0.323, 232, 223, CRYSTAL STRUCTURE OF TRYPSILIGASE (K60E/N143H/Y151H/D189K TRYPSIN) ORTHORHOMBIC FORM ZINC-BOUND
2565, p2b9lA1, 0.8420, 1.91, 0.333, 221, 219, CRYSTAL STRUCTURE OF PROPHENOLOXIDASE ACTIVATING FACTOR-II FROM THE BEETLE HOLOTRICHIA DIOMPHALIA
2566, p5ubmA_, 0.8404, 2.00, 0.295, 240, 220, CRYSTAL STRUCTURE OF HUMAN C1S IN COMPLEX WITH INHIBITOR GIGASTASIN
2567, p5yjmA_, 0.8379, 2.26, 0.381, 249, 223, HUMAN CHYMASE IN COMPLEX WITH 7-OXO-3-(PHENOXYIMINO)-14-DIAZEPANE DERIVATIVE
2568, p6c2wB1, 0.8378, 1.45, 0.391, 218, 215, CRYSTAL STRUCTURE OF HUMAN PROTHROMBIN MUTANT S101C/A470C
2569, p2xxlA2, 0.8378, 2.04, 0.344, 223, 221, CRYSTAL STRUCTURE OF DROSOPHILA GRASS CLIP SERINE PROTEASE OF TOLL PATHWAY
2570, p2xxlB2, 0.8373, 2.00, 0.329, 231, 222, CRYSTAL STRUCTURE OF DROSOPHILA GRASS CLIP SERINE PROTEASE OF TOLL PATHWAY
2571, p6bjrA3, 0.8366, 1.99, 0.329, 231, 222, CRYSTAL STRUCTURE OF PROTHROMBIN MUTANT S101C/A470C 
2572, d1elvA1, 0.8365, 1.47, 0.386, 218, 215, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN COMPLEMENT C1S PROTEASE
2573, d4kp0A_, 0.8347, 2.17, 0.290, 236, 224, CRYSTAL STRUCTURE OF THE HUMAN CHYMASE WITH TJK002
2574, d4k2yA_, 0.8328, 1.79, 0.339, 225, 218, CRYSTAL STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH FRAGMENT INHIBITOR 6-CHLORO-13-DIHYDRO-2H-INDOL-2-ONE
2575, d4xdeA1, 0.8317, 1.77, 0.317, 224, 218, COAGULATION FACTOR XII PROTEASE DOMAIN CRYSTAL STRUCTURE
2576, d3k65B_, 0.8297, 2.59, 0.293, 276, 229, CRYSTAL STRUCTURE OF PRETHOMBIN-2/FRAGMENT-2 COMPLEX
2577, p5i25A2, 0.8290, 2.59, 0.293, 276, 229, HUMAN RECOMBINANT COAGULATION FXI IN COMPLEX WITH A PEPTIDE DERIVED FROM HUMAN HIGH MOLECULAR WEIGHT KININOGEN (HKP)
2578, d4k69A_, 0.8253, 1.87, 0.232, 233, 220, CRYSTAL STRUCTURE OF HUMAN CHYMASE IN COMPLEX WITH FRAGMENT LINKED BENZIMIDAZOLONE INHIBITOR: (3S)-3-{3-[(6-BROMO-2-OXO-23-DIHYDRO-1H- INDOL-4-YL)METHYL]-2-OXO-23-DIHYDRO-1H-BENZIMIDAZOL-1-YL}HEXANOIC ACID
2579, p4o3tA_, 0.8208, 1.32, 0.385, 216, 213, ZYMOGEN HGF-BETA/MET WITH ZYMOGEN ACTIVATOR PEPTIDE ZAP.14
2580, p4o3uA_, 0.8184, 1.66, 0.343, 218, 216, ZYMOGEN HGF-BETA/MET WITH ZYMOGEN ACTIVATOR PEPTIDE ZAP2.3
2581, p3qumP_, 0.8183, 2.32, 0.316, 237, 225, CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN (PSA) IN FAB SANDWICH WITH A HIGH AFFINITY AND A PCA SELECTIVE ANTIBODY
2582, p3qumQ_, 0.8164, 2.32, 0.316, 237, 225, CRYSTAL STRUCTURE OF HUMAN PROSTATE SPECIFIC ANTIGEN (PSA) IN FAB SANDWICH WITH A HIGH AFFINITY AND A PCA SELECTIVE ANTIBODY
2583, d3h7oA_, 0.8158, 2.00, 0.545, 232, 220, CRYSTAL STRUCTURE OF SCABIES MITE INACTIVATED PROTEASE PARALOGUE S-I1 (SMIPP-S-I1)
2584, p5eodA3, 0.8130, 1.98, 0.341, 221, 220, HUMAN PLASMA COAGULATION FXI WITH PEPTIDE LP2
2585, p5eokA2, 0.8126, 2.22, 0.330, 234, 224, HUMAN PLASMA COAGULATION FACTOR XI IN COMPLEX WITH PEPTIDE P39
2586, d1chgA_, 0.8123, 1.80, 0.317, 224, 218, CHYMOTRYPSINOGEN2.5 ANGSTROMS CRYSTAL STRUCTURE COMPARISON WITH ALPHA-CHYMOTRYPSINAND IMPLICATIONS FOR ZYMOGEN ACTIVATION
2587, d4xe4A_, 0.8122, 2.34, 0.276, 246, 225, COAGULATION FACTOR XII PROTEASE DOMAIN CRYSTAL STRUCTURE
2588, d4qt8C_, 0.8113, 2.34, 0.276, 246, 225, CRYSTAL STRUCTURE OF RON SEMA-PSI-IPT1 EXTRACELLULAR DOMAINS IN COMPLEX WITH MSP BETA-CHAIN
2589, d1nn6A_, 0.8104, 1.34, 0.385, 216, 213, HUMAN PRO-CHYMASE
2590, d4qt8D_, 0.8089, 1.65, 0.329, 223, 216, CRYSTAL STRUCTURE OF RON SEMA-PSI-IPT1 EXTRACELLULAR DOMAINS IN COMPLEX WITH MSP BETA-CHAIN
2591, d3g01A_, 0.8089, 1.46, 0.302, 218, 215, STRUCTURE OF GRC MUTANT E192R/E193G
2592, p4j1yA3, 0.8056, 1.70, 0.318, 262, 217, THE X-RAY CRYSTAL STRUCTURE OF HUMAN COMPLEMENT PROTEASE C1S ZYMOGEN
2593, d3h7oB_, 0.8056, 1.29, 0.387, 215, 212, CRYSTAL STRUCTURE OF SCABIES MITE INACTIVATED PROTEASE PARALOGUE S-I1 (SMIPP-S-I1)
2594, d4dw2U_, 0.8050, 1.17, 0.398, 211, 211, THE CRYSTAL STRUCTURE OF UPA IN COMPLEX WITH THE FAB FRAGMENT OF MAB- 112
2595, p4wjgW1, 0.8046, 2.35, 0.286, 259, 224, STRUCTURE OF T. BRUCEI HAPTOGLOBIN-HEMOGLOBIN RECEPTOR BINDING TO HUMAN HAPTOGLOBIN-HEMOGLOBIN
2596, p4wjgM1, 0.8046, 2.35, 0.286, 259, 224, STRUCTURE OF T. BRUCEI HAPTOGLOBIN-HEMOGLOBIN RECEPTOR BINDING TO HUMAN HAPTOGLOBIN-HEMOGLOBIN
2597, p4wjg21, 0.8046, 1.18, 0.403, 212, 211, STRUCTURE OF T. BRUCEI HAPTOGLOBIN-HEMOGLOBIN RECEPTOR BINDING TO HUMAN HAPTOGLOBIN-HEMOGLOBIN
2598, p4wjgH1, 0.8045, 1.27, 0.302, 219, 212, STRUCTURE OF T. BRUCEI HAPTOGLOBIN-HEMOGLOBIN RECEPTOR BINDING TO HUMAN HAPTOGLOBIN-HEMOGLOBIN
2599, p4wjgC1, 0.8045, 2.00, 0.545, 232, 220, STRUCTURE OF T. BRUCEI HAPTOGLOBIN-HEMOGLOBIN RECEPTOR BINDING TO HUMAN HAPTOGLOBIN-HEMOGLOBIN
2600, p4lk4A1, 0.8031, 1.96, 0.349, 219, 218, STRUCTURE OF VIBRIO CHOLERAE VESB PROTEASE
2601, d3g01B_, 0.8015, 1.72, 0.304, 222, 217, STRUCTURE OF GRC MUTANT E192R/E193G
2602, p3t2nA2, 0.8013, 1.32, 0.387, 215, 212, HUMAN HEPSIN PROTEASE IN COMPLEX WITH THE FAB FRAGMENT OF AN INHIBITORY ANTIBODY
2603, d1fdpA_, 0.8011, 2.41, 0.386, 245, 223, PROENZYME OF HUMAN COMPLEMENT FACTOR D RECOMBINANT PROFACTOR D
2604, p2f83A4, 0.7979, 1.32, 0.387, 215, 212, CRYSTAL STRUCTURE AT 2.9 ANGSTROMS RESOLUTION OF HUMAN PLASMA COAGULATION FACTOR XI ZYMOGEN
2605, p3t2nB2, 0.7922, 1.86, 0.343, 219, 216, HUMAN HEPSIN PROTEASE IN COMPLEX WITH THE FAB FRAGMENT OF AN INHIBITORY ANTIBODY
2606, p4j1yB3, 0.7859, 1.84, 0.347, 220, 216, THE X-RAY CRYSTAL STRUCTURE OF HUMAN COMPLEMENT PROTEASE C1S ZYMOGEN
2607, d1md7A1, 0.7857, 1.69, 0.329, 223, 216, MONOMERIC STRUCTURE OF THE ZYMOGEN OF COMPLEMENT PROTEASE C1R
2608, d1gpzA1, 0.7844, 1.83, 0.338, 220, 216, THE CRYSTAL STRUCTURE OF THE ZYMOGEN CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R
2609, d1fdpD_, 0.7831, 1.69, 0.329, 223, 216, PROENZYME OF HUMAN COMPLEMENT FACTOR D RECOMBINANT PROFACTOR D
2610, d4niyD_, 0.7824, 1.34, 0.387, 215, 212, CRYSTAL STRUCTURE OF TRYPSILIGASE (K60E/N143H/Y151H/D189K TRYPSIN) COMPLEXED TO YRH-ECOTIN (M84Y/M85R/A86H ECOTIN)
2611, d1rs0A1, 0.7823, 1.70, 0.329, 222, 216, CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH DI-ISOPROPYL-PHOSPHATE (DIP)
2612, d1rrkA1, 0.7819, 1.87, 0.313, 227, 217, CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B
2613, d1gpzB1, 0.7817, 1.99, 0.373, 221, 217, THE CRYSTAL STRUCTURE OF THE ZYMOGEN CATALYTIC DOMAIN OF COMPLEMENT PROTEASE C1R
2614, d1fdpB_, 0.7813, 1.98, 0.373, 221, 217, PROENZYME OF HUMAN COMPLEMENT FACTOR D RECOMBINANT PROFACTOR D
2615, d1rtkA1, 0.7808, 2.38, 0.268, 296, 224, CRYSTAL STRUCTURE ANALYSIS OF THE BB SEGMENT OF FACTOR B COMPLEXED WITH 4-GUANIDINOBENZOIC ACID
2616, d1gvlA_, 0.7803, 2.38, 0.268, 296, 224, HUMAN PROKALLIKREIN 6 (HK6)/ PROZYME/ PROPROTEASE M/ PRONEUROSIN
2617, d1dleA_, 0.7770, 2.41, 0.284, 233, 222, FACTOR B SERINE PROTEASE DOMAIN
2618, d1dleB_, 0.7765, 1.82, 0.341, 218, 214, FACTOR B SERINE PROTEASE DOMAIN
2619, d4nivA_, 0.7761, 2.59, 0.294, 327, 231, CRYSTAL STRUCTURE OF TRYPSILIGASE (K60E/N143H/Y151H/D189K TRYPSIN) TRIGONAL FORM
2620, d1jbuH_, 0.7757, 2.59, 0.294, 327, 231, COAGULATION FACTOR VII ZYMOGEN (EGF2/PROTEASE) IN COMPLEX WITH INHIBITORY EXOSITE PEPTIDE A-183
2621, d2i6qA2, 0.7754, 2.91, 0.304, 285, 230, COMPLEMENT COMPONENT C2A
2622, d2i6sA2, 0.7727, 2.91, 0.304, 285, 230, COMPLEMENT COMPONENT C2A
2623, d1fdpC_, 0.7727, 2.90, 0.304, 285, 230, PROENZYME OF HUMAN COMPLEMENT FACTOR D RECOMBINANT PROFACTOR D
2624, p3hrzD3, 0.7689, 2.56, 0.290, 325, 231, COBRA VENOM FACTOR (CVF) IN COMPLEX WITH HUMAN FACTOR B
2625, d5lpeA_, 0.7650, 2.15, 0.289, 237, 218, KALLIKREIN-RELATED PEPTIDASE 10 COMPLEX WITH ZN2+
2626, d5lpfB_, 0.7631, 2.03, 0.344, 220, 215, KALLIKREIN-RELATED PEPTIDASE 10
2627, d5lpfA_, 0.7626, 1.86, 0.347, 217, 213, KALLIKREIN-RELATED PEPTIDASE 10
2628, d5lpeB_, 0.7624, 2.34, 0.335, 238, 221, KALLIKREIN-RELATED PEPTIDASE 10 COMPLEX WITH ZN2+
2629, d2odqA2, 0.7581, 2.34, 0.335, 238, 221, COMPLEMENT COMPONENT C2A THE CATALYTIC FRAGMENT OF C3- AND C5- CONVERTASE OF HUMAN COMPLEMENT
2630, d2odpA2, 0.7526, 2.16, 0.295, 274, 217, COMPLEMENT COMPONENT C2A THE CATALYTIC FRAGMENT OF C3- AND C5- CONVERTASE OF HUMAN COMPLEMENT
2631, d1p3cA_, 0.7343, 2.32, 0.346, 236, 217, GLUTAMYL ENDOPEPTIDASE FROM BACILLUS INTERMEDIUS
2632, d1p3eA_, 0.7342, 1.83, 0.355, 215, 211, STRUCTURE OF GLU ENDOPEPTIDASE IN COMPLEX WITH MPD
2633, p2xrcB2, 0.7283, 2.04, 0.313, 219, 214, HUMAN COMPLEMENT FACTOR I
2634, d1sgfA_, 0.7255, 2.08, 0.313, 219, 214, CRYSTAL STRUCTURE OF 7S NGF: A COMPLEX OF NERVE GROWTH FACTOR WITH FOUR BINDING PROTEINS (SERINE PROTEINASES)
2635, d1qy6A_, 0.7226, 2.62, 0.324, 237, 222, STRUCTUE OF V8 PROTEASE FROM STAPHYLOCOCCUS AUREUS
2636, d4jcnA_, 0.7220, 2.77, 0.327, 237, 223, STRUCTURE OF ESP SERINE PROTEASE FROM STAPHYLOCOCCUS EPIDERMIDIS
2637, d2o8lA_, 0.7208, 2.73, 0.261, 228, 222, STRUCTURE OF V8 PROTEASE FROM STAPHYLOCOCCUS AUREUS
2638, d1wczA_, 0.7207, 2.73, 0.261, 228, 222, CRYSTAL STRUCTURE OF AN ALKALINE FORM OF V8 PROTEASE FROM STAPHYLOCOCCUS AUREUS
2639, p4bxsA2, 0.7188, 2.04, 0.360, 230, 211, CRYSTAL STRUCTURE OF THE PROTHROMBINASE COMPLEX FROM THE VENOM OF PSEUDONAJA TEXTILIS
2640, p5jxfC1, 0.7180, 2.01, 0.360, 230, 211, CRYSTAL STRUCTURE OF FLAVOBACTERIUM PSYCHROPHILUM DPP11 IN COMPLEX WITH DIPEPTIDE ARG-ASP
2641, p5jxfB1, 0.7177, 1.96, 0.408, 226, 211, CRYSTAL STRUCTURE OF FLAVOBACTERIUM PSYCHROPHILUM DPP11 IN COMPLEX WITH DIPEPTIDE ARG-ASP
2642, p5jxfA1, 0.7176, 2.25, 0.325, 231, 212, CRYSTAL STRUCTURE OF FLAVOBACTERIUM PSYCHROPHILUM DPP11 IN COMPLEX WITH DIPEPTIDE ARG-ASP
2643, p5jxfD1, 0.7163, 1.79, 0.335, 231, 209, CRYSTAL STRUCTURE OF FLAVOBACTERIUM PSYCHROPHILUM DPP11 IN COMPLEX WITH DIPEPTIDE ARG-ASP
2644, p4xzyA1, 0.7160, 1.79, 0.335, 231, 209, CRYSTAL STRUCTURE OF DIPEPTIDYL PEPTIDASE 11 (DPP11) FROM PORPHYROMONAS GINGIVALIS
2645, p3wy8A_, 0.7160, 2.72, 0.336, 222, 220, CRYSTAL STRUCTURE OF PROTEASE ANISEP FROM ARTHROBACTER NICOTINOVORANS
2646, p5jwfB1, 0.7157, 1.77, 0.337, 231, 208, CRYSTAL STRUCTURE OF PORPHYROMONAS GINGIVALIS DPP11
2647, p4xzyB1, 0.7152, 1.93, 0.341, 211, 208, CRYSTAL STRUCTURE OF DIPEPTIDYL PEPTIDASE 11 (DPP11) FROM PORPHYROMONAS GINGIVALIS
2648, p5jwfA1, 0.7144, 2.87, 0.282, 245, 220, CRYSTAL STRUCTURE OF PORPHYROMONAS GINGIVALIS DPP11
2649, p4y02A1, 0.7142, 2.87, 0.282, 245, 220, CRYSTAL STRUCTURE OF DIPEPTIDYL PEPTIDASE 11 (DPP11) FROM PORPHYROMONAS GINGIVALIS (GROUND)
2650, p4y04A1, 0.7134, 2.84, 0.259, 225, 220, CRYSTAL STRUCTURE OF DIPEPTIDYL PEPTIDASE 11 (DPP11) FROM PORPHYROMONAS GINGIVALIS (SPACE)
2651, p5jwiA1, 0.7127, 2.27, 0.300, 221, 213, CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 IN COMPLEX WITH DIPEPTIDE ARG-GLU
2652, p5jwiB1, 0.7126, 2.20, 0.280, 253, 214, CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 IN COMPLEX WITH DIPEPTIDE ARG-GLU
2653, p5jwgB1, 0.7125, 2.19, 0.280, 253, 214, CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 IN COMPLEX WITH DIPEPTIDE ARG-ASP
2654, p5jxpA1, 0.7122, 2.19, 0.280, 253, 214, CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 IN ALTERNATE CONFORMATION
2655, p3woqB1, 0.7111, 2.19, 0.280, 253, 214, CRYSTAL STRUCTURE OF THE DAP BII HEXAPEPTIDE COMPLEX III
2656, p3woqA1, 0.7107, 2.20, 0.280, 253, 214, CRYSTAL STRUCTURE OF THE DAP BII HEXAPEPTIDE COMPLEX III
2657, p3womB1, 0.7107, 2.20, 0.280, 253, 214, CRYSTAL STRUCTURE OF THE DAP BII DIPEPTIDE COMPLEX II
2658, p3wopA1, 0.7106, 2.09, 0.276, 221, 210, CRYSTAL STRUCTURE OF THE DAP BII HEXAPEPTIDE COMPLEX II
2659, p3wonB1, 0.7106, 2.09, 0.276, 221, 210, CRYSTAL STRUCTURE OF THE DAP BII DIPEPTIDE COMPLEX III
2660, p3wolB1, 0.7106, 1.93, 0.345, 209, 206, CRYSTAL STRUCTURE OF THE DAP BII DIPEPTIDE COMPLEX I
2661, p3worA1, 0.7105, 1.67, 0.361, 235, 205, CRYSTAL STRUCTURE OF THE DAP BII OCTAPEPTIDE COMPLEX
2662, p5jwgA1, 0.7104, 2.32, 0.341, 220, 211, CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 IN COMPLEX WITH DIPEPTIDE ARG-ASP
2663, d1agjA_, 0.7102, 1.98, 0.369, 224, 206, EPIDERMOLYTIC TOXIN A FROM STAPHYLOCOCCUS AUREUS
2664, p4y06A1, 0.7101, 1.70, 0.360, 231, 203, CRYSTAL STRUCTURE OF THE DAP BII (G675R) DIPEPTIDE COMPLEX
2665, p3wolA1, 0.7100, 2.28, 0.288, 229, 208, CRYSTAL STRUCTURE OF THE DAP BII DIPEPTIDE COMPLEX I
2666, p3wooA1, 0.7099, 2.60, 0.254, 236, 213, CRYSTAL STRUCTURE OF THE DAP BII HEXAPEPTIDE COMPLEX I
2667, p3womA1, 0.7095, 2.40, 0.273, 231, 209, CRYSTAL STRUCTURE OF THE DAP BII DIPEPTIDE COMPLEX II
2668, p4y06B1, 0.7094, 1.52, 0.335, 200, 197, CRYSTAL STRUCTURE OF THE DAP BII (G675R) DIPEPTIDE COMPLEX
2669, p3wojB1, 0.7094, 1.19, 0.395, 195, 195, CRYSTAL STRUCTURE OF THE DAP BII
2670, d1duaA_, 0.7091, 2.77, 0.200, 277, 215, CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN A
2671, p5jxkA1, 0.7090, 2.84, 0.204, 277, 216, CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11
2672, d1agjB_, 0.7090, 2.40, 0.279, 232, 208, EPIDERMOLYTIC TOXIN A FROM STAPHYLOCOCCUS AUREUS
2673, d1dueA_, 0.7081, 1.41, 0.335, 201, 197, CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN A S195A MUTANT
2674, d1exfA_, 0.7079, 2.84, 0.204, 282, 216, EXFOLIATIVE TOXIN A
2675, p5jxkB1, 0.7077, 3.05, 0.352, 223, 213, CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11
2676, d4nsyB_, 0.7073, 3.05, 0.352, 223, 213, WILD-TYPE LYSOBACTER ENZYMOGENES LYSC ENDOPROTEINASE COVALENTLY INHIBITED BY TLCK
2677, d4nsyA_, 0.7071, 2.90, 0.204, 288, 216, WILD-TYPE LYSOBACTER ENZYMOGENES LYSC ENDOPROTEINASE COVALENTLY INHIBITED BY TLCK
2678, p3cp7A_, 0.7070, 2.90, 0.204, 288, 216, CRYSTAL STRUCTURE OF A THERMOSTABLE SERINE PROTEASE AL20 FROM EXTREMOPHILIC MICROOGANISM
2679, d4nsvB_, 0.7069, 2.94, 0.204, 282, 216, LYSOBACTER ENZYMOGENES LYSC ENDOPROTEINASE K30R MUTANT COVALENTLY INHIBITED BY TLCK
2680, d1sgfX_, 0.7067, 1.15, 0.383, 193, 193, CRYSTAL STRUCTURE OF 7S NGF: A COMPLEX OF NERVE GROWTH FACTOR WITH FOUR BINDING PROTEINS (SERINE PROTEINASES)
2681, p3cp7B_, 0.7065, 2.94, 0.311, 239, 212, CRYSTAL STRUCTURE OF A THERMOSTABLE SERINE PROTEASE AL20 FROM EXTREMOPHILIC MICROOGANISM
2682, d4nsvA_, 0.7062, 2.98, 0.227, 283, 216, LYSOBACTER ENZYMOGENES LYSC ENDOPROTEINASE K30R MUTANT COVALENTLY INHIBITED BY TLCK
2683, d5c2zB_, 0.7052, 2.75, 0.230, 286, 213, MOLECULAR INSIGHTS INTO THE SPECIFICITY OF EXFOLIATIVE TOXINS FROM STAPHYLOCOCCUS AUREUS
2684, d5lhsD_, 0.7045, 2.75, 0.230, 286, 213, THE LIGAND FREE CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2685, p3wopB1, 0.7039, 1.57, 0.333, 199, 195, CRYSTAL STRUCTURE OF THE DAP BII HEXAPEPTIDE COMPLEX II
2686, d1arbA_, 0.7038, 2.59, 0.210, 277, 210, THE PRIMARY STRUCTURE AND STRUCTURAL CHARACTERISTICS OF ACHROMOBACTER LYTICUS PROTEASE I A LYSINE-SPECIFIC SERINE PROTEASE
2687, d5lhsB_, 0.7036, 2.36, 0.353, 204, 204, THE LIGAND FREE CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2688, d5lhsC_, 0.7035, 2.36, 0.353, 204, 204, THE LIGAND FREE CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2689, d5c2zA1, 0.7035, 2.13, 0.353, 202, 201, MOLECULAR INSIGHTS INTO THE SPECIFICITY OF EXFOLIATIVE TOXINS FROM STAPHYLOCOCCUS AUREUS
2690, d1arcA_, 0.7029, 2.35, 0.355, 203, 203, THE PRIMARY STRUCTURE AND STRUCTURAL CHARACTERISTICS OF ACHROMOBACTER LYTICUS PROTEASE I A LYSINE-SPECIFIC SERINE PROTEASE
2691, p4y01A1, 0.7028, 2.26, 0.356, 202, 202, CRYSTAL STRUCTURE OF DIPEPTIDYL PEPTIDASE 11 (DPP11) FROM PORPHYROMONAS GINGIVALIS
2692, d4gpgA_, 0.7028, 2.84, 0.230, 273, 209, X/N JOINT REFINEMENT OF ACHROMOBACTER LYTICUS PROTEASE I FREE FORM AT PD8.0
2693, d5lhsA_, 0.7026, 2.83, 0.232, 271, 207, THE LIGAND FREE CATALYTIC DOMAIN OF MURINE UROKINASE-TYPE PLASMINOGEN ACTIVATOR
2694, d4inkA_, 0.7012, 2.62, 0.175, 215, 200, CRYSTAL STRUCTURE OF SPLD PROTEASE FROM STAPHYLOCOCCUS AUREUS AT 1.56 A RESOLUTION
2695, d4inlA_, 0.7001, 2.62, 0.175, 215, 200, CRYSTAL STRUCTURE OF SPLD PROTEASE FROM STAPHYLOCOCCUS AUREUS AT 2.1 A RESOLUTION
2696, p5jy0A1, 0.6991, 2.64, 0.165, 215, 200, CRYSTAL STRUCTURE OF PORPHYROMONAS ENDODONTALIS DPP11 IN COMPLEX WITH SUBSTRATE
2697, p4y01B1, 0.6991, 1.82, 0.291, 200, 189, CRYSTAL STRUCTURE OF DIPEPTIDYL PEPTIDASE 11 (DPP11) FROM PORPHYROMONAS GINGIVALIS
2698, p3worB1, 0.6972, 2.38, 0.301, 203, 193, CRYSTAL STRUCTURE OF THE DAP BII OCTAPEPTIDE COMPLEX
2699, p5j44B1, 0.6969, 2.50, 0.133, 216, 195, CRYSTAL STRUCTURE OF THE SECRETED EXTRACELLULAR PROTEIN A (SEPA) FROM SHIGELLA FLEXNERI
2700, p5j44A1, 0.6969, 2.50, 0.133, 216, 195, CRYSTAL STRUCTURE OF THE SECRETED EXTRACELLULAR PROTEIN A (SEPA) FROM SHIGELLA FLEXNERI
2701, p3wooB1, 0.6968, 2.29, 0.166, 216, 193, CRYSTAL STRUCTURE OF THE DAP BII HEXAPEPTIDE COMPLEX I
2702, p3wonA1, 0.6965, 2.43, 0.134, 216, 194, CRYSTAL STRUCTURE OF THE DAP BII DIPEPTIDE COMPLEX III
2703, p3ak5C1, 0.6963, 2.43, 0.134, 215, 194, HEMOGLOBIN PROTEASE (HBP) PASSENGER MISSING DOMAIN-2
2704, p1wxrA1, 0.6961, 1.88, 0.280, 203, 186, CRYSTAL STRUCTURE OF HEME BINDING PROTEIN AN AUTOTRANSPORTER HEMOGLOBINE PROTEASE FROM PATHOGENIC ESCHERICHIA COLI
2705, p3ak5B1, 0.6958, 3.16, 0.127, 346, 205, HEMOGLOBIN PROTEASE (HBP) PASSENGER MISSING DOMAIN-2
2706, p3ak5D1, 0.6957, 3.02, 0.132, 346, 204, HEMOGLOBIN PROTEASE (HBP) PASSENGER MISSING DOMAIN-2
2707, p3ak5A1, 0.6956, 3.13, 0.137, 359, 205, HEMOGLOBIN PROTEASE (HBP) PASSENGER MISSING DOMAIN-2
2708, p3wojA1, 0.6948, 3.13, 0.137, 359, 205, CRYSTAL STRUCTURE OF THE DAP BII
2709, d1qtfA_, 0.6948, 3.16, 0.127, 359, 205, CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN B
2710, p3woiA1, 0.6937, 3.21, 0.166, 342, 205, CRYSTAL STRUCTURE OF THE DAP BII (S657A)
2711, p3woiB1, 0.6922, 2.86, 0.139, 219, 202, CRYSTAL STRUCTURE OF THE DAP BII (S657A)
2712, d2w7uB_, 0.6917, 2.86, 0.139, 219, 202, SPLA SERINE PROTEASE OF STAPHYLOCOCCUS AUREUS (2.4A)
2713, d1dt2A_, 0.6909, 3.11, 0.152, 380, 204, CRYSTAL STRUCTURE OF EXFOLIATIVE TOXIN B
2714, d4mvnD_, 0.6906, 3.38, 0.155, 342, 207, CRYSTAL STRUCTURE OF THE STAPHYLOCOCCAL SERINE PROTEASE SPLA IN COMPLEX WITH A SPECIFIC PHOSPHONATE INHIBITOR
2715, d3ufaB_, 0.6902, 3.32, 0.155, 343, 206, CRYSTAL STRUCTURE OF THE STAPHYLOCOCCAL SERINE PROTEASE SPLA IN COMPLEX WITH A SPECIFIC PHOSPHONATE INHIBITOR
2716, d2w7uD_, 0.6902, 3.23, 0.156, 383, 205, SPLA SERINE PROTEASE OF STAPHYLOCOCCUS AUREUS (2.4A)
2717, d2w7uC_, 0.6900, 3.23, 0.156, 383, 205, SPLA SERINE PROTEASE OF STAPHYLOCOCCUS AUREUS (2.4A)
2718, d3ufaA_, 0.6896, 3.42, 0.164, 381, 207, CRYSTAL STRUCTURE OF THE STAPHYLOCOCCAL SERINE PROTEASE SPLA IN COMPLEX WITH A SPECIFIC PHOSPHONATE INHIBITOR
2719, d4mvnA_, 0.6890, 3.36, 0.145, 378, 207, CRYSTAL STRUCTURE OF THE STAPHYLOCOCCAL SERINE PROTEASE SPLA IN COMPLEX WITH A SPECIFIC PHOSPHONATE INHIBITOR
2720, d2w7uA_, 0.6882, 3.30, 0.155, 380, 206, SPLA SERINE PROTEASE OF STAPHYLOCOCCUS AUREUS (2.4A)
2721, p3wokA1, 0.6874, 3.09, 0.142, 421, 204, CRYSTAL STRUCTURE OF THE DAP BII (SPACE)
2722, d2as9A1, 0.6857, 3.09, 0.142, 421, 204, FUNCTIONAL AND STRUCTURAL CHARACTERIZATION OF SPL PROTEASES FROM STAPHYLOCOCCUS AUREUS
2723, d2vidB_, 0.6850, 3.29, 0.156, 343, 205, SERINE PROTEASE SPLB FROM STAPHYLOCOCCUS AUREUS AT 1.8A RESOLUTION
2724, d2vidA_, 0.6844, 3.21, 0.112, 429, 205, SERINE PROTEASE SPLB FROM STAPHYLOCOCCUS AUREUS AT 1.8A RESOLUTION
2725, d4mvnB_, 0.6833, 3.21, 0.112, 429, 205, CRYSTAL STRUCTURE OF THE STAPHYLOCOCCAL SERINE PROTEASE SPLA IN COMPLEX WITH A SPECIFIC PHOSPHONATE INHIBITOR
2726, d4k1sB_, 0.6829, 3.28, 0.122, 429, 205, GLY-SER-SPLB PROTEASE FROM STAPHYLOCOCCUS AUREUS AT 1.96 A RESOLUTION
2727, d2w7sA_, 0.6823, 3.27, 0.117, 416, 205, SPLA SERINE PROTEASE OF STAPHYLOCOCCUS AUREUS (1.8A)
2728, d2w7sB_, 0.6789, 3.23, 0.127, 429, 205, SPLA SERINE PROTEASE OF STAPHYLOCOCCUS AUREUS (1.8A)
2729, p3qo6B2, 0.6779, 3.27, 0.127, 428, 205, CRYSTAL STRUCTURE ANALYSIS OF THE PLANT PROTEASE DEG1
2730, d3lgiA_, 0.6777, 3.22, 0.112, 416, 205, STRUCTURE OF THE PROTEASE DOMAIN OF DEGS (DEGS-DELTAPDZ) AT 1.65 A
2731, p4om9A1, 0.6767, 3.30, 0.155, 384, 206, X-RAY CRYSTAL STRUCTURE OF THE PASSENGER DOMAIN OF PLASMID ENCODED TOXIN AN AUTROTANSPORTER ENTEROTOXIN FROM ENTEROAGGREGATIVE ESCHERICHIA COLI (EAEC)
2732, d4k1tC1, 0.6763, 2.73, 0.133, 242, 196, GLY-SER-SPLB PROTEASE FROM STAPHYLOCOCCUS AUREUS AT 1.60 A RESOLUTION
2733, p3qo6C2, 0.6763, 2.73, 0.133, 242, 196, CRYSTAL STRUCTURE ANALYSIS OF THE PLANT PROTEASE DEG1
2734, p3qo6A2, 0.6761, 3.27, 0.127, 415, 205, CRYSTAL STRUCTURE ANALYSIS OF THE PLANT PROTEASE DEG1
2735, d4k1sA_, 0.6752, 3.23, 0.127, 428, 205, GLY-SER-SPLB PROTEASE FROM STAPHYLOCOCCUS AUREUS AT 1.96 A RESOLUTION
2736, p6ew9A1, 0.6747, 3.22, 0.122, 429, 205, CRYSTAL STRUCTURE OF DEGS STRESS SENSOR PROTEASE IN COMPLEX WITH ACTIVATING DNRLGLVYQF PEPTIDE 
2737, p2xrcA2, 0.6746, 3.23, 0.127, 429, 205, HUMAN COMPLEMENT FACTOR I
2738, d2w7sD_, 0.6732, 3.23, 0.127, 429, 205, SPLA SERINE PROTEASE OF STAPHYLOCOCCUS AUREUS (1.8A)
2739, d4k1tB1, 0.6727, 3.23, 0.127, 416, 205, GLY-SER-SPLB PROTEASE FROM STAPHYLOCOCCUS AUREUS AT 1.60 A RESOLUTION
2740, d4k1tA1, 0.6723, 3.20, 0.127, 391, 204, GLY-SER-SPLB PROTEASE FROM STAPHYLOCOCCUS AUREUS AT 1.60 A RESOLUTION
2741, d3stjH1, 0.6723, 2.77, 0.133, 242, 196, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2742, d3stjC1, 0.6723, 3.36, 0.155, 381, 206, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2743, p5mm8A_, 0.6719, 2.76, 0.133, 242, 196, ATOMIC RESOLUTION STRUCTURE OF SPLE PROTEASE FROM STAPHYLOCOCCUS AUREUS
2744, d3stjD1, 0.6719, 2.78, 0.128, 242, 196, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2745, d3stjJ1, 0.6717, 2.78, 0.133, 241, 196, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2746, d3stjI1, 0.6717, 3.39, 0.150, 377, 206, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2747, d3stjF1, 0.6714, 3.39, 0.130, 265, 207, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2748, d3stjA1, 0.6713, 3.39, 0.130, 265, 207, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2749, d2w7sC_, 0.6713, 3.39, 0.130, 264, 207, SPLA SERINE PROTEASE OF STAPHYLOCOCCUS AUREUS (1.8A)
2750, d3stjE1, 0.6712, 2.97, 0.145, 216, 200, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2751, d3stjL1, 0.6710, 3.41, 0.130, 264, 207, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2752, d3stjG1, 0.6710, 2.45, 0.302, 202, 189, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2753, d3lgiB_, 0.6710, 2.77, 0.141, 216, 198, STRUCTURE OF THE PROTEASE DOMAIN OF DEGS (DEGS-DELTAPDZ) AT 1.65 A
2754, p3szeA1, 0.6709, 3.41, 0.130, 264, 207, CRYSTAL STRUCTURE OF THE PASSENGER DOMAIN OF THE E. COLI AUTOTRANSPORTER ESPP
2755, d3stjK1, 0.6708, 2.70, 0.144, 248, 195, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2756, d2rceC_, 0.6708, 2.70, 0.144, 248, 195, DFP MODIFIED DEGS DELTA PDZ
2757, d3stjB1, 0.6701, 3.57, 0.291, 224, 203, CRYSTAL STRUCTURE OF THE PROTEASE + PDZ1 DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2758, d3lh3C_, 0.6700, 3.22, 0.118, 414, 203, DFP MODIFIED DEGS DELTA PDZ
2759, d4mvnC_, 0.6697, 3.29, 0.122, 263, 205, CRYSTAL STRUCTURE OF THE STAPHYLOCOCCAL SERINE PROTEASE SPLA IN COMPLEX WITH A SPECIFIC PHOSPHONATE INHIBITOR
2760, d3lgvC_, 0.6689, 3.53, 0.291, 224, 203, H198P MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2761, d3lh3B_, 0.6688, 3.48, 0.292, 224, 202, DFP MODIFIED DEGS DELTA PDZ
2762, d2rceB_, 0.6688, 2.72, 0.144, 247, 195, DFP MODIFIED DEGS DELTA PDZ
2763, d3lh3F_, 0.6679, 3.21, 0.127, 263, 204, DFP MODIFIED DEGS DELTA PDZ
2764, d2rceF_, 0.6678, 3.26, 0.158, 331, 203, DFP MODIFIED DEGS DELTA PDZ
2765, p3otpB1, 0.6677, 3.19, 0.127, 263, 204, CRYSTAL STRUCTURE OF THE DEGP DODECAMER WITH A MODEL SUBSTRATE
2766, d3lgvB_, 0.6677, 3.48, 0.292, 224, 202, H198P MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2767, p3otpE1, 0.6675, 2.48, 0.132, 203, 190, CRYSTAL STRUCTURE OF THE DEGP DODECAMER WITH A MODEL SUBSTRATE
2768, p3otpC1, 0.6675, 2.48, 0.132, 203, 190, CRYSTAL STRUCTURE OF THE DEGP DODECAMER WITH A MODEL SUBSTRATE
2769, p3otpF1, 0.6674, 2.36, 0.132, 201, 189, CRYSTAL STRUCTURE OF THE DEGP DODECAMER WITH A MODEL SUBSTRATE
2770, p3otpD1, 0.6673, 3.12, 0.155, 349, 200, CRYSTAL STRUCTURE OF THE DEGP DODECAMER WITH A MODEL SUBSTRATE
2771, d3lgvF_, 0.6673, 3.25, 0.163, 340, 202, H198P MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2772, d2r3yB2, 0.6665, 3.26, 0.104, 425, 202, CRYSTAL STRUCTURE OF THE DEGS PROTEASE IN COMPLEX WITH THE YWF ACTIVATING PEPTIDE
2773, p3otpA1, 0.6664, 2.57, 0.168, 255, 191, CRYSTAL STRUCTURE OF THE DEGP DODECAMER WITH A MODEL SUBSTRATE
2774, d3lgvG_, 0.6661, 2.58, 0.168, 255, 191, H198P MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2775, p4ynnH1, 0.6658, 3.26, 0.114, 425, 202, STRUCTURE OF LEGIONELLA PNEUMOPHILA DEGQ (S190A VARIANT)
2776, d3lh3G_, 0.6658, 3.26, 0.119, 425, 202, DFP MODIFIED DEGS DELTA PDZ
2777, d2as9B1, 0.6658, 2.49, 0.175, 289, 189, FUNCTIONAL AND STRUCTURAL CHARACTERIZATION OF SPL PROTEASES FROM STAPHYLOCOCCUS AUREUS
2778, d1sozB2, 0.6657, 2.49, 0.180, 289, 189, CRYSTAL STRUCTURE OF DEGS PROTEASE IN COMPLEX WITH AN ACTIVATING PEPTIDE
2779, p4ynnA1, 0.6655, 2.49, 0.180, 289, 189, STRUCTURE OF LEGIONELLA PNEUMOPHILA DEGQ (S190A VARIANT)
2780, p3mh6A1, 0.6654, 2.49, 0.180, 254, 189, HTRA PROTEASES ARE ACTIVATED BY A CONSERVED MECHANISM THAT CAN BE TRIGGERED BY DISTINCT MOLECULAR CUES
2781, p4ynnB1, 0.6652, 2.50, 0.169, 289, 189, STRUCTURE OF LEGIONELLA PNEUMOPHILA DEGQ (S190A VARIANT)
2782, d1sozC2, 0.6652, 2.50, 0.180, 254, 189, CRYSTAL STRUCTURE OF DEGS PROTEASE IN COMPLEX WITH AN ACTIVATING PEPTIDE
2783, p4ynnD1, 0.6648, 3.27, 0.119, 350, 201, STRUCTURE OF LEGIONELLA PNEUMOPHILA DEGQ (S190A VARIANT)
2784, p4rqzB1, 0.6645, 2.87, 0.165, 246, 194, RE-REFINEMENT OF 1SOZ CRYSTAL STRUCTURE OF DEGS PROTEASE IN COMPLEX WITH AN ACTIVATING PEPTIDE
2785, p4ynnF1, 0.6644, 3.28, 0.119, 329, 201, STRUCTURE OF LEGIONELLA PNEUMOPHILA DEGQ (S190A VARIANT)
2786, p4ynnE1, 0.6644, 3.29, 0.124, 404, 201, STRUCTURE OF LEGIONELLA PNEUMOPHILA DEGQ (S190A VARIANT)
2787, p4ynnC1, 0.6644, 2.63, 0.144, 200, 188, STRUCTURE OF LEGIONELLA PNEUMOPHILA DEGQ (S190A VARIANT)
2788, p4ynnG1, 0.6641, 2.89, 0.155, 245, 194, STRUCTURE OF LEGIONELLA PNEUMOPHILA DEGQ (S190A VARIANT)
2789, d3lgiC_, 0.6641, 2.64, 0.144, 200, 188, STRUCTURE OF THE PROTEASE DOMAIN OF DEGS (DEGS-DELTAPDZ) AT 1.65 A
2790, d2qf0F_, 0.6641, 2.69, 0.138, 200, 189, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2791, d2qf0C_, 0.6640, 2.66, 0.144, 200, 188, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2792, p4rqzA1, 0.6639, 2.66, 0.144, 200, 188, RE-REFINEMENT OF 1SOZ CRYSTAL STRUCTURE OF DEGS PROTEASE IN COMPLEX WITH AN ACTIVATING PEPTIDE
2793, d2r3yA2, 0.6638, 2.48, 0.140, 199, 186, CRYSTAL STRUCTURE OF THE DEGS PROTEASE IN COMPLEX WITH THE YWF ACTIVATING PEPTIDE
2794, p3gdvA1, 0.6634, 2.43, 0.141, 198, 185, CRYSTAL STRUCTURE OF DEGS H198P/D320A MUTANT MODIFIED BY DFP AND IN COMPLEX WITH YQF PEPTIDE
2795, d1sozA2, 0.6634, 2.56, 0.145, 198, 186, CRYSTAL STRUCTURE OF DEGS PROTEASE IN COMPLEX WITH AN ACTIVATING PEPTIDE
2796, p3nziA_, 0.6633, 3.32, 0.125, 329, 200, SUBSTRATE INDUCED REMODELING OF THE ACTIVE SITE REGULATES HTRA1 ACTIVITY
2797, p3gdsA1, 0.6632, 2.49, 0.151, 204, 185, CRYSTAL STRUCTURE OF DEGS H198P/D320A MUTANT MODIFIED BY DFP IN COMPLEX WITH DNRDGNVYYF PEPTIDE
2798, d2r3yC2, 0.6632, 2.49, 0.151, 204, 185, CRYSTAL STRUCTURE OF THE DEGS PROTEASE IN COMPLEX WITH THE YWF ACTIVATING PEPTIDE
2799, d2qf0B_, 0.6631, 2.23, 0.126, 200, 183, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2800, d2rceG_, 0.6629, 2.25, 0.126, 199, 183, DFP MODIFIED DEGS DELTA PDZ
2801, p3gcoA1, 0.6625, 2.57, 0.145, 199, 186, CRYSTAL STRUCTURE OF DEGS H198P/D320A MUTANT MODIFIED BY DFP IN COMPLEX WITH DNRDGNVYQF OMP PEPTIDE
2802, p3gcnA1, 0.6624, 2.21, 0.126, 198, 182, CRYSTAL STRUCTURE OF DEGS H198P/D320A MUTANT MODIFIED BY DFP IN COMPLEX WITH OMP PEPTIDE (YQF)
2803, p4rqzC1, 0.6621, 2.42, 0.142, 196, 183, RE-REFINEMENT OF 1SOZ CRYSTAL STRUCTURE OF DEGS PROTEASE IN COMPLEX WITH AN ACTIVATING PEPTIDE
2804, d2r3uB_, 0.6621, 2.37, 0.143, 195, 182, CRYSTAL STRUCTURE OF THE PDZ DELETION MUTANT OF DEGS
2805, p6ew9C1, 0.6614, 2.78, 0.112, 209, 188, CRYSTAL STRUCTURE OF DEGS STRESS SENSOR PROTEASE IN COMPLEX WITH ACTIVATING DNRLGLVYQF PEPTIDE 
2806, d2qf3B_, 0.6611, 3.02, 0.099, 220, 191, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2807, d3lh3D_, 0.6606, 3.01, 0.156, 251, 192, DFP MODIFIED DEGS DELTA PDZ
2808, d3lgvH_, 0.6603, 3.01, 0.156, 251, 192, H198P MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2809, p3gdvB2, 0.6592, 2.66, 0.130, 201, 184, CRYSTAL STRUCTURE OF DEGS H198P/D320A MUTANT MODIFIED BY DFP AND IN COMPLEX WITH YQF PEPTIDE
2810, p3gduA1, 0.6588, 2.85, 0.112, 213, 188, CRYSTAL STRUCTURE OF DEGS H198P/D320A MUTANT MODIFIED BY DFP AND IN COMPLEX WITH YRF PEPTIDE
2811, p3gdvC1, 0.6582, 2.70, 0.118, 209, 187, CRYSTAL STRUCTURE OF DEGS H198P/D320A MUTANT MODIFIED BY DFP AND IN COMPLEX WITH YQF PEPTIDE
2812, p3gduC1, 0.6578, 2.20, 0.128, 197, 180, CRYSTAL STRUCTURE OF DEGS H198P/D320A MUTANT MODIFIED BY DFP AND IN COMPLEX WITH YRF PEPTIDE
2813, p3pv3B1, 0.6569, 2.97, 0.101, 208, 189, STRUCTURE OF LEGIONELLA FALLONII DEGQ (S193A VARIANT)
2814, p3gduB2, 0.6568, 1.57, 0.297, 189, 172, CRYSTAL STRUCTURE OF DEGS H198P/D320A MUTANT MODIFIED BY DFP AND IN COMPLEX WITH YRF PEPTIDE
2815, d2r3uA_, 0.6564, 2.51, 0.143, 194, 182, CRYSTAL STRUCTURE OF THE PDZ DELETION MUTANT OF DEGS
2816, p6ew9B1, 0.6557, 2.67, 0.131, 200, 183, CRYSTAL STRUCTURE OF DEGS STRESS SENSOR PROTEASE IN COMPLEX WITH ACTIVATING DNRLGLVYQF PEPTIDE 
2817, d3lgvA_, 0.6557, 2.68, 0.131, 200, 183, H198P MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2818, p3k6yA_, 0.6548, 3.01, 0.144, 202, 187, CRYSTAL STRUCTURE OF RV3671C PROTEASE FROM M. TUBERCULOSIS ACTIVE FORM
2819, d3lh3A_, 0.6540, 3.01, 0.144, 202, 187, DFP MODIFIED DEGS DELTA PDZ
2820, d1vcwA2, 0.6539, 2.53, 0.164, 198, 183, CRYSTAL STRUCTURE OF DEGS AFTER BACKSOAKING THE ACTIVATING PEPTIDE
2821, d3lh3I_, 0.6536, 3.02, 0.144, 202, 187, DFP MODIFIED DEGS DELTA PDZ
2822, d2rceD_, 0.6534, 3.03, 0.144, 202, 187, DFP MODIFIED DEGS DELTA PDZ
2823, d2rceI_, 0.6533, 2.92, 0.145, 202, 186, DFP MODIFIED DEGS DELTA PDZ
2824, d2qf0H_, 0.6526, 2.93, 0.145, 202, 186, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2825, d1vcwC2, 0.6526, 2.93, 0.145, 202, 186, CRYSTAL STRUCTURE OF DEGS AFTER BACKSOAKING THE ACTIVATING PEPTIDE
2826, d3lh3H_, 0.6524, 2.49, 0.144, 192, 181, DFP MODIFIED DEGS DELTA PDZ
2827, d2rceA_, 0.6519, 2.93, 0.145, 202, 186, DFP MODIFIED DEGS DELTA PDZ
2828, p3ou0A1, 0.6514, 2.93, 0.145, 202, 186, RE-REFINED 3CS0
2829, p4ic6B2, 0.6512, 2.93, 0.145, 202, 186, CRYSTAL STRUCTURE OF DEG8
2830, d2qf0G_, 0.6511, 3.11, 0.105, 228, 191, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2831, p4ic6C1, 0.6510, 3.11, 0.105, 228, 191, CRYSTAL STRUCTURE OF DEG8
2832, d1vcwB2, 0.6509, 2.90, 0.133, 292, 188, CRYSTAL STRUCTURE OF DEGS AFTER BACKSOAKING THE ACTIVATING PEPTIDE
2833, p4ic6A2, 0.6508, 2.90, 0.133, 292, 188, CRYSTAL STRUCTURE OF DEG8
2834, d3lgvE_, 0.6508, 2.93, 0.145, 202, 186, H198P MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2835, p5ilbA1, 0.6506, 3.09, 0.100, 213, 190, CRYSTAL STRUCTURE OF PROTEASE DOMAIN OF DEG2 LINKED WITH THE PDZ DOMAIN OF DEG9
2836, p3mh7A1, 0.6506, 2.84, 0.146, 202, 185, HTRA PROTEASES ARE ACTIVATED BY A CONSERVED MECHANISM THAT CAN BE TRIGGERED BY DISTINCT MOLECULAR CUES
2837, d2rceH_, 0.6503, 2.99, 0.101, 213, 189, DFP MODIFIED DEGS DELTA PDZ
2838, p5hmaA_, 0.6501, 2.68, 0.136, 196, 184, CRYSTAL STRUCTURE OF MAMO PROTEASE DOMAIN FROM MAGNETOSPIRILLUM MAGNETICUM (NI BOUND FORM)
2839, d3cs0A3, 0.6501, 2.92, 0.106, 205, 188, CRYSTAL STRUCTURE OF DEGP24
2840, p5ilbB1, 0.6497, 3.02, 0.101, 212, 189, CRYSTAL STRUCTURE OF PROTEASE DOMAIN OF DEG2 LINKED WITH THE PDZ DOMAIN OF DEG9
2841, d3tjnB_, 0.6495, 3.02, 0.101, 212, 189, HTRA1 CATALYTIC DOMAIN APO FORM
2842, d3lgvD_, 0.6495, 2.96, 0.096, 210, 188, H198P MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2843, d3lh3E_, 0.6489, 2.96, 0.101, 210, 188, DFP MODIFIED DEGS DELTA PDZ
2844, d2rceE_, 0.6487, 2.88, 0.135, 204, 185, DFP MODIFIED DEGS DELTA PDZ
2845, d2z9iC2, 0.6484, 2.90, 0.107, 206, 187, CRYSTAL STRUCTURE OF RV0983 FROM MYCOBACTERIUM TUBERCULOSIS- PROTEOLYTICALLY ACTIVE FORM
2846, d2z9iA2, 0.6483, 2.88, 0.135, 204, 185, CRYSTAL STRUCTURE OF RV0983 FROM MYCOBACTERIUM TUBERCULOSIS- PROTEOLYTICALLY ACTIVE FORM
2847, d2qf0D_, 0.6483, 2.88, 0.135, 204, 185, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2848, p4rr0A1, 0.6478, 2.89, 0.135, 201, 185, RE-REFINED 1VCW CRYSTAL STRUCTURE OF DEGS AFTER BACKSOAKING THE ACTIVATING PEPTIDE
2849, d3lgvI_, 0.6478, 2.88, 0.135, 204, 185, H198P MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2850, d1l1jB_, 0.6475, 2.92, 0.107, 207, 187, CRYSTAL STRUCTURE OF THE PROTEASE DOMAIN OF AN ATP- INDEPENDENT HEAT SHOCK PROTEASE HTRA
2851, d1y8tA2, 0.6470, 3.28, 0.105, 206, 191, CRYSTAL STRUCTURE OF RV0983 FROM MYCOBACTERIUM TUBERCULOSIS- PROTEOLYTICALLY ACTIVE FORM
2852, d1y8tC2, 0.6463, 2.71, 0.142, 203, 183, CRYSTAL STRUCTURE OF RV0983 FROM MYCOBACTERIUM TUBERCULOSIS- PROTEOLYTICALLY ACTIVE FORM
2853, d2qf3C_, 0.6460, 2.86, 0.108, 200, 186, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2854, p4rr0C1, 0.6458, 2.91, 0.130, 204, 185, RE-REFINED 1VCW CRYSTAL STRUCTURE OF DEGS AFTER BACKSOAKING THE ACTIVATING PEPTIDE
2855, d2z9iB2, 0.6458, 2.92, 0.102, 201, 186, CRYSTAL STRUCTURE OF RV0983 FROM MYCOBACTERIUM TUBERCULOSIS- PROTEOLYTICALLY ACTIVE FORM
2856, d1y8tB2, 0.6457, 2.22, 0.158, 192, 177, CRYSTAL STRUCTURE OF RV0983 FROM MYCOBACTERIUM TUBERCULOSIS- PROTEOLYTICALLY ACTIVE FORM
2857, d1l1jA_, 0.6456, 3.11, 0.106, 213, 189, CRYSTAL STRUCTURE OF THE PROTEASE DOMAIN OF AN ATP- INDEPENDENT HEAT SHOCK PROTEASE HTRA
2858, d5jd8A1, 0.6450, 2.80, 0.130, 204, 184, CRYSTAL STRUCTURE OF THE SERINE ENDOPROTEASE FROM YERSINIA PESTIS
2859, p3pv3A1, 0.6450, 2.89, 0.146, 204, 185, STRUCTURE OF LEGIONELLA FALLONII DEGQ (S193A VARIANT)
2860, p3pv3D1, 0.6447, 2.91, 0.130, 203, 185, STRUCTURE OF LEGIONELLA FALLONII DEGQ (S193A VARIANT)
2861, p5jykA1, 0.6444, 3.31, 0.105, 213, 191, DEG9 CRYSTAL UNDER 289K
2862, d1te0B2, 0.6444, 2.82, 0.130, 204, 184, STRUCTURAL ANALYSIS OF DEGS A STRESS SENSOR OF THE BACTERIAL PERIPLASM
2863, p5y09A1, 0.6441, 3.29, 0.110, 207, 191, CRYSTAL STRUCTURE OF DEG9 AT 295 K
2864, p5hm9A_, 0.6437, 2.81, 0.130, 204, 184, CRYSTAL STRUCTURE OF MAMO PROTEASE DOMAIN FROM MAGNETOSPIRILLUM MAGNETICUM (APO FORM)
2865, p5il9A1, 0.6434, 2.82, 0.130, 204, 184, CRYSTAL STRUCTURE OF DEG9
2866, d2r3uC_, 0.6420, 2.81, 0.130, 204, 184, CRYSTAL STRUCTURE OF THE PDZ DELETION MUTANT OF DEGS
2867, d2qf3A_, 0.6420, 2.82, 0.130, 204, 184, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2868, d3lh1A_, 0.6417, 3.25, 0.105, 215, 191, Q191A MUTANT OF THE DEGS-DELTAPDZ
2869, d1te0A2, 0.6412, 3.16, 0.105, 205, 190, STRUCTURAL ANALYSIS OF DEGS A STRESS SENSOR OF THE BACTERIAL PERIPLASM
2870, d4ic5A_, 0.6408, 3.18, 0.105, 203, 190, CRYSTAL STRUCTURE OF DEG5
2871, d4ic5B_, 0.6407, 3.33, 0.110, 213, 191, CRYSTAL STRUCTURE OF DEG5
2872, d2qf0A_, 0.6404, 3.39, 0.120, 212, 192, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2873, p5xdyA1, 0.6394, 3.26, 0.100, 210, 190, CRYSTAL STRUCTURE OF HTRA1 FROM MYCOBACTERIUM TUBERCULOSIS
2874, d4ic5C_, 0.6393, 3.15, 0.106, 213, 189, CRYSTAL STRUCTURE OF DEG5
2875, p3pv5A1, 0.6353, 2.95, 0.134, 200, 186, STRUCTURE OF LEGIONELLA FALLONII DEGQ (N189G/P190G VARIANT)
2876, p4flnB1, 0.6340, 2.95, 0.134, 200, 186, CRYSTAL STRUCTURE OF PLANT PROTEASE DEG2
2877, p4rr0B1, 0.6327, 3.25, 0.100, 216, 190, RE-REFINED 1VCW CRYSTAL STRUCTURE OF DEGS AFTER BACKSOAKING THE ACTIVATING PEPTIDE
2878, p4flnC1, 0.6321, 3.23, 0.105, 207, 190, CRYSTAL STRUCTURE OF PLANT PROTEASE DEG2
2879, d1qa7B_, 0.6304, 3.20, 0.105, 208, 190, CRYSTAL COMPLEX OF THE 3C PROTEINASE FROM HEPATITIS A VIRUS WITH ITS INHIBITOR AND IMPLICATIONS FOR THE POLYPROTEIN PROCESSING IN HAV
2880, d2qf0E_, 0.6301, 3.12, 0.102, 204, 187, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2881, p1zyoA_, 0.6294, 3.30, 0.100, 216, 190, CRYSTAL STRUCTURE OF THE SERINE PROTEASE DOMAIN OF SESBANIA MOSAIC VIRUS POLYPROTEIN
2882, d3tjoA1, 0.6292, 3.17, 0.101, 216, 189, HTRA1 CATALYTIC DOMAIN MUTATIONALLY INACTIVATED
2883, d3lguA_, 0.6285, 3.27, 0.105, 213, 190, Y162A MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2884, p3lt3A_, 0.6279, 2.99, 0.109, 195, 184, CRYSTAL STRUCTURE OF RV3671C FROM M. TUBERCULOSIS H37RV SER343ALA MUTANT INACTIVE FORM
2885, d5fhtA1, 0.6276, 3.27, 0.105, 214, 190, HTRA2 PROTEASE MUTANT V226K
2886, d2zleM3, 0.6275, 2.96, 0.102, 200, 186, CRYO-EM STRUCTURE OF DEGP12/OMP
2887, d2zleL3, 0.6275, 3.09, 0.101, 211, 188, CRYO-EM STRUCTURE OF DEGP12/OMP
2888, d2zleK3, 0.6275, 2.94, 0.103, 197, 185, CRYO-EM STRUCTURE OF DEGP12/OMP
2889, d2zleJ3, 0.6275, 3.15, 0.101, 201, 188, CRYO-EM STRUCTURE OF DEGP12/OMP
2890, d2zleI3, 0.6275, 3.36, 0.100, 209, 190, CRYO-EM STRUCTURE OF DEGP12/OMP
2891, d2zleH3, 0.6275, 3.19, 0.101, 202, 188, CRYO-EM STRUCTURE OF DEGP12/OMP
2892, d2zleG3, 0.6275, 3.18, 0.101, 204, 188, CRYO-EM STRUCTURE OF DEGP12/OMP
2893, d2zleF3, 0.6275, 2.79, 0.126, 196, 182, CRYO-EM STRUCTURE OF DEGP12/OMP
2894, d2zleE3, 0.6275, 3.15, 0.112, 201, 187, CRYO-EM STRUCTURE OF DEGP12/OMP
2895, d2zleC3, 0.6275, 3.00, 0.103, 202, 184, CRYO-EM STRUCTURE OF DEGP12/OMP
2896, d2zleB3, 0.6275, 3.12, 0.108, 201, 185, CRYO-EM STRUCTURE OF DEGP12/OMP
2897, d2zleA3, 0.6275, 3.00, 0.109, 204, 184, CRYO-EM STRUCTURE OF DEGP12/OMP
2898, p4flnA1, 0.6273, 3.07, 0.174, 216, 184, CRYSTAL STRUCTURE OF PLANT PROTEASE DEG2
2899, p4rqyA1, 0.6268, 3.07, 0.174, 216, 184, RE-REFINED STRUCTURE OF 1TE0 - STRUCTURAL ANALYSIS OF DEGS A STRESS SENSOR OF THE BACTERIAL PERIPLASM
2900, d1sotA2, 0.6268, 3.06, 0.103, 206, 185, CRYSTAL STRUCTURE OF THE DEGS STRESS SENSOR
2901, d3tjoD1, 0.6259, 3.11, 0.108, 213, 185, HTRA1 CATALYTIC DOMAIN MUTATIONALLY INACTIVATED
2902, d2qf0I_, 0.6258, 2.73, 0.099, 197, 181, STRUCTURE OF THE DELTA PDZ TRUNCATION OF THE DEGS PROTEASE
2903, d1sotB2, 0.6248, 2.89, 0.093, 206, 183, CRYSTAL STRUCTURE OF THE DEGS STRESS SENSOR
2904, p3pv5C1, 0.6238, 2.74, 0.094, 197, 181, STRUCTURE OF LEGIONELLA FALLONII DEGQ (N189G/P190G VARIANT)
2905, d3stiB1, 0.6236, 3.10, 0.103, 193, 184, CRYSTAL STRUCTURE OF THE PROTEASE DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2906, d1lcyA2, 0.6233, 3.05, 0.114, 213, 184, CRYSTAL STRUCTURE OF THE MITOCHONDRIAL SERINE PROTEASE HTRA2
2907, d3stiA1, 0.6227, 2.84, 0.099, 192, 181, CRYSTAL STRUCTURE OF THE PROTEASE DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2908, d3tjoB1, 0.6225, 3.03, 0.103, 204, 184, HTRA1 CATALYTIC DOMAIN MUTATIONALLY INACTIVATED
2909, p3k6zB_, 0.6225, 2.84, 0.150, 196, 180, CRYSTAL STRUCTURE OF RV3671C PROTEASE INACTIVE FORM
2910, d5m3oA1, 0.6223, 3.61, 0.115, 216, 192, HTRA2 A141S MUTANT STRUCTURE
2911, p4ri0A1, 0.6223, 2.82, 0.099, 193, 181, SERINE PROTEASE HTRA3 MUTATIONALLY INACTIVATED
2912, d3stiC_, 0.6223, 3.58, 0.115, 232, 192, CRYSTAL STRUCTURE OF THE PROTEASE DOMAIN OF DEGQ FROM ESCHERICHIA COLI
2913, d3mh4A1, 0.6223, 3.58, 0.115, 232, 192, HTRA PROTEASES ARE ACTIVATED BY A CONSERVED MECHANISM THAT CAN BE TRIGGERED BY DISTINCT MOLECULAR CUES
2914, d5to0A1, 0.6221, 3.05, 0.109, 213, 184, HTRA2 S276C MUTANT
2915, p3k6zA_, 0.6220, 3.52, 0.110, 223, 191, CRYSTAL STRUCTURE OF RV3671C PROTEASE INACTIVE FORM
2916, d3tjnD_, 0.6219, 2.73, 0.106, 195, 180, HTRA1 CATALYTIC DOMAIN APO FORM
2917, p4rqyB2, 0.6217, 3.24, 0.151, 209, 185, RE-REFINED STRUCTURE OF 1TE0 - STRUCTURAL ANALYSIS OF DEGS A STRESS SENSOR OF THE BACTERIAL PERIPLASM
2918, p4ri0B_, 0.6213, 3.24, 0.151, 209, 185, SERINE PROTEASE HTRA3 MUTATIONALLY INACTIVATED
2919, d1sotC2, 0.6210, 2.85, 0.156, 196, 180, CRYSTAL STRUCTURE OF THE DEGS STRESS SENSOR
2920, d4rr1A1, 0.6209, 2.82, 0.100, 191, 180, RE-REFINEMENT OF ENTRY 1SOT CRYSTAL STRUCTURE OF THE DEGS STRESS SENSOR
2921, p3pv5B1, 0.6209, 2.84, 0.137, 191, 183, STRUCTURE OF LEGIONELLA FALLONII DEGQ (N189G/P190G VARIANT)
2922, d3lgwA_, 0.6209, 2.84, 0.137, 191, 183, H198P/T167V DOUBLE MUTANT OF DEGS-DELTAPDZ PROTEASE
2923, d3tjnA_, 0.6205, 2.86, 0.161, 195, 180, HTRA1 CATALYTIC DOMAIN APO FORM
2924, d1qa7D_, 0.6199, 2.91, 0.154, 204, 182, CRYSTAL COMPLEX OF THE 3C PROTEINASE FROM HEPATITIS A VIRUS WITH ITS INHIBITOR AND IMPLICATIONS FOR THE POLYPROTEIN PROCESSING IN HAV
2925, p3pv2B1, 0.6198, 2.66, 0.140, 197, 178, STRUCTURE OF LEGIONELLA FALLONII DEGQ (WT)
2926, d3b8jA_, 0.6198, 2.74, 0.106, 203, 180, Q191A MUTANT OF DEGS-DELTAPDZ
2927, p3pv2C1, 0.6194, 2.79, 0.100, 202, 180, STRUCTURE OF LEGIONELLA FALLONII DEGQ (WT)
2928, p3pv3C1, 0.6191, 2.79, 0.100, 202, 180, STRUCTURE OF LEGIONELLA FALLONII DEGQ (S193A VARIANT)
2929, d5tnyA1, 0.6188, 2.75, 0.161, 200, 180, HTRA2 G399S MUTANT
2930, d5to1A1, 0.6182, 2.75, 0.161, 200, 180, HTRA2 EXPOSED (L266R F303A) MUTANT
2931, p3pv2A1, 0.6176, 2.75, 0.161, 195, 180, STRUCTURE OF LEGIONELLA FALLONII DEGQ (WT)
2932, p3pv2D1, 0.6170, 2.84, 0.099, 201, 181, STRUCTURE OF LEGIONELLA FALLONII DEGQ (WT)
2933, p3mh5A_, 0.6165, 2.89, 0.110, 206, 181, HTRA PROTEASES ARE ACTIVATED BY A CONSERVED MECHANISM THAT CAN BE TRIGGERED BY DISTINCT MOLECULAR CUES
2934, p5il9B1, 0.6163, 2.64, 0.112, 193, 178, CRYSTAL STRUCTURE OF DEG9
2935, d5m3nA1, 0.6159, 3.47, 0.128, 226, 188, HTRA2 WILD-TYPE STRUCTURE
2936, p4ri0C_, 0.6157, 2.97, 0.170, 193, 182, SERINE PROTEASE HTRA3 MUTATIONALLY INACTIVATED
2937, d5tnzA1, 0.6155, 2.73, 0.162, 195, 179, HTRA2 S142D MUTANT
2938, d3lgyA_, 0.6147, 2.70, 0.107, 195, 178, R178A MUTANT OF THE DEGS-DELTAPDZ PROTEASE
2939, p3pv5D1, 0.6130, 2.92, 0.110, 204, 181, STRUCTURE OF LEGIONELLA FALLONII DEGQ (N189G/P190G VARIANT)
2940, d4rr1C1, 0.6121, 2.79, 0.167, 195, 180, RE-REFINEMENT OF ENTRY 1SOT CRYSTAL STRUCTURE OF THE DEGS STRESS SENSOR
2941, d1ky9B3, 0.6115, 2.80, 0.167, 194, 180, CRYSTAL STRUCTURE OF DEGP (HTRA)
2942, d4rr1B1, 0.6113, 3.51, 0.122, 226, 188, RE-REFINEMENT OF ENTRY 1SOT CRYSTAL STRUCTURE OF THE DEGS STRESS SENSOR
2943, d3numA_, 0.6112, 3.51, 0.122, 226, 188, SUBSTRATE INDUCED REMODELING OF THE ACTIVE SITE REGULATES HTRA1 ACTIVITY
2944, d3lgtA_, 0.6111, 2.70, 0.124, 190, 178, Y162A/H198P DOUBLE MUTANT OF DEGS-DELTAPDZ PROTEASE
2945, d1ky9A2, 0.6111, 2.92, 0.123, 196, 179, CRYSTAL STRUCTURE OF DEGP (HTRA)
2946, p3lt3B_, 0.6105, 2.65, 0.136, 194, 177, CRYSTAL STRUCTURE OF RV3671C FROM M. TUBERCULOSIS H37RV SER343ALA MUTANT INACTIVE FORM
2947, d1qa7A_, 0.6105, 2.97, 0.132, 208, 182, CRYSTAL COMPLEX OF THE 3C PROTEINASE FROM HEPATITIS A VIRUS WITH ITS INHIBITOR AND IMPLICATIONS FOR THE POLYPROTEIN PROCESSING IN HAV
2948, p3nwuA_, 0.6101, 3.15, 0.109, 218, 184, SUBSTRATE INDUCED REMODELING OF THE ACTIVE SITE REGULATES HTRA1 ACTIVITY
2949, p3nwuC_, 0.6099, 2.99, 0.132, 208, 182, SUBSTRATE INDUCED REMODELING OF THE ACTIVE SITE REGULATES HTRA1 ACTIVITY
2950, p3nwuB_, 0.6096, 2.83, 0.138, 189, 181, SUBSTRATE INDUCED REMODELING OF THE ACTIVE SITE REGULATES HTRA1 ACTIVITY
2951, d1havA_, 0.6091, 3.00, 0.132, 208, 182, HEPATITIS A VIRUS 3C PROTEINASE
2952, p5t69A1, 0.6075, 2.58, 0.103, 185, 175, THE HHOA PROTEASE FROM SYNECHOCYSTIS SP. PCC 6803 ACTIVE SITE MUTANT
2953, d2wv5B_, 0.6068, 2.66, 0.102, 200, 177, CRYSTAL STRUCTURE OF FOOT-AND-MOUTH DISEASE VIRUS 3C PROTEASE IN COMPLEX WITH A DECAMERIC PEPTIDE CORRESPONDING TO THE VP1-2A CLEAVAGE JUNCTION WITH A GLN TO GLU SUBSTITUTION AT P1
2954, d2wv5D_, 0.6066, 2.86, 0.106, 199, 179, CRYSTAL STRUCTURE OF FOOT-AND-MOUTH DISEASE VIRUS 3C PROTEASE IN COMPLEX WITH A DECAMERIC PEPTIDE CORRESPONDING TO THE VP1-2A CLEAVAGE JUNCTION WITH A GLN TO GLU SUBSTITUTION AT P1
2955, d2cxvA_, 0.6062, 3.21, 0.109, 218, 184, DUAL MODES OF MODIFICATION OF HEPATITIS A VIRUS 3C PROTEASE BY A SERINE-DERIVED BETALACTONE: SELECTIVE CRYSTALLIZATION AND HIGH-RESOLUTION STRUCTURE OF THE HIS-102 ADDUCT
2956, d2h9hA_, 0.6058, 3.30, 0.137, 210, 183, AN EPISULFIDE CATION (THIIRANIUM RING) TRAPPED IN THE ACTIVE SITE OF HAV 3C PROTEINASE INACTIVATED BY PEPTIDE-BASED KETONE INHIBITORS
2957, d2h6mA_, 0.6056, 3.31, 0.137, 210, 183, AN EPISULFIDE CATION (THIIRANIUM RING) TRAPPED IN THE ACTIVE SITE OF HAV 3C PROTEINASE INACTIVATED BY PEPTIDE-BASED KETONE INHIBITORS
2958, p5hm2A_, 0.6053, 2.87, 0.106, 199, 179, CRYSTAL STRUCTURE OF THE 3C PROTEASE FROM SOUTH AFRICAN TERRITORIES TYPE 2 FOOT-AND-MOUTH DISEASE VIRUS
2959, d2wv5A_, 0.6053, 3.17, 0.149, 204, 181, CRYSTAL STRUCTURE OF FOOT-AND-MOUTH DISEASE VIRUS 3C PROTEASE IN COMPLEX WITH A DECAMERIC PEPTIDE CORRESPONDING TO THE VP1-2A CLEAVAGE JUNCTION WITH A GLN TO GLU SUBSTITUTION AT P1
2960, d2halA_, 0.6052, 3.25, 0.137, 209, 182, AN EPISULFIDE CATION (THIIRANIUM RING) TRAPPED IN THE ACTIVE SITE OF HAV 3C PROTEINASE INACTIVATED BY PEPTIDE-BASED KETONE INHIBITORS
2961, d2a4oA_, 0.6052, 2.97, 0.128, 196, 179, DUAL MODES OF MODIFICATION OF HEPATITIS A VIRUS 3C PROTEASE BY A SERINE DERIVED BETA-LACTONE: SELECTIVE CRYTSTALLIZATION AND HIGH RESOLUTION STRUCTURE OF THE HIS102 ADDUCT
2962, d2wv5C_, 0.6051, 3.22, 0.149, 204, 181, CRYSTAL STRUCTURE OF FOOT-AND-MOUTH DISEASE VIRUS 3C PROTEASE IN COMPLEX WITH A DECAMERIC PEPTIDE CORRESPONDING TO THE VP1-2A CLEAVAGE JUNCTION WITH A GLN TO GLU SUBSTITUTION AT P1
2963, p5t63A1, 0.6050, 2.81, 0.109, 193, 175, THE HHOA PROTEASE FROM SYNECHOCYSTIS SP. PCC 6803
2964, d2wv4A_, 0.6049, 2.98, 0.151, 206, 179, CRYSTAL STRUCTURE OF FOOT-AND-MOUTH DISEASE VIRUS 3C PROTEASE IN COMPLEX WITH A DECAMERIC PEPTIDE CORRESPONDING TO THE VP1-2A CLEAVAGE JUNCTION
2965, p5hm2E_, 0.6046, 3.41, 0.134, 217, 186, CRYSTAL STRUCTURE OF THE 3C PROTEASE FROM SOUTH AFRICAN TERRITORIES TYPE 2 FOOT-AND-MOUTH DISEASE VIRUS
2966, d2j92A1, 0.6035, 3.41, 0.134, 217, 186, 3C PROTEASE FROM TYPE A10(61) FOOT-AND-MOUTH DISEASE VIRUS- CRYSTAL PACKING MUTANT (K51Q)
2967, d1qa7C_, 0.6029, 2.82, 0.103, 190, 175, CRYSTAL COMPLEX OF THE 3C PROTEINASE FROM HEPATITIS A VIRUS WITH ITS INHIBITOR AND IMPLICATIONS FOR THE POLYPROTEIN PROCESSING IN HAV
2968, p5hm2C_, 0.6019, 3.09, 0.122, 184, 180, CRYSTAL STRUCTURE OF THE 3C PROTEASE FROM SOUTH AFRICAN TERRITORIES TYPE 2 FOOT-AND-MOUTH DISEASE VIRUS
2969, p5hm2D_, 0.6016, 3.09, 0.122, 184, 180, CRYSTAL STRUCTURE OF THE 3C PROTEASE FROM SOUTH AFRICAN TERRITORIES TYPE 2 FOOT-AND-MOUTH DISEASE VIRUS
2970, p5hm2B_, 0.6003, 3.02, 0.136, 197, 177, CRYSTAL STRUCTURE OF THE 3C PROTEASE FROM SOUTH AFRICAN TERRITORIES TYPE 2 FOOT-AND-MOUTH DISEASE VIRUS
2971, d2j92B_, 0.5990, 2.89, 0.109, 191, 175, 3C PROTEASE FROM TYPE A10(61) FOOT-AND-MOUTH DISEASE VIRUS- CRYSTAL PACKING MUTANT (K51Q)
2972, d2wv4B_, 0.5987, 3.37, 0.165, 205, 182, CRYSTAL STRUCTURE OF FOOT-AND-MOUTH DISEASE VIRUS 3C PROTEASE IN COMPLEX WITH A DECAMERIC PEPTIDE CORRESPONDING TO THE VP1-2A CLEAVAGE JUNCTION
2973, p5b6lA1, 0.5970, 3.14, 0.159, 197, 176, STRUCTURE OF DEG PROTEASE HHOA FROM SYNECHOCYSTIS SP. PCC 6803
2974, d1havB_, 0.5953, 3.36, 0.133, 214, 180, HEPATITIS A VIRUS 3C PROTEINASE
2975, p5gndA1, 0.5944, 3.36, 0.133, 214, 180, STRUCTURE OF DEG PROTEASE HHOA FROM SYNECHOCYSTIS SP. PCC 6803
2976, d2qgrA_, 0.5871, 3.36, 0.133, 214, 180, STRUCTURE OF THE R178A MUTANT OF DELTA PDZ DEGS PROTEASE
2977, p5wotA_, 0.5822, 3.36, 0.133, 214, 180, NMR SOLUTION STRUCTURE OF A-LYTIC PROTEASE USING TWO 4D-SPECTRA
2978, p5mrrB_, 0.5808, 3.36, 0.133, 214, 180, CRYSTAL STRUCTURE OF L1 PROTEASE OF LYSOBACTER SP. XL1
2979, p5mrrA_, 0.5793, 3.36, 0.133, 214, 180, CRYSTAL STRUCTURE OF L1 PROTEASE OF LYSOBACTER SP. XL1
2980, d2bhgA1, 0.5792, 3.36, 0.133, 214, 180, 3C PROTEASE FROM TYPE A10(61) FOOT-AND-MOUTH DISEASE VIRUS
2981, p5mrrC_, 0.5776, 3.36, 0.133, 214, 180, CRYSTAL STRUCTURE OF L1 PROTEASE OF LYSOBACTER SP. XL1
2982, p5mrsA_, 0.5775, 3.36, 0.133, 214, 180, CRYSTAL STRUCTURE OF L1 PROTEASE LYSOBACTER SP. XL1 IN COMPLEX WITH AEBSF
2983, d3ureB_, 0.5774, 3.36, 0.133, 214, 180, REPACK MUTANT (T181I W199L Q210I) OF ALPHA-LYTIC PROTEASE
2984, p5mrrD_, 0.5770, 3.36, 0.133, 214, 180, CRYSTAL STRUCTURE OF L1 PROTEASE OF LYSOBACTER SP. XL1
2985, d2h5dA_, 0.5768, 3.36, 0.133, 214, 180, 0.9A RESOLUTION CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE COMPLEXED WITH A TRANSITION STATE ANALOGUE MEOSUC-ALA-ALA-PRO-VAL BORONIC ACID
2986, d2bhgB_, 0.5768, 3.36, 0.133, 214, 180, 3C PROTEASE FROM TYPE A10(61) FOOT-AND-MOUTH DISEASE VIRUS
2987, p5mrsC_, 0.5767, 3.14, 0.151, 206, 179, CRYSTAL STRUCTURE OF L1 PROTEASE LYSOBACTER SP. XL1 IN COMPLEX WITH AEBSF
2988, d1p12E_, 0.5766, 3.27, 0.110, 208, 181, CRYSTAL STRUCTURES OF ALPHA-LYTIC PROTEASE COMPLEXES WITH IRREVERSIBLY BOUND PHOSPHONATE ESTERS
2989, d1p11E_, 0.5765, 3.18, 0.117, 201, 179, CRYSTAL STRUCTURES OF ALPHA-LYTIC PROTEASE COMPLEXES WITH IRREVERSIBLY BOUND PHOSPHONATE ESTERS
2990, d1p04A_, 0.5764, 3.04, 0.136, 196, 176, STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
2991, d3lprA_, 0.5763, 2.75, 0.104, 186, 173, STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
2992, d1p03A_, 0.5763, 3.10, 0.107, 202, 178, STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
2993, d1gbmA_, 0.5763, 2.86, 0.126, 188, 174, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID
2994, d8lprA_, 0.5762, 2.85, 0.155, 183, 174, STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
2995, d6lprA_, 0.5762, 3.15, 0.160, 196, 175, STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
2996, d2lprA_, 0.5762, 2.91, 0.161, 183, 174, STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
2997, d1p10A_, 0.5762, 3.01, 0.126, 197, 175, STRUCTURAL PLASTICITY AS A DETERMINANT OF ENZYME SPECIFICITY. CREATING BROADLY SPECIFIC PROTEASES
2998, d1p02A_, 0.5762, 3.04, 0.175, 197, 177, STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
2999, d1p01A_, 0.5762, 3.13, 0.160, 197, 175, SERINE PROTEASE MECHANISM. STRUCTURE OF AN INHIBITORY COMPLEX OF ALPHA-LYTIC PROTEASE AND A TIGHTLY BOUND PEPTIDE BORONIC ACID
3000, d7lprA_, 0.5761, 3.20, 0.124, 193, 177, STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
3001, p5mrsB_, 0.5760, 3.05, 0.159, 183, 176, CRYSTAL STRUCTURE OF L1 PROTEASE LYSOBACTER SP. XL1 IN COMPLEX WITH AEBSF
3002, d4proA_, 0.5760, 3.29, 0.134, 207, 179, ALPHA-LYTIC PROTEASE COMPLEXED WITH PRO REGION
3003, d1p05A_, 0.5760, 3.13, 0.166, 192, 175, STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
3004, d1gbiA_, 0.5760, 3.11, 0.181, 198, 177, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID
3005, d5lprA_, 0.5759, 2.59, 0.154, 187, 169, STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
3006, d1p06A_, 0.5759, 3.10, 0.124, 194, 177, STRUCTURE ANALYSIS OF SPECIFICITY. ALPHA-LYTIC PROTEASE COMPLEXES WITH ANALOGUES OF REACTION INTERMEDIATES
3007, d9lprA_, 0.5758, 3.09, 0.126, 190, 175, STRUCTURAL BASIS FOR BROAD SPECIFICITY IN ALPHA-LYTIC PROTEASE MUTANTS
3008, d1gbkA_, 0.5758, 3.21, 0.118, 201, 178, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID
3009, d1gbhA_, 0.5758, 3.06, 0.119, 198, 176, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID
3010, d1gblA_, 0.5757, 2.80, 0.127, 187, 173, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID
3011, d1gbfA_, 0.5757, 2.67, 0.111, 187, 171, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID
3012, d1gbcA_, 0.5757, 2.96, 0.145, 190, 173, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-LEUCINE BORONIC ACID
3013, d2alpA_, 0.5755, 3.41, 0.125, 217, 184, REFINED STRUCTURE OF ALPHA-LYTIC PROTEASE AT 1.7 ANGSTROMS RESOLUTION. ANALYSIS OF HYDROGEN BONDING AND SOLVENT STRUCTURE
3014, d1gbbA_, 0.5755, 2.96, 0.133, 192, 173, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-ALANINE BORONIC ACID
3015, d1gbdA_, 0.5754, 2.93, 0.116, 184, 173, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA COMPLEX WITH METHOXYSUCCINYL-ALA-ALA-PRO-PHENYLALANINE BORONIC ACID
3016, d1p09A_, 0.5753, 3.00, 0.133, 192, 173, STRUCTURAL PLASTICITY AS A DETERMINANT OF ENZYME SPECIFICITY. CREATING BROADLY SPECIFIC PROTEASES
3017, d1gbjA_, 0.5752, 2.80, 0.123, 188, 171, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA
3018, d1gbaA_, 0.5752, 3.09, 0.162, 193, 173, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY ALA
3019, d3urdA_, 0.5751, 3.25, 0.161, 191, 174, T181A MUTANT OF ALPHA-LYTIC PROTEASE
3020, d3urcA_, 0.5751, 2.94, 0.134, 188, 172, T181G MUTANT OF ALPHA-LYTIC PROTEASE
3021, d1boqA_, 0.5751, 2.97, 0.134, 187, 172, PRO REGION C-TERMINUS: PROTEASE ACTIVE SITE INTERACTIONS ARE CRITICAL IN CATALYZING THE FOLDING OF ALPHA-LYTIC PROTEASE
3022, p5mrsD_, 0.5750, 2.91, 0.134, 191, 172, CRYSTAL STRUCTURE OF L1 PROTEASE LYSOBACTER SP. XL1 IN COMPLEX WITH AEBSF
3023, d1gbeA_, 0.5750, 3.00, 0.137, 199, 175, ALPHA-LYTIC PROTEASE WITH MET 190 REPLACED BY ALA AND GLY 216 REPLACED BY LEU
3024, d3qgjC_, 0.5749, 3.10, 0.163, 189, 172, 1.3A STRUCTURE OF ALPHA-LYTIC PROTEASE BOUND TO AC-ALAALAPRO-ALANAL
3025, d3m7tA_, 0.5749, 3.08, 0.127, 196, 173, CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE SB2+3 E8A/R105S MUTANT
3026, d2h5cA_, 0.5749, 3.10, 0.163, 190, 172, 0.82A RESOLUTION CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE AT PH 5
3027, d1ssxA_, 0.5749, 2.45, 0.114, 179, 166, 0.83A RESOLUTION CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE AT PH 8
3028, d1qrwA_, 0.5749, 2.77, 0.135, 183, 170, CRYSTAL STRUCTURE OF AN ALPHA-LYTIC PROTEASE MUTANT WITH ACCELERATED FOLDING KINETICS R102H/G134S PH 8
3029, d1qq4A_, 0.5749, 2.96, 0.110, 188, 172, CRYSTAL STRUCTURE OF AN ALPHA-LYTIC PROTEASE MUTANT WITH ACCELERATED FOLDING KINETICS R102H/G134S
3030, d1talA_, 0.5748, 3.29, 0.154, 205, 175, ALPHA-LYTIC PROTEASE AT 120 K (SINGLE STRUCTURE MODEL)
3031, d1qrxA_, 0.5748, 2.93, 0.111, 187, 171, CRYSTAL STRUCTURE OF WILD-TYPE ALPHA-LYTIC PROTEASE AT 1.6 A PH 5.14
3032, d3qgjA_, 0.5746, 2.86, 0.141, 190, 170, 1.3A STRUCTURE OF ALPHA-LYTIC PROTEASE BOUND TO AC-ALAALAPRO-ALANAL
3033, d3proA_, 0.5745, 2.58, 0.114, 181, 167, ALPHA-LYTIC PROTEASE COMPLEXED WITH C-TERMINAL TRUNCATED PRO REGION
3034, d3m7uA_, 0.5745, 3.57, 0.140, 208, 178, CRYSTAL STRUCTURE OF ALPHA-LYTIC PROTEASE SB1+2 R64A/E182Q MUTANT
3035, d3ureA_, 0.5744, 3.56, 0.169, 199, 178, REPACK MUTANT (T181I W199L Q210I) OF ALPHA-LYTIC PROTEASE
3036, d2ullA_, 0.5744, 3.31, 0.140, 213, 179, MULTIPLE CONFORMATION STRUCTURE OF ALPHA-LYTIC PROTEASE AT 120 K
3037, d4proB_, 0.5735, 2.96, 0.147, 179, 170, ALPHA-LYTIC PROTEASE COMPLEXED WITH PRO REGION
3038, d3proB_, 0.5730, 2.97, 0.147, 183, 170, ALPHA-LYTIC PROTEASE COMPLEXED WITH C-TERMINAL TRUNCATED PRO REGION
3039, p5mrtB_, 0.5723, 2.91, 0.148, 172, 169, CRYSTAL STRUCTURE OF L5 PROTEASE LYSOBACTER SP. XL1
3040, d3sjoB_, 0.5709, 3.48, 0.120, 216, 183, STRUCTURE OF EV71 3C IN COMPLEX WITH RUPINTRIVIR (AG7088)
3041, d3sjoF_, 0.5708, 2.76, 0.149, 180, 168, STRUCTURE OF EV71 3C IN COMPLEX WITH RUPINTRIVIR (AG7088)
3042, d3sjoH_, 0.5700, 2.76, 0.149, 180, 168, STRUCTURE OF EV71 3C IN COMPLEX WITH RUPINTRIVIR (AG7088)
3043, d3sjoG_, 0.5700, 3.46, 0.117, 200, 180, STRUCTURE OF EV71 3C IN COMPLEX WITH RUPINTRIVIR (AG7088)
3044, d2sfaA_, 0.5698, 3.50, 0.111, 200, 180, SERINE PROTEINASE FROM STREPTOMYCES FRADIAE ATCC 14544
3045, d3sj8A_, 0.5691, 3.37, 0.128, 212, 179, CRYSTAL STRUCTURE OF THE 3C PROTEASE FROM COXSACKIEVIRUS A16
3046, d3sjoE_, 0.5685, 3.37, 0.128, 212, 179, STRUCTURE OF EV71 3C IN COMPLEX WITH RUPINTRIVIR (AG7088)
3047, d2vb0A_, 0.5685, 3.38, 0.128, 212, 179, CRYSTAL STRUCTURE OF COXSACKIEVIRUS B3 PROTEINASE 3C
3048, d3sjoC_, 0.5683, 3.48, 0.122, 201, 181, STRUCTURE OF EV71 3C IN COMPLEX WITH RUPINTRIVIR (AG7088)
3049, d3sjiA_, 0.5682, 3.52, 0.111, 200, 180, CRYSTAL STRUCTURE OF CVA16 3C IN COMPLEX WITH RUPINTRIVIR (AG7088)
3050, d3sj9A_, 0.5681, 3.37, 0.128, 212, 179, CRYSTAL STRUCTURE OF THE C147A MUTANT 3C OF CVA16 IN COMPLEX WITH FAGLRQAVTQ PEPTIDE
3051, d3ruoA1, 0.5681, 3.38, 0.128, 212, 179, COMPLEX STRUCTURE OF HEVB EV93 MAIN PROTEASE 3C WITH RUPINTRIVIR (AG7088)
3052, d2qaaB_, 0.5678, 3.50, 0.111, 200, 180, CRYSTAL STRUCTURE OF THE SECOND TETRAHEDRAL INTERMEDIATES OF SGPB AT PH 7.3
3053, d3zvaA1, 0.5671, 2.71, 0.156, 179, 167, 3C PROTEASE OF ENTEROVIRUS 68 COMPLEXED WITH MICHAEL RECEPTOR INHIBITOR 75
3054, d3zvbA1, 0.5670, 3.54, 0.106, 201, 180, 3C PROTEASE OF ENTEROVIRUS 68 COMPLEXED WITH MICHAEL RECEPTOR INHIBITOR 81
3055, d5gsoE_, 0.5668, 3.52, 0.122, 201, 181, CRYSTAL STRUCTURES OF EV71 3C PROTEASE IN COMPLEX WITH NK-1.8K
3056, d3zveA1, 0.5668, 3.46, 0.112, 201, 179, 3C PROTEASE OF ENTEROVIRUS 68 COMPLEXED WITH MICHAEL RECEPTOR INHIBITOR 84
3057, d3zvdA1, 0.5667, 3.46, 0.112, 201, 179, 3C PROTEASE OF ENTEROVIRUS 68 COMPLEXED WITH MICHAEL RECEPTOR INHIBITOR 83
3058, d3zvgA1, 0.5666, 3.41, 0.140, 213, 179, 3C PROTEASE OF ENTEROVIRUS 68 COMPLEXED WITH MICHAEL RECEPTOR INHIBITOR 98
3059, d3zvcA1, 0.5666, 3.42, 0.123, 201, 179, 3C PROTEASE OF ENTEROVIRUS 68 COMPLEXED WITH MICHAEL RECEPTOR INHIBITOR 82
3060, d3sjoD_, 0.5666, 3.44, 0.123, 201, 179, STRUCTURE OF EV71 3C IN COMPLEX WITH RUPINTRIVIR (AG7088)
3061, d3r0fA_, 0.5666, 3.53, 0.122, 201, 180, HUMAN ENTEROVIRUS 71 3C PROTEASE MUTANT H133G IN COMPLEX WITH RUPINTRIVIR
3062, d3zvfA1, 0.5665, 3.30, 0.114, 185, 175, 3C PROTEASE OF ENTEROVIRUS 68 COMPLEXED WITH MICHAEL RECEPTOR INHIBITOR 85
3063, d3zv9A1, 0.5665, 3.46, 0.119, 196, 177, 3C PROTEASE OF ENTEROVIRUS 68 COMPLEXED WITH MICHAEL RECEPTOR INHIBITOR 74
3064, d3sjoA_, 0.5665, 2.88, 0.163, 175, 166, STRUCTURE OF EV71 3C IN COMPLEX WITH RUPINTRIVIR (AG7088)
3065, d3sjkA_, 0.5665, 3.51, 0.134, 213, 179, CRYSTAL STRUCTURE OF THE C147A MUTANT 3C FROM ENTEROVIRUS 71
3066, p6ffnA_, 0.5658, 2.86, 0.164, 174, 165, STRUCTURE-BASED DESIGN AND SYNTHESIS OF MACROCYCLIC HUMAN RHINOVIRUS 3C PROTEASE INHIBITORS
3067, d5gswA_, 0.5658, 2.38, 0.127, 169, 158, CRYSTAL STRUCTURE OF EV71 3C IN COMPLEX WITH N69S 1.8K
3068, p6ffsA_, 0.5657, 3.65, 0.179, 198, 173, STRUCTURE-BASED DESIGN AND SYNTHESIS OF MACROCYCLIC HUMAN RHINOVIRUS 3C PROTEASE INHIBITORS
3069, d3zv8A1, 0.5657, 3.36, 0.178, 199, 169, CRYSTAL STRUCTURE OF 3C PROTEASE OF ENTEROVIRUS 68
3070, p1hiaB_, 0.5653, 3.39, 0.178, 199, 169, KALLIKREIN COMPLEXED WITH HIRUSTASIN
3071, d5gsoD_, 0.5650, 3.39, 0.178, 199, 169, CRYSTAL STRUCTURES OF EV71 3C PROTEASE IN COMPLEX WITH NK-1.8K
3072, p2w5eC_, 0.5650, 3.21, 0.118, 184, 170, STRUCTURAL AND BIOCHEMICAL ANALYSIS OF HUMAN PATHOGENIC ASTROVIRUS SERINE PROTEASE AT 2.0 ANGSTROM RESOLUTION
3073, d5gswE_, 0.5648, 3.42, 0.178, 199, 169, CRYSTAL STRUCTURE OF EV71 3C IN COMPLEX WITH N69S 1.8K
3074, d5gswB_, 0.5648, 3.43, 0.178, 199, 169, CRYSTAL STRUCTURE OF EV71 3C IN COMPLEX WITH N69S 1.8K
3075, d3sgqE_, 0.5648, 3.41, 0.195, 198, 169, GLN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
3076, d5gswD_, 0.5647, 3.46, 0.178, 199, 169, CRYSTAL STRUCTURE OF EV71 3C IN COMPLEX WITH N69S 1.8K
3077, d2qa9E_, 0.5647, 3.43, 0.189, 198, 169, CRYSTAL STRUCTURE OF THE SECOND TETRAHEDRAL INTERMEDIATES OF SGPB AT PH 4.2
3078, d5fx6A_, 0.5646, 3.07, 0.120, 175, 167, NOVEL INHIBITORS OF HUMAN RHINOVIRUS 3C PROTEASE
3079, p2w5eE_, 0.5646, 3.45, 0.178, 199, 169, STRUCTURAL AND BIOCHEMICAL ANALYSIS OF HUMAN PATHOGENIC ASTROVIRUS SERINE PROTEASE AT 2.0 ANGSTROM RESOLUTION
3080, p2w5eA_, 0.5645, 3.70, 0.192, 198, 172, STRUCTURAL AND BIOCHEMICAL ANALYSIS OF HUMAN PATHOGENIC ASTROVIRUS SERINE PROTEASE AT 2.0 ANGSTROM RESOLUTION
3081, d2ijd11, 0.5643, 3.70, 0.192, 198, 172, CRYSTAL STRUCTURE OF THE POLIOVIRUS PRECURSOR PROTEIN 3CD
3082, p1hiaY_, 0.5643, 3.70, 0.192, 198, 172, KALLIKREIN COMPLEXED WITH HIRUSTASIN
3083, d5wq2A1, 0.5642, 3.70, 0.192, 198, 172, CRYSTAL STRUCTURE OF 3C PROTEASE FROM A MILD HUMAN ENTEROVIRUS 71 IN COMPLEX WITH RUPINTRIVIR
3084, d5hxfA1, 0.5642, 3.70, 0.192, 198, 172, CRYSTAL STRUCTURE OF 3C PROTEASE FROM A MILD HUMAN ENTEROVIRUS 71 IN COMPLEX WITH RUPINTRIVIR
3085, d2nu3E_, 0.5641, 3.70, 0.192, 198, 172, ACCOMMODATION OF POSITIVELY-CHARGED RESIDUES IN A HYDROPHOBIC SPECIFICITY POCKET: CRYSTAL STRUCTURES OF SGPB IN COMPLEX WITH OMTKY3 VARIANTS LYS18I AND ARG18I
3086, d3zz6A1, 0.5640, 3.71, 0.192, 198, 172, CRYSTAL STRUCTURE OF 3C PROTEASE OF COXSACKIEVIRUS B3 COMPLEXED WITH MICHAEL RECEPTOR INHIBITOR 75
3087, d1sgpE_, 0.5640, 3.70, 0.192, 198, 172, ALA 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
3088, d5gsoA_, 0.5639, 3.70, 0.192, 198, 172, CRYSTAL STRUCTURES OF EV71 3C PROTEASE IN COMPLEX WITH NK-1.8K
3089, d2sgfE_, 0.5639, 3.70, 0.192, 198, 172, PHE 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
3090, d2qaaA_, 0.5639, 3.70, 0.192, 198, 172, CRYSTAL STRUCTURE OF THE SECOND TETRAHEDRAL INTERMEDIATES OF SGPB AT PH 7.3
3091, d2nu2E_, 0.5639, 3.71, 0.192, 198, 172, ACCOMMODATION OF POSITIVELY-CHARGED RESIDUES IN A HYDROPHOBIC SPECIFICITY POCKET: CRYSTAL STRUCTURES OF SGPB IN COMPLEX WITH OMTKY3 VARIANTS LYS18I AND ARG18I
3092, d2nu1E_, 0.5639, 3.71, 0.192, 198, 172, MOLECULAR STRUCTURES OF THE COMPLEXES OF SGPB WITH OMTKY3 AROMATIC P1 VARIANTS TRP18I HIS18I PHE18I AND TYR18I
3093, d4dcdA1, 0.5638, 3.71, 0.174, 199, 172, 1.6A RESOLUTION STRUCTURE OF POLIOVIRUS 3C PROTEASE CONTAINING A COVALENTLY BOUND DIPEPTIDYL INHIBITOR
3094, d3zz9A1, 0.5638, 3.71, 0.192, 198, 172, CRYSTAL STRUCTURE OF 3C PROTEASE OF COXSACKIEVIRUS B3 COMPLEXED WITH ALPHA BETA-UNSATURATED ETHYL ESTER INHIBITOR 83
3095, d2sgqE_, 0.5638, 3.71, 0.192, 198, 172, GLN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
3096, d2sgpE_, 0.5638, 3.70, 0.192, 198, 172, PRO 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
3097, d1sgqE_, 0.5638, 3.71, 0.192, 198, 172, GLY 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
3098, d1sgeE_, 0.5638, 3.70, 0.192, 198, 172, GLU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
3099, d1sgdE_, 0.5637, 3.80, 0.184, 198, 174, ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
3100, d5dp7A1, 0.5636, 3.71, 0.192, 198, 172, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 5
3101, d3qzqB_, 0.5636, 3.70, 0.192, 198, 172, HUMAN ENTEROVIRUS 71 3C PROTEASE MUTANT E71D IN COMPLEX WITH RUPINTRIVIR
3102, d1sgnE_, 0.5636, 3.71, 0.192, 198, 172, ASN 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
3103, d1ct4E_, 0.5636, 3.71, 0.192, 198, 172, CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-VAL18I IN COMPLEX WITH SGPB
3104, d1csoE_, 0.5636, 3.71, 0.192, 198, 172, CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-ILE18I IN COMPLEX WITH SGPB
3105, d5dp5A1, 0.5635, 3.71, 0.192, 198, 172, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 4
3106, d2ijd21, 0.5635, 3.71, 0.192, 198, 172, CRYSTAL STRUCTURE OF THE POLIOVIRUS PRECURSOR PROTEIN 3CD
3107, d1l1nB_, 0.5635, 3.71, 0.192, 198, 172, POLIOVIRUS 3C PROTEINASE
3108, d1ds2E_, 0.5635, 3.71, 0.192, 198, 172, CRYSTAL STRUCTURE OF SGPB:OMTKY3-COO-LEU18I
3109, d5gswC_, 0.5634, 3.71, 0.192, 198, 172, CRYSTAL STRUCTURE OF EV71 3C IN COMPLEX WITH N69S 1.8K
3110, d3zz5A1, 0.5634, 3.71, 0.192, 198, 172, CRYSTAL STRUCTURE OF 3C PROTEASE OF COXSACKIEVIRUS B3 COMPLEXED WITH ALPHA BETA-UNSATURATED ETHYL ESTER INHIBITOR 74
3111, d1sgyE_, 0.5634, 3.73, 0.192, 198, 172, TYR 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 6.5
3112, d1sgrE_, 0.5634, 3.72, 0.192, 198, 172, LEU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B
3113, d1ct2E_, 0.5634, 3.72, 0.192, 198, 172, CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-THR18I IN COMPLEX WITH SGPB
3114, d5gsoC_, 0.5633, 3.48, 0.178, 199, 169, CRYSTAL STRUCTURES OF EV71 3C PROTEASE IN COMPLEX WITH NK-1.8K
3115, d2sgeE_, 0.5632, 3.71, 0.192, 198, 172, GLU 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
3116, d2nu4E_, 0.5632, 3.72, 0.192, 198, 172, ACCOMMODATION OF POSITIVELY-CHARGED RESIDUES IN A HYDROPHOBIC SPECIFICITY POCKET: CRYSTAL STRUCTURES OF SGPB IN COMPLEX WITH OMTKY3 VARIANTS LYS18I AND ARG18I
3117, d5bpeA_, 0.5631, 3.72, 0.192, 198, 172, CRYSTAL STRUCTURE OF EV71 3CPRO IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR
3118, p2w5eD_, 0.5631, 3.72, 0.192, 198, 172, STRUCTURAL AND BIOCHEMICAL ANALYSIS OF HUMAN PATHOGENIC ASTROVIRUS SERINE PROTEASE AT 2.0 ANGSTROM RESOLUTION
3119, d2sgdE_, 0.5631, 3.73, 0.192, 198, 172, ASP 18 VARIANT OF TURKEY OVOMUCOID INHIBITOR THIRD DOMAIN COMPLEXED WITH STREPTOMYCES GRISEUS PROTEINASE B AT PH 10.7
3120, d2nu0E_, 0.5631, 3.73, 0.192, 198, 172, MOLECULAR STRUCTURES OF THE COMPLEXES OF SGPB WITH OMTKY3 AROMATIC P1 VARIANTS TRP18I HIS18I PHE18I AND TYR18I
3121, d1ct0E_, 0.5631, 3.72, 0.192, 198, 172, CRYSTAL STRUCTURE OF THE OMTKY3 P1 VARIANT OMTKY3-SER18I IN COMPLEX WITH SGPB
3122, d1cqqA_, 0.5631, 3.73, 0.192, 198, 172, TYPE 2 RHINOVIRUS 3C PROTEASE WITH AG7088 INHIBITOR
3123, d3zz7A1, 0.5630, 3.73, 0.192, 198, 172, CRYSTAL STRUCTURE OF 3C PROTEASE OF COXSACKIEVIRUS B3 COMPLEXED WITH ALPHA BETA-UNSATURATED ETHYL ESTER INHIBITOR 81
3124, d3zyeA1, 0.5630, 3.38, 0.190, 197, 168, CRYSTAL STRUCTURE OF 3C PROTEASE MUTANT (T68A) OF COXSACKIEVIRUS B3
3125, d5c1xB1, 0.5628, 3.47, 0.189, 198, 169, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND VIII
3126, d3q3yA1, 0.5628, 3.46, 0.189, 198, 169, COMPLEX STRUCTURE OF HEVB EV93 MAIN PROTEASE 3C WITH COMPOUND 1 (AG7404)
3127, d2zu3A_, 0.5628, 3.45, 0.195, 198, 169, COMPLEX STRUCTURE OF CVB3 3C PROTEASE WITH TG-0204998
3128, p2w5eB_, 0.5628, 3.73, 0.192, 198, 172, STRUCTURAL AND BIOCHEMICAL ANALYSIS OF HUMAN PATHOGENIC ASTROVIRUS SERINE PROTEASE AT 2.0 ANGSTROM RESOLUTION
3129, d4sgbE_, 0.5627, 3.76, 0.192, 198, 172, STRUCTURE OF THE COMPLEX OF STREPTOMYCES GRISEUS PROTEINASE B AND POLYPEPTIDE CHYMOTRYPSIN INHIBITOR-1 FROM RUSSET BURBANK POTATO TUBERS AT 2.1 ANGSTROMS RESOLUTION
3130, d3sgbE_, 0.5627, 3.49, 0.189, 198, 169, STRUCTURE OF THE COMPLEX OF STREPTOMYCES GRISEUS PROTEASE B AND THE THIRD DOMAIN OF THE TURKEY OVOMUCOID INHIBITOR AT 1.8 ANGSTROMS RESOLUTION
3131, d3qzqC_, 0.5627, 3.56, 0.189, 193, 169, HUMAN ENTEROVIRUS 71 3C PROTEASE MUTANT E71D IN COMPLEX WITH RUPINTRIVIR
3132, d1hpgA_, 0.5627, 3.32, 0.120, 179, 167, A GLUTAMIC ACID SPECIFIC SERINE PROTEASE UTILIZES A NOVEL HISTIDINE TRIAD IN SUBSTRATE BINDING
3133, p5mrtA_, 0.5626, 3.31, 0.120, 179, 167, CRYSTAL STRUCTURE OF L5 PROTEASE LYSOBACTER SP. XL1
3134, d5gsoB_, 0.5626, 3.34, 0.120, 179, 167, CRYSTAL STRUCTURES OF EV71 3C PROTEASE IN COMPLEX WITH NK-1.8K
3135, d3zzaA1, 0.5626, 3.34, 0.120, 179, 167, CRYSTAL STRUCTURE OF 3C PROTEASE OF COXSACKIEVIRUS B3 COMPLEXED WITH ALPHA BETA-UNSATURATED ETHYL ESTER INHIBITOR 84
3136, d5dp4B1, 0.5624, 3.47, 0.174, 191, 167, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 3
3137, d5fx5A_, 0.5623, 3.47, 0.174, 191, 167, NOVEL INHIBITORS OF HUMAN RHINOVIRUS 3C PROTEASE
3138, d3zzbA1, 0.5623, 3.32, 0.108, 179, 167, CRYSTAL STRUCTURE OF 3C PROTEASE OF COXSACKIEVIRUS B3 COMPLEXED WITH ALPHA BETA-UNSATURATED ETHYL ESTER INHIBITOR 85
3139, d2zu1B_, 0.5623, 3.41, 0.102, 179, 167, CRYSTAL STRUCTURE OF CVB3 3C PROTEASE MUTANT C147A
3140, p5nfsA_, 0.5622, 3.37, 0.108, 182, 167, STRUCTURE OF COXSACKIEVIRUS B3 3C PROTEASE IN COMPLEX WITH THE ALPHA- KETOAMIDE (S)-N-BENZYL-3-((S)-2-CINNAMAMIDO-3-PHENYLPROPANAMIDO)-2- OXO-4-((S)-2-OXOPYRROLIDIN-3-YL)BUTANAMIDE (CINNAMOYL-PHENYLALANINE- GLNLACTAM-CO-CO-NH-BENZYL) 
3141, d5iytA_, 0.5622, 3.38, 0.102, 179, 167, COMPLEX STRUCTURE OF EV-B93 MAIN PROTEASE 3C WITH N-ETHYL 4-((1- CYCLOHEPTYL-12-DIHYDROPYRAZOL-3-ONE-5-YL)-AMINO)-4-OXO-2Z-BUTENAMIDE
3142, d2ouaB_, 0.5622, 3.35, 0.108, 179, 167, CRYSTAL STRUCTURE OF NOCARDIOPSIS PROTEASE (NAPASE)
3143, d3zz8A1, 0.5621, 3.38, 0.108, 179, 167, CRYSTAL STRUCTURE OF 3C PROTEASE OF COXSACKIEVIRUS B3 COMPLEXED WITH ALPHA BETA-UNSATURATED ETHYL ESTER INHIBITOR 82
3144, d3qzrA_, 0.5621, 3.45, 0.131, 182, 168, HUMAN ENTEROVIRUS 71 3C PROTEASE MUTANT E71A IN COMPLEX WITH RUPINTRIVIR
3145, d5dp6B_, 0.5620, 3.33, 0.188, 185, 165, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 7
3146, d5dp4C1, 0.5620, 3.49, 0.083, 183, 169, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 3
3147, d3qzqD_, 0.5620, 3.41, 0.083, 183, 168, HUMAN ENTEROVIRUS 71 3C PROTEASE MUTANT E71D IN COMPLEX WITH RUPINTRIVIR
3148, d3q3yB1, 0.5620, 3.60, 0.113, 181, 168, COMPLEX STRUCTURE OF HEVB EV93 MAIN PROTEASE 3C WITH COMPOUND 1 (AG7404)
3149, d5dp6A_, 0.5619, 3.42, 0.083, 183, 168, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 7
3150, d3ruoB1, 0.5619, 3.50, 0.083, 183, 169, COMPLEX STRUCTURE OF HEVB EV93 MAIN PROTEASE 3C WITH RUPINTRIVIR (AG7088)
3151, d2zu1A_, 0.5619, 3.51, 0.083, 183, 169, CRYSTAL STRUCTURE OF CVB3 3C PROTEASE MUTANT C147A
3152, d5dp8A1, 0.5618, 3.50, 0.083, 183, 169, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 8
3153, d5c1xA1, 0.5618, 3.48, 0.119, 179, 168, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND VIII
3154, d5c1uB1, 0.5618, 3.44, 0.108, 181, 166, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND XB
3155, d3zydA1, 0.5618, 3.50, 0.083, 183, 169, CRYSTAL STRUCTURE OF 3C PROTEASE OF COXSACKIEVIRUS B3
3156, d3r0fB_, 0.5618, 3.42, 0.083, 183, 168, HUMAN ENTEROVIRUS 71 3C PROTEASE MUTANT H133G IN COMPLEX WITH RUPINTRIVIR
3157, d5dp9A1, 0.5617, 3.48, 0.119, 179, 168, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 9
3158, d5dpaA1, 0.5616, 3.39, 0.120, 179, 167, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 6
3159, d5dp6D_, 0.5615, 3.38, 0.120, 182, 166, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 7
3160, d5dp6C_, 0.5615, 3.38, 0.120, 182, 166, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 7
3161, d2ztxA_, 0.5615, 3.45, 0.114, 181, 167, COMPLEX STRUCTURE OF CVB3 3C PROTEASE WITH EPDTC
3162, d5iytB_, 0.5614, 3.38, 0.120, 182, 166, COMPLEX STRUCTURE OF EV-B93 MAIN PROTEASE 3C WITH N-ETHYL 4-((1- CYCLOHEPTYL-12-DIHYDROPYRAZOL-3-ONE-5-YL)-AMINO)-4-OXO-2Z-BUTENAMIDE
3163, d4ghtB1, 0.5614, 3.51, 0.083, 183, 169, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH AG7088
3164, d2ztzA_, 0.5614, 3.51, 0.083, 183, 169, CRYSTAL STRUCTURE OF 3C PROTEASE FROM CVB3 IN SPACE GROUP P21
3165, d2gkvE_, 0.5614, 1.71, 0.303, 150, 145, CRYSTAL STRUCTURE OF THE SGPB:P14 -ALA32 OMTKY3-DEL(1-5) COMPLEX
3166, d2ztzB_, 0.5612, 3.41, 0.096, 179, 166, CRYSTAL STRUCTURE OF 3C PROTEASE FROM CVB3 IN SPACE GROUP P21
3167, d5dp4D1, 0.5611, 2.53, 0.135, 162, 155, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 3
3168, d5dp3A1, 0.5611, 3.63, 0.113, 181, 168, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 2
3169, d2xyaA1, 0.5611, 3.42, 0.108, 180, 166, NON-COVALENT INHIBTORS OF RHINOVIRUS 3C PROTEASE.
3170, d5c1yA1, 0.5610, 3.39, 0.188, 185, 165, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 1
3171, d3qzqA_, 0.5610, 3.49, 0.108, 181, 167, HUMAN ENTEROVIRUS 71 3C PROTEASE MUTANT E71D IN COMPLEX WITH RUPINTRIVIR
3172, d5dp4A1, 0.5609, 3.30, 0.189, 185, 164, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 3
3173, d5c20A1, 0.5607, 3.51, 0.126, 180, 167, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND 2
3174, d4ghqA1, 0.5606, 2.52, 0.129, 162, 155, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE
3175, p2w5eF_, 0.5606, 2.52, 0.129, 162, 155, STRUCTURAL AND BIOCHEMICAL ANALYSIS OF HUMAN PATHOGENIC ASTROVIRUS SERINE PROTEASE AT 2.0 ANGSTROM RESOLUTION
3176, d3zzdA_, 0.5605, 2.52, 0.129, 162, 155, CRYSTAL STRUCTURE OF 3C PROTEASE MUTANT (T68A AND N126Y) OF COXSACKIEVIRUS B3 COMPLEXED WITH ALPHA BETA-UNSATURATED ETHYL ESTER INHIBITOR 85
3177, d2in2A_, 0.5605, 3.39, 0.090, 180, 166, NMR STRUCTURE OF THE APO HUMAN RHINOVIRUS 3C PROTEASE (SEROTYPE 14)
3178, d4ghtA1, 0.5604, 1.76, 0.303, 150, 145, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH AG7088
3179, d3zz3A1, 0.5604, 3.44, 0.114, 181, 166, CRYSTAL STRUCTURE OF 3C PROTEASE MUTANT (N126Y) OF COXSACKIEVIRUS B3
3180, d2ouaA_, 0.5602, 3.44, 0.120, 181, 166, CRYSTAL STRUCTURE OF NOCARDIOPSIS PROTEASE (NAPASE)
3181, d3zzcA_, 0.5601, 3.41, 0.188, 185, 165, CRYSTAL STRUCTURE OF 3C PROTEASE MUTANT (T68A AND N126Y) OF COXSACKIEVIRUS B3 COMPLEXED WITH ALPHA BETA-UNSATURATED ETHYL ESTER INHIBITOR 83
3182, d1l1nA_, 0.5599, 3.39, 0.114, 180, 166, POLIOVIRUS 3C PROTEINASE
3183, d3qzrB_, 0.5597, 3.42, 0.182, 185, 165, HUMAN ENTEROVIRUS 71 3C PROTEASE MUTANT E71A IN COMPLEX WITH RUPINTRIVIR
3184, d2ea3A_, 0.5596, 3.30, 0.097, 181, 165, CRYSTAL STRUCTURE OF CELLULOMONAS BOGORIENSIS CHYMOTRYPSIN
3185, d3q3xA1, 0.5594, 3.42, 0.188, 185, 165, CRYSTAL STRUCTURE OF THE MAIN PROTEASE (3C) FROM HUMAN ENTEROVIRUS B EV93
3186, d5c1uA1, 0.5593, 3.40, 0.188, 185, 165, CRYSTAL STRUCTURE OF EV71 3C PROTEINASE IN COMPLEX WITH COMPOUND XB
3187, d3zz3B1, 0.5592, 3.42, 0.188, 185, 165, CRYSTAL STRUCTURE OF 3C PROTEASE MUTANT (N126Y) OF COXSACKIEVIRUS B3
3188, p2b0fA_, 0.5578, 3.41, 0.188, 185, 165, NMR STRUCTURE OF THE HUMAN RHINOVIRUS 3C PROTEASE (SEROTYPE 14) WITH COVALENTLY BOUND ACE-LEALFQ-ETHYLPROPIONATE INHIBITOR
3189, d3zz4A1, 0.5568, 3.44, 0.090, 180, 166, CRYSTAL STRUCTURE OF 3C PROTEASE MUTANT (T68A AND N126Y) OF COXSACKIEVIRUS B3
3190, d2sgaA_, 0.5567, 3.40, 0.114, 180, 166, ELECTRON DENSITY CALCULATIONS AS AN EXTENSION OF PROTEIN STRUCTURE REFINEMENT. STREPTOMYCES GRISEUS PROTEASE AT 1.5 ANGSTROMS RESOLUTION
3191, d4sgaE_, 0.5565, 3.42, 0.188, 185, 165, STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS
3192, d1sgcA_, 0.5564, 3.40, 0.188, 185, 165, THE 1.8 ANGSTROMS STRUCTURE OF THE COMPLEX BETWEEN CHYMOSTATIN AND STREPTOMYCES GRISEUS PROTEASE A. A MODEL FOR SERINE PROTEASE CATALYTIC TETRAHEDRAL INTERMEDIATES
3193, d3sgaE_, 0.5562, 3.41, 0.182, 185, 165, STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS
3194, d5sgaE_, 0.5560, 3.42, 0.188, 185, 165, STRUCTURES OF PRODUCT AND INHIBITOR COMPLEXES OF STREPTOMYCES GRISEUS PROTEASE A AT 1.8 ANGSTROMS RESOLUTION. A MODEL FOR SERINE PROTEASE CATALYSIS
3195, d3zz4B1, 0.5560, 3.42, 0.188, 185, 165, CRYSTAL STRUCTURE OF 3C PROTEASE MUTANT (T68A AND N126Y) OF COXSACKIEVIRUS B3
3196, d3q3xB1, 0.5560, 3.36, 0.109, 180, 165, CRYSTAL STRUCTURE OF THE MAIN PROTEASE (3C) FROM HUMAN ENTEROVIRUS B EV93
3197, d3osyE1, 0.5549, 3.36, 0.121, 176, 165, HUMAN ENTEROVIRUS 71 3C PROTEASE
3198, d3osyD1, 0.5549, 3.42, 0.188, 185, 165, HUMAN ENTEROVIRUS 71 3C PROTEASE
3199, d3osyC1, 0.5549, 3.42, 0.182, 185, 165, HUMAN ENTEROVIRUS 71 3C PROTEASE
3200, d3osyA1, 0.5549, 3.42, 0.182, 185, 165, HUMAN ENTEROVIRUS 71 3C PROTEASE
3201, d3osyB1, 0.5547, 3.35, 0.109, 180, 165, HUMAN ENTEROVIRUS 71 3C PROTEASE
3202, d4ashB1, 0.5507, 3.31, 0.091, 180, 165, CRYSTAL STRUCTURE OF THE NS6 PROTEASE FROM MURINE NOROVIRUS 1
3203, d2pfeB_, 0.5491, 3.45, 0.090, 178, 166, CRYSTAL STRUCTURE OF THERMOBIFIDA FUSCA PROTEASE A (TFPA)
3204, d2pfeA_, 0.5485, 3.55, 0.181, 185, 166, CRYSTAL STRUCTURE OF THERMOBIFIDA FUSCA PROTEASE A (TFPA)
3205, d2ztyA_, 0.5469, 3.50, 0.108, 181, 167, CRYSTAL STRUCTURE OF 3C PROTEASE FROM CVB3 IN SPACE GROUP C2
3206, d2iphA_, 0.5438, 3.40, 0.114, 180, 166, X-RAY STRUCTURE AT 1.75 A RESOLUTION OF A NOROVIRUS PROTEASE LINKED TO AN ACTIVE SITE DIRECTED PEPTIDE INHIBITOR
3207, p3ur6B_, 0.5402, 3.39, 0.188, 185, 165, 1.5A RESOLUTION STRUCTURE OF APO NORWALK VIRUS PROTEASE
3208, d2iphB_, 0.5395, 3.43, 0.182, 185, 165, X-RAY STRUCTURE AT 1.75 A RESOLUTION OF A NOROVIRUS PROTEASE LINKED TO AN ACTIVE SITE DIRECTED PEPTIDE INHIBITOR
3209, p4inhE_, 0.5374, 3.39, 0.182, 185, 165, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3210, p4inhG_, 0.5370, 3.34, 0.097, 181, 165, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3211, p1etsH1, 0.5370, 3.33, 0.189, 185, 164, REFINED 2.3 ANGSTROMS X-RAY CRYSTAL STRUCTURE OF BOVINE THROMBIN COMPLEXES FORMED WITH THE BENZAMIDINE AND ARGININE-BASED THROMBIN INHIBITORS NAPAP 4-TAPAP AND MQPA: A STARTING POINT FOR IMPROVING ANTITHROMBOTICS
3212, p4inhH_, 0.5367, 3.43, 0.188, 185, 165, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3213, d1wqsD_, 0.5366, 3.45, 0.139, 180, 166, CRYSTAL STRUCTURE OF NOROVIRUS 3C-LIKE PROTEASE
3214, p4inhA_, 0.5365, 2.57, 0.123, 162, 155, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3215, p4inhB_, 0.5362, 3.27, 0.190, 185, 163, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3216, p4imzA_, 0.5357, 3.39, 0.188, 185, 165, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3217, d1wqsB_, 0.5357, 3.39, 0.182, 185, 165, CRYSTAL STRUCTURE OF NOROVIRUS 3C-LIKE PROTEASE
3218, p2lncA_, 0.5353, 3.30, 0.115, 180, 165, SOLUTION NMR STRUCTURE OF NORWALK VIRUS PROTEASE
3219, d4in1A1, 0.5352, 3.42, 0.108, 180, 166, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3220, d4x2vA_, 0.5351, 3.40, 0.120, 180, 166, CRYSTAL STRUCTURE OF THE MURINE NOROVIRUS NS6 PROTEASE (INACTIVE C139A MUTANT) WITH A C-TERMINAL EXTENSION TO INCLUDE RESIDUE P1 PRIME OF NS7
3221, d5wejA_, 0.5350, 3.32, 0.109, 180, 165, 1.95 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH A DIPEPTIDYL OXAZOLIDINONE-BASED INHIBITOR
3222, d4x2vC_, 0.5348, 3.43, 0.114, 180, 166, CRYSTAL STRUCTURE OF THE MURINE NOROVIRUS NS6 PROTEASE (INACTIVE C139A MUTANT) WITH A C-TERMINAL EXTENSION TO INCLUDE RESIDUE P1 PRIME OF NS7
3223, d4ashA1, 0.5347, 3.40, 0.102, 180, 166, CRYSTAL STRUCTURE OF THE NS6 PROTEASE FROM MURINE NOROVIRUS 1
3224, d4x2vB1, 0.5340, 2.56, 0.123, 162, 155, CRYSTAL STRUCTURE OF THE MURINE NOROVIRUS NS6 PROTEASE (INACTIVE C139A MUTANT) WITH A C-TERMINAL EXTENSION TO INCLUDE RESIDUE P1 PRIME OF NS7
3225, p4inhC_, 0.5340, 3.44, 0.182, 185, 165, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3226, d4xbdB1, 0.5336, 3.41, 0.182, 185, 165, 1.45A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE COMPLEX WITH A COVALENTLY BOUND DIPEPTIDYL INHIBITOR (1R2S)-2-({N-[(BENZYLOXY) CARBONYL]-3-CYCLOHEXYL-L-ALANYL}AMINO)-1-HYDROXY-3-[(3S)-2- OXOPYRROLIDIN-3-YL]PROPANE-1-SULFONIC ACID (ORTHORHOMBIC P FORM)
3227, d4x2wA_, 0.5333, 3.42, 0.121, 178, 165, CRYSTAL STRUCTURE OF THE MURINE NOROVIRUS NS6 PROTEASE (INACTIVE C139A MUTANT) WITH A C-TERMINAL EXTENSION TO INCLUDE RESIDUES P1 PRIME - P2 PRIME OF NS7
3228, d4xbcA1, 0.5332, 3.72, 0.161, 187, 168, 1.60 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE COMPLEX WITH A COVALENTLY BOUND DIPEPTIDYL INHIBITOR (1R2S)-2-({N-[(BENZYLOXY) CARBONYL]-3-CYCLOHEXYL-L-ALANYL}AMINO)-1-HYDROXY-3-[(3S)-2- OXOPYRROLIDIN-3-YL]PROPANE-1-SULFONIC ACID (HEXAGONAL FORM)
3229, d1wqsC_, 0.5331, 3.54, 0.181, 195, 166, CRYSTAL STRUCTURE OF NOROVIRUS 3C-LIKE PROTEASE
3230, p4imqA_, 0.5325, 3.40, 0.096, 181, 166, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3231, d5t6dA1, 0.5318, 3.44, 0.114, 180, 166, 2.10 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE DIPEPTIDYL INHIBITOR 7L (HEXAGONAL FORM)
3232, p4inhD_, 0.5317, 3.28, 0.104, 180, 164, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3233, d5t6gA1, 0.5316, 3.23, 0.116, 180, 164, 2.45 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE DIPEPTIDYL INHIBITOR 7M (HEXAGONAL FORM)
3234, d5dg6A1, 0.5313, 3.44, 0.102, 180, 166, 2.35A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX AN OXADIAZOLE-BASED CELL PERMEABLE MACROCYCLIC (21-MER) INHIBITOR
3235, p4inhF_, 0.5313, 3.44, 0.133, 180, 166, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3236, d4x2vD_, 0.5311, 3.44, 0.139, 180, 166, CRYSTAL STRUCTURE OF THE MURINE NOROVIRUS NS6 PROTEASE (INACTIVE C139A MUTANT) WITH A C-TERMINAL EXTENSION TO INCLUDE RESIDUE P1 PRIME OF NS7
3237, d1wqsA_, 0.5308, 3.33, 0.134, 182, 164, CRYSTAL STRUCTURE OF NOROVIRUS 3C-LIKE PROTEASE
3238, d1ezxC_, 0.5306, 3.82, 0.202, 188, 168, CRYSTAL STRUCTURE OF A SERPIN:PROTEASE COMPLEX
3239, d5t6fA1, 0.5304, 3.44, 0.114, 180, 166, 1.90 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE DIPEPTIDYL INHIBITOR 7L (ORTHORHOMBIC P FORM)
3240, d5e0hA1, 0.5302, 3.38, 0.110, 180, 164, 1.95 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH A TRIAZOLE-BASED MACROCYCLIC (18-MER) INHIBITOR
3241, d2fyrA_, 0.5301, 3.31, 0.104, 179, 164, CRYSTAL STRUCTURE OF NORWALK VIRUS PROTEASE GROWN IN THE PRESENCE OF AEBSF
3242, p3ur9B_, 0.5297, 3.29, 0.104, 180, 164, 1.65A RESOLUTION STRUCTURE OF NORWALK VIRUS PROTEASE CONTAINING A COVALENTLY BOUND DIPEPTIDYL INHIBITOR
3243, d5e0gA1, 0.5288, 3.44, 0.121, 175, 165, 1.20 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH A TRIAZOLE-BASED MACROCYCLIC (17-MER) INHIBITOR
3244, p1a0hB1, 0.5288, 3.44, 0.114, 180, 166, THE X-RAY CRYSTAL STRUCTURE OF PPACK-MEIZOTHROMBIN DESF1: KRINGLE/THROMBIN AND CARBOHYDRATE/KRINGLE/THROMBIN INTERACTIONS AND LOCATION OF THE LINKER CHAIN
3245, d2fyqA_, 0.5285, 3.32, 0.104, 178, 164, CRYSTAL STRUCTURE OF THE NORWALK VIRUS PROTEASE
3246, d5wejB_, 0.5281, 3.44, 0.139, 180, 166, 1.95 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH A DIPEPTIDYL OXAZOLIDINONE-BASED INHIBITOR
3247, d4x2yB_, 0.5274, 3.43, 0.133, 180, 166, CRYSTAL STRUCTURE OF A CHIMERIC MURINE NOROVIRUS NS6 PROTEASE (INACTIVE C139A MUTANT) IN WHICH THE P4-P4 PRIME RESIDUES OF THE CLEAVAGE JUNCTION IN THE EXTENDED C-TERMINUS HAVE BEEN REPLACED BY THE CORRESPONDING RESIDUES FROM THE NS2-3 JUNCTION.
3248, d4xbbA1, 0.5270, 3.28, 0.104, 180, 164, 1.85A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE COMPLEX WITH A COVALENTLY BOUND DIPEPTIDYL INHIBITOR DIETHYL [(1R2S)-2-[(N-{[(3- CHLOROBENZYL)OXY]CARBONYL}-3-CYCLOHEXYL-L-ALANYL)AMINO]-1-HYDROXY-3- (2-OXO-2H-PYRROL-3-YL)PROPYL]PHOSPHONATE
3249, p3ur6A_, 0.5264, 3.29, 0.104, 180, 164, 1.5A RESOLUTION STRUCTURE OF APO NORWALK VIRUS PROTEASE
3250, d4x2wB_, 0.5258, 3.29, 0.104, 180, 164, CRYSTAL STRUCTURE OF THE MURINE NOROVIRUS NS6 PROTEASE (INACTIVE C139A MUTANT) WITH A C-TERMINAL EXTENSION TO INCLUDE RESIDUES P1 PRIME - P2 PRIME OF NS7
3251, d5t6gB_, 0.5248, 3.42, 0.108, 180, 166, 2.45 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE DIPEPTIDYL INHIBITOR 7M (HEXAGONAL FORM)
3252, d5e0jA1, 0.5239, 3.40, 0.115, 176, 165, 1.20 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH A TRIAZOLE-BASED MACROCYCLIC (21-MER) INHIBITOR
3253, p8gchF_, 0.5221, 3.27, 0.104, 180, 164, GAMMA-CHYMOTRYPSIN IS A COMPLEX OF ALPHA-CHYMOTRYPSIN WITH ITS OWN AUTOLYSIS PRODUCTS
3254, p1n8oB_, 0.5221, 3.28, 0.104, 180, 164, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN BOVINE CHYMOTRYPSIN AND ECOTIN
3255, p1gctB_, 0.5221, 3.32, 0.104, 180, 164, IS GAMMA-CHYMOTRYPSIN A TETRAPEPTIDE ACYL-ENZYME ADDUCT OF GAMMA- CHYMOTRYPSIN?
3256, d5t6dB_, 0.5220, 3.32, 0.104, 179, 164, 2.10 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE DIPEPTIDYL INHIBITOR 7L (HEXAGONAL FORM)
3257, d4x2yA_, 0.5219, 3.40, 0.109, 180, 165, CRYSTAL STRUCTURE OF A CHIMERIC MURINE NOROVIRUS NS6 PROTEASE (INACTIVE C139A MUTANT) IN WHICH THE P4-P4 PRIME RESIDUES OF THE CLEAVAGE JUNCTION IN THE EXTENDED C-TERMINUS HAVE BEEN REPLACED BY THE CORRESPONDING RESIDUES FROM THE NS2-3 JUNCTION.
3258, d5e0hB1, 0.5217, 3.31, 0.098, 182, 164, 1.95 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH A TRIAZOLE-BASED MACROCYCLIC (18-MER) INHIBITOR
3259, p2vgcB_, 0.5215, 3.29, 0.104, 180, 164, GAMMA-CHYMOTRYPSIN D-PARA-CHLORO-1-ACETAMIDO BORONIC ACID INHIBITOR COMPLEX
3260, d5t6fB1, 0.5209, 3.44, 0.133, 180, 166, 1.90 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE DIPEPTIDYL INHIBITOR 7L (ORTHORHOMBIC P FORM)
3261, p4gchF_, 0.5206, 3.31, 0.189, 185, 164, STRUCTURE AND ACTIVITY OF TWO PHOTOREVERSIBLE CINNAMATES BOUND TO CHYMOTRYPSIN
3262, p3ur9A_, 0.5205, 3.45, 0.114, 180, 166, 1.65A RESOLUTION STRUCTURE OF NORWALK VIRUS PROTEASE CONTAINING A COVALENTLY BOUND DIPEPTIDYL INHIBITOR
3263, p5y4lB1, 0.5193, 3.35, 0.109, 180, 165, PRRSV NSP4
3264, d4x2xA_, 0.5184, 3.29, 0.104, 180, 164, CRYSTAL STRUCTURE OF THE MURINE NOROVIRUS NS6 PROTEASE (INACTIVE C139A MUTANT) WITH A C-TERMINAL EXTENSION TO INCLUDE RESIDUES P1 PRIME - P4 PRIME OF NS7
3265, p4in2A_, 0.5174, 3.32, 0.127, 180, 165, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3266, d4xbdA1, 0.5162, 3.28, 0.104, 180, 164, 1.45A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE COMPLEX WITH A COVALENTLY BOUND DIPEPTIDYL INHIBITOR (1R2S)-2-({N-[(BENZYLOXY) CARBONYL]-3-CYCLOHEXYL-L-ALANYL}AMINO)-1-HYDROXY-3-[(3S)-2- OXOPYRROLIDIN-3-YL]PROPANE-1-SULFONIC ACID (ORTHORHOMBIC P FORM)
3267, p4in2B_, 0.5161, 3.36, 0.122, 176, 164, STRUCTURAL BASIS OF SUBSTRATE SPECIFICITY AND PROTEASE INHIBITION IN NORWALK VIRUS
3268, d5tg1A_, 0.5159, 3.29, 0.104, 180, 164, 1.40 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE A M-CHLOROPHENYL SUBSTITUTED MACROCYCLIC INHIBITOR (17-MER)
3269, d5dg6B1, 0.5136, 3.30, 0.104, 180, 164, 2.35A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX AN OXADIAZOLE-BASED CELL PERMEABLE MACROCYCLIC (21-MER) INHIBITOR
3270, d5dgjA1, 0.5118, 3.24, 0.110, 180, 164, 1.0A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX AN OXADIAZOLE-BASED CELL PERMEABLE MACROCYCLIC (20-MER) INHIBITOR
3271, p5y4lA1, 0.5108, 2.59, 0.123, 162, 155, PRRSV NSP4
3272, p5y4lC1, 0.5090, 3.47, 0.133, 180, 166, PRRSV NSP4
3273, p5y4lD1, 0.5084, 3.77, 0.105, 182, 171, PRRSV NSP4
3274, p5xw1A_, 0.5084, 3.29, 0.104, 180, 164, CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR; PRN; AT PH10 
3275, d5tg2A_, 0.5053, 3.44, 0.102, 180, 166, 1.75 A RESOLUTION STRUCTURE OF NOROVIRUS 3CL PROTEASE IN COMPLEX WITH THE A N-PENTYL SUBSTITUTED MACROCYCLIC INHIBITOR (17-MER)
3276, p5xwaA_, 0.5044, 3.75, 0.204, 188, 167, CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR PRY AT PH 10
3277, p5xw9A_, 0.5041, 3.75, 0.204, 188, 167, CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR PRY AT PH 7
3278, p5xw8A_, 0.5041, 3.48, 0.139, 180, 166, CRYSTAL STRUCTURE OF PORCINE PANCREATIC TRYPSIN WITH TRIPEPTIDE INHIBITOR PRN AT PH 7
3279, p4fxgJ1, 0.5015, 3.23, 0.092, 180, 163, COMPLEMENT C4 IN COMPLEX WITH MASP-2
3280, p2pgqB1, 0.5011, 3.53, 0.114, 176, 166, HUMAN THROMBIN MUTANT C191A-C220A IN COMPLEX WITH THE INHIBITOR PPACK
3281, p5jpmJ1, 0.5006, 3.57, 0.200, 183, 165, STRUCTURE OF THE COMPLEX OF HUMAN COMPLEMENT C4 WITH MASP-2 REBUILT USING IMDFF
3282, p1avgH1, 0.5003, 3.50, 0.108, 180, 166, THROMBIN INHIBITOR FROM TRIATOMA PALLIDIPENNIS
3283, p3htcH1, 0.5001, 3.27, 0.104, 180, 164, THE STRUCTURE OF A COMPLEX OF RECOMBINANT HIRUDIN AND HUMAN ALPHA-THROMBIN
